## Supplementary Table 1 Risk of bias of included studies

| Ref.                                      | Selection bias<br>(random sequence<br>generation) | Selection bias (allocation concealment) | Performance<br>bias | Detection<br>bias | Attrition<br>bias | Reporting<br>bias | Other<br>bias   |
|---|---|---|---------------------|-------------------|-------------------|-------------------|-----------------|
| Lee M, 2024 <sup>1</sup>                  | Low risk  | Unclear risk                            | Low risk            | Low risk          | Low risk          | Low risk          | Low risk        |
| Peters JC, 2024 <sup>2</sup>              | Unclear risk                                      | Unclear risk                            | Unclear risk        | Low risk          | Low risk          | Unclear<br>risk   | Unclear<br>risk |
| Okuka N, 2024 <sup>3</sup>                | Low risk  | Low risk                                | Low risk            | Low risk          | Low risk          | Low risk          | Low risk        |
| Pereira V, 2024 <sup>4</sup>              | Low risk  | Unclear risk                            | Unclear risk        | Low risk          | Low risk          | Low risk          | Low risk        |
| Salte OBK, 2024 <sup>5</sup>              | Low risk  | Unclear risk                            | Unclear risk        | Low risk          | Low risk          | Low risk          | Low risk        |
| Moravcová K, 2024 <sup>6</sup>            | Unclear risk                                      | Unclear risk                            | Low risk            | Low risk          | Low risk          | Low risk          | Low risk        |
| Holmberg S <sub>1</sub> 2024 <sup>7</sup> | Unclear risk                                      | Unclear risk                            | Unclear risk        | Low risk          | Unclear<br>risk   | Low risk          | Unclear<br>risk |
| Eriksson JW, 2024 <sup>8</sup>            | Low risk  | Low risk                                | Unclear risk        | Low risk          | Low risk          | Low risk          | Low risk        |
| Gonzalez-Gil AM, 2024 <sup>9</sup>        | Low risk  | Low risk                                | Low risk            | Low risk          | Low risk          | Low risk          | Low risk        |
| Keawtep P, 2024 <sup>10</sup>             | Low risk  | Unclear risk                            | Low risk            | Low risk          | Low risk          | Low risk          | Low risk        |

| Li S, 2024 <sup>11</sup>                    | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear         | Unclear         | Unclear         |
|---|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
|   |              |              |              |          | risk            | risk            | risk            |
| Lee DC, 2024 <sup>12</sup>                  | Unclear risk | Low risk     | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Sandby K, 2024 <sup>13</sup>                | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Heinonen S, 2023 <sup>14</sup>              | Low risk     | Low risk     | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| da Silva CSO, 2023 <sup>15</sup>            | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Fallah F, 2023 <sup>16</sup>                | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Lauw S, 2023 <sup>17</sup>                  | Low risk     | Unclear risk | High risk    | Low risk | Low risk        | Low risk        | Low risk        |
| Bamgboye M, 2023 <sup>18</sup>              | Low risk     | Low risk     | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Möller F, 2023 <sup>19</sup>                | Unclear risk | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| García-Cordero J, 2023 <sup>20</sup>        | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Zhu R, 2023 <sup>21</sup>                   | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Unclear<br>risk |
| Hematinezhad Touli M,<br>2022 <sup>22</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Unclear<br>risk |

| Nora CL, 2023 <sup>23</sup>          | Low risk     | Low risk     | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
|--------------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Sun J, 2023 <sup>24</sup>            | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Taha MM, 2023 <sup>25</sup>          | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Perin L, 2023 <sup>26</sup>          | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Zhang N, 2023 <sup>27</sup>          | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Elsayed MM, 2023 <sup>28</sup>       | Low risk     | Low risk     | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Cabrera-Rode E, 2023 <sup>29</sup>   | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Maaloul R, 2023 <sup>30</sup>        | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Unclear<br>risk |
| Muñoz-Pérez DM, 2023 <sup>31</sup>   | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Saeidi A, 2023 <sup>32</sup>         | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Unclear<br>risk |
| Quist JS, 2023 <sup>33</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Delgado-Floody P, 2022 <sup>34</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Unclear<br>risk |
| Ghorbani Y, 2023 <sup>35</sup>       | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Garvey WT, 2022 <sup>36</sup>        | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |

| Kosiborod MN, 2023 <sup>37</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
|-------------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Guo H, 2022 <sup>38</sup>           | Low risk     | Unclear risk | Unclear risk | Low risk | High risk       | Low risk        | Unclear<br>risk |
| Yoshino M, 2022 <sup>39</sup>       | Unclear risk | Unclear risk | Unclear risk | Low risk | unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Goralska J, 2022 <sup>40</sup>      | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Zhaohu H, 2022 <sup>41</sup>        | Low risk     | Unclear risk | Unclear risk | Low risk | High risk       | Low risk        | Low risk        |
| Seyam MK, 2022 <sup>42</sup>        | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Osuna-Prieto FJ, 2022 <sup>43</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Lange UG, 2022 <sup>44</sup>        | Low risk     | Unclear risk | High risk    | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Mo SJ, 2022 <sup>45</sup>           | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Ataeinosrat A, 2022 <sup>46</sup>   | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Unclear<br>risk |
| Salminen P, 2022 <sup>47</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Zhang X, 2022 <sup>48</sup>         | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |

| Senkus KE, 2022 <sup>49</sup>          | Low risk     | Low risk     | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
|--|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Haji-Ghazi Tehrani L , $2022^{50}$     | Low risk     | Low risk     | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Murphy R, 2022 <sup>51</sup>           | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Lockard B, 2022 <sup>52</sup>          | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| de Luis D, 2022 <sup>53</sup>          | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Ilich JZ, 2022 <sup>54</sup>           | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Unclear<br>risk |
| Ruggenenti P, 2022 <sup>55</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Sohn M, 2022 <sup>56</sup>             | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Li S, 2022 <sup>57</sup>               | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Unclear<br>risk |
| Lugones-Sánchez C , 2022 <sup>58</sup> | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Kim MJ, 2022 <sup>59</sup>             | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Sánchez E, 2021 <sup>60</sup>          | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |

| Eskandaros MS, 2022 <sup>61</sup>            | Low risk     | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
|--|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Mateos R, 2022 <sup>62</sup>                 | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| de Oliveira Fialho CG,<br>2022 <sup>63</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Grangeiro É D, 2021 <sup>64</sup>            | Low risk     | Low risk     | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Schiavo L, 2022 <sup>65</sup>                | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Haidari F, 2021 <sup>66</sup>                | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Kafyra M, 2021 <sup>67</sup>                 | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Unclear<br>risk |
| Lee YK, 2021 <sup>68</sup>                   | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Unclear<br>risk |
| de Sousa ART, 2021 <sup>69</sup>             | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Unclear<br>risk |
| Rajaie H, 2021 <sup>70</sup>                 | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Félix-Soriano E, 2021 <sup>71</sup>          | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Astbury NM, 2021 <sup>72</sup>               | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |

| Muñoz-Perez DM, 2021 <sup>73</sup> | Low risk      | Unclear risk   | Low risk       | Low risk | Low risk | Low risk | Low risk |
|------------------------------------|---------------|----------------|----------------|----------|----------|----------|----------|
| Vergara M, 2021 <sup>74</sup>      | Low risk      | Low risk       | Low risk       | Low risk | Low risk | Low risk | Low risk |
| Cai L, 2021 <sup>75</sup>          | Unclear risk  | Unclear risk   | Unclear risk   | Low risk | Low risk | Low risk | Low risk |
| Umphonsathien $M$ , $2022^{76}$    | Low risk      | Unclear risk   | High risk      | Low risk | Low risk | Low risk | Low risk |
| Paul S, 2021 <sup>77</sup>         | Unclear risk  | Unclear risk   | Low risk       | Low risk | Low risk | Unclear  | Unclear  |
| 10010, 2021                        | Official fish | Officient from | LOW HOR        | 2011131  | ZOW HSK  | risk     | risk     |
| Jamka M, 2021 <sup>78</sup>        | Unclear risk  | Unclear risk   | Unclear risk   | Low risk | Low risk | Low risk | Unclear  |
| ,                                  |               |                |                |          |          |          | risk     |
| Trouwborst I, 2021 <sup>79</sup>   | Low risk      | Low risk       | Unclear risk   | Low risk | Low risk | Low risk | Low risk |
| Siu PM, 2021 <sup>80</sup>         | Low risk      | Low risk       | Low risk       | Low risk | Low risk | Low risk | Low risk |
| Moholdt T, 2021 <sup>81</sup>      | Low risk      | Low risk       | Low risk       | Low risk | Low risk | Low risk | Low risk |
| Leung GKW, 202182                  | Low risk      | Low risk       | Unclear risk   | Low risk | Low risk | Low risk | Low risk |
| Cooney C, 2021 <sup>83</sup>       | Low risk      | Low risk       | Unclear risk   | Low risk | Low risk | Unclear  | Low risk |
|                                    | LOW 115K      | LOW 115K       | Officieal fisk | LOW 115K | LOW 115K | risk     | LOW 115K |

| Azizi S, 2021 <sup>84</sup>                   | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |
|---|--------------|--------------|--------------|----------|-----------|-----------------|-----------------|
| Biteli P, 2021 <sup>85</sup>                  | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk  | Low risk        | Unclear<br>risk |
| Naing S, 2020 <sup>86</sup>                   | Low risk     | Unclear risk | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk        |
| de Melo CM, 2021 <sup>87</sup>                | Low risk     | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |
| Han Y, 2022 <sup>88</sup>                     | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Unclear<br>risk |
| de Luis D, 2021 <sup>89</sup>                 | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk  | Unclear<br>risk | Unclear<br>risk |
| Noer ER, 2020 <sup>90</sup>                   | Unclear risk | Unclear risk | High risk    | Low risk | Low risk  | Low risk        | Unclear<br>risk |
| Höchsmann C, 2021 <sup>91</sup>               | Low risk     | Unclear risk | Unclear risk | Low risk | High risk | Low risk        | Low risk        |
| Lopes AL, 2021 <sup>92</sup>                  | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |
| Wheeler MJ, 2020 <sup>93</sup>                | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |
| Hajizadeh-Sharafabad F,<br>2021 <sup>94</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |

| Zhang T, 2020 <sup>95</sup>                  | Low risk         | Low risk           | Low risk            | Low risk     | Low risk    | Low risk | Low risk    |
|--|------------------|--------------------|---------------------|--------------|-------------|----------|-------------|
| Wongpipit W, 2021 <sup>96</sup>              | Low risk         | Low risk           | Low risk            | Low risk     | Low risk    | Unclear  | Low risk    |
| OI I   |                  |                    |                     |              |             | risk     |             |
| Rondanelli M <sub>.</sub> 2020 <sup>97</sup> | Low risk         | Low risk           | Low risk            | Low risk     | Low risk    | Unclear  | Low risk    |
| , ,  | Zow Hen          | 20111011           | 2011 11011          | 20111311     | 2011 11311  | risk     | 20 11 11011 |
| Glaysher MA, 2021 <sup>98</sup>              | Low risk         | Low risk           | Low risk            | Low risk     | Low risk    | Low risk | Low risk    |
| Fechner E, 2020 <sup>99</sup>                | Low risk         | Low risk           | Unclear risk        | Low risk     | Low risk    | Low risk | Low risk    |
| Yousefi R, 2021 <sup>100</sup>               | Low risk         | Low risk           | Low risk            | Low risk     | Low risk    | Low risk | Low risk    |
| Park W, 2020 <sup>101</sup>                  | Low risk         | Unclear risk       | Unclear risk        | Low risk     | Low risk    | Low risk | Low risk    |
| Brennan AM, 2020 <sup>102</sup>              | Low risk         | Unclear risk       | Unclear risk        | Low risk     | Low risk    | Low risk | Low risk    |
| Jung K, 2020 <sup>103</sup>                  | Low risk         | Unclear risk       | Unclear risk        | Low risk     | Low risk    | Low risk | Low risk    |
| Heiston EM, 2021 <sup>104</sup>              | I In along whole | I In al can ut -1. | I In al a an at -1. | I assaulat   | I a u!a1.   | Unclear  | Unclear     |
| TIEISTOTI EIVI, ZUZI                         | Unclear risk     | Unclear risk       | Unclear risk        | Low risk     | Low risk    | risk     | risk        |
| Sun J, 2020 <sup>105</sup>                   | Low risk         | Unclear risk       | Unclear risk        | L oruz miolo | I our micle | Unclear  | Unclear     |
| Juli J. 2020                                 | LOW FISK         | Unclear risk       | Unclear risk        | Low risk     | Low risk    | risk     | risk        |
| Haidari F, 2020 <sup>106</sup>               | Low risk         | Low risk           | Low risk            | Low risk     | Low risk    | Low risk | Low risk    |

| Haidari F, 2020 <sup>107</sup>        | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk        |
|---------------------------------------|--------------|--------------|--------------|----------|----------|-----------------|-----------------|
| Vogel C, 2020 <sup>108</sup>          | Low risk     | Low risk     | Unclear risk | Low risk | Low risk | Low risk        | Low risk        |
| Michalczyk MM, 2020 <sup>109</sup>    | Low risk     | Low risk     | Unclear risk | Low risk | Low risk | Low risk        | Low risk        |
| Moszak M, 2020 <sup>110</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Batista-Jorge GC, 2020 <sup>111</sup> | Low risk     | Low risk     | Unclear risk | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Colleluori G, 2020 <sup>112</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Poon ET, 2020 <sup>113</sup>          | Low risk     | Low risk     | Unclear risk | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Basciani S, 2020 <sup>114</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Psota TL, 2020 <sup>115</sup>         | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Unclear<br>risk |
| Ghanim H, 2020 <sup>116</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Santos A, 2020 <sup>117</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Bakker N, 2020 <sup>118</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |

| Kim J, 2020 <sup>119</sup>           | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear<br>risk | Low risk        |
|--------------------------------------|--------------|--------------|--------------|----------|----------|-----------------|-----------------|
| López-Gómez JJ, 2020 <sup>120</sup>  | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Unclear<br>risk |
| Sadowska-Krępa E , $2020^{121}$      | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear<br>risk | Unclear<br>risk |
| Hannon BA, 2020 <sup>122</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Michael DR, 2020 <sup>123</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Kuszewski JC, 2020 <sup>124</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Meslier V, 2020 <sup>125</sup>       | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Razmpoosh E, 2020 <sup>126</sup>     | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk        |
| Headland ML, 2020 <sup>127</sup>     | Low risk     | Low risk     | Unclear risk | Low risk | Low risk | Low risk        | Low risk        |
| Bittel AJ, 2020 <sup>128</sup>       | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear<br>risk | Unclear<br>risk |
| Hadi A, 2019 <sup>129</sup>          | Low risk     | Unclear risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Dellis D, 2020 <sup>130</sup>        | Low risk     | Low risk     | Unclear risk | Low risk | Low risk | Low risk        | Low risk        |
| Porter Starr KN, 2019 <sup>131</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |

| Ratajczak M, 2019 <sup>132</sup> | Unclear risk   | Unclear risk   | Unclear risk | Low risk  | Low risk   | Unclear<br>risk | Low risk |
|----------------------------------|----------------|----------------|--------------|-----------|------------|-----------------|----------|
| Fatahi S, 2019 <sup>133</sup>    | Low risk       | Unclear risk   | High risk    | Low risk  | Low risk   | Unclear         | Unclear  |
| ,                                |                |                | 8            |           |            | risk            | risk     |
| Peradze N, 2019 <sup>134</sup>   | unclear risk   | Unclear risk   | Low risk     | Low risk  | Low risk   | Low risk        | Low risk |
| Ghasemi E, 2019 <sup>135</sup>   | Low risk       | Unclear risk   | Unclear risk | Low risk  | Low risk   | Low risk        | Low risk |
| Rakvaag E, 2019 <sup>136</sup>   | Low risk       | Low risk       | Low risk     | Low risk  | Low risk   | Low risk        | Low risk |
| Cao L,, 2019 <sup>137</sup>      | Low risk       | Low risk       | Low risk     | Low risk  | Low risk   | Unclear         | Low risk |
| 2015                             | Zow How        | Zow Hox        | 20111311     | 2011 1131 | 2011 11310 | risk            | LOW HOR  |
| Rosqvist F,, 2019 <sup>138</sup> | Low risk       | Low risk       | Low risk     | Low risk  | Low risk   | Low risk        | Low risk |
| Pavić E, 2019 <sup>139</sup>     | Low risk       | Low risk       | Low risk     | Low risk  | Low risk   | Low risk        | Low risk |
| Farr OM, 2019 <sup>140</sup>     | Unclear risk   | Unclear risk   | Low risk     | Low risk  | Unclear    | Low risk        | Low risk |
| 1 di 1 O (1), 2017               | Officieal fisk | Officiear fisk | LOW 115K     | LOW 115K  | risk       | LOW 115K        | LOW 115K |
| Kim CO, 2019 <sup>141</sup>      | Unclear risk   | Unclear risk   | Low risk     | Low risk  | Low risk   | Low risk        | Low risk |
| Abbaspour N, 2019 <sup>142</sup> | Unclear risk   | Unclear risk   | Unclear risk | Low risk  | Low risk   | Low risk        | Low risk |
| Lahelma M, 2019 <sup>143</sup>   | Unclear risk   | Unclear risk   | Low risk     | Low risk  | Low risk   | Low risk        | Low risk |
| Haywood CJ, 2019 <sup>144</sup>  | Unclear risk   | Unclear risk   | Unclear risk | Low risk  | Low risk   | Low risk        | Unclear  |

|   |              |              |              |          |          |                 | risk            |
|---|--------------|--------------|--------------|----------|----------|-----------------|-----------------|
| Angelino D, 2019 <sup>145</sup>         | Low risk     | Unclear risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Apiñaniz A, 2019 <sup>146</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Tuccinardi D, 2019 <sup>147</sup>       | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Hernández-Lepe MA , 2019 <sup>148</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Aller R, 2019 <sup>149</sup>            | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear<br>risk | Unclear<br>risk |
| Smith-Ryan AE, 2019 <sup>150</sup>      | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk        |
| Asano M, 2019 <sup>151</sup>            | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Clayton ZS, 2019 <sup>152</sup>         | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Bowen J, 2019 <sup>153</sup>            | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Yari Z, 2022 <sup>154</sup>             | Low risk     | Unclear risk | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Novin ZS, 2018 <sup>155</sup>           | Low risk     | Unclear risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        |

| Erickson ML, 2019 <sup>156</sup>   | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk  | Unclear<br>risk | Low risk        |
|------------------------------------|--------------|--------------|--------------|----------|-----------|-----------------|-----------------|
| Cho AR, 2019 <sup>157</sup>        | Low risk     | High risk    | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |
| Aller R, 2019 <sup>158</sup>       | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk  | Unclear<br>risk | Low risk        |
| Choi HR, 2018 <sup>159</sup>       | Low risk     | Unclear risk | Unclear risk | Low risk | High risk | Low risk        | Low risk        |
| Subih HS, 2018 <sup>160</sup>      | Unclear risk | Unclear risk | Unclear risk | Low risk | High risk | Unclear<br>risk | Unclear<br>risk |
| Headland ML, 2019 <sup>161</sup>   | Low risk     | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |
| Gorostegi-Anduaga I , $2018^{162}$ | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |
| Yousefi R, 2018 <sup>163</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |
| Oh M, 2018 <sup>164</sup>          | Low risk     | Low risk     | High risk    | Low risk | Low risk  | Unclear<br>risk | Low risk        |
| Varsamis P, 2019 <sup>165</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |
| Loves S, 2018 <sup>166</sup>       | Low risk     | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |

| Camacho-Cardenosa A,<br>2018 <sup>167</sup> | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk |
|---|--------------|--------------|--------------|----------|----------|-----------------|----------|
| Kakutani R, 2018 <sup>168</sup>             | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk |
| Oliveira-de-Lira L, 2018 <sup>169</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk |
| Allaire J,, 2018 <sup>170</sup>             | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk |
| Gram AS, 2018 <sup>171</sup>                | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk |
| Azevedo FR, 2018 <sup>172</sup>             | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk |
| Fatahi S, 2018 <sup>173</sup>               | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk | Unclear<br>risk | Low risk |
| Alcántara-Aragón V , $2018^{174}$           | Low risk     | Unclear risk | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk |
| Mundbjerg LH, 2018 <sup>175</sup>           | Unclear risk | Low risk     | Unclear risk | Low risk | Low risk | Low risk        | Low risk |
| McKay DL, 2018 <sup>176</sup>               | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk |
| Lee YJ, 2018 <sup>177</sup>                 | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk |
| Padilla-Camberos E , $2018^{178}$           | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk |
| Ramos-Lopez O, 2018 <sup>179</sup>          | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear         | Unclear  |

|                                      |              |              |              |          |                 | risk            | risk            |
|--------------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Mateo-Gallego R, 2018 <sup>180</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Shrivastava U, 2017 <sup>181</sup>   | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Wagmacker DS, 2017 <sup>182</sup>    | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Ando Y, 2017 <sup>183</sup>          | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Rock CL, 2017 <sup>184</sup>         | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Schiavon CA, 2018 <sup>185</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Blomquist C, 2018 <sup>186</sup>     | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Unclear<br>risk |
| Lima RPA, 2017 <sup>187</sup>        | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Ferreira TDS, 2017 <sup>188</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| O'Doherty AF, 2017 <sup>189</sup>    | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Pedley CF, 2018 <sup>190</sup>       | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Chung J, 2017 <sup>191</sup>         | Unclear risk | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Fedewa MV, 2018 <sup>192</sup>       | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear         | Unclear         |

|  |              |              |              |          |           | risk            | risk            |
|--|--------------|--------------|--------------|----------|-----------|-----------------|-----------------|
| Kleist B, 2017 <sup>193</sup>                | Unclear risk | Unclear risk | Unclear risk | Low risk | High risk | Low risk        | Unclear<br>risk |
| Vella CA, 2017 <sup>194</sup>                | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk  | Unclear<br>risk | Low risk        |
| Gulati S, 2017 <sup>195</sup>                | Unclear risk | Unclear risk | High risk    | Low risk | Low risk  | Low risk        | Low risk        |
| Rodriguez-Cristobal JJ , 2017 <sup>196</sup> | Low risk     | Low risk     | Unclear risk | Low risk | High risk | Low risk        | Low risk        |
| Vink RG, 2017 <sup>197</sup>                 | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk  | Low risk        | Low risk        |
| Vors C, 2017 <sup>198</sup>                  | Low risk     | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |
| Ribeiro C, 2017 <sup>199</sup>               | Low risk     | Unclear risk | High risk    | Low risk | Low risk  | Low risk        | Low risk        |
| Ard JD, 2017 <sup>200</sup>                  | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk  | Unclear<br>risk | Unclear<br>risk |
| Littlefield LA, 2017 <sup>201</sup>          | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk  | Unclear<br>risk | Unclear<br>risk |
| Houghton D, 2017 <sup>202</sup>              | Low risk     | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |
| Trepanowski JF, 2017 <sup>203</sup>          | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk  | Unclear         | Low risk        |

|                                  |              |              |              |          |          | risk            |                 |
|----------------------------------|--------------|--------------|--------------|----------|----------|-----------------|-----------------|
| Fathi Y, 2017 <sup>204</sup>     | Low risk     | Unclear risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Juliana N, 2017 <sup>205</sup>   | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Bonfante IL, 2017 <sup>206</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk        |
| Heggen E, 2017 <sup>207</sup>    | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear<br>risk | Unclear<br>risk |
| Williams EJ, 2017 <sup>208</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Peterli R, 2017 <sup>209</sup>   | Low risk     | Low risk     | Unclear risk | Low risk | Low risk | Low risk        | Low risk        |
| Merra G, 2017 <sup>210</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Pal S, 2017 <sup>211</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Bergeron N, 2016 <sup>212</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Wittmann K, 2016 <sup>213</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        |
| Veum VL, 2017 <sup>214</sup>     | Low risk     | Low risk     | Unclear risk | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Coelho R, 2017 <sup>215</sup>    | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk        |
| Kirwan JP, 2016 <sup>216</sup>   | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        |

| Madjd A, 2016 <sup>217</sup>      | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
|-----------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Duncan S, 2016 <sup>218</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Lee M, 2016 <sup>219</sup>        | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Normandin E, 2017 <sup>220</sup>  | Low risk     | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| de Luis D, 2016 <sup>221</sup>    | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Madjd A, 2017 <sup>222</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Mosikanon K, 2017 <sup>223</sup>  | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Nikseresht M, 2016 <sup>224</sup> | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Raatz SK, 2016 <sup>225</sup>     | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Unclear<br>risk |
| Ruggenenti P, 2017 <sup>226</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Risstad H, 2016 <sup>227</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Tomeleri CM, 2016 <sup>228</sup>  | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear         | Unclear         |

|                                   |              |              |              |          |           | risk            | risk     |
|-----------------------------------|--------------|--------------|--------------|----------|-----------|-----------------|----------|
| Cox AJ, 2017 <sup>229</sup>       | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Camolas J, 2017 <sup>230</sup>    | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk  | Unclear<br>risk | Low risk |
| Valsesia A, 2016 <sup>231</sup>   | Low risk     | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Weiss EP, 2016 <sup>232</sup>     | Low risk     | Unclear risk | Unclear risk | Low risk | High risk | Low risk        | Low risk |
| Byun MS, 2016 <sup>233</sup>      | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Mensinger JL, 2016 <sup>234</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk |
| Arzola-Paniagua MA , $2016^{235}$ | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Dempsey PC, 2016 <sup>236</sup>   | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk |
| Firouzjaei A, 2016 <sup>237</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Dutour A, 2016 <sup>238</sup>     | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk |
| Tan S, 2016 <sup>239</sup>        | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Unclear         | Low risk |

|                                   |                |                |              |          |          | risk     |          |
|-----------------------------------|----------------|----------------|--------------|----------|----------|----------|----------|
| N. IAI 2017/240                   |                | TT 1 . 1       | TT 1 .1      |          | unclear  | Unclear  | Unclear  |
| Ma W, 2016 <sup>240</sup>         | Unclear risk   | Unclear risk   | Unclear risk | Low risk | risk     | risk     | risk     |
| Rigamonti AE, 2017 <sup>241</sup> | Unclear risk   | Unclear risk   | Low risk     | Low risk | Unclear  | Unclear  | Low risk |
| Rigamonti AE, 2017                | Onclear risk   | Unclear risk   | LOW IISK     | LOW IISK | risk     | risk     | LOW FISK |
| Ji M, 2016 <sup>242</sup>         | Unclear risk   | Unclear risk   | High risk    | Low risk | Low risk | Unclear  | Low risk |
| J1171, 2010                       | Officieal fisk | Officieal fisk | Tilgittisk   | LOW 115K | LOW 115K | risk     | LOW 115K |
| Daubenmier J, 2016 <sup>243</sup> | Low risk       | Low risk       | Low risk     | Low risk | Low risk | Low risk | Low risk |
| Razny U, 2015 <sup>244</sup>      | Low risk       | Low risk       | Low risk     | Low risk | Low risk | Low risk | Low risk |
| Magkos F, 2016 <sup>245</sup>     | Unclear risk   | Unclear risk   | Unclear risk | Low risk | Low risk | Low risk | Low risk |
| Hosseini B, 2016 <sup>246</sup>   | Low risk       | Low risk       | Low risk     | Low risk | Low risk | Low risk | Low risk |
| Li J, 2016 <sup>247</sup>         | Unclear risk   | Unclear risk   | Low risk     | Low risk | Low risk | Low risk | Low risk |
| Chroma III 2017248                | TT 1 · 1       | TT 1 '1        | т 1          | т • 1    | Unclear  | т • 1    | т 1      |
| Stroeve JH, 2016 <sup>248</sup>   | Unclear risk   | Unclear risk   | Low risk     | Low risk | risk     | Low risk | Low risk |
| Le T. 2016 <sup>249</sup>         | Unclear risk   | Unclear risk   | Low risk     | Low risk | Low risk | Unclear  | Low risk |
| LC 1, 2010                        | Officieal fisk | Officieal fisk | LOW 115K     | LOW HSK  | LOW 11SK | risk     | LOW 115K |
| Ohara T, 2016 <sup>250</sup>      | Unclear risk   | Unclear risk   | Low risk     | Low risk | Low risk | Low risk | Low risk |

| Juraschek SP, 2016 <sup>251</sup> | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk        |
|-----------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Henson J, 2016 <sup>252</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Loftus HL, 2015 <sup>253</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Besnier F, 2015 <sup>254</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Said M, 2017 <sup>255</sup>       | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Unclear<br>risk |
| Fisher G, 2015 <sup>256</sup>     | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Barbour JA,, 2015 <sup>257</sup>  | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Ribeiro AS, 2016 <sup>258</sup>   | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Rozati M, 2015 <sup>259</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Yang J, 2015 <sup>260</sup>       | Low risk     | Unclear risk | High risk    | Low risk | Unclear<br>risk | Unclear<br>risk | Low risk        |
| Pi-Sunyer X, 2015 <sup>261</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Osama AJ, 2015 <sup>262</sup>     | Unclear risk | Unclear risk | High risk    | Low risk | Low risk        | Unclear<br>risk | Unclear<br>risk |
| Chen IJ, 2016 <sup>263</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |

| Romero-Moraleda B , 2015 <sup>264</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
|---|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Rossi FE, 2016 <sup>265</sup>           | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Song MY, 2015 <sup>266</sup>            | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| Soto-Molina H, 2015 <sup>267</sup>      | Unclear risk | Unclear risk | Low risk     | Low risk | High risk       | Low risk        | Low risk        |
| Mahdavi R, 2015 <sup>268</sup>          | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Bruun JM, 2015 <sup>269</sup>           | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Gatterer H, 2015 <sup>270</sup>         | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Mateo-Gallego R, 2017 <sup>271</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Xu M, 2015 <sup>272</sup>               | Low risk     | Low risk     | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| Cho IJ, 2016 <sup>273</sup>             | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Robert SA, 2015 <sup>274</sup>          | Unclear risk | Unclear risk | Unclear risk | Low risk | unclear<br>risk | Unclear<br>risk | Unclear<br>risk |

| Ghafouri K, 2015 <sup>275</sup>          | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
|--|--------------|--------------|--------------|----------|-----------------|-----------------|----------|
| Alencar MK, 2015 <sup>276</sup>          | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Fuller NR, 2015 <sup>277</sup>           | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| McFarlin BK, 2015 <sup>278</sup>         | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Macías-Cervantes MH, 2015 <sup>279</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Risstad H, 2015 <sup>280</sup>           | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Dodevska MS, 2016 <sup>281</sup>         | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Rezaeipour M, 2014 <sup>282</sup>        | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Bajerska J, 2015 <sup>283</sup>          | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Yamauchi K, 2014 <sup>284</sup>          | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear         | Low risk |

|                                    |              |              |              |          |                 | risk            |                 |
|------------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Moreira AP, 2016 <sup>285</sup>    | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Cases J, 2015 <sup>286</sup>       | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Unclear<br>risk | Low risk        |
| Worsley R, 2015 <sup>287</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Hoddy KK, 2014 <sup>288</sup>      | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Tay J, 2014 <sup>289</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Foraker RE, 2014 <sup>290</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk        | Unclear<br>risk |
| Choo J, 2014 <sup>291</sup>        | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| van Nielen M,, 2014 <sup>292</sup> | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Moreira Alves RD , $2014^{293}$    | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Bracale R, 2014 <sup>294</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |

| Telles S, 2014 <sup>295</sup>   | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        | Low risk        |
|---------------------------------|--------------|--------------|----------|----------|-----------------|-----------------|-----------------|
| Larsen RN, 2014 <sup>296</sup>  | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Guo Y, 2014 <sup>297</sup>      | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Saslow LR, 2014 <sup>298</sup>  | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        | Low risk        |
| Tapsell LC, 2014 <sup>299</sup> | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        | Low risk        |
| Lowndes J, 2014 <sup>300</sup>  | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Thorp AA, 2014 <sup>301</sup>   | Low risk     | Unclear risk | Low risk | Low risk | Low risk        | Low risk        | Low risk        |
| Wong AT, 2014 <sup>302</sup>    | Unclear risk | Unclear risk | Low risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Calbet JA, 2015 <sup>303</sup>  | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Mirzaei K, 2014 <sup>304</sup>  | Low risk     | Unclear risk | Low risk | Low risk | unclear<br>risk | Unclear<br>risk | Low risk        |
| Mellberg C, 2014 <sup>305</sup> | Low risk     | Unclear risk | Low risk | Low risk | High risk       | Low risk        | Low risk        |

|                                     |                   |                 |              |             | unclear      | Unclear  | Unclear     |
|-------------------------------------|-------------------|-----------------|--------------|-------------|--------------|----------|-------------|
| Milsom VA, 2014 <sup>306</sup>      | Unclear risk      | Unclear risk    | Unclear risk | Low risk    | risk         | risk     | risk        |
| C1: : 16 2010 <sup>207</sup>        |                   |                 |              |             | unclear      | Unclear  | Unclear     |
| Shirai K, 2013 <sup>307</sup>       | Unclear risk      | Unclear risk    | Unclear risk | Low risk    | risk         | risk     | risk        |
| Rabinovitz HR 2014 <sup>308</sup>   | I In also a wiel. | والموامع بالمال | I assaulate  | I oznawiala | I azuz #2a1. | Unclear  | I assautale |
| Rabinovitz Tik, 2014                | Unclear risk      | Unclear risk    | Low risk     | Low risk    | Low risk     | risk     | Low risk    |
| Mielgo-Ayuso J, 2014 <sup>309</sup> | Low risk          | Low risk        | Low risk     | Low risk    | Low risk     | Unclear  | Low risk    |
| Wileigo-11y uso j, 2014             | LOW 115K          | LOW 115K        | LOW 115K     | LOW 115K    | LOW 115K     | risk     | LOW 115K    |
| Hollander P, 2013 <sup>310</sup>    | Low risk          | Unclear risk    | Low risk     | Low risk    | Low risk     | Low risk | Low risk    |
| Alves NE, 2014 <sup>311</sup>       | Unclear risk      | Unclear risk    | Low risk     | Low risk    | Low risk     | Unclear  | Low risk    |
| THVCSTVL, ZOTT                      | Officieal fisk    | Officieal fisk  | LOW 115K     | LOW 115K    | LOW 115K     | risk     | LOW 115K    |
| Ruth MR, 2013 <sup>312</sup>        | Low risk          | Unclear risk    | Low risk     | Low risk    | Low risk     | Unclear  | Low risk    |
| radi virt, 2010                     | LOW HISK          | Officieal 113K  | LOW 113K     | LOW 113K    | LOW 113K     | risk     | LOW HSK     |
| Tovar J, 2014 <sup>313</sup>        | Low risk          | Low risk        | Low risk     | Low risk    | Low risk     | Low risk | Low risk    |
| Croymans DM, 2014 <sup>314</sup>    | Low risk          | Low risk        | Low risk     | Low risk    | Low risk     | Unclear  | Low risk    |
| Cloymans DW1, 2014                  | LOW 115K          | LOW 115K        | LOW 115K     | LOW 115K    | LOW 115K     | risk     | LOW 115K    |
| Vetter ML, 2013 <sup>315</sup>      | Unclear risk      | Unclear risk    | Unclear risk | Low risk    | Low risk     | Unclear  | Unclear     |
| . 3000 1.12, 2010                   | Official flox     | Officient 113K  | OTRICUI IISK | LOW 113K    | LOW 115K     | risk     | risk        |

|                                     |              |              |              |          |           | TT 1     |          |
|-------------------------------------|--------------|--------------|--------------|----------|-----------|----------|----------|
| Vinkers CD, 2014 <sup>316</sup>     | Low risk     | Unclear risk | Low risk     | Low risk | High risk | Unclear  | Unclear  |
|                                     |              |              |              |          | O         | risk     | risk     |
| Potogo ID 201.4317                  | TT 1 '1      | TT 1 '1      | т • 1        | т • 1    | т • 1     | Unclear  | т • 1    |
| Botero JP, 2014 <sup>317</sup>      | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | risk     | Low risk |
| Hu X, 2013 <sup>318</sup>           | TT 1 · 1     | TT 1 · 1     | TT 1 · 1     | т 1      | Unclear   | т 1      | Unclear  |
| 11u A, 2013                         | Unclear risk | Unclear risk | Unclear risk | Low risk | risk      | Low risk | risk     |
| Kim SH, 2013 <sup>319</sup>         | Unclear risk | Unclear risk | Low risk     | Low risk | High risk | Low risk | Low risk |
| Bouchonville M, 2014 <sup>320</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk | Low risk |
| Romero Moraleda B ,                 |              |              |              |          |           | Unclear  |          |
| 2013 <sup>321</sup>                 | Low risk     | Unclear risk | Low risk     | Low risk | High risk | risk     | Low risk |
| Ikramuddin S, 2013 <sup>322</sup>   | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk | Low risk |
| TI C 2012 <sup>222</sup>            |              |              |              |          |           | Unclear  |          |
| Tey S, 2013 <sup>323</sup>          | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | risk     | Low risk |
| NI: -1.1 IN                         | TT 1 · 1     | TT 1 · 1     | T 1          | T . 1    | Unclear   | Unclear  | Unclear  |
| Nicklas JM, 2013 <sup>324</sup>     | Unclear risk | Unclear risk | Low risk     | Low risk | risk      | risk     | risk     |
| Cto also T 2012325                  | T .1         | т 1          | т • 1        | т • 1    | Unclear   | т • 1    | т • 1    |
| Stocks T, 2013 <sup>325</sup>       | Low risk     | Low risk     | Low risk     | Low risk | risk      | Low risk | Low risk |

| Wright OR, 2013 <sup>326</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
|-----------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|----------|
| Kim SH, 2014 <sup>327,328</sup>   | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Munro IA, 2013 <sup>328</sup>     | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Astell KJ, 2013 <sup>329</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Tonstad S, 2014 <sup>330</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Venojärvi M, 2013 <sup>331</sup>  | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Lamprecht M, 2013 <sup>332</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Tang M, 2013 <sup>333</sup>       | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Reimer RA, 2013 <sup>334</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Fuller NR, 2013 <sup>335</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Jakubowicz D, 2013 <sup>336</sup> | Low risk     | Low risk     | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk |

| Beebe N, 2013 <sup>337</sup>         | Low risk       | Unclear risk   | Low risk     | Low risk   | Unclear<br>risk | Low risk        | Low risk        |
|--------------------------------------|----------------|----------------|--------------|------------|-----------------|-----------------|-----------------|
| Unick JL, 2013 <sup>338</sup>        | Low risk       | Low risk       | Low risk     | Low risk   | Low risk        | Low risk        | Low risk        |
| Mohler ER, 2013 <sup>339</sup>       | Low risk       | Unclear risk   | Low risk     | Low risk   | Low risk        | Low risk        | Low risk        |
| Bhutani S, 2013 <sup>340</sup>       | Unclear risk   | Unclear risk   | Low risk     | Low risk   | High risk       | Unclear<br>risk | Low risk        |
| Webber KH, 2013 <sup>341</sup>       | Unclear risk   | Unclear risk   | Unclear risk | Low risk   | Low risk        | Unclear<br>risk | Unclear<br>risk |
| Marinik EL, 2013 <sup>342</sup>      | Unclear risk   | Unclear risk   | Low risk     | Low risk   | Low risk        | Unclear<br>risk | Low risk        |
| Zhu W, 2013 <sup>343</sup>           | Low risk       | Unclear risk   | Low risk     | Low risk   | Low risk        | Low risk        | Low risk        |
| García-Unciti M, 2012 <sup>344</sup> | Unclear risk   | Unclear risk   | Low risk     | Low risk   | unclear         | Unclear         | Unclear         |
| Garcia Grieffi Wi, 2012              | Officieal 115K | Officieal fisk | LOW 115K     | LOW 115K   | risk            | risk            | risk            |
| Vix M, 2013 <sup>345</sup>           | Low risk       | Low risk       | Low risk     | Low risk   | Low risk        | Unclear         | Low risk        |
|                                      | 2011 1101      | 2011 11010     | 2011 11010   | 2011 11010 | 2011 115K       | risk            | 2011 11010      |
| Klempel MC, 2012 <sup>346</sup>      | Unclear risk   | Unclear risk   | Low risk     | Low risk   | Low risk        | Unclear         | Low risk        |
|                                      | Official flow  | Chelear HSK    | LOW HOR      | 20W 113K   | LOW 113K        | risk            | LOW 115K        |

| Venojärvi M, 2013 <sup>347</sup> | Unclear risk   | Unclear risk   | Low risk       | Low risk | Low risk | Low risk        | Low risk |
|----------------------------------|----------------|----------------|----------------|----------|----------|-----------------|----------|
| Ho SS, 2012 <sup>348</sup>       | Unclear risk   | Unclear risk   | Low risk       | Low risk | Low risk | Unclear<br>risk | Low risk |
| Fayh AP, 2013 <sup>349</sup>     | Unclear risk   | Unclear risk   | Low risk       | Low risk | Low risk | Low risk        | Low risk |
| Sengupta K, 2012 <sup>350</sup>  | Low risk       | Low risk       | Low risk       | Low risk | Low risk | Low risk        | Low risk |
| Itariu BK, 2012 <sup>351</sup>   | Low risk       | Unclear risk   | Low risk       | Low risk | Low risk | Unclear<br>risk | Low risk |
| Whyte LJ, 2013 <sup>352</sup>    | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | unclear  | Unclear         | Unclear  |
| 7711y te Ej, 2013                | Officieal 115K | Officieal fisk | Officieal fisk | LOW 115K | risk     | risk            | risk     |
| Melanson KJ, 2012 <sup>353</sup> | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | unclear  | Unclear         | Unclear  |
| Melanson Kj, 2012                | Officieal fisk | Officieal fisk | Officieal fisk | LOW 115K | risk     | risk            | risk     |
| Panca I 2012354                  | Tt-1-          | T              | T: 1-1-        | T:-1.    | T:-1-    | T: -1.          | Unclear  |
| Ponce J, 2012 <sup>354</sup>     | Low risk       | Low risk       | Low risk       | Low risk | Low risk | Low risk        | risk     |
| Vlammal MC 2012355               | т • 1          | TT 1 · 1       | TT 1 · 1       | т • 1    | т 1      | Unclear         | т • 1    |
| Klempel MC, 2013 <sup>355</sup>  | Low risk       | Unclear risk   | Unclear risk   | Low risk | Low risk | risk            | Low risk |
| Zhang X, 2012 <sup>356</sup>     | Low risk       | Low risk       | Low risk       | Low risk | Low risk | Low risk        | Low risk |
| Ke B, 2012 <sup>357</sup>        | Low risk       | Unclear risk   | Low risk       | Low risk | Low risk | Unclear         | Low risk |

|                                   |              |              |              |          |                 | risk            |                 |
|-----------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Abdi H, 2012 <sup>358</sup>       | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Foster GD, 2012 <sup>359</sup>    | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Ebbeling CB, 2012 <sup>360</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Kelly AS, 2012 <sup>361</sup>     | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| Suliburska J, 2012 <sup>362</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Alizadeh M, 2012 <sup>363</sup>   | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Bjermo H, 2012 <sup>364</sup>     | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Backhouse K, 2012 <sup>365</sup>  | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| Kim JW, 2012 <sup>366</sup>       | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Greene NP, 2012 <sup>367</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear         | unclear         | Low risk        |

|                                  |              |              |              |          | risk            | risk            |                 |
|----------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Boesten JE, 2012 <sup>368</sup>  | Low risk     | Low risk     | Low risk     | Low risk | High risk       | Low risk        | Low risk        |
| Chen SC, 2012 <sup>369</sup>     | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Elisha B, 2012 <sup>370</sup>    | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Maersk M, 2012 <sup>371</sup>    | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Unclear<br>risk |
| Ross AB, 2012 <sup>372</sup>     | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Andersson U, 2012 <sup>373</sup> | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Familiari P, 2011 <sup>374</sup> | unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| Dillard TH, 2013 <sup>375</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Lee JA, 2012 <sup>376</sup>      | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Unclear<br>risk | Low risk        |
| Zunino SJ, 2012 <sup>377</sup>   | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |

| Timmers S, 2011 <sup>378</sup>   | Unclear risk | Unclear risk   | Low risk       | Low risk | Low risk | Unclear<br>risk | Unclear<br>risk |
|----------------------------------|--------------|----------------|----------------|----------|----------|-----------------|-----------------|
| Balducci S, 2012 <sup>379</sup>  | Low risk     | Low risk       | Low risk       | Low risk | Low risk | Low risk        | Low risk        |
| Valente EA, 2011 <sup>380</sup>  | Unclear risk | Unclear risk   | Low risk       | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Farina MG, 2012 <sup>381</sup>   | Unclear risk | Unclear risk   | Low risk       | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Leichtle AB, 2011 <sup>382</sup> | Low risk     | Low risk       | Unclear risk   | Low risk | Low risk | Low risk        | Low risk        |
| Petry NM, 2011 <sup>383</sup>    | Unclear risk | Unclear risk   | Unclear risk   | Low risk | Unclear  | Unclear         | Unclear         |
| 1002) 11012, 2011                | Chelear Hox  | Officient flox | Officient flox | Low Hor  | risk     | risk            | risk            |
| Brown AL, 2011 <sup>384</sup>    | Low risk     | Low risk       | Low risk       | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Kim EK, 2011 <sup>385</sup>      | Unclear risk | Unclear risk   | Low risk       | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Pfeuffer M, 2011 <sup>386</sup>  | Unclear risk | Unclear risk   | Low risk       | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Lyon M, 2011 <sup>387</sup>      | Low risk     | Low risk       | Low risk       | Low risk | Low risk | Low risk        | Low risk        |

| Dekkers JC, 2011 <sup>388</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk         | Low risk         | Low risk         |
|----------------------------------|--------------|--------------|--------------|----------|------------------|------------------|------------------|
| Farnetti S, 2011 <sup>389</sup>  | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear          | Unclear          | Unclear          |
| Venn BJ, 2010 <sup>390</sup>     | Unclear risk | Unclear risk | Unclear risk | Low risk | risk<br>Low risk | risk<br>Low risk | risk<br>Low risk |
| Chen SC, 2010 <sup>391</sup>     | Low risk     | Unclear risk | Low risk     | Low risk | Low risk         | Unclear<br>risk  | Low risk         |
| Miyashita M, 2010 <sup>392</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk  | Unclear<br>risk  | Unclear<br>risk  |
| Morenga LT, 2010 <sup>393</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk         | Unclear<br>risk  | Low risk         |
| Pal S, 2011 <sup>394</sup>       | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk         | Low risk         | Low risk         |
| Greenway FL, 2010 <sup>395</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk         | Low risk         | Low risk         |
| Torres MR, 2010 <sup>396</sup>   | Low risk     | Unclear risk | Low risk     | Low risk | Low risk         | Unclear<br>risk  | Low risk         |
| Herrera MF, 2010 <sup>397</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk         | Low risk         | Low risk         |
| Palacios C, 2011 <sup>398</sup>  | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear          | Unclear          | Unclear          |

|                                     |                |                |                |            | risk     | risk            | risk            |
|-------------------------------------|----------------|----------------|----------------|------------|----------|-----------------|-----------------|
| Ferré R, 2012 <sup>399</sup>        | Unclear risk   | Unclear risk   | Unclear risk   | Low risk   | Unclear  | Unclear         | Unclear         |
| Terre R, 2012                       | Officieal fisk | Officieal fisk | Officieal fisk | LOW 115K   | risk     | risk            | risk            |
| Pal S, 2010 <sup>400</sup>          | Unclear risk   | Unclear risk   | Low risk       | Low risk   | Low risk | Low risk        | Low risk        |
| Hermsdorff HH, 2011 <sup>401</sup>  | Unclear risk   | Unclear risk   | Unclear risk   | Low risk   | Unclear  | Unclear         | Unclear         |
| Tierinsdom Tiit, 2011               | Officieal fisk | Officieal fisk | Officieal fisk | LOW 115K   | risk     | risk            | risk            |
| Plotnikoff RC, 2010 <sup>402</sup>  | Low risk       | Low risk       | Low risk       | Low risk   | Low risk | Low risk        | Low risk        |
| Papakonstantinou $E$ , $2010^{403}$ | Unclear risk   | Unclear risk   | Low risk       | Low risk   | Low risk | Unclear<br>risk | Low risk        |
| Wycherley TP, 2010 <sup>404</sup>   | Unclear risk   | Unclear risk   | Unclear risk   | Low risk   | Low risk | Unclear<br>risk | Unclear<br>risk |
| Jorde R, 2010 <sup>405</sup>        | Low risk       | Low risk       | Low risk       | Low risk   | Low risk | Low risk        | Low risk        |
| Hernandez TL, 2010 <sup>406</sup>   | Unclear risk   | Unclear risk   | Unclear risk   | Low risk   | Unclear  | Unclear         | Low risk        |
| ,                                   |                |                |                | <b></b>    | risk     | risk            | 30 2221         |
| Ibáñez J. 2010 <sup>407</sup>       | Unclear risk   | Unclear risk   | Unclear risk   | Low risk   | Unclear  | Unclear         | Unclear         |
| , <u></u>                           | Cicion IIII    | Cheren How     | Chelear Holy   | 2011 11010 | risk     | risk            | risk            |
| Gripeteg L, 2010 <sup>408</sup>     | Unclear risk   | Unclear risk   | Low risk       | Low risk   | Low risk | Low risk        | Low risk        |

| Tapsell L, 2010 <sup>409</sup>                          | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
|---|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Armendáriz-Anguiano<br>AL, 2011 <sup>410</sup>          | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Amare F, 2024 <sup>411</sup>                            | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Chen CY, 2024 <sup>412</sup>                            | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Chandake S, 2024 <sup>413</sup>                         | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Baba Y, 2024 <sup>414</sup>                             | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Sooriyaarachchi P, 2024 <sup>415</sup>                  | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Lee Y, 2024 <sup>416</sup>                              | Low risk     | Low risk     | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Elahikhah M, 2024 <sup>417</sup>                        | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Dotimas LG, 2024 <sup>418</sup>                         | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Govindasamy K, 2024 <sup>419</sup>                      | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Shin SM, 2024 <sup>420</sup>                            | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Mongkolsucharitkul P , $2024^{421} \label{eq:proposed}$ | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |

| Laouani A, 2024 <sup>422</sup>          | Unclear risk           | Unclear risk    | Low risk          | Low risk     | Low risk | Low risk     | Low risk |
|---|------------------------|-----------------|-------------------|--------------|----------|--------------|----------|
| Khan G <sub>1</sub> 2024 <sup>423</sup> | I I a al a a u ui al a | I Imalaan niale | I In al con viole | Lourniale    | Unclear  | Unclear      | Unclear  |
| Kildii G, 2024                          | Unclear risk           | Unclear risk    | Unclear risk      | Low risk     | risk     | risk         | risk     |
| Diao Z, 2024 <sup>424</sup>             | Low risk               | Low risk        | Low risk          | Low risk     | Low risk | Low risk     | Low risk |
| López-Yerena A, 2023 <sup>425</sup>     | Low risk               | Low risk        | Low risk          | Low risk     | Low risk | Low risk     | Low risk |
| Aghabeiglooei Z, 2023 <sup>426</sup>    | Low risk               | Low risk        | Low risk          | Low risk     | Low risk | Low risk     | Low risk |
| Tricò D, 2024 <sup>427</sup>            | Low risk               | Low risk        | Low risk          | Low risk     | Low risk | Low risk     | Low risk |
| Lincoff AM, 2023428                     | Low risk               | Low risk        | Low risk          | Low risk     | Low risk | Low risk     | Low risk |
| Zhang X, 2023 <sup>429</sup>            | Low risk               | Low risk        | Low risk          | Low risk     | Low risk | Low risk     | Low risk |
| Luo Y, 2023 <sup>430</sup>              | Unclear risk           | Unclear risk    | Unclear risk      | Low risk     | Low risk | Low risk     | Low risk |
| Sordi AF, 2023 <sup>431</sup>           | Unclear risk           | Unclear risk    | Unclear risk      | I ozuz miole | Unclear  | I ozuz miole | Unclear  |
| 50101 AF, 2025                          | Officiear risk         | Unclear risk    | Unclear risk      | Low risk     | risk     | Low risk     | risk     |
| Carter S, 2023 <sup>432</sup>           | Low risk               | Low risk        | Low risk          | Low risk     | Low risk | Low risk     | Low risk |
| Clina JG, 2023 <sup>433</sup>           | Unclear risk           | Unclear risk    | Low risk          | Low risk     | Low risk | Low risk     | Low risk |
| Niu Y, 2023 <sup>434</sup>              | Low risk               | Unclear risk    | Low risk          | Low risk     | Low risk | Low risk     | Low risk |
| Grohmann T, 2023 <sup>435</sup>         | Low risk               | Low risk        | Low risk          | Low risk     | Low risk | Low risk     | Low risk |

| Sun L, 2023 <sup>436</sup>        | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
|-----------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Quaresma LS, 2023 <sup>437</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Aldubayan MA, 2023 <sup>438</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Cho E, 2023 <sup>439</sup>        | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Castaldo G, 2023 <sup>440</sup>   | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Unclear<br>risk |
| Ghalichi F, 2023441               | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Felipe LA, 2023 <sup>442</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Ragland TJ, 2023 <sup>443</sup>   | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Cai H, 2023 <sup>444</sup>        | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Turner-McGrievy GM , $2023^{445}$ | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Belany P, 2023 <sup>446</sup>     | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Gayathri R, 2023 <sup>447</sup>   | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |

| Cruvinel BAC, 2023 <sup>448</sup>        | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
|--|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Hassan RHA, 2023 <sup>449</sup>          | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Carvalho APSd, 2023 <sup>450</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Sohn M, 2023 <sup>451</sup>              | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Rondanelli M, 2022 <sup>452</sup>        | Low risk     | Low risk     | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| Rebello CJJ, 2022 <sup>453</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Xu R, 2022 <sup>454</sup>                | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Reis PCdSG, 2022 <sup>455</sup>          | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Colak D, 2022 <sup>456</sup>             | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Freer CL, 2022 <sup>457</sup>            | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Yin W, 2022 <sup>458</sup>               | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Coker MS, 2022 <sup>459</sup>            | Low risk     | Low risk     | Low risk     | Low risk | High risk       | Low risk        | Low risk        |
| Mohammadi-Sartang M, 2023 <sup>460</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Jamshed H, 2022 <sup>461</sup>           | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |

| Roach LA, 2022 <sup>462</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk |
|-------------------------------------|--------------|--------------|--------------|----------|----------|-----------------|----------|
| Kleinloog JPD, 2022 <sup>463</sup>  | Low risk     | Unclear risk | Low risk     | Low risk | Low risk | Low risk        | Low risk |
| Pavão TP, 2022 <sup>464</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk |
| Castela I, 2022 <sup>465</sup>      | Low risk     | Low risk     | Unclear risk | Low risk | Low risk | Low risk        | Low risk |
| Chekima K, 2022 <sup>466</sup>      | Low risk     | Unclear risk | Low risk     | Low risk | Low risk | Low risk        | Low risk |
| Cipryan L, 2022 <sup>467</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk |
| Ali Sangouni A, 2022 <sup>468</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk |
| Timmons JF, 2023 <sup>469</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk |
| Catley D, 2022 <sup>470</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk |
| Mendelson M, 2022 <sup>471</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk |
| Ruban A, 2022 <sup>472</sup>        | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk |
| Li Y, 2022 <sup>473</sup>           | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk |
| Vodouhè M, 2022 <sup>474</sup>      | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear  | Low risk        | Low risk |

|                                       |              |              |              |          | risk            |                 |          |
|---------------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|----------|
| Dimitrov Ulian M, 2022 <sup>475</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Viveros-Watty PE, 2022 <sup>476</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Chair SY, 2022 <sup>477</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Karandish M, 2022 <sup>478</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Lim SL, 2022 <sup>479</sup>           | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Thomsen MN, 2022 <sup>480</sup>       | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Seeberg KA, 2022 <sup>481</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Ruegsegger GN, 2022 <sup>482</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Unclear<br>risk | Low risk |
| Liu B, 2021 <sup>483</sup>            | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Cao JJ, 2021 <sup>484</sup>           | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Kang C, 2021 <sup>485</sup>           | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Che T, 2021 <sup>486</sup>            | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Miller L, 2021 <sup>487</sup>         | Unclear risk | Unclear risk | Low risk     | Low risk | High risk       | Low risk        | Low risk |

| Batrakoulis A, 2021 <sup>488</sup>        | Low risk     | Low risk     | Low risk     | Low risk | High risk       | Low risk        | Low risk |
|---|--------------|--------------|--------------|----------|-----------------|-----------------|----------|
| Chang WL, 2021 <sup>489</sup>             | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Serna A, 2022 <sup>490</sup>              | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Delgado-Floody P ,<br>2021 <sup>491</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Falkenhain K, 2021 <sup>492</sup>         | Unclear risk | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Said MA, 2021 <sup>493</sup>              | Low risk     | Low risk     | Low risk     | Low risk | Unclear<br>risk | Unclear<br>risk | Low risk |
| Ahmadniay Motlagh H, 2021 <sup>494</sup>  | Low risk     | Low risk     | Low risk     | Low risk | High risk       | Low risk        | Low risk |
| Te Morenga L, 2021 <sup>495</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Shikishima Y, 2021 <sup>496</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Liddle DM, 2021 <sup>497</sup>            | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Wang J, 2021 <sup>498</sup>               | Low risk     | Low risk     | Low risk     | Low risk | High risk       | Low risk        | Low risk |
| Grytten E, 2021 <sup>499</sup>            | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |

| Schroor MM, 2021 <sup>500</sup>      | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk        | Low risk |
|--------------------------------------|--------------|--------------|----------|----------|-----------------|-----------------|----------|
| Bhoite R, 2021 <sup>501</sup>        | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk        | Low risk |
| van der Merwe M, 2021 <sup>502</sup> | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk        | Low risk |
| Waliłko E, 2021 <sup>503</sup>       | Unclear risk | Unclear risk | Low risk | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Ng SC, 2022 <sup>504</sup>           | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        | Low risk |
| do Rosario VA, 2021 <sup>505</sup>   | Low risk     | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Amaro-Gahete FJ, 2021 <sup>506</sup> | Low risk     | Unclear risk | Low risk | Low risk | Unclear<br>risk | Unclear<br>risk | Low risk |
| Kim KW, 2021 <sup>507</sup>          | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        | Low risk |
| Jiang W, 2021 <sup>508</sup>         | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Low risk        | Low risk |
| D'Amuri A, 2021 <sup>509</sup>       | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Yılmaz SK, 2021 <sup>510</sup>       | Low risk     | Low risk     | Low risk | Low risk | Low risk        | Unclear<br>risk | Low risk |

| Barnard ND, 2022 <sup>511</sup>        | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk |
|--|--------------|--------------|--------------|----------|-----------------|-----------------|----------|
| Netto Cândido TL , 2021 <sup>512</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Abbott K, 2020 <sup>513</sup>          | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Kruschitz R, 2020 <sup>514</sup>       | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Kahleova H, 2020 <sup>515</sup>        | Low risk     | Low risk     | Low risk     | Low risk | High risk       | Low risk        | Low risk |
| Cheshmazar E, 2020 <sup>516</sup>      | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Bove KB, 2020 <sup>517</sup>           | Low risk     | Low risk     | Low risk     | Low risk | High risk       | Low risk        | Low risk |
| de Ligt M, 2020 <sup>518</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Bratlie M, 2021 <sup>519</sup>         | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Klomklorm A, 2020 <sup>520</sup>       | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Unclear<br>risk | Low risk |
| Li L, 2020 <sup>521</sup>              | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Cienfuegos S, 2020 <sup>522</sup>      | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk |

| Jamar G, 2020 <sup>523</sup>           | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
|--|--------------|--------------|--------------|----------|-----------|-----------------|----------|
| Goss AM, 2020 <sup>524</sup>           | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Jafari-Maskouni S, 2020 <sup>525</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Takagi T, 2020 <sup>526</sup>          | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Remie CME, 2020 <sup>527</sup>         | Low risk     | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Joris PJ, 2020 <sup>528</sup>          | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Smeets E, 2021 <sup>529</sup>          | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Campa F, 2020 <sup>530</sup>           | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Reimer RA, 2020 <sup>531</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Rock CL, 2020 <sup>532</sup>           | Unclear risk | Unclear risk | Unclear risk | Low risk | High risk | Low risk        | Low risk |
| Vors C, 2020 <sup>533</sup>            | Low risk     | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| Lopez HL, 2020 <sup>534</sup>          | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Low risk        | Low risk |
| AlFaris NA, 2020 <sup>535</sup>        | Low risk     | Low risk     | Unclear risk | Low risk | Low risk  | Unclear<br>risk | Low risk |
| Chow LS, 2020 <sup>536</sup>           | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk  | Low risk        | Low risk |
| Marco-Benedí V, 2020 <sup>537</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk |

| Lin X, 2020 <sup>538</sup>           | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
|--------------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Lorkowski SW, 2020 <sup>539</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk        | Unclear<br>risk |
| Tsintzas K, 2020 <sup>540</sup>      | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Dolati S, 2020 <sup>541</sup>        | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Edinburgh RM, 2020 <sup>542</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Asgary S, 2020 <sup>543</sup>        | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Perissiou M, 2020 <sup>544</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Kuo YC, 2020 <sup>545</sup>          | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Unclear<br>risk |
| Nishimura M, 2020 <sup>546</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Gajewska D, 2019 <sup>547</sup>      | Low risk     | Unclear risk | Unclear risk | Low risk | High risk       | Unclear<br>risk | Low risk        |
| Karimi-Nazari E, 2019 <sup>548</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Tanaka Y, 2020 <sup>549</sup>        | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Mollentze WF, 2019 <sup>550</sup>    | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |

| Chiang TL, 2019 <sup>551</sup>     | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk | Low risk |
|------------------------------------|--------------|--------------|--------------|----------|-----------------|----------|----------|
| Kraus WE, 2019 <sup>552</sup>      | Low risk     | Low risk     | Low risk     | Low risk | High risk       | Low risk | Low risk |
| Malik VS, 2019 <sup>553</sup>      | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk | Low risk |
| Aghasi M, 2019 <sup>554</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk | Low risk |
| Hirsh SP, 2019 <sup>555</sup>      | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk | Low risk |
| Byrne CS, 2019 <sup>556</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk | Low risk |
| Taylor PJ, 2019 <sup>557</sup>     | Low risk     | High risk    | Low risk     | Low risk | Low risk        | Low risk | Low risk |
| Nunes PRP, 2019 <sup>558</sup>     | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk | Low risk |
| Ejtahed HS, 2019 <sup>559</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk | Low risk |
| Schroeder EC, 2019 <sup>560</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk | Low risk |
| Rynarzewski J, 2019 <sup>561</sup> | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk | Low risk |
| Otten J, 2019 <sup>562</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk | Low risk |
| Aliashrafi S, 2019 <sup>563</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk | Low risk |
| Ballin M, 2019 <sup>564</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk | Low risk |
| de Souza RGM, 2018 <sup>565</sup>  | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk | Low risk |

| Amozadeh H, 2018 <sup>566</sup>           | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Low risk |
|---|--------------|--------------|--------------|----------|-----------------|-----------------|----------|
| Galvão Cândido F ,<br>2018 <sup>567</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Zapata-Lamana R, 2018 <sup>568</sup>      | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk |
| Dollerup OL, 2018 <sup>569</sup>          | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| González-Sarrías A , $2018^{570}$         | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Kim J, 2018 <sup>571</sup>                | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Berk KA, 2018 <sup>572</sup>              | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Madjd A, 2018 <sup>573</sup>              | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Khezri SS, 2018 <sup>574</sup>            | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Engel S, 2018 <sup>575</sup>              | Unclear risk | Unclear risk | High risk    | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Bendtsen LQ, 2018 <sup>576</sup>          | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk |
| Jaacks LM, 2018 <sup>577</sup>            | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Kempf K, 2018 <sup>578</sup>              | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |

| Mraovic T, 2018 <sup>579</sup>                | Low risk        | Unclear risk | Unclear risk | Low risk | Unclear  | Unclear  | Low risk |
|---|-----------------|--------------|--------------|----------|----------|----------|----------|
| *   |                 |              |              |          | risk     | risk     |          |
| Saito S, 2017 <sup>580</sup>                  | Low risk        | Low risk     | Low risk     | Low risk | Low risk | Low risk | Low risk |
| Aoe S, 2017 <sup>581</sup>                    | TTo also models | TT11-        | T:-1-        | T: 1-1-  | Unclear  | T: -1.   | T:-1-    |
| A0e 3, 2017                                   | Unclear risk    | Unclear risk | Low risk     | Low risk | risk     | Low risk | Low risk |
| Gokulakrishnan K ,                            | TT 1 · 1        | TT 1 · 1     | т 1          | т • 1    | Unclear  | т • 1    | т • 1    |
| 2017 <sup>582</sup>                           | Unclear risk    | Unclear risk | Low risk     | Low risk | risk     | Low risk | Low risk |
| Mousa A, 2017 <sup>583</sup>                  | Low risk        | Low risk     | Low risk     | Low risk | Low risk | Low risk | Low risk |
|   |                 |              |              |          |          |          |          |
| Saslow LR, 2017 <sup>584</sup>                | Low risk        | Low risk     | Low risk     | Low risk | Low risk | Low risk | Low risk |
| Schauer PR, 2017 <sup>585</sup>               | Unclear risk    | Unclear risk | Low risk     | Low risk | Low risk | Low risk | Low risk |
| D 44 N 2017586                                |                 | 1            |              |          | Unclear  |          |          |
| Paquette M <sub>1</sub> , 2017 <sup>586</sup> | Unclear risk    | Unclear risk | Low risk     | Low risk | risk     | Low risk | Low risk |
| Taghizadeh M, 2017 <sup>587</sup>             | Low risk        | Low risk     | Low risk     | Low risk | Low risk | Low risk | Low risk |
| Melchart D, 2017 <sup>588</sup>               | Low risk        | Low risk     | Low risk     | Low risk | Low risk | Low risk | Low risk |
| Blædel T, 2016 <sup>589</sup>                 | Low risk        | Low risk     | Low risk     | Low risk | Low risk | Low risk | Low risk |
| Alqurashi RM, 2016 <sup>590</sup>             | Low risk        | Low risk     | Low risk     | Low risk | Low risk | Low risk | Low risk |

| O'Neil PM, 2016 <sup>591</sup>   | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
|----------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Kim H, 2016 <sup>592</sup>       | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Tovar J, 2016 <sup>593</sup>     | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Madjd A, 2016 <sup>594</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Li X, 2016 <sup>595</sup>        | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Jamal SN, 2016 <sup>596</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Wolf E, 2016 <sup>597</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Kong Z, 2016 <sup>598</sup>      | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Most J, 2016 <sup>599</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Welsh P, 2016 <sup>600</sup>     | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Järvi A, 2016 <sup>601</sup>     | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Weiland A, 2016 <sup>602</sup>   | Low risk     | Low risk     | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| Dejgaard TF, 2016 <sup>603</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |

|                                    |          |              |          |          |                 | Unclear         |          |
|------------------------------------|----------|--------------|----------|----------|-----------------|-----------------|----------|
| Higashikawa F, 2016 <sup>604</sup> | Low risk | Low risk     | Low risk | Low risk | Low risk        | risk            | Low risk |
| Nelson K, 2016 <sup>605</sup>      | Low risk | Low risk     | Low risk | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Madjd A, 2016 <sup>606</sup>       | Low risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        | Low risk |
| Madjd A, 2015 <sup>607</sup>       | Low risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        | Low risk |
| Rebello CJ, 2015 <sup>608</sup>    | Low risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        | Low risk |
| Perez A, 2015 <sup>609</sup>       | Low risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        | Low risk |
| Tapsell LC, 2015 <sup>610</sup>    | Low risk | Low risk     | Low risk | Low risk | Low risk        | Low risk        | Low risk |
| Tripkovic L, 2015 <sup>611</sup>   | Low risk | Low risk     | Low risk | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Chambers ES, 2015 <sup>612</sup>   | Low risk | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Liu Y, 2015 <sup>613</sup>         | Low risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk        | Low risk |
| Mingrone G, 2015 <sup>614</sup>    | Low risk | Unclear risk | Low risk | Low risk | Low risk        | Low risk        | Low risk |
| Davinelli S, 2015 <sup>615</sup>   | Low risk | Low risk     | Low risk | Low risk | Low risk        | Unclear         | Low risk |

|   |              |              |              |          |                 | risk            |                 |
|---|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Shlisky JD, 2015 <sup>616</sup>           | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Hu T, 2015 <sup>617</sup>                 | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| de Barros F, 2015 <sup>618</sup>          | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Austel A, 2015 <sup>619</sup>             | Low risk     | Low risk     | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Ding SA, 2015 <sup>620</sup>              | Low risk     | Unclear risk | Unclear risk | Low risk | High risk       | Low risk        | Low risk        |
| McEvoy CT, 2015 <sup>621</sup>            | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Unclear<br>risk |
| Hosseinpour-Niazi S , 2015 <sup>622</sup> | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Mirtaheri E, 2015 <sup>623</sup>          | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Stonehouse W, 2015 <sup>624</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Nowotny B, 2015 <sup>625</sup>            | Low risk     | Low risk     | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Ivey KL, 2015 <sup>626</sup>              | Low risk     | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk        |

| Taghizadeh M, 2015 <sup>627</sup>  | Low risk       | Low risk       | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
|------------------------------------|----------------|----------------|--------------|----------|-----------------|-----------------|----------|
| Nickols-Richardson SM,             | Unclear risk   | Unclear risk   | Unclear risk | Low risk | Low risk        | Unclear         | Low risk |
| 2014 <sup>628</sup>                | Officieal fisk | Officieal fisk | Ulicleal HSK | LOW 115K | LOW 115K        | risk            | LOW 115K |
| Zare R, 2014 <sup>629</sup>        | Low risk       | Low risk       | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Sousa N, 2014 <sup>630</sup>       | Unclear risk   | Unclear risk   | Unclear risk | Low risk | Low risk        | Low risk        | Low risk |
| Hernández-Cordero S , $2014^{631}$ | Low risk       | Unclear risk   | High risk    | Low risk | High risk       | Low risk        | Low risk |
| Schwander F, 2014 <sup>632</sup>   | Low risk       | Unclear risk   | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Halperin F, 2014 <sup>633</sup>    | Low risk       | Unclear risk   | Unclear risk | Low risk | Low risk        | Low risk        | Low risk |
| Choi MS, 2014 <sup>634</sup>       | Unclear risk   | Unclear risk   | Low risk     | Low risk | Unclear<br>risk | Unclear<br>risk | Low risk |
| Bozzetto L, 2014 <sup>635</sup>    | Low risk       | Unclear risk   | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Lin PH, 2014 <sup>636</sup>        | Low risk       | Unclear risk   | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Geliebter A, 2014 <sup>637</sup>   | Low risk       | Unclear risk   | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk |

| Rondanelli M, 2014 <sup>638</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
|-----------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|----------|
| Liu X, 2013 <sup>639</sup>        | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk |
| Kashyap SR, 2013 <sup>640</sup>   | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Mishra S, 2013 <sup>641</sup>     | Low risk     | Low risk     | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Liang Z, 2013 <sup>642</sup>      | Low risk     | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Munro IA, 2013 <sup>643</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| de Bock M, 2013 <sup>644</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Cho SH, 2013 <sup>645</sup>       | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Azadbakht L, 2013 <sup>646</sup>  | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Salehpour A, 2012 <sup>647</sup>  | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Buchowski MS, 2012 <sup>648</sup> | Unclear risk | Low risk     | Unclear risk | Low risk | Low risk        | Low risk        | Low risk |
| Munro IA, 2012 <sup>649</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |

| Thies F, 2012 <sup>650</sup>              | Unclear risk | Unclear risk | Low risk     | Low risk | High risk       | Low risk        | Low risk        |
|---|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Rizkalla SW, 2012 <sup>651</sup>          | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| Tovar J, 2012 <sup>652</sup>              | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Taniguchi-Fukatsu A , 2012 <sup>653</sup> | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Unclear<br>risk | Low risk        |
| Krebs JD, 2012 <sup>654</sup>             | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Gargari BP, 2011 <sup>655</sup>           | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| Fidler MC, 2011 <sup>656</sup>            | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Khoo J, 2011 <sup>657</sup>               | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Derosa G, 2011 <sup>658</sup>             | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Søvik TT, 2011 <sup>659</sup>             | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |

| Shah M, 2011 <sup>660</sup>        | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Low risk | Unclear<br>risk | Low risk |
|------------------------------------|----------------|----------------|----------------|----------|----------|-----------------|----------|
| Tanaka T, 2011 <sup>661</sup>      | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Unclear  | Unclear         | Unclear  |
| Turum 1, 2011                      | Officient 115K | Officical 113K | Officient fish | LOW 113K | risk     | risk            | risk     |
| Te Morenga LA, 2011 <sup>662</sup> | Low risk       | Low risk       | Low risk       | Low risk | Low risk | Unclear         | Low risk |
| 10 1/1010116u 211, <b>2</b> 011    | LOW 113K       | LOW HISK       | LOW 113K       | LOW 113K | LOW 113K | risk            | LOW 113K |
| Cho JK, 2011 <sup>663</sup>        | Low risk       | Low risk       | Low risk       | Low risk | Low risk | Unclear         | Low risk |
| Cho jix, 2011                      | LOW 115K       | LOW 115K       | LOW 115K       | LOW 115K | LOW 115K | risk            | LOW 115K |
| Kreider RB, 2011 <sup>664</sup>    | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Unclear  | Unclear         | Unclear  |
| Richael RD, 2011                   | Officieal fisk | Ulicleal lisk  | Officieal fisk | LOW 115K | risk     | risk            | risk     |
| Harvie MN, 2011 <sup>665</sup>     | unclear risk   | Unclear risk   | Low risk       | Low risk | Low risk | Unclear         | Low risk |
| Tiaivie wiiv, 2011                 | unclear risk   | Unclear risk   | LOW IISK       | LOW 11SK | LOW HSK  | risk            | LOW 11SK |
| Njike VY, 2011 <sup>666</sup>      | Low risk       | Low risk       | Low risk       | Low risk | Low risk | Unclear         | Low risk |
| 191Re V 1, 2011                    | LOW IISK       | LOW 115K       | LOW 115K       | LOW 115K | LOW 115K | risk            | LOW 115K |
| Choquette S <sub>2011667</sub>     | Unclear risk   | Unclear risk   | Low risk       | Low risk | Unclear  | I ozuz miole    | Low risk |
| Choquette 5, 2011                  | Officiear risk | Unclear risk   | LOW IISK       | LOW IISK | risk     | Low risk        | LOW FISK |
| Larsen RN, 2011 <sup>668</sup>     | Low risk       | Low risk       | Low risk       | Low risk | Low risk | Low risk        | Low risk |

| Frank I, 2011 <sup>669</sup>          | Unclear risk   | Unclear risk   | Uiah miak      | Low risk | Unclear  | Unclear  | Unclear  |
|---------------------------------------|----------------|----------------|----------------|----------|----------|----------|----------|
| Trank 1, 2011                         | Unclear risk   | Unclear risk   | High risk      | LOW IISK | risk     | risk     | risk     |
| Llaneza P, 2011 <sup>670</sup>        | Low risk       | Low risk       | Low risk       | Low risk | Unclear  | Unclear  | Low risk |
| Elancza I , 2011                      | LOW 115K       | LOW 115K       | LOW 115K       | LOW 115K | risk     | risk     | LOW 115K |
| DeFina LF, 2011 <sup>671</sup>        | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Low risk | Unclear  | Low risk |
| Dernia Er, 2011                       | Officical 115K | Officical 113K | Officieal fisk | LOW 115K | LOW 113K | risk     | LOW 115K |
| Sieverdes JC, 2011 <sup>672</sup>     | Low risk       | Low risk       | Low risk       | Low risk | Low risk | Low risk | Low risk |
| Raben A, 2011 <sup>673</sup>          | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Unclear  | Unclear  | Unclear  |
| Rabell II, 2011                       | Officieal fisk | Officieal fisk | Ulicleal HSK   | LOW 115K | risk     | risk     | risk     |
| Bladbjerg EM, 2010 <sup>674</sup>     | Low risk       | Low risk       | Low risk       | Low risk | Unclear  | Low risk | Low risk |
| bladejerg Elvi, 2010                  | LOW 113K       | LOW 115K       | LOW 115K       | LOW 115K | risk     | LOW 115K | LOW 115K |
| Li S, 2010 <sup>675</sup>             | Low risk       | Low risk       | Low risk       | Low risk | Low risk | Low risk | Low risk |
| Ilanne-Parikka P, 2010 <sup>676</sup> | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Unclear  | Low risk | Low risk |
| namic-rankar, 2010                    | Officieal fisk | Officieal fisk | Ulicleal HSK   | LOW 115K | risk     | LOW 115K | LOW 115K |
| Beck EJ, 2010 <sup>677</sup>          | Low risk       | Unclear risk   | Low risk       | Low risk | Low risk | Low risk | Low risk |
| Hodgson JM, 2010 <sup>678</sup>       | Low risk       | Unclear risk   | Low risk       | Low risk | Low risk | Low risk | Low risk |
| Michishita T, 2010 <sup>679</sup>     | Unclear risk   | Unclear risk   | Low risk       | Low risk | Low risk | Unclear  | Low risk |

|                                      |              |              |              |          |                 | risk            |          |
|--------------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|----------|
| Blumenthal JA, 2010 <sup>680</sup>   | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Larson-Meyer DE, 2010 <sup>681</sup> | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Elhayany A, 2010 <sup>682</sup>      | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk |
| Sluijs I, 2010 <sup>683</sup>        | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Rizvi ZA, 2024 <sup>684</sup>        | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Horváth J, 2024 <sup>685</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Nemati M, 2024 <sup>686</sup>        | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Low risk        | Low risk |
| AlMalki SM, 2024 <sup>687</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Suder A, 2024 <sup>688</sup>         | Unclear risk | Low risk     | High risk    | Low risk | Unclear<br>risk | Low risk        | Low risk |
| Amiri P, 2024 <sup>689</sup>         | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Rodrigo-Carbó C, 2024 <sup>690</sup> | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Stockton MB, 2024 <sup>691</sup>     | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk |

| Mana V 2024692                     | T ::-1.          | Т:-1.                  | T:t-1-       | T:-1-       | T: -1.   | T!-1-    | T: -1-      |
|------------------------------------|------------------|------------------------|--------------|-------------|----------|----------|-------------|
| Wang Y, 2024 <sup>692</sup>        | Low risk         | Low risk               | Low risk     | Low risk    | Low risk | Low risk | Low risk    |
| Ostadrahimi A, 2024 <sup>693</sup> | Low risk         | Unclear risk           | Low risk     | Low risk    | Low risk | Low risk | Low risk    |
| Turner-McGrievy GM,                |                  |                        |              |             | Unclear  | Unclear  | Unclear     |
| 2024 <sup>694</sup>                | Unclear risk     | Unclear risk           | Unclear risk | Low risk    | risk     | risk     | risk        |
| Delfan M, 2024 <sup>695</sup>      | I In along whole | I I a al a a u ui al e | I assaulate  | I are viale | T a      | Unclear  | I arm wiele |
| Delian Wi, 2024                    | Unclear risk     | Unclear risk           | Low risk     | Low risk    | Low risk | risk     | Low risk    |
| D A 2024696                        | TT 1 · 1         | TT 1 · 1               | TT 1 · 1     | т • 1       | Unclear  | т • 1    | т • 1       |
| Pammer A, 2024 <sup>696</sup>      | Unclear risk     | Unclear risk           | Unclear risk | Low risk    | risk     | Low risk | Low risk    |
| D V 2024697                        |                  | TT 1 . 1               | TT 1 . 1     | <b>.</b>    |          | Unclear  | T . 1       |
| Duan Y, 2024 <sup>697</sup>        | Low risk         | Unclear risk           | Unclear risk | Low risk    | Low risk | risk     | Low risk    |
| D 11 1.C 2000608                   | 1                | 1 · 1                  |              |             |          | Unclear  |             |
| Rolland C, 2009 <sup>698</sup>     | Unclear risk     | Unclear risk           | Unclear risk | Low risk    | Low risk | risk     | Low risk    |
| E 1 CD 2000699                     |                  | T 1                    | TT 1 . 1     | <b>.</b>    | Unclear  | Unclear  | T . 1       |
| Foster GD, 2009 <sup>699</sup>     | Low risk         | Low risk               | Unclear risk | Low risk    | risk     | risk     | Low risk    |
| Tac: Ch II 2000700                 | TT 1 · 1         | TT 1 . 1               | TT 1 . 1     | т • 1       | т • 1    | Unclear  | т • 1       |
| Tsai Ch H, 2009 <sup>700</sup>     | Unclear risk     | Unclear risk           | Unclear risk | Low risk    | Low risk | risk     | Low risk    |
| E (1 A 2000 <sup>701</sup>         |                  | TT 1 . 1               |              | <b>.</b>    |          | Unclear  | T . 1       |
| Fontbonne A, 2009 <sup>701</sup>   | Unclear risk     | Unclear risk           | Low risk     | Low risk    | Low risk | risk     | Low risk    |

| Shikany JM, 2009 <sup>702</sup>   | Unclear risk | Unclear risk | Low risk     | Low risk   | Low risk   | Unclear  | Low risk  |
|-----------------------------------|--------------|--------------|--------------|------------|------------|----------|-----------|
| ·· , , · , ====                   |              | Cherent Hor  | 2011 110K    | 20 1101    | 2011010    | risk     | 20111010  |
| Frisch S, 2009 <sup>703</sup>     | Low risk     | Unclear risk | Unclear risk | Low risk   | Low risk   | Low risk | Low risk  |
| N: DC 2000 <sup>704</sup>         | 1            | ** 1 · · ·   |              |            |            | Unclear  | ·         |
| Nieman DC, 2009 <sup>704</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk   | Low risk   | risk     | Low risk  |
| 1: 147/ 2000705                   |              | ** 1 · · ·   | TT 1 . 1     |            | Unclear    | Unclear  |           |
| Lin WY, 2009 <sup>705</sup>       | Low risk     | Unclear risk | Unclear risk | Low risk   | risk       | risk     | Low risk  |
| A 1. DI 2000 <sup>706</sup>       |              | TT 1 . 1     | TT 1 . 1     | <b>.</b>   | Unclear    | Unclear  | Unclear   |
| Arsenault BJ, 2009 <sup>706</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk   | risk       | risk     | risk      |
| D 1 M 2000707                     | 1            | ** 1 · · ·   | TT 1 . 1     |            | Unclear    | Unclear  | Unclear   |
| Brochu M, 2009 <sup>707</sup>     | Unclear risk | Unclear risk | Unclear risk | k Low risk | risk       | risk     | risk      |
| Aasheim ET, 2009 <sup>708</sup>   | Low risk     | Unclear risk | Low risk     | Low risk   | Low risk   | Low risk | Low risk  |
|                                   |              |              |              |            | Unclear    | Unclear  |           |
| Assunção ML, 2009 <sup>709</sup>  | Unclear risk | Unclear risk | Low risk     | Low risk   | risk       | risk     | Low risk  |
|                                   |              |              |              |            | 11010      | Unclear  |           |
| Shah K, 2009 <sup>710</sup>       | Low risk     | Unclear risk | Low risk     | Low risk   | Low risk   |          | Low risk  |
|                                   |              |              |              |            |            | risk     |           |
| Davis NJ, 2009 <sup>711</sup>     | Low risk     | Low risk     | Low risk     | Low risk   | Low risk   | Unclear  | Low risk  |
| Davis Nj., 2007                   | 2011 11010   | LUW IISK     | LOW 115K     | LOW 115K   | . LOW 115K | risk     | 2011 1101 |

| Sacks FM, 2009 <sup>712</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
|----------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Digenio AG, 2009 <sup>713</sup>  | Low risk     | Unclear risk | Low risk     | Low risk | Low risk        | Low risk        | Low risk        |
| Kirk E, 2009 <sup>714</sup>      | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Hursel R, 2009 <sup>715</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Andersson K, 2009 <sup>716</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Layman DK, 2009 <sup>717</sup>   | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Kim JY, 2008 <sup>718</sup>      | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Unclear<br>risk |
| Lasker DA, 2008 <sup>719</sup>   | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| St-Onge MP, 2008 <sup>720</sup>  | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Hibi M, 2008 <sup>721</sup>      | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |

| Treyzon L, 2008 <sup>722</sup>    | Low risk       | Unclear risk   | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk |
|-----------------------------------|----------------|----------------|--------------|----------|----------|-----------------|----------|
| Volpe SL, 2008 <sup>723</sup>     | Unclear risk   | Unclear risk   | Unclear risk | Low risk | Unclear  | Unclear         | Unclear  |
| voipe 31, 2000                    | Officieal fisk | Ulicieal lisk  | Ulicleal HSK | LOW 115K | risk     | risk            | risk     |
| Morgan LM, 2009 <sup>724</sup>    | Unclear risk   | Unclear risk   | Unclear risk | Low risk | Unclear  | Unclear         | Unclear  |
| Worgan Livi, 2007                 | Officieal fisk | Unclear risk   | Unclear risk | LOW 11SK | risk     | risk            | risk     |
| Lindqvist HM, 2009 <sup>725</sup> | Unclear risk   | Unclear risk   | Low risk     | Low risk | Low risk | Unclear         | Low risk |
| Emaqvist Tilvi, 2007              | Officieal fisk | Ulicieal fisk  | LOW 115K     | LOW 115K | LOW 115K | risk            | LOW 115K |
| Shai I, 2008 <sup>726</sup>       | Low risk       | Unclear risk   | Unclear risk | Low risk | Low risk | Unclear         | Low risk |
| 51tai 1, 2000                     | LOW 115K       | Ulicieal fisk  | Ulicleal HSK | LOW 115K | LOW 115K | risk            | LOW 115K |
| Nakou E, 2008 <sup>727</sup>      | Unclear risk   | Unclear risk   | Low risk     | Low risk | Low risk | Unclear         | Low risk |
| Nakou E, 2000                     | Officieal fisk | Officieal fisk | LOW 115K     | LOW 115K | LOW 115K | risk            | LOW 115K |
| Pierce GL, 2008 <sup>728</sup>    | Unclear risk   | Unclear risk   | Low risk     | Low risk | Unclear  | Unclear         | Low risk |
| TICICC GL, 2000                   | Officieal fisk | Officieal fisk | LOW 115K     | LOW 115K | risk     | risk            | LOW 115K |
| Miyashita M, 2008 <sup>729</sup>  | Unclear risk   | Unclear risk   | Unclear risk | Low risk | Unclear  | Unclear         | Unclear  |
| 1v11y a3111ta 1v1, 2000           | Officieal fisk | Officieal fisk | Ulicleal HSK | LOW 115K | risk     | risk            | risk     |
| Arciero PJ, 2008 <sup>730</sup>   | Unclear risk   | Unclear risk   | Low risk     | Low risk | Low risk | Unclear         | Low risk |
| 7 HCICIO 1 J., 2000               | Officieal 115K | Officieal fisk | LUW 115K     | LOW 115K | LOW 115K | risk            | LUW 115K |

| Wycherley TP, 2008 <sup>731</sup>    | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Low risk        | Unclear         | Low risk |
|--------------------------------------|----------------|----------------|----------------|----------|-----------------|-----------------|----------|
| Lockwood CM. 2008 <sup>732</sup>     | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Unclear         | risk<br>Unclear | Unclear  |
| Eccawood Civi, 2000                  | Officieal 115K | Officieal fisk | Officieal fisk | LOW 115K | risk            | risk            | risk     |
| Larson-Meyer DE, 2008 <sup>733</sup> | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Low risk        | Low risk        | Low risk |
| Schjerve IE, 2008 <sup>734</sup>     | Unclear risk   | Unclear risk   | Low risk       | Low risk | Unclear<br>risk | Unclear<br>risk | Low risk |
| König D, 2008 <sup>735</sup>         | Low risk       | Low risk       | Unclear risk   | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Borges RL, 2007 <sup>736</sup>       | Unclear risk   | Unclear risk   | Low risk       | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Mutungi G, 2008 <sup>737</sup>       | Low risk       | Low risk       | Low risk       | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Jensen L, 2008 <sup>738</sup>        | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Low risk        | Low risk        | Low risk |
| Salas-Salvadó J, 2008 <sup>739</sup> | Low risk       | Low risk       | Low risk       | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Burton FL, 2008 <sup>740</sup>       | Unclear risk   | Unclear risk   | Low risk       | Low risk | Low risk        | Unclear<br>risk | Low risk |

| Karandish M, 2009 <sup>741</sup>    | Unclear risk             | Unclear risk   | Low risk       | Low risk | Unclear     | Unclear  | Low risk |
|-------------------------------------|--------------------------|----------------|----------------|----------|-------------|----------|----------|
| ratatation ivi, 2009                | Officient fisk           | Officical 113K | LOW 113K       | LOW 115K | risk        | risk     | LOW 115K |
| Burke LE, 2007 <sup>742</sup>       | Low risk                 | Low risk       | Low risk       | Low risk | Low risk    | Low risk | Low risk |
| Bertéus Forslund H ,                | Low risk                 | Low risk       | Low risk       | Low risk | Low risk    | Unclear  | Low risk |
| $2008^{743}$                        | LOW 115K                 | LOW 115K       | LOW 115K       | LOW 115K | LOW 115K    | risk     | LOW 115K |
| Meckling KA, 2007 <sup>744</sup>    | Unclear risk             | Unclear risk   | High risk      | Low risk | High risk   | Unclear  | Low risk |
| Wiceking Ref., 2007                 | Officieal 115K           | Officical 113K | riigh risk     | LOW 115K | Hightiisk   | risk     | LOW 115K |
| de Rougemont A, 2007 <sup>745</sup> | Unclear risk             | Unclear risk   | Unclear risk   | Low risk | Unclear     | Unclear  | Unclear  |
| de Rougemont 11, 2007               | <b>U</b> 1.0100011 11011 |                | Officieal fish | LOW 113K | risk        | risk     | risk     |
| Liao FH, 2007 <sup>746</sup>        | Unclear risk             | Unclear risk   | Unclear risk   | Low risk | Low risk    | Unclear  | Low risk |
| 2007                                | Official flox            | Officient flow | Official fish  | Zow How  | 26 11 11011 | risk     | LOW HOR  |
| Rave K, 2007 <sup>747</sup>         | Unclear risk             | Unclear risk   | Low risk       | Low risk | Low risk    | Unclear  | Low risk |
| ,                                   | Chercul Han              | Official fish  | Zow How        | 20111311 | 2011131     | risk     | Zevi Her |
| Sahin M, 2007 <sup>748</sup>        | Unclear risk             | Unclear risk   | Low risk       | Low risk | Low risk    | Unclear  | Low risk |
| ,                                   | <del></del>              |                |                |          |             | risk     |          |
| Thomas TR, 2007 <sup>749</sup>      | Unclear risk             | Unclear risk   | Low risk       | Low risk | Low risk    | Unclear  | Low risk |
| ,                                   | Official fish            |                | LOW HOR        | LOW 115K | A LOW HOR   | risk     |          |
| Ebbeling CB, 2007 <sup>750</sup>    | Low risk                 | Low risk       | Low risk       | Low risk | Low risk    | Low risk | Low risk |

| Steck SE, 2007 <sup>751</sup>            | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
|--|--------------|--------------|--------------|----------|-----------------|-----------------|----------|
| Rock CL, 2007 <sup>752</sup>             | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Brunerova L, 2007 <sup>753</sup>         | Unclear risk | Unclear risk | High risk    | Low risk | Unclear<br>risk | Unclear<br>risk | Low risk |
| Maki KC, 2007 <sup>754</sup>             | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Gardner CD, 2007 <sup>755</sup>          | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Low risk        | Low risk |
| Lindqvist H, 2007 <sup>756</sup>         | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Aubertin-Leheudre M, 2007 <sup>757</sup> | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Major GC, 2007 <sup>758</sup>            | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Vincent HK, 2006 <sup>759</sup>          | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk |
| Bougoulia M, 2006 <sup>760</sup>         | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear         | Unclear         | Unclear  |

|                                   |              |              |              |          | risk            | risk            | risk            |
|-----------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Wood RJ, 2007 <sup>761</sup>      | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Burke LE, 2006 <sup>762</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Vincent HK, 2006 <sup>763</sup>   | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Low risk        |
| McLaughlin T, 2006 <sup>764</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Anderson JW, 2006 <sup>765</sup>  | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Fenkci S, 2006 <sup>766</sup>     | Unclear risk | unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Kuo CS, 2006 <sup>767</sup>       | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Nestel P, 2007 <sup>768</sup>     | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Satoh N, 2006 <sup>769</sup>      | Unclear risk | Unclear risk | Low risk     | Low risk | Unclear         | Unclear         | Low risk        |

|                                   |   |                         |                                  |            | risk       | risk    |          |  |
|-----------------------------------|---|-------------------------|----------------------------------|------------|------------|---------|----------|--|
| Turker I, 2006 <sup>770</sup>     | Unclear risk                                  | Unclear risk            | Unclear risk                     | Low risk   | Low risk   | Unclear | Unclear  |  |
| ,                                 |   | <b>C</b> 11010011 11011 | <b>C</b> 11010 <b>0</b> 11 11011 | 2011 11011 | 2011 11011 | risk    | risk     |  |
| Ahn CW, 2006 <sup>771</sup>       | Unclear risk                                  | Unclear risk            | Low risk                         | Low risk   | Unclear    | Unclear | Low risk |  |
| Aim CW, 2000                      | Officieal fisk                                | Unclear risk            | LOW 11SK                         | LOW 11SK   | risk       | risk    | LOW 115K |  |
| Hackman RM, 2006 <sup>772</sup>   | Low risk                                      | Low risk                | Low risk                         | Low risk   | Low risk   | Unclear | Low risk |  |
| Trackman Rivi, 2000               | LOW 115K                                      | LOW 115K                | LOW 115K                         | LOW 115K   | LOW 115K   | risk    | LOW 115K |  |
| Krebs JD, 2006 <sup>773</sup>     | Unclear risk                                  | Unclear risk            | Low risk                         | Low risk   | Low risk   | Unclear | Low risk |  |
| Kiebs JD, 2000                    | Official fish Conclear fish Low fish Low fish | LOW 11SK                | risk                             | LOW HSK    |            |         |          |  |
| Wood RJ, 2006 <sup>774</sup>      | Unclear risk                                  | Unclear risk            | Low risk                         | Low risk   | Unclear    | Unclear | Low risk |  |
| Wood NJ, 2000                     | Officieal fisk                                | Unclear risk            | LOW 11SK                         | LOW 11SK   | risk       | risk    | LOW TISK |  |
| Löfgren P, 2005 <sup>775</sup>    | Unclear risk                                  | Unclear risk            | Unclear risk                     | Low risk   | Unclear    | Unclear | Unclear  |  |
| Loigich 1, 2005                   | Officieal fisk                                | Ulicleal fisk           | Ulicleal HSK                     | LOW 115K   | risk       | risk    | risk     |  |
| Petersen M. 2006 <sup>776</sup>   | Low risk                                      | Low risk                | Low risk                         | Low risk   | Low risk   | Unclear | Low risk |  |
| reterserrivi, 2000                | LOW FISK                                      | LOW FISK                | LOW FISK                         | LOW IISK   | LOW IISK   | risk    | LOW FISK |  |
| Wang TF, 2005 <sup>777</sup>      | Unclear risk                                  | Unclear risk            | Low risk                         | Low risk   | Unclear    | Unclear | Low risk |  |
| wang 11, 2000                     | Officiear risk                                | Unclear risk            | LOW IISK                         | LOW IISK   | risk       | risk    | LOW IISK |  |
| Robitaille J, 2005 <sup>778</sup> | Unclear risk                                  | Unclear risk            | Unclear risk                     | Low risk   | Low risk   | Unclear | Low risk |  |

|                                  |              |              |              |          |          | risk            |                 |
|----------------------------------|--------------|--------------|--------------|----------|----------|-----------------|-----------------|
| Noakes M, 2005 <sup>779</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Poston WS, 2005 <sup>780</sup>   | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Ebbeling CB, 2005 <sup>781</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Frank LL, 2005 <sup>782</sup>    | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Berne C, 2005 <sup>783</sup>     | Low risk     | Low risk     | Low risk     | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Gaullier JM, 2005 <sup>784</sup> | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk | Unclear<br>risk | Unclear<br>risk |
| Zemel MB, 2005 <sup>785</sup>    | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | Unclear<br>risk | Low risk        |
| Patalay M, 2005 <sup>786</sup>   | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk | Unclear<br>risk | Unclear<br>risk |
| Pieterse Z, 2005 <sup>787</sup>  | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk | Unclear         | Low risk        |

|                                    |              |              |              |          |                 | risk            |                 |
|------------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Derosa G, 2005 <sup>788</sup>      | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Maeda H, 2005 <sup>789</sup>       | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Pereira MA, 2004 <sup>790</sup>    | Low risk     | Low risk     | Low risk     | Low risk | High risk       | Unclear<br>risk | Low risk        |
| Aude YW, 2004 <sup>791</sup>       | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Brinkworth GD, 2004 <sup>792</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Low risk        | Low risk        |
| Melanson KJ, 2004 <sup>793</sup>   | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Yesilbursa D, 2005 <sup>794</sup>  | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Unclear<br>risk |
| Seshadri P, 2004 <sup>795</sup>    | Low risk     | Low risk     | High risk    | Low risk | Unclear<br>risk | Low risk        | Low risk        |
| Miyashita Y, 2004 <sup>796</sup>   | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear         | Unclear         |

|                                       |              |              |              |          |           | risk            | risk            |
|---------------------------------------|--------------|--------------|--------------|----------|-----------|-----------------|-----------------|
| Flechtner-Mors M, 2004 <sup>797</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk  | Unclear<br>risk | Low risk        |
| Mhurchu CN, 2004 <sup>798</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Low risk        | Low risk        |
| Esposito K, 2004 <sup>799</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk        |
| Carels RA, 2004 <sup>800</sup>        | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk  | Unclear<br>risk | Low risk        |
| Stern L, 2004 <sup>801</sup>          | Low risk     | Low risk     | Unclear risk | Low risk | Low risk  | Low risk        | Low risk        |
| Brinkworth GD, 2004 <sup>802</sup>    | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk  | Unclear<br>risk | Low risk        |
| Albert SG, 2004 <sup>803</sup>        | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Unclear<br>risk | Unclear<br>risk |
| Rachmani R, 2004 <sup>804</sup>       | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk        |
| Poston WS, 2003 <sup>805</sup>        | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk        |
| Bloch KV, 2003806                     | Low risk     | Low risk     | Low risk     | Low risk | High risk | Unclear         | Low risk        |

|                                 |              |                |                |          |            | risk     |          |
|---------------------------------|--------------|----------------|----------------|----------|------------|----------|----------|
| Lovejoy JC, 2003 <sup>807</sup> | Low risk     | Low risk       | Low risk       | Low risk | Low risk   | Low risk | Low risk |
| Ash S, 2003 <sup>808</sup>      | Low risk     | Unclear risk   | Low risk       | Low risk | Low risk   | Unclear  | Low risk |
| 13110, 2000                     | LOW 115K     | Officieal fisk | LOW 115K       | LOW 115K | LOW 115K   | risk     | LOW 115K |
| Foster GD, 2003 <sup>809</sup>  | Low risk     | Low risk       | Low risk       | Low risk | Low risk   | Unclear  | Low risk |
| 100001 02 , 2000                | LOW HON      | Low Hor        | LOW HOR        | 2011131  | Zow Hsk    | risk     | LOW HOR  |
| Melanson K, 2003 <sup>810</sup> | Unclear risk | Unclear risk   | Unclear risk   | Low risk | Low risk   | Unclear  | Unclear  |
| ,                               | Chereur Hen  | Chereur Hon    | Officient fish | 20111311 | 2011 11311 | risk     | risk     |
| Allison DB, 2003 <sup>811</sup> | Low risk     | Unclear risk   | Unclear risk   | Low risk | Low risk   | Unclear  | Low risk |
| ,                               |              |                |                |          |            | risk     |          |
| Esposito K, 2003 <sup>812</sup> | Low risk     | Low risk       | Low risk       | Low risk | Low risk   | Unclear  | Low risk |
| 1 ,                             |              |                |                |          |            | risk     |          |
| Lantz H, 2003 <sup>813</sup>    | Low risk     | Unclear risk   | Unclear risk   | Low risk | Low risk   | Unclear  | Low risk |
|                                 |              |                |                |          |            | risk     |          |
| James AP, 2003 <sup>814</sup>   | Unclear risk | Unclear risk   | Unclear risk   | Low risk | Unclear    | Unclear  | Unclear  |
| ,                               |              |                |                |          | risk       | risk     | risk     |
| Hirose K, 2002 <sup>815</sup>   | Low risk     | Low risk       | Low risk       | Low risk | Low risk   | Unclear  | Low risk |
| ·                               |              |                |                | ·        |            | risk     |          |

| Sharman MJ, 2024 <sup>816</sup>  | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk |
|----------------------------------|--------------|--------------|--------------|----------|-----------|-----------------|----------|
| Bakris G, 2002 <sup>817</sup>    | Unclear risk | Unclear risk | Unclear risk | Low risk | High risk | Unclear<br>risk | Low risk |
| Hanefeld M, 2002 <sup>818</sup>  | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk |
| Dunstan DW, 2002 <sup>819</sup>  | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk |
| Larsen TM, 2002 <sup>820</sup>   | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk |
| Nieman DC, 2002 <sup>821</sup>   | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk  | Unclear<br>risk | Low risk |
| Anderson JW, 2002 <sup>822</sup> | Low risk     | Low risk     | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk |
| Miles JM, 2002 <sup>823</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk |
| Kelley DE, 2002 <sup>824</sup>   | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk  | Unclear<br>risk | Low risk |

| Heilbronn LK, 2002 <sup>825</sup>  | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Low risk    | Unclear<br>risk | Low risk |  |
|------------------------------------|----------------|----------------|----------------|----------|-------------|-----------------|----------|--|
| Janssen I, 2002 <sup>826</sup>     | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Unclear     | Unclear         | Unclear  |  |
| Juli35CH 1, 2002                   | Officieal fisk | Officieal fisk | Officieal fisk | LOW 115K | risk        | risk            | risk     |  |
| Yip I, 2001 <sup>827</sup>         | Low risk       | Unclear risk   | Low risk       | Low risk | Low risk    | Unclear         | Low risk |  |
| 11p 1, 2001                        | LOW 115K       | Officieal fisk | LOW 115K       | LOW 115K | LOW 115K    | risk            | LOW 115K |  |
| Gokcel A, 2001 <sup>828</sup>      | Unclear risk   | Low risk       | Low risk       | Low risk | Low risk    | Unclear         | Low risk |  |
| Gorcei II, 2001                    | Officieal fisk | LOW 115K       | LOW 115K       | LOW 115K | LOW 115K    | risk            | LUW 115K |  |
| Volpe SL, 2001 <sup>829</sup>      | Low risk       | Low risk       | Low risk       | Low risk | Low risk    | Unclear         | Low risk |  |
| Volpe 31, 2001                     | LOW 115K       | LOW 115K       | LOW 115K       | LOW 115K | LOW 115K    | risk            | LOW HOR  |  |
| Dumont M, 2001 <sup>830</sup>      | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Unclear     | Unclear         | Unclear  |  |
| Damont M, 2001                     | Official fish  | Officieal 115K | Officied fisk  | LOW 115K | risk        | risk            | risk     |  |
| Boozer CN, 2001 <sup>831</sup>     | Low risk       | Low risk       | Low risk       | Low risk | Low risk    | Unclear         | Low risk |  |
| boozer ert, 2001                   | LOW 113K       | LOW 113K       | LOW 113K       | LOW 113K | LOW 113K    | risk            | LOW 113K |  |
| Birketvedt GS, 2000 <sup>832</sup> | Unclear risk   | Unclear risk   | Unclear risk   | Low risk | Low risk    | Unclear         | Low risk |  |
| Direct Cat Co, 2000                | Official fish  | Officieal 115K | Officied fisk  | LOW 115K | LOW 113K    | risk            | LOW 115K |  |
| Richelsen B, 2000 <sup>833</sup>   | Unclear risk   | Unclear risk   | Low risk       | Low risk | sk Low risk | Unclear         | Low risk |  |
| 2000                               | Officient 115K | Officical fish | LOW 113K       | LOW HAR  | LOW 113K    | risk            | LUW 115K |  |

| Halimi S, 2000 <sup>834</sup>                | Low risk       | Low risk        | Low risk       | Low risk | Low risk | Unclear<br>risk | Low risk |
|--|----------------|-----------------|----------------|----------|----------|-----------------|----------|
| Wadden TA, 2001 <sup>835</sup>               | Unclear risk   | Unclear risk    | Unclear risk   | Low risk | Unclear  | Unclear         | Unclear  |
| Wadden 171, 2001                             | Officieal fisk | Ulicleal fisk   | Ulicleal HSK   | LOW 115K | risk     | risk            | risk     |
| Fujioka K, 2000 <sup>836</sup>               | Unclear risk   | Unclear risk    | Low risk       | Low risk | Low risk | Unclear         | Low risk |
| Tujioka IX, 2000                             | Officieal 115K | Officieal fisk  | LOW 115K       | LOW 115K | LOW 115K | risk            | LOW 115K |
| Ditschuneit HH, 2002 <sup>837</sup>          | Low risk       | Low risk        | Low risk       | Low risk | Low risk | Unclear         | Low risk |
| Ditterial IIII, 2002                         | LOW HSK        | LOW 113K        | ion Low risk L |          | LOW 113K | risk            | LOW 113K |
| Fogelholm M <sub>1</sub> 2000 <sup>838</sup> | Unclear risk   | Unclear risk    | Unclear risk   | Low risk | Low risk | Unclear         | Low risk |
| 1 ogeniomi 1/1, <b>2</b> 000                 | Chelear Hak    | Officieal fisk  | Officient 115K | LOW 113K | LOW 113K | risk            | LOW 113K |
| Donnelly JE, 2000 <sup>839</sup>             | Unclear risk   | Unclear risk    | Unclear risk   | Low risk | Unclear  | Unclear         | Low risk |
| 2 cratery 32, 2000                           | Officient flow | Officient flore | Official field | 2011131  | risk     | risk            | Low Hist |
| Golay A, 2000 <sup>840</sup>                 | Unclear risk   | Unclear risk    | Unclear risk   | Low risk | Unclear  | Unclear         | Unclear  |
| 2014y 11, 2000                               | Officient flow | Officient flore | Official field | 2011131  | risk     | risk            | risk     |
| Mori TA, 1999 <sup>841</sup>                 | Unclear risk   | Unclear risk    | Unclear risk   | Low risk | Low risk | Unclear         | Low risk |
| ,  | Officient flow | Officient flore | Official field | 2011131  | Zow Han  | risk            | Low Hist |
| Vidgren HM, 1999 <sup>842</sup>              | Low risk       | Low risk        | Low risk       | Low risk | Low risk | Low risk        | Low risk |
| Roger P, 1999 <sup>843</sup>                 | Unclear risk   | Unclear risk    | Low risk       | Low risk | Unclear  | Unclear         | Unclear  |

|                                       |              |              |              |          | risk            | risk            | risk            |
|---------------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Pittler MH, 1999 <sup>844</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Ditschuneit HH, 1999 <sup>845</sup>   | Low risk     | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Andersen RE, 1999 <sup>846</sup>      | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Davidson MH, 1999 <sup>847</sup>      | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Charles MA, 1998 <sup>848</sup>       | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Riddle MC, 1998 <sup>849</sup>        | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Marckmann P, 1998 <sup>850</sup>      | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Sjöström L, 1998 <sup>851</sup>       | Low risk     | Low risk     | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Agurs-Collins TD, 1997 <sup>852</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear         | Low risk        |

|  |                |                           |                   |              |            | risk    |            |  |
|--|----------------|---------------------------|-------------------|--------------|------------|---------|------------|--|
| Kraemer WJ, 1997 <sup>853</sup>              | Unclear risk   | Unclear risk              | I In al con minte | I ozuz miale | Unclear    | Unclear | Unclear    |  |
| Kraemer WJ, 1997                             | Unclear risk   | Unclear risk              | Unclear risk      | Low risk     | risk       | risk    | risk       |  |
| Rössner S, 1997 <sup>854</sup>               | Unclear risk   | Unclear risk              | High risk         | Low risk     | Unclear    | Unclear | Unclear    |  |
| 103311C1 3, 1777                             | Officieal fisk | Officieal fisk            | High Hisk         | LOW 115K     | risk       | risk    | risk       |  |
| Pontiroli AE, 1996 <sup>855</sup>            | Unclear risk   | Unclear risk              | Low risk          | Low risk     | Low risk   | Unclear | Low risk   |  |
| TORRION TIE, 1990                            | Officieal fisk | Unclear risk Unclear risk |                   | LOW HOR      |            | risk    | LOW 115K   |  |
| Golay A, 1996 <sup>856</sup>                 | Unclear risk   | Unclear risk              | Unclear risk      | Low risk     | Low risk   | Unclear | Unclear    |  |
| Goldy 11, 1990                               | Officieal 115K | Officieal fisk            | Officied 115K     | LOW 113K     | LOW 113K   | risk    | risk       |  |
| Pascale RW, 1995 <sup>857</sup>              | Unclear risk   | Unclear risk              | Unclear risk      | Low risk     | Low risk   | Unclear | Low risk   |  |
| 1 000000 1111, 1330                          | Official flox  | Officieur fion            | Officieur fisik   | LOW HISK     | LOW HISK   | risk    | 2011 11010 |  |
| DeFronzo RA, 1995 <sup>858</sup>             | Unclear risk   | Unclear risk              | Unclear risk      | Low risk     | Low risk   | Unclear | Unclear    |  |
| ,  | Oneseur Hen    | Official flow             | Official fish     | 20111311     | 2011 11511 | risk    | risk       |  |
| O'Kane M <sub>.</sub> 1994 <sup>859</sup>    | Unclear risk   | Unclear risk              | Unclear risk      | Low risk     | Low risk   | Unclear | Low risk   |  |
| ,  | Oneseur Hen    | Official flow             | Official fish     | 20111311     | 2011 11311 | risk    | 20111311   |  |
| Giugliano D <sub>1</sub> 1993 <sup>860</sup> | Unclear risk   | Unclear risk              | Low risk          | Low risk     | Unclear    | Unclear | Low risk   |  |
| 20   | Cheleur Hon    | Chefeur Holy              | 2011 11010        | 2011 1131    | risk       | risk    | 2011 11010 |  |
| Puddey IB, 1992 <sup>861</sup>               | Unclear risk   | Unclear risk              | Low risk          | Low risk     | Low risk   | Unclear | Low risk   |  |

|                                 |              |              |              |          |                 | risk            | _               |
|---------------------------------|--------------|--------------|--------------|----------|-----------------|-----------------|-----------------|
| Wolever TM, 1992 <sup>862</sup> | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Golay A, 1992 <sup>863</sup>    | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Jalkanen L, 1991 <sup>864</sup> | Unclear risk | Unclear risk | Unclear risk | Low risk | Unclear<br>risk | Unclear<br>risk | Unclear<br>risk |
| Nieman DC, 1990 <sup>865</sup>  | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk        | Unclear<br>risk | Low risk        |
| Lalor BC, 1990 <sup>866</sup>   | Unclear risk | Unclear risk | Low risk     | Low risk | Low risk        | Unclear<br>risk | Low risk        |

## **Supplementary Table 2 Baseline characteristics of included trials**

| Ref.                                   | Country           | Treatment              | No. of patients | Age   | Female | Mean Baseline BMI (kg/m²) | All-cause<br>mortality | Cardiovascular<br>death | Non-fatal<br>myocardial<br>infarction | Non-fatal<br>stroke |
|--|-------------------|------------------------|-----------------|-------|--------|---------------------------|------------------------|-------------------------|---------------------------------------|---------------------|
| Lee M, 2024 <sup>1</sup>               | korea             | others                 | 93              | 53.5  | 100    | 26.4                      | /                      | /                       | /                                     | /                   |
| Peters JC, 2024 <sup>2</sup>           | USA               | others                 | 20              | 35.8  | 70     | 30.9                      | /                      | /                       | /                                     | /                   |
| Okuka N, 2024 <sup>3</sup>             | Serbia            | others                 | 48              | 39.19 | 100    |                           | /                      | /                       | /                                     | /                   |
| Pereira V, 2024 <sup>4</sup>           | Portugal          | diet                   | 112             | 45    | 72.3   | 34                        | /                      | /                       | /                                     | /                   |
| Salte OBK, 2024 <sup>5</sup>           | Norway            | surgery                | 60              | 48    | 73     | 54.9                      | /                      | /                       | /                                     | /                   |
| Moravcová K, 2024 <sup>6</sup>         | Czech<br>Republic | others                 | 100             | 43.3  | 71     | 43.3                      | /                      | /                       | /                                     | /                   |
| Holmberg S, 2024 <sup>7</sup>          | Sweden            | diet                   | 176             | 56.5  | 79.5   | 32.8                      | /                      | /                       | /                                     | /                   |
| Eriksson JW, 2024 <sup>8</sup>         | Sweden            | surgery +<br>diet      | 24              | 42    | 91.67  | 39.8                      | /                      | /                       | /                                     | /                   |
| Gonzalez-Gil AM ,<br>2024 <sup>9</sup> | USA               | exercise +<br>medicine | 83              | 72.4  | 0      | 37.0                      | /                      | /                       | /                                     | /                   |

| Keawtep P, 2024 <sup>10</sup>               | Thailand | diet +<br>exercise | 92   | 52.84 | 100   | 29.06 | / | / | / | / |
|---|----------|--------------------|------|-------|-------|-------|---|---|---|---|
| Li S, 2024 <sup>11</sup>                    | China    | exercise           | 54   | 36.82 | 55.56 | 29.95 | / | / | / | / |
| Lee DC, 2024 <sup>12</sup>                  | USA      | exercise           | 406  | 50    | 53    | 31.2  | / | / | / | / |
| Sandby K, 2024 <sup>13</sup>                | Denmark  | diet               | 80   | 58    | 0     | 32.4  | / | / | / | / |
| Heinonen S, 2023 <sup>14</sup>              | Finland  | surgery            | 119  | 46.8  | 70.59 | 44.2  | / | / | / | / |
| da Silva CSO, 2023 <sup>15</sup>            | Brazil   | diet               | 24   | 38.29 | 100   | 29.08 | / | / | / | / |
| Fallah F, 2023 <sup>16</sup>                | Iran     | medicine           | 45   | 38.2  | 100   | 32.9  | / | / | / | / |
| Lauw S, 2023 <sup>17</sup>                  | China    | others             | 55   | 42.4  | 74.55 | 28.8  | / | / | / | / |
| Bamgboye M, 2023 <sup>18</sup>              | USA      | others             | 353  | 42.69 | 67    | 32.32 | / | / | / | / |
| Möller F, 2023 <sup>19</sup>                | Sweden   | surgery            | 34   | 39.1  | 46.81 | 54.5  | / | / | / | / |
| García-Cordero J , 2023 <sup>20</sup>       | Spain    | diet               | 29   | 45.2  | 41.38 | 30.1  | / | / | / | / |
| Zhu R, 2023 <sup>21</sup>                   | Denmark  | diet +<br>exercise | 2165 | 55    | 67.9  | 33.9  | / | / | / | / |
| Hematinezhad Touli<br>M, 2022 <sup>22</sup> | Iran     | others             | 40   |       | 0     | 29.1  | / | / | / | / |

| Nora CL, 2023 <sup>23</sup>           | USA      | others             | 29  | 27.6  | 48.28 | 30.6  | / | / | / | / |
|---------------------------------------|----------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Sun J, 2023 <sup>24</sup>             | China    | diet               | 298 | 34    | 69.21 | 30.3  | / | / | / | / |
| Taha MM, 2023 <sup>25</sup>           | Egypt    | exercise           | 53  | 48.64 | 100   | 34.4  | / | / | / | / |
| Perin L, 2023 <sup>26</sup>           | Brasil   | diet               | 85  | 35.9  | 89.41 | 32.7  | / | / | / | / |
| Zhang N, 2023 <sup>27</sup>           | China    | diet +<br>exercise | 746 | 70.1  | 53.9  | 27.67 | / | / | / | / |
| Elsayed MM, 2023 <sup>28</sup>        | Egypt    | others             | 76  | 67.83 | 50    | 34.55 | / | / | / | / |
| Cabrera-Rode E, 2023 <sup>29</sup>    | Cuba     | others             | 160 | 43    | 86.88 | 33.1  | / | / | / | / |
| Maaloul R, 2023 <sup>30</sup>         | Tunisia  | diet +<br>exercise | 20  | 31.8  | 0     | 33.1  | / | / | / | / |
| Muñoz-Pérez DM, 2023 <sup>31</sup>    | Colombia | diet               | 44  | 50.8  | 77.27 | 35.59 | / | / | / | / |
| Saeidi A, 2023 <sup>32</sup>          | Iran     | others             | 68  | 27.6  | 0     | 33.6  | / | / | / | / |
| Quist JS, 2023 <sup>33</sup>          | Denmark  | exercise           | 90  | 36    | 52    | 29.6  | / | / | / | / |
| Delgado-Floody P , 2022 <sup>34</sup> | Chile    | exercise           | 18  | 41.3  | 100   | 44.2  | / | / | / | / |
| Ghorbani Y, 2023 <sup>35</sup>        | Canada   | others             | 28  | 46.4  | 78.57 | 44    | / | / | / | / |

| Garvey WT, 2022 <sup>36</sup>       | USA     | medicine           | 304  | 47.3  | 77.63 | 38.5  | 0.70% | / | / | / |
|-------------------------------------|---------|--------------------|------|-------|-------|-------|-------|---|---|---|
| Kosiborod MN, 2023 <sup>37</sup>    | USA     | medicine           | 2764 | 46.22 | 75    | 38.2  | /     | / | / | / |
| Guo H, 2022 <sup>38</sup>           | China   | diet               | 69   | 39.2  | 72.5  | 29.3  | /     | / | / | / |
| Yoshino M, 2022 <sup>39</sup>       | USA     | lifestyle          | 18   | 51.8  | 94.44 | 37.3  | /     | / | / | / |
| Goralska J, 2022 <sup>40</sup>      | Poland  | others             | 62   | 47.5  | 24.35 | 33.6  | /     | / | / | / |
| Zhaohu H, 2022 <sup>41</sup>        | China   | medicine           | 309  | 51.8  | 38.51 | 29.9  | /     | / | / | / |
| Seyam MK, 2022 <sup>42</sup>        | Arabia  | diet +<br>exercise | 70   | 30.3  | 0     | 35.2  | /     | / | / | / |
| Osuna-Prieto FJ, 2022 <sup>43</sup> | Spain   | exercise           | 24   | 40.2  | 0     | 31.6  | /     | / | / | / |
| Lange UG,2022 <sup>44</sup>         | Germany | diet               | 69   | 46.7  | 68.12 | 47.5  | /     | / | / | / |
| Mo SJ, 2022 <sup>45</sup>           | Korea   | others             | 59   | 37.49 | 22.03 | 26.84 | /     | / | / | / |
| Ataeinosrat A, 2022 <sup>46</sup>   | Iran    | exercise           | 44   | 27.5  | 0     | 35.7  | /     | / | / | / |
| Salminen P, 2022 <sup>47</sup>      | Finland | surgery            | 240  | 48.5  | 69.58 | 45.9  | /     | / | / | / |
| Zhang X, 2022 <sup>48</sup>         | USA     | others             | 93   | 42    | 58.06 | 32.6  | /     | / | / | / |
| Senkus KE, 2022 <sup>49</sup>       | USA     | diet +<br>exercise | 163  | 70.2  | 62    | 33.6  | /     | / | / | / |
| Haji-Ghazi Tehrani L,               | Iran    | diet               | 48   | 32.1  | 100   | 33.3  | /     | / | / | / |

| 2022 <sup>50</sup>                           |                |                    |     |       |       |       |   |       |   |       |
|--|----------------|--------------------|-----|-------|-------|-------|---|-------|---|-------|
| Murphy R, 2022 <sup>51</sup>                 | New<br>Zealand | surgery            | 103 | 46    | 51.75 | 42.8  | / | /     | / | /     |
| Lockard B, 2022 <sup>52</sup>                | USA            | diet               | 51  | 34.5  | 100   | 34.0  | / | /     | / | /     |
| de Luis D, 2022 <sup>53</sup>                | Spain          | diet               | 319 | 47.2  | 74.7  | 37.9  | / | /     | / | /     |
| Ilich JZ, 2022 <sup>54</sup>                 | USA            | others             | 97  | 55.8  | 100   | 31    | / | /     | / | /     |
| Ruggenenti P, 2022 <sup>55</sup>             | Italy          | diet               | 103 | 63.9  | 21.4  | 32.2  | / | 3.40% | / | 3.40% |
| Sohn M, 2022 <sup>56</sup>                   | korea          | others             | 81  | 46.7  | 60.49 | 27.2  | / | /     | / | /     |
| Li S, 2022 <sup>57</sup>                     | China          | diet               | 53  | 36.8  | 0     | 29.43 | / | /     | / | /     |
| Lugones-Sánchez C, 2022 <sup>58</sup>        | Spain          | diet +<br>exercise | 650 | 48.3  | 68.46 | 33    | / | /     | / | /     |
| Kim MJ, 2022 <sup>59</sup>                   | korea          | diet               | 104 | 38.7  | 100   | 25.5  | / | /     | / | /     |
| Sánchez E, 2021 <sup>60</sup>                | Spain          | diet               | 30  | 40.4  | 73.33 | 37.9  | / | /     | / | /     |
| Eskandaros MS, 2022 <sup>61</sup>            | Egypt          | surgery            | 121 | 46.87 | 65.29 | 45.84 | / | /     | / | /     |
| Mateos R, 2022 <sup>62</sup>                 | Spain          | others             | 60  | 38.3  | 28.33 | 30.2  | / | /     | / | /     |
| de Oliveira Fialho CG,<br>2022 <sup>63</sup> | Brazil         | others             | 24  | 33.1  | 100   | 34.3  | / | /     | / | /     |

| Grangeiro É D, 2021 <sup>64</sup>   | Brazil    | diet               | 40  | 29.05 | 100   | 30.33 | / | / | / | / |
|-------------------------------------|-----------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Schiavo L, 2022 <sup>65</sup>       | Italy     | diet               | 70  | 42    | 37.14 | 48.8  | / | / | / | / |
| Haidari F, 2021 <sup>66</sup>       | Iran      | diet               | 63  | 35.3  | 100   | 34.8  | / | / | / | / |
| Kafyra M, 2021 <sup>67</sup>        | Greece    | diet               | 202 | 47    | 70.29 | 31.34 | / | / | / | / |
| Lee YK, 2021 <sup>68</sup>          | korea     | exercise           | 24  | 56.8  | 100   | 25.7  | / | / | / | / |
| de Sousa ART, 2021 <sup>69</sup>    | Brazil    | surgery            | 61  | 42.39 | 100   | 47.09 | / | / | / | / |
| Rajaie H,2021 <sup>70</sup>         | Iran      | others             | 81  | 38.97 | 100   |       | / | / | / | / |
| Félix-Soriano E, 2021 <sup>71</sup> | Spain     | exercise           | 71  | 58.51 | 100   | 30.62 | / | / | / | / |
| Astbury NM, 2021 <sup>72</sup>      | UK        | diet               | 179 | 50.8  | 55    | 36.9  | / | / | / | / |
| Muñoz-Perez DM, 2021 <sup>73</sup>  | Colombia  | diet               | 44  | 50.8  | 77.27 | 35.6  | / | / | / | / |
| Vergara M, 2021 <sup>74</sup>       | USA       | diet               | 208 | 40    | 60    |       | / | / | / | / |
| Cai L,2021 <sup>75</sup>            | China     | diet +<br>exercise | 44  | 24.82 | 34.09 | 27.59 | / | / | / | / |
| Umphonsathien $M$ , $2022^{76}$     | Thailand  | diet               | 40  | 49.6  | 72.5  | 30.1  | / | / | / | / |
| Paul S, 2021 <sup>77</sup>          | Australia | others             | 10  | 50    | 0     | 32.1  | / | / | / | / |

| Jamka M,2021 <sup>78</sup>       | Poland             | exercise  | 101 | 55    | 100   | 35.92 | / | / | / | / |
|----------------------------------|--------------------|-----------|-----|-------|-------|-------|---|---|---|---|
| Trouwborst I, 2021 <sup>79</sup> | The<br>Netherlands | diet      | 782 | 41.5  | 64.7  | 34.4  | / | / | / | / |
| Siu PM, 2021 <sup>80</sup>       | Hong Kong          | exercise  | 543 | 61.9  | 77.9  | 25.6  | / | / | / | / |
| Moholdt T, 2021 <sup>81</sup>    | Australia          | exercise  | 24  | 35.67 | 0     | 30.87 | / | / | / | / |
| Leung GKW, 2021 <sup>82</sup>    | Australia          | diet      | 19  | 41    | 68.42 | 30.7  | / | / | / | / |
| Cooney C, 2021 <sup>83</sup>     | Ireland            | diet      | 54  | 57.5  | 53.7  | 30.7  | / | / | / | / |
| Azizi S, 2021 <sup>84</sup>      | Iran               | others    | 45  | 48.69 | 35.56 | 29.03 | / | / | / | / |
| Biteli P, 2021 <sup>85</sup>     | Brazil             | exercise  | 70  | 60.6  | 100   |       | / | / | / | / |
| Naing S, 2020 <sup>86</sup>      | USA                | medicine  | 18  | 53.5  | 50    | 36.47 | / | / | / | / |
| de Melo CM, 2021 <sup>87</sup>   | Brazil             | diet      | 37  | 40.7  | 0     | 34.6  | / | / | / | / |
| Han Y, 2022 <sup>88</sup>        | korea              | others    | 383 | 48.9  | 57.96 | 27.5  | / | / | / | / |
| de Luis D,2021 <sup>89</sup>     | Spain              | diet      | 269 | 50.2  | 74    | 37.3  | / | / | / | / |
| Noer ER, 2020 <sup>90</sup>      | Indonesia          | diet      | 43  | 19.2  | 90.7  | 30    | / | / | / | / |
| Höchsmann C, 2021 <sup>91</sup>  | USA                | lifestyle | 803 | 49.4  | 84.4  | 37.2  | / | / | / | / |
| Lopes AL, 2021 <sup>92</sup>     | Brazil             | diet +    | 12  | 25.6  | 0     | 32.34 | / | / | / | / |

|   |                    | exercise           |     |       |       |       |   |   |   | _ |
|---|--------------------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Wheeler MJ, 2020 <sup>93</sup>                | Australia          | exercise           | 67  | 67    | 52.24 | 31.2  | / | / | / | / |
| Hajizadeh-Sharafabad<br>F, 2021 <sup>94</sup> | Iran               | others             | 45  | 53.82 | 60    | 34.11 | / | / | / | / |
| Zhang T, 2020 <sup>95</sup>                   | China              | others             | 24  | 39.9  | 0     | 28.1  | / | / | / | / |
| Wongpipit W, 2021%                            | China              | others             | 18  | 22    | 0     | 30    | / | / | / | / |
| Rondanelli M, 2020 <sup>97</sup>              | Italy              | others             | 54  | 51.5  | 48.15 | 29.34 | / | / | / | / |
| Glaysher MA, 202198                           | UK                 | others             | 140 | 52    | 45    | 36.2  | / | / | / | / |
| Fechner E, 2020 <sup>99</sup>                 | The<br>Netherlands | diet               | 40  | 61.4  | 52.5  | 29.4  | / | / | / | / |
| Yousefi R, 2021 <sup>100</sup>                | Iran               | others             | 40  | 34.23 | 82.5  | 31.84 | / | / | / | / |
| Park W, 2020 <sup>101</sup>                   | korea              | exercise           | 20  | 68.8  | 0     | 26.1  | / | / | / | / |
| Brennan AM, 2020 <sup>102</sup>               | USA                | exercise           | 61  | 68.6  | 63.93 | 36.3  | / | / | / | / |
| Jung K, 2020 <sup>103</sup>                   | korea              | exercise           | 32  | 47.5  | 100   | 25.9  | / | / | / | / |
| Heiston EM, 2021 <sup>104</sup>               | USA                | diet +<br>exercise | 25  | 47    | 100   | 37.6  | / | / | / | / |
| Sun J, 2020 <sup>105</sup>                    | China              | exercise           | 300 | 21.71 | 0     | 30.85 | / | / | / | / |

| Haidari F, 2020 <sup>106</sup>         | Iran               | diet      | 38  | 36.05 | 100   | 33.23 | / | / | / | / |
|--|--------------------|-----------|-----|-------|-------|-------|---|---|---|---|
| Haidari F, 2020 <sup>107</sup>         | Iran               | others    | 60  | 31.61 | 100   | 33.45 | / | / | / | / |
| Vogel C, 2020 <sup>108</sup>           | Brazil             | others    | 29  | 37.21 | 0     | 32.59 | / | / | / | / |
| Michalczyk MM , 2020 <sup>109</sup>    | Poland             | diet      | 91  | 42    | 100   | 32.86 | / | / | / | / |
| Moszak M, 2020 <sup>110</sup>          | Poland             | others    | 81  | 49.1  | 62.96 | 39.6  | / | / | / | / |
| Batista-Jorge GC , 2020 <sup>111</sup> | Brazil             | others    | 22  |       | 0     | 35.69 | / | / | / | / |
| Colleluori G, 2020 <sup>112</sup>      | USA                | others    | 23  | 51.7  | 0     | 40.6  | / | / | / | / |
| Poon ET, 2020 <sup>113</sup>           | Hong Kong          | exercise  | 24  | 48.1  | 0     | 25.9  | / | / | / | / |
| Basciani S, 2020 <sup>114</sup>        | Italy              | diet      | 48  | 56.2  | 60.42 | 35.9  | / | / | / | / |
| Psota TL, 2020 <sup>115</sup>          | USA                | lifestyle | 101 | 38.9  | 100   | 30.8  | / | / | / | / |
| Ghanim H, 2020 <sup>116</sup>          | USA                | medicine  | 64  | 46    | 62.5  | 31.7  | / | / | / | / |
| Santos A, 2020 <sup>117</sup>          | Brazil             | diet      | 149 | 39.63 | 85.23 | 45.77 | / | / | / | / |
| Bakker N, 2020 <sup>118</sup>          | The<br>Netherlands | others    | 56  | 46.7  | 100   | 42    | / | / | / | / |
| Kim J, 2020 <sup>119</sup>             | korea              | exercise  | 25  | 71.04 | 100   |       | / | / | / | / |

| López-Gómez JJ ,<br>2020 <sup>120</sup> | Spain     | diet               | 112 | 61.02 | 72.3  | 39.56 | / | / | / | / |
|---|-----------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Sadowska-Krępa E , $2020^{121}$         | Poland    | diet +<br>exercise | 39  | 58.7  | 0     | 31.6  | / | / | / | / |
| Hannon BA, 2020 <sup>122</sup>          | USA       | others             | 115 | 35.7  | 63    | 33.1  | / | / | / | / |
| Michael DR, 2020 <sup>123</sup>         | UK        | others             | 220 | 45.91 | 60.45 | 29.06 | / | / | / | / |
| Kuszewski JC, 2020 <sup>124</sup>       | Australia | others             | 152 | 65.6  | 54.61 | 30.8  | / | / | / | / |
| Meslier V, 2020 <sup>125</sup>          | Italy     | diet               | 82  | 43    | 52.44 | 31.1  | / | / | / | / |
| Razmpoosh E, 2020 <sup>126</sup>        | Iran      | diet               | 65  | 36.5  | 100   | 31.5  | / | / | / | / |
| Headland ML, 2020 <sup>127</sup>        | Australia | diet               | 109 | 54.9  | 94    | 33    | / | / | / | / |
| Bittel AJ, 2020 <sup>128</sup>          | USA       | exercise           | 10  | 50    | 0     | 33    | / | / | / | / |
| Hadi A, 2019 <sup>129</sup>             | Iran      | others             | 59  | 35.55 | 33.9  | 30.87 | / | / | / | / |
| Dellis D, 2020 <sup>130</sup>           | Greece    | diet               | 70  | 50    | 52.86 | 33.67 | / | / | / | / |
| Porter Starr KN , 2019 <sup>131</sup>   | USA       | diet               | 80  | 60    | 90    | 37.3  | / | / | / | / |
| Ratajczak M, 2019 <sup>132</sup>        | Poland    | exercise           | 39  | 50    | 100   | 35.5  | / | / | / | / |
| Fatahi S, 2019 <sup>133</sup>           | Iran      | others             | 99  | 53.5  | 100   | 33.29 | / | / | / | / |

| Peradze N, 2019 <sup>134</sup>            | USA       | medicine | 20  |       | 0     | 35.3  | / | / | / | / |
|---|-----------|----------|-----|-------|-------|-------|---|---|---|---|
| Ghasemi E, 2019 <sup>135</sup>            | Iran      | exercise | 30  | 22.37 | 100   | 27.5  | / | / | / | / |
| Rakvaag E, 2019 <sup>136</sup>            | Denmark   | diet     | 65  | 64.5  | 52.31 | 29.36 | / | / | / | / |
| Cao L,, 2019 <sup>137</sup>               | China     | exercise | 28  | 64.2  | 100   | 27.1  | / | / | / | / |
| Rosqvist F,, 2019 <sup>138</sup>          | Sweden    | others   | 60  | 42    | 38.33 | 28    | / | / | / | / |
| Pavić E, 2019 <sup>139</sup>              | Croatia   | diet     | 124 | 47.6  | 74.19 | 41.6  | / | / | / | / |
| Farr OM, 2019 <sup>140</sup>              | USA       | medicine | 40  | 55    | 0     | 35.76 | / | / | / | / |
| Kim CO, 2019 <sup>141</sup>               | korea     | others   | 78  | 35.5  | 60.26 | 25.81 | / | / | / | / |
| Abbaspour N, 2019 <sup>142</sup>          | USA       | others   | 48  | 29.8  | 39.58 | 31.3  | / | / | / | / |
| Lahelma M, 2019 <sup>143</sup>            | Finland   | exercise | 53  |       | 47.17 | 28    | / | / | / | / |
| Haywood CJ, 2019 <sup>144</sup>           | Australia | diet     | 117 | 70.2  | 61.54 | 40.1  | / | / | / | / |
| Angelino D, 2019 <sup>145</sup>           | Italy     | others   | 41  | 53    | 60.98 | 30.9  | / | / | / | / |
| Apiñaniz A, 2019 <sup>146</sup>           | Spain     | others   | 110 | 38.5  | 71.82 | 32.7  | / | / | / | / |
| Tuccinardi D, 2019 <sup>147</sup>         | USA       | others   | 10  | 50.7  | 40    | 36.8  | / | / | / | / |
| Hernández-Lepe MA,<br>2019 <sup>148</sup> | Mexico    | others   | 52  | 26    | 0     | 30.2  | / | / | / | / |
| Aller R, 2019 <sup>149</sup>              | Spain     | diet     | 269 | 49.8  | 74.1  | 34.9  | / | / | / | / |

| Smith-Ryan AE ,<br>2019 <sup>150</sup>      | USA       | diet               | 42  | 35.3  | 50    | 32.8  | / | / | / | / |
|---|-----------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Asano M, 2019 <sup>151</sup>                | Japan     | diet               | 60  | 46.3  | 48.33 | 26.4  | / | / | / | / |
| Clayton ZS, 2019 <sup>152</sup>             | USA       | others             | 45  | 37.4  | 61.22 | 33.0  | / | / | / | / |
| Bowen J, 2019 <sup>153</sup>                | Australia | others             | 76  | 60.7  | 40.79 | 33.8  | / | / | / | / |
| Yari Z, 2022 <sup>154</sup>                 | Iran      | others             | 46  | 45    | 50    | 30.72 | / | / | / | / |
| Novin ZS, 2018 <sup>155</sup>               | Iran      | others             | 42  | 34.19 | 100   | 31.05 | / | / | / | / |
| Erickson ML, 2019 <sup>156</sup>            | USA       | lifestyle          | 16  | 66.1  | 68.75 | 35.9  | / | / | / | / |
| Cho AR, 2019 <sup>157</sup>                 | korea     | diet +<br>exercise | 31  | 36.7  | 48.39 | 27.3  | / | / | / | / |
| Aller R, 2019 <sup>158</sup>                | Spain     | diet               | 362 | 49.1  | 72.15 | 36.4  | / | / | / | / |
| Choi HR, 2018 <sup>159</sup>                | korea     | diet               | 37  | 26.7  | 35.14 | 29.2  | / | / | / | / |
| Subih HS, 2018 <sup>160</sup>               | Jordan    | others             | 45  |       | 100   | 38.4  | / | / | / | / |
| Headland ML, 2019 <sup>161</sup>            | Australia | diet               | 332 | 49.3  | 83.1  | 33.5  | / | / | / | / |
| Gorostegi-Anduaga I,<br>2018 <sup>162</sup> | Spain     | diet +<br>exercise | 167 | 53.7  | 35.33 |       | / | / | / | / |
| Yousefi R, 2018 <sup>163</sup>              | Iran      | others             | 38  | 39.98 | 81.58 | 32.83 | / | / | / | / |

| Oh M, 2018 <sup>164</sup>                   | korea       | diet +<br>exercise | 45  | 36.5  | 57.78 | 27.4  | / | / | / | / |
|---|-------------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Varsamis P, 2019 <sup>165</sup>             | Australia   | others             | 28  | 23    | 53.57 | 31    | / | / | / | / |
| Loves S, 2018 <sup>166</sup>                | Netherlands | medicine           | 16  |       | 0     | 35.2  | / | / | / | / |
| Camacho-Cardenosa<br>A, 2018 <sup>167</sup> | Spain       | exercise           | 59  | 40.89 | 100   | 28.98 | / | / | / | / |
| Kakutani R, 2018 <sup>168</sup>             | Japan       | others             | 80  | 49.8  | 16.25 | 27.14 | / | / | / | / |
| Oliveira-de-Lira L , $2018^{169}$           | Brazil      | others             | 75  | 34.07 | 100   |       | / | / | / | / |
| Allaire J,, 2018 <sup>170</sup>             | Canada      | others             | 138 | 52    | 70    | 29.4  | / | / | / | / |
| Gram AS, 2018 <sup>171</sup>                | Denmark     | exercise           | 90  | 34.58 | 48.89 | 29.87 | / | / | / | / |
| Azevedo FR, 2018 <sup>172</sup>             | Brazil      | surgery            | 20  | 51    | 0     | 31.9  | / | / | / | / |
| Fatahi S, 2018 <sup>173</sup>               | Iran        | diet               | 75  | 36.9  | 100   | 32.4  | / | / | / | / |
| Alcántara-Aragón V , $2018^{174}$           | Spain       | others             | 183 | 44.5  | 83.6  | 34.75 | / | / | / | / |
| Mundbjerg LH, 2018 <sup>175</sup>           | Denmark     | surgery            | 60  | 42.3  | 70    | 43    | / | / | / | / |
| McKay DL, 2018 <sup>176</sup>               | USA         | others             | 26  | 59.7  | 19.23 | 29.2  | / | / | / | / |

| Lee YJ, 2018 <sup>177</sup>         | korea  | diet     | 75  | 45.1  | 65.33 | 27.3  | / | / | / | / |
|-------------------------------------|--------|----------|-----|-------|-------|-------|---|---|---|---|
| Padilla-Camberos E, $2018^{178}$    | Mexico | others   | 28  | 33.3  | 39.29 | 35.2  | / | / | / | / |
| Ramos-Lopez O , 2018 <sup>179</sup> | Spain  | diet     | 107 | 46.8  | 66.36 | 31.8  | / | / | / | / |
| Mateo-Gallego R , $2018^{180}$      | Spain  | diet     | 76  | 44    | 100   | 32.8  | / | / | / | / |
| Shrivastava U, 2017 <sup>181</sup>  | India  | others   | 267 | 37.1  | 14.23 | 28.21 | / | / | / | / |
| Wagmacker DS , 2017 <sup>182</sup>  | Brazil | exercise | 66  | 24    | 100   | 29    | / | / | / | / |
| Ando Y, 2017 <sup>183</sup>         | Japan  | others   | 17  | 47    | 17.65 | 25.7  | / | / | / | / |
| Rock CL, 2017 <sup>184</sup>        | USA    | others   | 100 | 52.7  | 58    | 32.4  | / | / | / | / |
| Schiavon CA, 2018 <sup>185</sup>    | Brazil | surgery  | 100 | 43.8  | 76    | 36.9  | / | / | / | / |
| Blomquist C, 2018 <sup>186</sup>    | Sweden | diet     | 56  | 60.5  | 100   | 32.5  | / | / | / | / |
| Lima RPA, 2017 <sup>187</sup>       | Brazil | others   | 40  |       | 100   | 30.5  | / | / | / | / |
| Ferreira TDS, 2017 <sup>188</sup>   | Brazil | others   | 16  | 34.31 | 100   | 34.2  | / | / | / | / |
| O'Doherty AF, 2017 <sup>189</sup>   | UK     | others   | 11  | 31.5  | 0     | 29.9  | / | / | / | / |

| Pedley CF, 2018 <sup>190</sup>              | USA                | lifestyle          | 301 | 58    | 57    |       | / | / | / | / |
|---|--------------------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Chung J, 2017 <sup>191</sup>                | korea              | exercise           | 36  | 48.95 | 100   | 25.08 | / | / | / | / |
| Fedewa MV, 2018 <sup>192</sup>              | USA                | exercise           | 44  | 20.4  | 100   | 29.8  | / | / | / | / |
| Kleist B, 2017 <sup>193</sup>               | Germany            | diet +<br>exercise | 82  | 39.4  | 56.1  | 31.9  | / | / | / | / |
| Vella CA, 2017 <sup>194</sup>               | USA                | exercise           | 17  | 26.2  | 59    | 31.6  | / | / | / | / |
| Gulati S, 2017 <sup>195</sup>               | India              | others             | 122 |       | 57.38 | 30.4  | / | / | / | / |
| Rodriguez-Cristobal JJ, 2017 <sup>196</sup> | Spain              | others             | 846 | 56.53 | 77.19 | 34.1  | / | / | / | / |
| Vink RG, 2017 <sup>197</sup>                | The<br>Netherlands | diet               | 16  | 48.8  | 62.5  | 32.4  | / | / | / | / |
| Vors C, 2017 <sup>198</sup>                 | France             | others             | 8   | 31    | 0     | 33    | / | / | / | / |
| Ribeiro C, 2017 <sup>199</sup>              | Brazil             | others             | 78  | 36    | 69.23 | 31.8  | / | / | / | / |
| Ard JD, 2017 <sup>200</sup>                 | USA                | lifestyle          | 409 | 46.5  | 100   | 38.6  | / | / | / | / |
| Littlefield LA, 2017 <sup>201</sup>         | USA                | exercise           | 9   | 43    | 0     | 31.8  | / | / | / | / |
| Houghton D, 2017 <sup>202</sup>             | UK                 | exercise           | 27  | 54    | 0     | 31    | / | / | / | / |
| Trepanowski JF ,                            | USA                | diet               | 100 | 44    | 14    | 35    | / | / | / | / |

| 2017 <sup>203</sup>              |             |          |            |       |       |       |   |   |   |   |
|----------------------------------|-------------|----------|------------|-------|-------|-------|---|---|---|---|
| Fathi Y, 2017 <sup>204</sup>     | Iran        | others   | 133        | 35.58 | 100   | 29.04 | / | / | / | / |
| Juliana N, 2017 <sup>205</sup>   | Malaysia    | others   | 31         | 49.8  | 100   | 30.2  | / | / | / | / |
| Bonfante IL, 2017 <sup>206</sup> | Brazil      | exercise | 22         | 49.13 | 0     | 30.86 | / | / | / | / |
| Heggen E, 2017 <sup>207</sup>    | Norway      | others   | 108        | 51    | 73.15 | 30.5  | / | / | / | / |
| Williams EJ, 2017 <sup>208</sup> | Australia   | others   | 56         | 59.7  | 57.14 | 35.8  | / | / | / | / |
| Peterli R, 2017 <sup>209</sup>   | Switzerland | surgery  | 128        | 43    | 72    | 44    | / | / | / | / |
| Merra G, 2017 <sup>210</sup>     | Italy       | diet     | 54         | 44.6  | 70    | 31.31 | / | / | / | / |
| Pal S, 2017 <sup>211</sup>       | Australia   | others   | 107        | 49.14 | 57.48 | 32.38 | / | / | / | / |
| Bergeron N, 2016 <sup>212</sup>  | USA         | others   | 52         | 44.1  | 61.54 | 30.7  | / | / | / | / |
| Wittmann K, 2016 <sup>213</sup>  | Germany     | others   | <i>7</i> 5 | 77    | 100   | 24.1  | / | / | / | / |
| Veum VL, 2017 <sup>214</sup>     | Norway      | diet     | 38         |       | 0     | 33.9  | / | / | / | / |
| Coelho R, 2017 <sup>215</sup>    | Brasil      | others   | 15         | 31    | 100   | 31    | / | / | / | / |
| Kirwan JP, 2016 <sup>216</sup>   | USA         | diet     | 33         | 39    | 81.82 | 33.1  | / | / | / | / |
| Madjd A, 2016 <sup>217</sup>     | Iran        | exercise | 75         | 29.5  | 100   | 32    | / | / | / | / |
| Duncan S, 2016 <sup>218</sup>    | Australia   | others   | 313        | 54    | 43.77 | 32.8  | / | / | / | / |

| Lee M, 2016 <sup>219</sup>        | korea       | others             | 63  | 30.59 | 37.5  | 27.87 | / | / | / | / |
|-----------------------------------|-------------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Normandin E, 2017 <sup>220</sup>  | USA         | diet +<br>exercise | 126 | 69.5  | 56.35 | 30.6  | / | / | / | / |
| de Luis D,2016 <sup>221</sup>     | Spain       | diet               | 29  | 45.8  | 58.62 | 33.17 | / | / | / | / |
| Madjd A, 2017 <sup>222</sup>      | Iran        | diet               | 81  | 34.79 | 100   | 33.02 | / | / | / | / |
| Mosikanon K, 2017 <sup>223</sup>  | Thailand    | others             | 44  | 41.27 | 70.45 | 27.71 | / | / | / | / |
| Nikseresht M, 2016 <sup>224</sup> | Iran        | exercise           | 33  | 39.66 | 0     |       | / | / | / | / |
| Raatz SK, 2016 <sup>225</sup>     | USA         | others             | 19  | 51.6  | 57.89 | 29.2  | / | / | / | / |
| Ruggenenti P, 2017 <sup>226</sup> | Italy       | diet               | 70  | 59.8  | 14.9  | 29.8  | / | / | / | / |
| Risstad H, 2016 <sup>227</sup>    | Norway      | surgery            | 113 | 39.7  | 64.6  | 53.4  | / | / | / | / |
| Tomeleri CM, 2016 <sup>228</sup>  | Brazil      | exercise           | 38  | 68.2  | 100   | 27.5  | / | / | / | / |
| Cox AJ, 2017 <sup>229</sup>       | Australia   | others             | 115 | 35.5  | 66.96 | 26.3  | / | / | / | / |
| Camolas J, 2017 <sup>230</sup>    | Portugal    | lifestyle          | 94  | 44.86 | 80.85 | 43.14 | / | / | / | / |
| Valsesia A, 2016 <sup>231</sup>   | Switzerland | diet               | 383 | 42    | 0     | 34.3  | / | / | / | / |
| Weiss EP, 2016 <sup>232</sup>     | USA         | diet +<br>exercise | 52  | 57    | 75    | 27.7  | / | / | / | / |
| Byun MS, 2016 <sup>233</sup>      | korea       | others             | 166 |       | 51.8  | 25.16 | / | / | / | / |

| Mensinger JL, 2016 <sup>234</sup>       | USA       | others   | 80  |       | 100   | 38    | / | / | / | / |
|---|-----------|----------|-----|-------|-------|-------|---|---|---|---|
| Arzola-Paniagua MA, 2016 <sup>235</sup> | Mexico    | medicine | 84  | 38.7  | 83.33 | 35.1  | / | / | / | / |
| Dempsey PC, 2016 <sup>236</sup>         | Australia | exercise | 24  | 62    | 41.67 | 62    | / | / | / | / |
| Firouzjaei A, 2016 <sup>237</sup>       | China     | medicine | 39  | 41.33 | 58.97 | 27.9  | / | / | / | / |
| Dutour A, 2016 <sup>238</sup>           | France    | medicine | 44  | 52    | 52    | 36.1  | / | / | / | / |
| Tan S, $2016^{239}$                     | China     | exercise | 26  | 50.3  | 100   | 28.2  | / | / | / | / |
| Ma W, 2016 <sup>240</sup>               | USA       | diet     | 768 | 50.7  | 63.8  | 32.6  | / | / | / | / |
| Rigamonti AE, 2017 <sup>241</sup>       | Italy     | surgery  | 10  | 38.8  | 60    | 46    | / | / | / | / |
| Ji M, 2016 <sup>242</sup>               | China     | medicine | 166 | 53.85 | 61.45 | 27.7  | / | / | / | / |
| Daubenmier J, 2016 <sup>243</sup>       | USA       | others   | 194 | 47.5  | 82.47 | 35.5  | / | / | / | / |
| Razny U, 2015 <sup>244</sup>            | Poland    | diet     | 48  | 47    | 79.17 | 34.75 | / | / | / | / |
| Magkos F, 2016 <sup>245</sup>           | USA       | others   | 33  | 44    | 81.82 | 37.9  | / | / | / | / |
| Hosseini B, 2016 <sup>246</sup>         | Iran      | others   | 42  |       | 0     | 31.8  | / | / | / | / |
| Li J, 2016 <sup>247</sup>               | USA       | diet     | 34  | 53.5  | 67.65 | 30.9  | / | / | / | / |
| Stroeve JH, 2016 <sup>248</sup>         | Denmark   | diet     | 558 | 42    | 64.16 | 32.7  | / | / | / | / |
| Le T, 2016 <sup>249</sup>               | USA       | diet     | 245 | 50    | 100   | 33.5  | / | / | / | / |

| Ohara T, 2016 <sup>250</sup>      | Japan           | others             | 74   | 49.1  | 50    | 26.4 | / | / | / | / |
|-----------------------------------|-----------------|--------------------|------|-------|-------|------|---|---|---|---|
| Juraschek SP, 2016 <sup>251</sup> | USA             | diet               | 163  | 52.6  | 52    | 32.3 | / | / | / | / |
| Henson J, 2016 <sup>252</sup>     | UK              | exercise           | 22   | 66.6  | 100   | 32.9 | / | / | / | / |
| Loftus HL, 2015 <sup>253</sup>    | Australia       | others             | 30   | 41.4  | 70.73 | 32.5 | / | / | / | / |
| Besnier F, 2015 <sup>254</sup>    | France          | diet +<br>exercise | 136  | 30.1  | 100   | 33.1 | / | / | / | / |
| Said M, 2017 <sup>255</sup>       | Saudi<br>Arabia | exercise           | 32   | 30.12 | 100   | 32.6 | / | / | / | / |
| Fisher G, 2015 <sup>256</sup>     | USA             | exercise           | 28   | 20    | 0     | 29.5 | / | / | / | / |
| Barbour JA,, 2015 <sup>257</sup>  | Australia       | others             | 61   | 65    | 52.46 | 31   | / | / | / | / |
| Ribeiro AS, 2016 <sup>258</sup>   | UK              | others             | 28   | 23.1  | 100   | 29.5 | / | / | / | / |
| Rozati M, 2015 <sup>259</sup>     | USA             | others             | 41   | 72    | 65.85 | 29   | / | / | / | / |
| Yang J, 2015 <sup>260</sup>       | China           | surgery            | 64   | 40.9  | 65.63 | 32.1 | / | / | / | / |
| Pi-Sunyer X, 2015 <sup>261</sup>  | USA             | medicine           | 3731 | 45.1  | 78.5  | 38.3 | / | / | / | / |
| Osama AJ, 2015 <sup>262</sup>     | Saudi<br>Arabia | exercise           | 100  | 36.76 | 44    | 33   | / | / | / | / |
| Chen IJ, 2016 <sup>263</sup>      | Taiwan          | others             | 77   | 44.5  | 100   | 30.5 | / | / | / | / |

| Romero-Moraleda B,                    | Cracin    |          | 170 | 20.2  | E2 22 | 20.45 | / | , | / |   |
|---------------------------------------|-----------|----------|-----|-------|-------|-------|---|---|---|---|
| $2015^{264}$                          | Spain     | exercise | 173 | 38.2  | 53.33 | 30.45 | / | / | / | / |
| Rossi FE, 2016 <sup>265</sup>         | Brazil    | exercise | 70  | 61    | 100   | 28.89 | / | / | / | / |
| Song MY, 2015 <sup>266</sup>          | korea     | others   | 28  | 29.34 | 100   | 36.03 | / | / | / | / |
| Soto-Molina H, 2015 <sup>267</sup>    | Mexico    | medicine | 156 | 38.9  | 85.26 | 35.1  | / | / | / | / |
| Mahdavi R, 2015 <sup>268</sup>        | Iran      | others   | 84  | 40.3  | 100   | 32.3  | / | / | / | / |
| Bruun JM, 2015 <sup>269</sup>         | Denmark   | others   | 47  | 38.6  | 63.83 | 32.1  | / | / | / | / |
| Gatterer H, 2015 <sup>270</sup>       | Germany   | others   | 27  | 51.3  | 68.75 | 37.1  | / | / | / | / |
| Mateo-Gallego R , 2017 <sup>271</sup> | Spain     | diet     | 91  | 44    | 100   | 37.7  | / | / | / | / |
| Xu M, 2015 <sup>272</sup>             | USA       | diet     | 743 | 51.1  | 39    | 32.66 | / | / | / | / |
| Cho IJ, 2016 <sup>273</sup>           | korea     | others   | 41  | 40    | 53.66 | 27.1  | / | / | / | / |
| Robert SA, 2015 <sup>274</sup>        | Malaysia  | medicine | 42  | 34    | 0     | 35.9  | / | / | / | / |
| Ghafouri K, 2015 <sup>275</sup>       | UK        | exercise | 10  | 35.9  | 0     | 30.4  | / | / | / | / |
| Alencar MK, 2015 <sup>276</sup>       | USA       | others   | 10  | 52    | 100   | 39.1  | / | / | / | / |
| Fuller NR, 2015 <sup>277</sup>        | Australia | diet     | 140 | 59.8  | 55    | 34.6  | / | / | / | / |
| McFarlin BK, 2015 <sup>278</sup>      | USA       | others   | 14  | 22    | 100   | 31    | / | / | / | / |

| Macías-Cervantes                   | Marrian            | diet +             | 40  | 42.6  | 0     | 20.0  | / | 1 | /     |   |
|------------------------------------|--------------------|--------------------|-----|-------|-------|-------|---|---|-------|---|
| MH, 2015 <sup>279</sup>            | Mexico             | exercise           | 43  | 42.6  | 0     | 28.9  | / | / | /     | / |
| Risstad H, 2015 <sup>280</sup>     | Norway             | surgery            | 60  | 35.6  | 70    | 55    | / | / | 1.67% | / |
| Dodevska MS, 2016 <sup>281</sup>   | Serbia             | diet               | 50  | 57.66 | 62    | 32.07 | / | / | /     | / |
| Rezaeipour M, 2014 <sup>282</sup>  | Ukraine            | diet +<br>exercise | 30  | 58.8  | 0     | 30.65 | / | / | /     | / |
| Bajerska J, 2015 <sup>283</sup>    | Poland             | others             | 44  | 53    | 61.36 | 35    | / | / | /     | / |
| Yamauchi K, 2014 <sup>284</sup>    | Japan              | lifestyle          | 18  | 57.2  | 50    | 28    | / | / | /     | / |
| Moreira AP, 2016 <sup>285</sup>    | Brazil             | diet               | 65  | 27    | 0     | 29.9  | / | / | /     | / |
| Cases J, 2015 <sup>286</sup>       | France             | others             | 17  | 40.7  | 52.94 | 31.2  | / | / | /     | / |
| Worsley R, 2015 <sup>287</sup>     | Australia          | medicine           | 117 | 53.2  | 100   | 32.8  | / | / | /     | / |
| Hoddy KK, 2014 <sup>288</sup>      | USA                | others             | 59  | 45    | 84.75 | 34    | / | / | /     | / |
| Tay J, 2014 <sup>289</sup>         | Australia          | diet               | 115 | 58    | 42.61 | 34.6  | / | / | /     | / |
| Foraker RE, 2014 <sup>290</sup>    | USA                | diet               | 79  | 41.4  | 100   | 30.3  | / | / | /     | / |
| Choo J, 2014 <sup>291</sup>        | korea              | exercise           | 110 | 43.1  | 100   | 28.5  | / | / | /     | / |
| van Nielen M,, 2014 <sup>292</sup> | The<br>Netherlands | others             | 15  | 61    | 100   |       | / | / | /     | / |

| Moreira Alves RD, 2014 <sup>293</sup> | Brazil          | others             | 69  | 27.3  | 0     | 29.8  | / | / | / | / |
|---------------------------------------|-----------------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Bracale R, 2014 <sup>294</sup>        | Italy           | others             | 13  | 36.3  | 100   | 48    | / | / | / | / |
| Telles S, 2014 <sup>295</sup>         | India           | exercise           | 68  | 33.2  | 51.47 | 36.4  | / | / | / | / |
| Larsen RN, 2014 <sup>296</sup>        | Australia       | exercise           | 19  | 53.8  | 42    | 31.2  | / | / | / | / |
| Guo Y, 2014 <sup>297</sup>            | China           | others             | 64  | 37    | 48.44 | 34.2  | / | / | / | / |
| Saslow LR, 2014 <sup>298</sup>        | USA             | diet               | 34  | 59.7  | 73.53 | 36.8  | / | / | / | / |
| Tapsell LC, 2014 <sup>299</sup>       | Australia       | diet               | 112 | 48.9  | 75.22 | 29.98 | / | / | / | / |
| Lowndes J, 2014 <sup>300</sup>        | USA             | diet               | 65  | 39.12 | 47.69 | 28.58 | / | / | / | / |
| Thorp AA, 2014 <sup>301</sup>         | Australia       | others             | 23  | 48.2  | 26.09 | 29.6  | / | / | / | / |
| Wong AT, 2014 <sup>302</sup>          | Australia       | others             | 25  | 60    | 48    | 34    | / | / | / | / |
| Calbet JA, 2015 <sup>303</sup>        | Spain<br>Sweden | diet +<br>exercise | 15  | 41    | 0     | 30.4  | / | / | / | / |
| Mirzaei K, 2014 <sup>304</sup>        | Iran            | medicine           | 94  | 40.2  | 75.53 | 35.2  | / | / | / | / |
| Mellberg C, 2014 <sup>305</sup>       | Sweden          | diet               | 70  | 59.9  | 100   | 32.7  | / | / | / | / |
| Milsom VA, 2014 <sup>306</sup>        | USA             | others             | 112 | 48.01 | 89.29 | 31.44 | / | / | / | / |

| Shirai K, 2013 <sup>307</sup>        | Japan              | diet      | 229 | 51.1  | 55.02 | 30.4  | / | / | / | / |
|--------------------------------------|--------------------|-----------|-----|-------|-------|-------|---|---|---|---|
| Rabinovitz HR, 2014 <sup>308</sup>   | Israel             | diet      | 59  | 60.7  | 64.41 | 32.4  | / | / | / | / |
| Mielgo-Ayuso J , 2014 <sup>309</sup> | Spain              | others    | 78  |       | 100   | 34    | / | / | / | / |
| Hollander P, 2013 <sup>310</sup>     | USA                | medicine  | 424 | 53.9  | 54    | 36.6  | / | / | / | / |
| Alves NE, 2014 <sup>311</sup>        | Brazil             | diet      | 22  | 35.04 | 100   | 28.72 | / | / | / | / |
| Ruth MR, 2013 <sup>312</sup>         | USA                | diet      | 55  | 42.5  | 89    | 36.5  | / | / | / | / |
| Tovar J, 2014 <sup>313</sup>         | Sweden             | diet      | 64  | 61.6  | 100   | 28.8  | / | / | / | / |
| Croymans DM, 2014 <sup>314</sup>     | USA                | exercise  | 36  | 21    | 0     | 31.4  | / | / | / | / |
| Vetter ML, 2013 <sup>315</sup>       | USA                | lifestyle | 390 | 51.5  | 79.7  | 38.5  | / | / | / | / |
| Vinkers CD, 2014 <sup>316</sup>      | The<br>Netherlands | others    | 143 | 55.69 | 40.56 | 29.59 | / | / | / | / |
| Botero JP, 2014 <sup>317</sup>       | Brazil             | exercise  | 32  | 35    | 100   | 31.97 | / | / | / | / |
| Hu X, 2013 <sup>318</sup>            | china              | others    | 39  | 23.2  | 68.75 | 25.9  | / | / | / | / |
| Kim SH, 2013 <sup>319</sup>          | USA                | medicine  | 51  | 58    | 64.7  | 31.9  | / | / | / | / |
| Bouchonville $M$ , $2014^{320}$      | USA                | exercise  | 107 | 70    | 62.62 | 37.2  | / | / | / | / |

| Romero Moraleda B,                | C :       |           | 06  | 26.2  | Γ0    | 22.64 | , | / | / |   |
|-----------------------------------|-----------|-----------|-----|-------|-------|-------|---|---|---|---|
| 2013 <sup>321</sup>               | Spain     | exercise  | 96  | 36.2  | 50    | 33.64 | / | / | / | / |
| Ikramuddin S, 2013 <sup>322</sup> | USA       | surgery   | 120 | 49    | 60    | 34.6  | / | / | / | / |
| Tey S, 2013 <sup>323</sup>        | new       | others    | 107 | 42.5  | 57    | 30.6  | / | / | / | / |
| 1ey 3, 2013                       | Zealand   | others    | 107 | 42.5  | 57    | 30.0  | / | / | / | / |
| Nicklas JM, 2013 <sup>324</sup>   | USA       | diet      | 710 | 52    | 61    |       | / | / | / | / |
| Stocks T, 2013 <sup>325</sup>     | Denmark   | diet      | 585 | 37.1  | 75.38 | 35.5  | / | / | / | / |
| Wright OR, 2013 <sup>326</sup>    | Australia | others    | 16  | 53.1  | 0     | 32.8  | / | / | / | / |
| Kim SH, 2014 <sup>327,328</sup>   | korea     | lifestyle | 35  | 48.4  | 45.71 | 28.2  | / | / | / | / |
| Munro IA, 2013 <sup>328</sup>     | Australia | others    | 33  | 40.58 | 66.67 | 32.54 | / | / | / | / |
| Astell KJ, 2013 <sup>329</sup>    | Australia | others    | 33  | 46.6  | 78.79 | 32.2  | / | / | / | / |
| Tonstad S, 2014 <sup>330</sup>    | USA       | diet      | 173 | 48.4  | 73.99 | 36.5  | / | / | / | / |
| Venojärvi M, 2013 <sup>331</sup>  | Finland   | exercise  | 115 | 54.5  | 0     | 29.6  | / | / | / | / |
| Lamprecht M, 2013 <sup>332</sup>  | Austria   | others    | 42  | 41    | 100   | 34.5  | / | / | / | / |
| Tang M, 2013 <sup>333</sup>       | USA       | diet      | 43  | 48    | 0     | 31.7  | / | / | / | / |
| Reimer RA, 2013 <sup>334</sup>    | Japan     | others    | 56  |       | 55.36 | 27.0  | / | / | / | / |

| Fuller NR, 2013 <sup>335</sup>        | Australia | surgery            | 66   | 45.9  | 66.67 | 36.4  | / | / | / | / |
|---------------------------------------|-----------|--------------------|------|-------|-------|-------|---|---|---|---|
| Jakubowicz D, 2013 <sup>336</sup>     | Israel    | diet               | 93   | 45.8  | 100   | 32.4  | / | / | / | / |
| Beebe N, 2013 <sup>337</sup>          | USA       | diet +<br>exercise | 26   | 61.5  | 100   | 34.3  | / | / | / | / |
| Unick JL, 2013 <sup>338</sup>         | USA       | lifestyle          | 2503 |       | 0     | 35.9  | / | / | / | / |
| Mohler ER, 2013 <sup>339</sup>        | USA       | diet               | 121  | 45.7  | 65    | 35.8  | / | / | / | / |
| Bhutani S,2013 <sup>340</sup>         | USA       | diet +<br>exercise | 83   | 44    | 98.39 | 35    | / | / | / | / |
| Webber KH, 2013 <sup>341</sup>        | USA       | others             | 50   | 46    | 86    | 35.1  | / | / | / | / |
| Marinik EL, 2013 <sup>342</sup>       | USA       | medicine           | 16   | 49.5  | 50    | 33    | / | / | / | / |
| Zhu W, 2013 <sup>343</sup>            | China     | others             | 43   | 20.2  | 90.7  | 25.9  | / | / | / | / |
| García-Unciti M , 2012 <sup>344</sup> | Spain     | diet +<br>exercise | 34   | 50    | 100   | 34.9  | / | / | / | / |
| Vix M, 2013 <sup>345</sup>            | France    | surgery            | 100  | 35.18 | 82    | 46.25 | / | / | / | / |
| Klempel MC, 2012 <sup>346</sup>       | USA       | diet               | 54   | 47    | 100   | 35    | / | / | / | / |
| Venojärvi M, 2013 <sup>347</sup>      | Finland   | exercise           | 115  | 54    | 0     | 29.6  | / | / | / | / |
| Ho SS, 2012 <sup>348</sup>            | Australia | exercise           | 64   | 53    | 84.38 | 32.9  | / | / | / | / |

| Fayh AP, 2013 <sup>349</sup>      | Brazil  | diet +<br>exercise | 48  | 31.9  | 66.7  | 34.8  | / | / | / | / |
|-----------------------------------|---------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Sengupta K, 2012 <sup>350</sup>   | India   | medicine           | 41  | 39.5  | 70.7  | 33.7  | / | / | / | / |
| Itariu BK,2012 <sup>351</sup>     | Austria | others             | 55  | 38.5  | 83.64 | 46.6  | / | / | / | / |
| Whyte LJ, 2013 <sup>352</sup>     | UK      | exercise           | 10  | 26.9  | 0     | 29.9  | / | / | / | / |
| Melanson KJ, 2012 <sup>353</sup>  | USA     | diet               | 157 | 38.7  | 87.9  | 31.34 | / | / | / | / |
| Ponce J, 2012 <sup>354</sup>      | USA     | surgery            | 30  | 40.8  | 86.7  | 35    | / | / | / | / |
| Klempel MC, 2013 <sup>355</sup>   | USA     | diet               | 32  | 42.8  | 100   | 35.4  | / | / | / | / |
| Zhang X, 2012 <sup>356</sup>      | USA     | diet               | 734 | 50.9  | 61.17 | 32.7  | / | / | / | / |
| Ke B, 2012 <sup>357</sup>         | China   | diet +<br>medicine | 85  | 46.1  | 49.41 | 28.6  | / | / | / | / |
| Abdi H, 2012 <sup>358</sup>       | Iran    | others             | 169 | 38    | 0     | 31.78 | / | / | / | / |
| Foster GD, 2012 <sup>359</sup>    | USA     | diet               | 123 | 46.8  | 91.06 | 34    | / | / | / | / |
| Ebbeling CB, 2012 <sup>360</sup>  | USA     | diet               | 21  | 30.3  | 38    | 34.4  | / | / | / | / |
| Kelly AS, 2012 <sup>361</sup>     | USA     | medicine           | 50  | 58.5  | 76    | 35.6  | / | / | / | / |
| Suliburska J, 2012 <sup>362</sup> | Poland  | others             | 46  | 50.41 | 50    | 32.76 | / | / | / | / |
| Alizadeh M, 2012 <sup>363</sup>   | Iran    | diet               | 68  | 35.3  | 100   |       | / | / | / | / |

| Bjermo H, 2012 <sup>364</sup>    | Sweden             | others             | 61  |       | 0     | 30.8  | / | / | / | / |
|----------------------------------|--------------------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Backhouse K, 2012 <sup>365</sup> | UK                 | medicine           | 30  | 57.8  | 100   | 33    | / | / | / | / |
| Kim JW, 2012 <sup>366</sup>      | korea              | exercise           | 30  | 53.46 | 100   | 25.08 | / | / | / | / |
| Greene NP, 2012 <sup>367</sup>   | USA                | exercise           | 18  | 45    | 44.44 | 31.9  | / | / | / | / |
| Boesten JE,2012 <sup>368</sup>   | The<br>Netherlands | medicine           | 222 | 59.2  | 39.64 | 32.2  | / | / | / | / |
| Chen SC, 2012 <sup>369</sup>     | Taiwan             | others             | 63  | 32.8  | 66.7  | 27.81 | / | / | / | / |
| Elisha B,2012 <sup>370</sup>     | Canada             | diet +<br>exercise | 132 | 57.2  | 100   | 35    | / | / | / | / |
| Maersk M, 2012 <sup>371</sup>    | Denmark            | others             | 47  | 39    | 63.83 | 32.1  | / | / | / | / |
| Ross AB, 2012 <sup>372</sup>     | UK                 | others             | 267 | 45.7  | 50.45 | 30.2  | / | / | / | / |
| Andersson U, 2012 <sup>373</sup> | Sweden             | others             | 31  | 57    | 70.97 | 35.3  | / | / | / | / |
| Familiari P, 2011 <sup>374</sup> | Italy              | surgery            | 67  | 41    | 70.15 | 41.5  | / | / | / | / |
| Dillard TH, 2013 <sup>375</sup>  | Canada             | surgery            | 26  |       | 75    | 41.9  | / | / | / | / |
| Lee JA, 2012 <sup>376</sup>      | korea              | exercise           | 16  | 54.5  | 100   | 25.16 | / | / | / | / |
| Zunino SJ, 2012 <sup>377</sup>   | USA                | others             | 20  | 31    | 65    | 34.4  | / | / | / | / |

| Timmers S, 2011 <sup>378</sup>   | The<br>Netherlands | others             | 11  | 31.59 | 0     | 31.59 | / | / | / | / |
|----------------------------------|--------------------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Balducci S, 2012 <sup>379</sup>  | Italy              | exercise           | 73  | 60.6  | 45.2  | 31.3  | / | / | / | / |
| Valente EA,2011 <sup>380</sup>   | USA                | diet +<br>exercise | 27  | 66.6  | 59.26 | 31.7  | / | / | / | / |
| Farina MG, 2012 <sup>381</sup>   | Italy              | surgery            | 50  | 35    | 78    | 41.8  | / | / | / | / |
| Leichtle AB, 2011 <sup>382</sup> | Israel             | diet               | 90  | 53    | 0     | 28.7  | / | / | / | / |
| Petry NM, 2011 <sup>383</sup>    | USA                | surgery            | 56  | 45.7  | 87.5  | 34.1  | / | / | / | / |
| Brown AL, 2011 <sup>384</sup>    | UK                 | others             | 137 | 49.4  | 0     | 31.5  | / | / | / | / |
| Kim EK, 2011 <sup>385</sup>      | korea              | others             | 22  | 38.6  | 68.18 | 27.7  | / | / | / | / |
| Pfeuffer M, 2011 <sup>386</sup>  | Germany            | others             | 81  |       | 0     | 28.3  | / | / | / | / |
| Lyon M, 2011 <sup>387</sup>      | France             | others             | 59  | 37.2  | 53.33 | 30.5  | / | / | / | / |
| Dekkers JC, 2011 <sup>388</sup>  | The<br>Netherlands | lifestyle          | 276 | 44    | 30.8  | 29.7  | / | / | / | / |
| Farnetti S, 2011 <sup>389</sup>  | Italy              | others             | 12  | 41    | 100   | 32.8  | / | / | / | / |
| Venn BJ, 2010 <sup>390</sup>     | UK                 | diet               | 108 | 42    | 86.11 | 35.4  | / | / | / | / |
| Chen SC, 2010 <sup>391</sup>     | Taiwan             | exercise           | 104 | 58.3  | 46.73 | 33.4  | / | / | / | / |

| Miyashita M, 2010 <sup>392</sup>        | Japan          | exercise           | 10   | 46   | 0     | 31.6 | / | / | / | / |
|---|----------------|--------------------|------|------|-------|------|---|---|---|---|
| Morenga LT, 2010 <sup>393</sup>         | New<br>Zealand | diet               | 83   | 41.7 | 100   | 32.6 | / | / | / | / |
| Pal S, 2011 <sup>394</sup>              | Australia      | diet               | 57   | 43   | 61.4  | 34.4 | / | / | / | / |
| Greenway FL, 2010 <sup>395</sup>        | USA            | medicine           | 1742 | 44.2 | 85    | 36.2 | / | / | / | / |
| Torres MR, 2010 <sup>396</sup>          | Brazil         | diet               | 50   | 40.4 | 90    | 32.2 | / | / | / | / |
| Herrera MF, 2010 <sup>397</sup>         | Mexico         | surgery            | 22   | 38.3 | 81.82 | 44.7 | / | / | / | / |
| Palacios C, 2011 <sup>398</sup>         | USA            | others             | 24   | 37.7 | 80    | 38.4 | / | / | / | / |
| Ferré R, 2012 <sup>399</sup>            | Spain          | lifestyle          | 142  | 54.1 | 74.6  | 31.6 | / | / | / | / |
| Pal S, 2010 <sup>400</sup>              | Australia      | others             | 20   |      | 100   |      | / | / | / | / |
| Hermsdorff HH , $2011^{401}$            | Spain          | diet               | 30   | 36   | 43.33 | 32.5 | / | / | / | / |
| Plotnikoff RC, 2010 <sup>402</sup>      | Canada         | exercise           | 48   | 55   | 66.67 | 35   | / | / | / | / |
| Papakonstantinou E, 2010 <sup>403</sup> | Greece         | diet               | 17   | 46   | 70.59 | 34   | / | / | / | / |
| Wycherley TP, 2010 <sup>404</sup>       | Australia      | diet +<br>exercise | 59   | 56.1 | 0     | 35.4 | / | / | / | / |

| Jorde R, 2010 <sup>405</sup>            | Norway    | others   | 438 | 47.5  | 64.2  | 34.7  | / | / | / | / |
|---|-----------|----------|-----|-------|-------|-------|---|---|---|---|
| Hernandez TL, 2010 <sup>406</sup>       | USA       | diet     | 32  | 43.1  | 68.75 | 36.3  | / | / | / | / |
| Ibáñez J, 2010 <sup>407</sup>           | Spain     | exercise | 34  | 50    | 100   | 34.9  | / | / | / | / |
| Gripeteg L, 2010 <sup>408</sup>         | Sweden    | diet     | 169 | 41.3  | 64.5  | 41.6  | / | / | / | / |
| Tapsell L, 2010 <sup>409</sup>          | Australia | diet     | 122 | 44.4  | 0     | 31    | / | / | / | / |
| Armendáriz-Anguiano $AL$ , $2011^{410}$ | Mexico    | diet     | 54  | 35.4  | 67.2  | 31.6  | / | / | / | / |
| Amare F, 2024 <sup>411</sup>            | Ethiopia  | exercise | 20  | 49.15 | 0     | 27.67 | / | / | / | / |
| Chen CY, 2024 <sup>412</sup>            | Taiwan    | others   | 53  | 59.8  | 100   | 26.7  | / | / | / | / |
| Chandake S, 2024 <sup>413</sup>         | India     | others   | 48  | 43.5  | 70.8  | 30.96 | / | / | / | / |
| Baba Y, 2024 <sup>414</sup>             | Japan     | others   | 40  | 47.75 | 80    | 26.78 | / | / | / | / |
| Sooriyaarachchi P, 2024 <sup>415</sup>  | Sri Lanka | others   | 50  | 36.1  | 78    | 31    | / | / | / | / |
| Lee Y, 2024 <sup>416</sup>              | korea     | others   | 21  | 30.24 | 100   | 24.59 | / | / | / | / |
| Elahikhah M, 2024 <sup>417</sup>        | Iran      | others   | 41  | 36.95 | 100   | 34.37 | / | / | / | / |
| Dotimas LG, 2024 <sup>418</sup>         | USA       | others   | 39  | 26.5  | 43.59 | 27.3  | / | / | / | / |
| Govindasamy K ,                         | India     | exercise | 60  |       | 0     | 30.04 | / | / | / | / |

| 2024 <sup>419</sup>                          |           |           |       |       |       |       |   |   |   |   |
|--|-----------|-----------|-------|-------|-------|-------|---|---|---|---|
| Shin SM, 2024 <sup>420</sup>                 | korea     | others    | 100   | 48.02 | 85    | 27.43 | / | / | / | / |
| Mongkolsucharitkul<br>P, 2024 <sup>421</sup> | Thailand  | others    | 41    | 50    | 58.5  | 30    | / | / | / | / |
| Laouani A, 2024 <sup>422</sup>               | Tunisia   | others    | 43    | 41.32 | 100   | 34.54 | / | / | / | / |
| Khan G, 2024 <sup>423</sup>                  | Pakistan  | others    | 60    |       | 40    | 31.43 | / | / | / | / |
| Diao Z, 2024 <sup>424</sup>                  | Iran      | diet      | 120   | 42.51 | 39.17 | 28.29 | / | / | / | / |
| López-Yerena A , 2023 <sup>425</sup>         | Spain     | others    | 40    | 40.8  | 32.5  | 31.16 | / | / | / | / |
| Aghabeiglooei $Z$ , $2023^{426}$             | Iran      | diet      | 60    | 35.2  | 100   | 31.34 | / | / | / | / |
| Tricò D, 2024 <sup>427</sup>                 | Italy     | diet      | 23    | 67.2  | 47.8  | 29.4  | / | / | / | / |
| Lincoff AM, 2023 <sup>428</sup>              | USA       | medicine  | 17604 | 61.6  | 27.7  | 33.3  | / | / | / | / |
| Zhang X, 2023 <sup>429</sup>                 | USA       | lifestyle | 40    | 50    | 90    | 36.1  | / | / | / | / |
| Luo Y, 2023 <sup>430</sup>                   | China     | diet      | 1348  | 55    | 52.3  | 24.2  | / | / | / | / |
| Sordi AF, 2023 <sup>431</sup>                | Brazil    | others    | 35    | 47    | 24.24 | 31.4  | / | / | / | / |
| Carter S, 2023 <sup>432</sup>                | Australia | others    | 140   | 47.5  | 70    | 30.7  | / | / | / | / |

| Clina JG, 2023 <sup>433</sup>              | USA     | diet               | 106 | 54.8  | 75.47 | 38.8  | / | / | / | / |
|--|---------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Niu Y, 2023 <sup>434</sup>                 | China   | exercise           | 81  | 18.52 | 0     | 26.25 | / | / | / | / |
| Grohmann T, 2023 <sup>435</sup>            | UK      | others             | 14  | 57.7  | 71.43 | 35.9  | / | / | / | / |
| Sun L, 2023 <sup>436</sup>                 | China   | medicine           | 39  | 47.17 | 66.67 | 26.48 | / | / | / | / |
| Quaresma LS, 2023 <sup>437</sup>           | Brazil  | others             | 20  |       | 100   | 34.2  | / | / | / | / |
| Aldubayan MA , 2023 <sup>438</sup>         | Denmark | others             | 82  | 45    | 68    | 32    | / | / | / | / |
| Cho E, 2023 <sup>439</sup>                 | korea   | others             | 100 | 50    | 37    | 28.2  | / | / | / | / |
| Castaldo G, 2023440                        | Italy   | others             | 60  | 37.77 | 80    | 46.59 | / | / | / | / |
| Ghalichi F, 2023 <sup>441</sup>            | Iran    | others             | 44  | 52.39 | 22.73 | 36.71 | / | / | / | / |
| Felipe LA, 2023 <sup>442</sup>             | Brazil  | surgery            | 32  | 42.44 | 100   | 46.32 | / | / | / | / |
| Ragland TJ, 2023 <sup>443</sup>            | USA     | diet +<br>exercise | 25  | 48.6  | 100   | 37.6  | / | / | / | / |
| Cai H, 2023 <sup>444</sup>                 | China   | others             | 156 | 40.9  | 36.54 | 30    | / | / | / | / |
| Turner-McGrievy<br>GM, 2023 <sup>445</sup> | USA     | diet               | 159 | 48.3  | 79    |       | / | / | / | / |
| Belany P, 2023 <sup>446</sup>              | USA     | diet               | 37  | 33    | 51    | 30.6  | / | / | / | / |

| Gayathri R, 2023 <sup>447</sup>          | India     | others   | 352 | 38    | 0     | 28.4  | / | / | / | / |
|--|-----------|----------|-----|-------|-------|-------|---|---|---|---|
| Cruvinel BAC, 2023448                    | Brasil    | others   | 30  | 49    | 60    | 32.78 | / | / | / | / |
| Hassan RHA, 2023 <sup>449</sup>          | Egypt     | others   | 10  | 34.5  | 100   |       | / | / | / | / |
| Carvalho APSd , 2023 <sup>450</sup>      | Brazil    | diet     | 87  | 43.18 | 100   | 36.6  | / | / | / | / |
| Sohn M, 2023 <sup>451</sup>              | korea     | others   | 99  | 40.2  | 57.58 | 27.4  | / | / | / | / |
| Rondanelli M, 2022 <sup>452</sup>        | Italy     | others   | 28  | 58.75 | 100   | 31.55 | / | / | / | / |
| Rebello CJJ, 2022 <sup>453</sup>         | USA       | others   | 36  | 45    | 77.78 | 34.18 | / | / | / | / |
| Xu R, 2022 <sup>454</sup>                | China     | diet     | 48  | 21.3  | 56.25 | 25.86 | / | / | / | / |
| Reis PCdSG, 2022 <sup>455</sup>          | Brazil    | others   | 35  | 48.29 | 100   | 31.1  | / | / | / | / |
| Colak D, 2022 <sup>456</sup>             | Slovenia  | surgery  | 26  | 50.7  | 73.08 | 47.8  | / | / | / | / |
| Freer CL, 2022 <sup>457</sup>            | Australia | exercise | 29  | 67.3  | 44.83 | 31.9  | / | / | / | / |
| Yin W, 2022 <sup>458</sup>               | China     | others   | 99  | 47.3  | 59.6  | 29.15 | / | / | / | / |
| Coker MS, 2022 <sup>459</sup>            | USA       | others   | 29  | 68.3  | 58.62 | 32.3  | / | / | / | / |
| Mohammadi-Sartang M, 2023 <sup>460</sup> | Iran      | others   | 84  | 43.6  | 67.86 | 30.3  | / | / | / | / |
| Jamshed H, 2022 <sup>461</sup>           | USA       | diet     | 90  | 43    | 80    | 39.6  | / | / | / | / |

| Roach LA, 2022 <sup>462</sup>        | Australia          | others             | 124 | 53   | 55.65 | 30    | / | / | / | / |
|--------------------------------------|--------------------|--------------------|-----|------|-------|-------|---|---|---|---|
| Kleinloog JPD, 2022 <sup>463</sup>   | The<br>Netherlands | exercise           | 17  | 67   | 0     | 30.3  | / | / | / | / |
| Pavão TP, 2022 <sup>464</sup>        | Brazil             | others             | 18  | 37.4 | 61.1  | 28.96 | / | / | / | / |
| Castela I, 2022 <sup>465</sup>       | Norway             | diet               | 28  | 39.3 | 78.57 | 35.4  | / | / | / | / |
| Chekima K, 2022 <sup>466</sup>       | Malaysia           | others             | 40  | 26.4 | 57.5  | 29.4  | / | / | / | / |
| Cipryan L, 2022 <sup>467</sup>       | Czechia            | diet +<br>exercise | 91  | 43   | 70.33 | 30    | / | / | / | / |
| Ali Sangouni A , 2022 <sup>468</sup> | Iran               | others             | 71  | 50   | 43.67 | 27.38 | / | / | / | / |
| Timmons JF, 2023 <sup>469</sup>      | Ireland            | exercise           | 18  | 25.7 | 0     | 27.7  | / | / | / | / |
| Catley D, 2022 <sup>470</sup>        | South Africa       | others             | 494 | 67.7 | 88.66 | 34.54 | / | / | / | / |
| Mendelson M, 2022 <sup>471</sup>     | France             | exercise           | 60  | 54   | 31.67 | 31.5  | / | / | / | / |
| Ruban A, 2022 <sup>472</sup>         | UK                 | surgery            | 170 | 51.8 | 46    | 36.3  | / | / | / | / |
| Li Y, 2022 <sup>473</sup>            | China              | others             | 69  | 30.9 | 0     | 31.32 | / | / | / | / |
| Vodouhè M, 2022 <sup>474</sup>       | Canada             | others             | 56  |      | 61    | 33    | / | / | / | / |
| Dimitrov Ulian M ,                   | Brazil             | others             | 55  | 33   | 100   | 33.6  | / | / | / | / |

| 2022 <sup>475</sup>                    |           |          |     |       |       |        |   |   |   |   |
|--|-----------|----------|-----|-------|-------|--------|---|---|---|---|
| Viveros-Watty PE , $2022^{476}$        | Mexico    | others   | 45  | 21.54 | 68.89 | 31.79  | / | / | / | / |
| Chair SY, 2022 <sup>477</sup>          | China     | diet     | 101 | 35.23 | 63.33 | 26.56  | / | / | / | / |
| Karandish M, 2022 <sup>478</sup>       | Iran      | others   | 82  | 36.04 | 68.29 | 30.21  | / | / | / | / |
| Lim SL, 2022 <sup>479</sup>            | Singapore | others   | 148 | 53.1  | 39.86 | 29.8   | / | / | / | / |
| Thomsen MN, 2022 <sup>480</sup>        | Denmark   | diet     | 67  | 66.7  | 47.76 | 33.4   | / | / | / | / |
| Seeberg KA, 2022 <sup>481</sup>        | Norway    | surgery  | 100 | 46.5  | 65    | 42     | / | / | / | / |
| Ruegsegger GN ,<br>2022 <sup>482</sup> | USA       | diet     | 12  | 35.9  | 0     | 32.4   | / | / | / | / |
| Liu B, 2021 <sup>483</sup>             | Australia | diet     | 76  | 51    | 100   | 32.1   | / | / | / | / |
| Cao JJ, 2021 <sup>484</sup>            | USA       | others   | 102 | 40.6  | 75.49 | 34.6   | / | / | / | / |
| Kang C, 2021 <sup>485</sup>            | China     | medicine | 159 | 48.49 | 45.28 | 27.334 | / | / | / | / |
| Che T, 2021 <sup>486</sup>             | China     | others   | 120 | 48.5  | 45.83 | 26.25  | / | / | / | / |
| Miller L, 2021 <sup>487</sup>          | USA       | others   | 22  | 42.5  | 68.18 | 32.5   | / | / | / | / |
| Batrakoulis A, 2021 <sup>488</sup>     | Greece    | exercise | 35  | 36.4  | 100   | 29.1   | / | / | / | / |
| Chang WL, 2021 <sup>489</sup>          | Malaysia  | others   | 49  | 29    | 65.3  | 25.25  | / | / | / | / |

| Serna A, 2022 <sup>490</sup>                | Spain              | others   | 33  | 33.76 | 51.5  | 28.2  | / | / | / | / |
|---|--------------------|----------|-----|-------|-------|-------|---|---|---|---|
| Delgado-Floody P , 2021 <sup>491</sup>      | Chile              | exercise | 26  | 40.14 | 100   | 41.77 | / | / | / | / |
| Falkenhain K, 2021 <sup>492</sup>           | USA                | others   | 155 | 41    | 71    | 34    | / | / | / | / |
| Said MA, 2021 <sup>493</sup>                | Saudi<br>Arabia    | exercise | 57  | 21.74 | 0     | 36.21 | / | / | / | / |
| Ahmadniay Motlagh<br>H, 2021 <sup>494</sup> | Sweden             | others   | 52  | 39.81 | 100   | 30.78 | / | / | / | / |
| Te Morenga L, 2021 <sup>495</sup>           | New<br>Zealand     | others   | 41  | 33.9  | 48.78 | 31.6  | / | / | / | / |
| Shikishima Y, 2021 <sup>496</sup>           | Japan              | others   | 38  | 46.6  | 50    | 25.2  | / | / | / | / |
| Liddle DM, 2021 <sup>497</sup>              | Canada             | others   | 44  | 45.4  | 68.18 | 33.4  | / | / | / | / |
| Wang J, 2021 <sup>498</sup>                 | USA                | others   | 95  | 47.7  | 74.74 | 30.9  | / | / | / | / |
| Grytten E, 2021 <sup>499</sup>              | Norway             | others   | 39  | 56    | 41.03 | 29.2  | / | / | / | / |
| Schroor MM, 2021 <sup>500</sup>             | The<br>Netherlands | diet     | 18  | 65    | 0     | 30.5  | / | / | / | / |
| Bhoite R, 2021 <sup>501</sup>               | India              | others   | 100 | 51    | 49    | 28.7  | / | / | / | / |

| van der Merwe M ,<br>2021 <sup>502</sup> | USA       | others   | 57  | 36.18 | 100   | 30.55 | / | / | / | / |
|--|-----------|----------|-----|-------|-------|-------|---|---|---|---|
| Waliłko E, 2021 <sup>503</sup>           | Poland    | diet     | 35  | 41.5  | 88.57 | 33.6  | / | / | / | / |
| Ng SC, 2022 <sup>504</sup>               | China     | others   | 61  | 55.5  | 70.49 | 32.1  | / | / | / | / |
| do Rosario VA, 2021 <sup>505</sup>       | Australia | others   | 16  | 65.9  | 81.25 | 30.6  | / | / | / | / |
| Amaro-Gahete FJ , 2021 <sup>506</sup>    | Spain     | exercise | 12  | 42.5  | 0     | 32.3  | / | / | / | / |
| Kim KW, 2021 <sup>507</sup>              | korea     | others   | 120 | 36.88 | 100   | 28.53 | / | / | / | / |
| Jiang W, 2021 <sup>508</sup>             | China     | others   | 254 | 31.85 | 41.34 | 32.42 | / | / | / | / |
| D'Amuri A, 2021 <sup>509</sup>           | Italy     | exercise | 32  | 38.5  | 47    | 35.6  | / | / | / | / |
| Yılmaz SK, 2021 <sup>510</sup>           | Turkey    | diet     | 60  | 33.2  | 100   | 32.5  | / | / | / | / |
| Barnard ND, 2022 <sup>511</sup>          | USA       | diet     | 62  | 57.4  | 77.42 | 34    | / | / | / | / |
| Netto Cândido TL, 2021 <sup>512</sup>    | Brazil    | diet     | 52  | 26.81 | 100   | 29.9  | / | / | / | / |
| Abbott K, 2020 <sup>513</sup>            | Australia | others   | 61  | 51.5  | 63.93 | 32.9  | / | / | / | / |
| Kruschitz R, 2020 <sup>514</sup>         | Austria   | surgery  | 50  | 42    | 80    | 44    | / | / | / | / |
| Kahleova H, 2020 <sup>515</sup>          | USA       | diet     | 223 | 54.4  | 87    | 33.4  | / | / | / | / |

| Cheshmazar E, 2020 <sup>516</sup>      | Iran               | others | 55 | 37.63 | 66.1  | 32.33 | / | / | / | / |
|--|--------------------|--------|----|-------|-------|-------|---|---|---|---|
| Bove KB, 2020 <sup>517</sup>           | Denmark            | others | 56 | 63.7  | 100   | 30.1  | / | / | / | / |
| de Ligt M,2020 <sup>518</sup>          | Netherlands        | others | 41 | 62    | 41.46 | 29    | / | / | / | / |
| Bratlie M, 2021 <sup>519</sup>         | Norway             | others | 63 | 45.5  | 55.38 | 32.3  | / | / | / | / |
| Klomklorm A, 2020 <sup>520</sup>       | Thailand           | others | 36 | 41.6  | 91.67 | 28.3  | / | / | / | / |
| Li L, 2020 <sup>521</sup>              | UK                 | others | 15 | 28.7  | 66.67 | 28.3  | / | / | / | / |
| Cienfuegos S, 2020 <sup>522</sup>      | USA                | others | 58 | 46    | 91.38 | 37    | / | / | / | / |
| Jamar G, 2020 <sup>523</sup>           | Brazil             | others | 35 | 46.5  | 60    | 34.4  | / | / | / | / |
| Goss AM, 2020 <sup>524</sup>           | USA                | diet   | 34 | 70.2  | 64.71 | 34.3  | / | / | / | / |
| Jafari-Maskouni S, 2020 <sup>525</sup> | Iran               | others | 52 | 51.29 | 67.31 | 28.97 | / | / | / | / |
| Takagi T, 2020 <sup>526</sup>          | Japan              | others | 24 | 46.7  | 0     | 28.8  | / | / | / | / |
| Remie CME, 2020 <sup>527</sup>         | Netherlands        | others | 12 | 59    | 58.33 | 30.2  | / | / | / | / |
| Joris PJ, 2020 <sup>528</sup>          | The<br>Netherlands | others | 59 | 60    | 32.2  | 28.5  | / | / | / | / |
| Smeets E, 2021 <sup>529</sup>          | The<br>Netherlands | diet   | 18 | 65    | 0     | 30.5  | / | / | / | / |

| Campa F, 2020 <sup>530</sup> Italy         exercise         39         56.5         100         37.1         /           |                                   |           |          |     |       |       |       |   |   |   |   |
|--|-----------------------------------|-----------|----------|-----|-------|-------|-------|---|---|---|---|
| Rock CL, 2020 <sup>532</sup> USA         others         100         55.6         62         32.8         /               | Campa F, 2020 <sup>530</sup>      | Italy     | exercise | 39  | 56.5  | 100   | 37.1  | / | / | / | / |
| Vors C, 2020 <sup>533</sup> France others 58 59 100 29.7 / / / / / Lopez HL, 2020 <sup>534</sup> USA others 65 35.2 50.77 28.5 / / / / / / AlFaris NA, 2020 <sup>535</sup> Saudi Arabia diet 78 100 35.1 / / / / / / / / / Chow LS, 2020 <sup>536</sup> USA others 20 45.5 85 34.1 / / / / / / / / / Marco-Benedí V , 2020 <sup>537</sup> Spain diet 73 55.6 56.2 32.8 / / / / / / / / / / / 2020 <sup>537</sup> Canada others 26 45.5 65.38 34.1 / / / / / / / / Lorkowski SW, 2020 <sup>539</sup> USA surgery 90 49.43 67.78 36.33 / / / / / / / Lorkowski SW, 2020 <sup>540</sup> UK diet 8 46.4 0 32.3 / / / / / / / / Sintzas K, 2020 <sup>541</sup> Iran others 40 38.43 100 27.47 / / / / / / Edinburgh RM, 2020 <sup>542</sup> UK exercise 30 0 30.9 / / / / / / Asgary S, 2020 <sup>543</sup> Iran others 40 32.58 55 29.65 / / / / / /   | Reimer RA, 2020 <sup>531</sup>    | Canada    | others   | 290 | 54.8  | 68.28 | 39.9  | / | / | / | / |
| Lopez HL, 2020 <sup>534</sup> USA others 65 35.2 50.77 28.5 / / / / / / AlFaris NA, 2020 <sup>535</sup> Saudi Arabia diet 78 100 35.1 / / / / / / / / / / / / / / / / / / /  | Rock CL, 2020 <sup>532</sup>      | USA       | others   | 100 | 55.6  | 62    | 32.8  | / | / | / | / |
| AlFaris NA, 2020 <sup>536</sup> Saudi Arabia  Chow LS, 2020 <sup>536</sup> USA  others  20  45.5  85  34.1  /  Marco-Benedí V  Spain  diet  73  55.6  56.2  32.8  /  /  Lin X, 2020 <sup>538</sup> Canada  others  26  45.5  65.38  34.1  /  /  Lorkowski SW, 2020 <sup>539</sup> USA  surgery  90  49.43  67.78  36.33  /  Tsintzas K, 2020 <sup>540</sup> UK  diet  8  46.4  0  38.43  100  27.47  /  Asgary S, 2020 <sup>543</sup> Iran  others  40  32.58  55  29.65  /  /  /  /  /  /  /  /  /  /  /  /  /  | Vors C, 2020 <sup>533</sup>       | France    | others   | 58  | 59    | 100   | 29.7  | / | / | / | / |
| AlFaris NA, 2020 <sup>535</sup> Arabia  Chow LS, 2020 <sup>536</sup> USA  others  20  45.5  85  34.1  /  Marco-Benedí V  Spain  diet  73  55.6  56.2  32.8  /  Lin X, 2020 <sup>537</sup> Canada  others  26  45.5  65.38  34.1  /  /  Lorkowski SW, 2020 <sup>539</sup> USA  surgery  90  49.43  67.78  36.33  /  Tsintzas K, 2020 <sup>540</sup> UK  diet  8  46.4  0  32.3  /  J  /  Asgary S, 2020 <sup>543</sup> Iran  others  40  32.58  55  29.65  /  /  /  /  /  /  /  /  /  /  /  /  /  | Lopez HL, 2020 <sup>534</sup>     | USA       | others   | 65  | 35.2  | 50.77 | 28.5  | / | / | / | / |
| Marco-Benedí         V         Spain         diet         73         55.6         56.2         32.8         /         /         /         /         /           Lin X, 2020 <sup>538</sup> Canada         others         26         45.5         65.38         34.1         /< | AlFaris NA, 2020 <sup>535</sup>   |           | diet     | 78  |       | 100   | 35.1  | / | / | / | / |
| Spain diet 73 55.6 56.2 32.8 / / / / / Lin X, 2020 <sup>538</sup> Canada others 26 45.5 65.38 34.1 / / / / Lorkowski SW, 2020 <sup>539</sup> USA surgery 90 49.43 67.78 36.33 / / / / Tsintzas K, 2020 <sup>540</sup> UK diet 8 46.4 0 32.3 / / / / Dolati S, 2020 <sup>541</sup> Iran others 40 38.43 100 27.47 / / / Edinburgh RM, 2020 <sup>542</sup> UK exercise 30 0 30.9 / / / / Asgary S, 2020 <sup>543</sup> Iran others 40 32.58 55 29.65 / / / /   | Chow LS, 2020 <sup>536</sup>      | USA       | others   | 20  | 45.5  | 85    | 34.1  | / | / | / | / |
| Lorkowski SW, 2020 <sup>539</sup> USA       surgery       90       49.43       67.78       36.33       /   |                                   | Spain     | diet     | 73  | 55.6  | 56.2  | 32.8  | / | / | / | / |
| Tsintzas K, 2020 <sup>540</sup> UK diet 8 46.4 0 32.3 / / / / / Dolati S, 2020 <sup>541</sup> Iran others 40 38.43 100 27.47 / / / / Edinburgh RM, 2020 <sup>542</sup> UK exercise 30 0 30.9 / / / / Asgary S, 2020 <sup>543</sup> Iran others 40 32.58 55 29.65 / / / /   | Lin X, 2020 <sup>538</sup>        | Canada    | others   | 26  | 45.5  | 65.38 | 34.1  | / | / | / | / |
| Dolati S, 2020 <sup>541</sup> Iran       others       40       38.43       100       27.47       /       /       /       /         Edinburgh RM, 2020 <sup>542</sup> UK       exercise       30       0       30.9       /       /       /       /       /         Asgary S, 2020 <sup>543</sup> Iran       others       40       32.58       55       29.65       /       /       /       /       /   | Lorkowski SW, 2020 <sup>539</sup> | USA       | surgery  | 90  | 49.43 | 67.78 | 36.33 | / | / | / | / |
| Edinburgh RM, 2020 <sup>542</sup> UK exercise 30 0 30.9 / / / / / Asgary S, 2020 <sup>543</sup> Iran others 40 32.58 55 29.65 / / / /  | Tsintzas K, 2020 <sup>540</sup>   | UK        | diet     | 8   | 46.4  | 0     | 32.3  | / | / | / | / |
| Asgary S, 2020 <sup>543</sup> Iran others 40 32.58 55 29.65 / / / /  | Dolati S, 2020 <sup>541</sup>     | Iran      | others   | 40  | 38.43 | 100   | 27.47 | / | / | / | / |
|  | Edinburgh RM, 2020 <sup>542</sup> | UK        | exercise | 30  |       | 0     | 30.9  | / | / | / | / |
| Perissiou M, $2020^{544}$ Australia diet + 64 35.3 32.81 30.3 / / / /  | Asgary S, 2020 <sup>543</sup>     | Iran      | others   | 40  | 32.58 | 55    | 29.65 | / | / | / | / |
|  | Perissiou M, 2020 <sup>544</sup>  | Australia | diet +   | 64  | 35.3  | 32.81 | 30.3  | / | / | / | / |

|                                       |              | exercise |     |       |            |       |   |   |   |   |
|---------------------------------------|--------------|----------|-----|-------|------------|-------|---|---|---|---|
| Kuo YC,2020 <sup>545</sup>            | Taiwan       | exercise | 28  | 37.6  | <i>7</i> 5 | 30.75 | / | / | / | / |
| Nishimura M, 2020 <sup>546</sup>      | Japan        | others   | 67  | 49.85 | 85.19      | 24.8  | / | / | / | / |
| Gajewska D, 2019 <sup>547</sup>       | Poland       | others   | 150 | 60.7  | 50.67      | 32.8  | / | / | / | / |
| Karimi-Nazari E , 2019 <sup>548</sup> | Iran         | others   | 75  | 57.92 | 64         | 29.05 | / | / | / | / |
| Tanaka Y,2020 <sup>549</sup>          | Japan        | others   | 96  | 41.4  | 49         | 26.1  | / | / | / | / |
| Mollentze WF, 2019 <sup>550</sup>     | South Africa | diet     | 18  | 55.09 | 0          | 40.7  | / | / | / | / |
| Chiang TL, 2019 <sup>551</sup>        | Taiwan       | exercise | 32  | 19.72 | 0          | 30.38 | / | / | / | / |
| Kraus WE, 2019 <sup>552</sup>         | USA          | diet     | 218 | 38    | 69.72      | 25.2  | / | / | / | / |
| Malik VS, 2019 <sup>553</sup>         | India        | others   | 166 | 37.1  | 45         | 28.1  | / | / | / | / |
| Aghasi M,2019 <sup>554</sup>          | Iran         | others   | 83  | 53.6  | 53.01      | 29.08 | / | / | / | / |
| Hirsh SP, 2019 <sup>555</sup>         | USA          | diet     | 22  | 41    | 68.18      | 27.3  | / | / | / | / |
| Byrne CS, 2019 <sup>556</sup>         | UK           | others   | 23  | 60    | 57         |       | / | / | / | / |
| Taylor PJ, 2019 <sup>557</sup>        | Australia    | others   | 20  | 60.55 | 50         | 34.22 | / | / | / | / |
| Nunes PRP, 2019 <sup>558</sup>        | Brazil       | exercise | 26  | 62.6  | 100        | 31    | / | / | / | / |
| Ejtahed HS, 2019 <sup>559</sup>       | Iran         | medicine | 36  | 36    | 100        | 34    | / | / | / | / |

| Schroeder EC, 2019 <sup>560</sup>       | USA     | exercise           | 69  | 58    | 61    | 32.4  | / | / | / | / |
|---|---------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Rynarzewski J, 2019 <sup>561</sup>      | Germany | others             | 12  | 68    | 75    | 33.5  | / | / | / | / |
| Otten J, 2019 <sup>562</sup>            | Sweden  | diet +<br>exercise | 22  | 60    | 36.36 | 31    | / | / | / | / |
| Aliashrafi S, 2019 <sup>563</sup>       | Iran    | others             | 44  | 35.04 | 77.4  |       | / | / | / | / |
| Ballin M, 2019 <sup>564</sup>           | Sweden  | exercise           | 72  | 70.7  | 52    | 29.2  | / | / | / | / |
| de Souza RGM, 2018 <sup>565</sup>       | Brazil  | others             | 46  |       | 100   | 32.92 | / | / | / | / |
| Amozadeh H, 2018 <sup>566</sup>         | Iran    | others             | 39  | 28.11 | 100   | 33.36 | / | / | / | / |
| Galvão Cândido F, 2018 <sup>567</sup>   | Brazil  | others             | 41  | 27    | 100   | 30.1  | / | / | / | / |
| Zapata-Lamana R , 2018 <sup>568</sup>   | Chile   | exercise           | 52  | 23.3  | 100   | 33.8  | / | / | / | / |
| Dollerup OL, 2018 <sup>569</sup>        | Denmark | others             | 40  | 59    | 0     | 32.9  | / | / | / | / |
| González-Sarrías A, 2018 <sup>570</sup> | Spain   | others             | 49  | 45.7  | 34.69 | 30.4  | / | / | / | / |
| Kim J, 2018 <sup>571</sup>              | korea   | others             | 90  | 38.4  | 70    | 28.4  | / | / | / | / |
| Berk KA, 2018 <sup>572</sup>            | The     | others             | 158 | 53.7  | 55.7  | 36.3  | / | / | / | / |

|                                       | Netherlands |                     |     |      |       |       |   |   |   |       |
|---------------------------------------|-------------|---------------------|-----|------|-------|-------|---|---|---|-------|
| Madjd A,2018 <sup>573</sup>           | UK          | others              | 71  | 31.9 | 100   | 33.7  | / | / | / | /     |
| Khezri SS, 2018 <sup>574</sup>        | Iran        | others              | 39  | 43.7 | 82.05 | 32.1  | / | / | / | /     |
| Engel S, 2018 <sup>575</sup>          | Denmark     | others              | 60  | 38.4 | 66.67 | 31.8  | / | / | / | /     |
| Bendtsen LQ, 2018 <sup>576</sup>      | Denmark     | others              | 80  | 44   | 86.25 | 31.2  | / | / | / | /     |
| Jaacks LM, 2018 <sup>577</sup>        | USA         | diet                | 20  | 51.4 | 73.3  |       | / | / | / | /     |
| Kempf K, 2018 <sup>578</sup>          | Germany     | others              | 180 | 45   | 55    | 33.2  | / | / | / | /     |
| Mraovic T, 2018 <sup>579</sup>        | Serbia      | diet                | 97  | 32   | 100   | 30.14 | / | / | / | /     |
| Saito S, 2017 <sup>580</sup>          | Japan       | others              | 114 | 52   | 21.05 | 26.9  | / | / | / | /     |
| Aoe S, 2017 <sup>581</sup>            | Japan       | others              | 98  |      | 0     | 27.6  | / | / | / | /     |
| Gokulakrishnan K, 2017 <sup>582</sup> | India       | lifestyle           | 150 | 44.5 | 39.4  | 28    | / | / | / | /     |
| Mousa A, 2017 <sup>583</sup>          | Australia   | others              | 54  | 31.9 | 35.19 | 30.9  | / | / | / | /     |
| Saslow LR, 2017 <sup>584</sup>        | USA         | diet +<br>lifestyle | 25  | 55.7 | 68    |       | / | / | / | /     |
| Schauer PR, 2017 <sup>585</sup>       | USA         | surgery +           | 134 | 49   | 66    | 37    | / | / | / | 0.70% |

|                                   |             | medicine  |     |       |       |       |   |   |   |   |
|-----------------------------------|-------------|-----------|-----|-------|-------|-------|---|---|---|---|
| Paquette M, 2017 <sup>586</sup>   | Canada      | others    | 41  | 59    | 56.1  | 31    | / | / | / | / |
| Taghizadeh M, 2017 <sup>587</sup> | Iran        | others    | 50  | 33.7  | 100   | 32.4  | / | / | / | / |
| Melchart D, 2017 <sup>588</sup>   | Germany     | others    | 166 | 50.6  | 74.1  | 31.7  | / | / | / | / |
| Blædel T, 2016 <sup>589</sup>     | Denmark     | others    | 21  | 32.9  | 0     | 29.3  | / | / | / | / |
| Alqurashi RM, 2016 <sup>590</sup> | UK          | others    | 23  | 46    | 0     | 27.6  | / | / | / | / |
| O'Neil PM, 2016 <sup>591</sup>    | USA         | others    | 563 |       | 71    |       | / | / | / | / |
| Kim H, 2016 <sup>592</sup>        | Japan       | others    | 139 | 81.2  | 100   | 25.1  | / | / | / | / |
| Tovar J, 2016 <sup>593</sup>      | Sweden      | diet      | 47  |       | 74.47 | 27.8  | / | / | / | / |
| Madjd A, 2016 <sup>594</sup>      | UK          | others    | 80  | 33.61 | 100   | 32.16 | / | / | / | / |
| Li X, 2016 <sup>595</sup>         | China       | others    | 298 | 59.5  | 47.99 | 26.76 | / | / | / | / |
| Jamal SN, 2016 <sup>596</sup>     | Malaysia    | lifestyle | 194 | 40.5  | 72.7  | 32.4  | / | / | / | / |
| Wolf E, 2016 <sup>597</sup>       | Germany     | others    | 79  | 43    | 63.83 | 48.4  | / | / | / | / |
| Kong Z, 2016 <sup>598</sup>       | China       | exercise  | 26  | 21    | 100   | 25.7  | / | / | / | / |
| Most J, 2016 <sup>599</sup>       | Netherlands | others    | 38  | 38    | 47.37 | 29.7  | / | / | / | / |
| Welsh P, 2016 <sup>600</sup>      | UK          | others    | 151 | 52.5  | 44.37 | 30.5  | / | / | / | / |

| Järvi A, 2016 <sup>601</sup>       | Sweden    | others                  | 62  |       | 0     | 31.8  | / | / | / | / |
|------------------------------------|-----------|-------------------------|-----|-------|-------|-------|---|---|---|---|
| Weiland A, 2016 <sup>602</sup>     | Germany   | others                  | 119 | 62.5  | 0     | 30.6  | / | / | / | / |
| Dejgaard TF, 2016 <sup>603</sup>   | Denmark   | medicine                | 100 | 48    | 35    | 30.1  | / | / | / | / |
| Higashikawa F, 2016 <sup>604</sup> | japan     | others                  | 62  | 53.6  | 62.9  | 27.1  | / | / | / | / |
| Nelson K, 2016 <sup>605</sup>      | Australia | others                  | 10  | 46.6  | 40    | 30.8  | / | / | / | / |
| Madjd A, 2016 <sup>606</sup>       | Iran      | others                  | 89  | 31.99 | 100   | 32.09 | / | / | / | / |
| Madjd A, 2015 <sup>607</sup>       | Iran      | others                  | 71  | 31.9  | 100   | 33.7  | / | / | / | / |
| Rebello CJ, 2015 <sup>608</sup>    | USA       | others                  | 28  | 54.7  | 71.43 | 33.1  | / | / | / | / |
| Perez A, 2015 <sup>609</sup>       | USA       | lifestyle +<br>medicine | 92  | 45.1  | 100   | 33.3  | / | / | / | / |
| Tapsell LC, 2015 <sup>610</sup>    | Australia | lifestyle               | 377 | 45    | 74    | 32    | / | / | / | / |
| Tripkovic L, 2015 <sup>611</sup>   | UK        | others                  | 10  | 39.8  | 0     | 30.2  | / | / | / | / |
| Chambers ES, 2015 <sup>612</sup>   | UK        | others                  | 49  | 54.4  | 61.22 |       | / | / | / | / |
| Liu Y, 2015 <sup>613</sup>         | France    | others                  | 52  |       | 64.52 | 31.4  | / | / | / | / |
| Mingrone G, 2015 <sup>614</sup>    | Italy     | surgery                 | 53  |       | 0     | 44.6  | / | / | / | / |
| Davinelli S, 2015 <sup>615</sup>   | Italy     | others                  | 42  |       | 30.95 | 28.7  | / | / | / | / |
| Shlisky JD, 2015 <sup>616</sup>    | USA       | diet                    | 104 | 33.7  | 100   | 29.2  | / | / | / | / |

| II T 201 E617                               | T TC A    | 1        | 140        | 46.0  | 00.5  |       |   | 1 |   |   |
|---|-----------|----------|------------|-------|-------|-------|---|---|---|---|
| Hu T, 2015 <sup>617</sup>                   | USA       | diet     | 148        | 46.8  | 88.5  |       | / | / | / | / |
| de Barros F, 2015 <sup>618</sup>            | Brazil    | surgery  | 50         | 36.72 | 92    | 47.43 | / | / | / | / |
| Austel A, 2015 <sup>619</sup>               | Germany   | diet     | 212        | 52.51 | 82.08 | 30.09 | / | / | / | / |
| Ding SA, 2015 <sup>620</sup>                | USA       | surgery  | 40         | 51    | 45    | 36.5  | / | / | / | / |
| McEvoy CT, 2015 <sup>621</sup>              | Ireland   | others   | 92         | 56    | 64.13 | 31    | / | / | / | / |
| Hosseinpour-Niazi S,<br>2015 <sup>622</sup> | Iran      | others   | 62         | 58.1  | 77.42 | 27.8  | / | / | / | / |
| Mirtaheri E, 2015 <sup>623</sup>            | Iran      | others   | 58         | 34.8  | 57.81 | 33.2  | / | / | / | / |
| Stonehouse W, 2015 <sup>624</sup>           | Australia | others   | 28         | 56.8  | 0     | 30    | / | / | / | / |
| Nowotny B, 2015 <sup>625</sup>              | Germany   | others   | 37         | 54    | 54.05 | 34.7  | / | / | / | / |
| Ivey KL, 2015 <sup>626</sup>                | Australia | others   | 156        | 67    | 38.46 | 31    | / | / | / | / |
| Taghizadeh M, 2015 <sup>627</sup>           | Iran      | others   | 78         | 36.5  | 76.92 | 31.3  | / | / | / | / |
| Nickols-Richardson                          | I IC A    | 1:-1     | <i>(</i> 0 | 25.0  | 100   | 01    | 1 | , | , | / |
| SM, 2014 <sup>628</sup>                     | USA       | diet     | 60         | 35.9  | 100   | 31    | / | / | / | / |
| Zare R, 2014 <sup>629</sup>                 | Iran      | others   | 88         | 37.22 | 100   | 31.11 | / | / | / | / |
| Sousa N, 2014 <sup>630</sup>                | Portugal  | exercise | 48         | 69.1  | 0     | 27.1  | / | / | / | / |
| Hernández-Cordero                           | Mexico    | others   | 240        | 33.4  | 100   | 31.2  | / | / | / | / |

| S, 2014 <sup>631</sup>            |                |         |     |       |       |       |   |   |   |   |
|-----------------------------------|----------------|---------|-----|-------|-------|-------|---|---|---|---|
| Schwander F, 2014 <sup>632</sup>  | Switzerland    | diet    | 17  | 44.1  | 0     | 38.8  | / | / | / | / |
| Halperin F, 2014 <sup>633</sup>   | USA            | surgery | 38  | 51.7  | 60.52 | 36.3  | / | / | / | / |
| Choi MS, 2014 <sup>634</sup>      | korea          | others  | 45  | 48.68 | 51.11 | 25.07 | / | / | / | / |
| Bozzetto L, 2014 <sup>635</sup>   | Italy          | others  | 38  | 59    | 17.78 | 30    | / | / | / | / |
| Lin PH, 2014 <sup>636</sup>       | China          | others  | 123 | 38.21 | 60.16 | 28.32 | / | / | / | / |
| Geliebter A, 2014 <sup>637</sup>  | USA            | others  | 36  | 33.9  | 50    | 32.8  | / | / | / | / |
| Rondanelli M, 2014 <sup>638</sup> | Italy          | others  | 55  | 54.1  | 54.5  | 30.7  | / | / | / | / |
| Liu X, 2013 <sup>639</sup>        | China          | diet    | 49  | 47.9  | 100   | 26.7  | / | / | / | / |
| Kashyap SR, 2013 <sup>640</sup>   | USA            | surgery | 54  | 48.4  | 59.3  | 36.1  | / | / | / | / |
| Mishra S, 2013 <sup>641</sup>     | USA            | others  | 291 | 45.2  | 83.16 | 35    | / | / | / | / |
| Liang Z, 2013 <sup>642</sup>      | China          | surgery | 54  | 51.15 | 30.69 | 30.37 | / | / | / | / |
| Munro IA, 2013 <sup>643</sup>     | Australia      | others  | 39  | 46.13 | 76.92 | 32.42 | / | / | / | / |
| de Bock M,2013 <sup>644</sup>     | New<br>Zealand | others  | 45  | 46.4  | 0     | 28    | / | / | / | / |
| Cho SH, 2013 <sup>645</sup>       | korea          | others  | 53  | 42.44 | 84.91 | 27.55 | / | / | / | / |
| Azadbakht L, 2013 <sup>646</sup>  | Iran           | diet    | 60  | 42.1  | 100   | 27    | / | / | / | / |

| Salehpour A, 2012 <sup>647</sup>            | Iran             | others   | 85   | 37   | 100   | 29.8  | / | / | / | / |
|---|------------------|----------|------|------|-------|-------|---|---|---|---|
| Buchowski MS, 2012 <sup>648</sup>           | USA              | diet     | 40   | 30.3 | 100   | 32    | / | / | / | / |
| Munro IA, 2012 <sup>649</sup>               | Australia        | others   | 32   | 41.3 | 81.25 | 32.8  | / | / | / | / |
| Thies F, 2012 <sup>650</sup>                | UK               | others   | 225  | 51.1 | 60.44 | 26.6  | / | / | / | / |
| Rizkalla SW, 2012 <sup>651</sup>            | France           | diet     | 13   | 45   | 38.46 | 31.86 | / | / | / | / |
| Tovar J, 2012 <sup>652</sup>                | Sweden           | diet     | 44   | 63.3 | 81.82 | 28.5  | / | / | / | / |
| Taniguchi-Fukatsu A,<br>2012 <sup>653</sup> | Japan            | others   | 11   | 45.2 | 36.36 | 27.6  | / | / | / | / |
| Krebs JD, 2012 <sup>654</sup>               | New<br>Zealand   | diet     | 419  | 58   | 60    | 36.6  | / | / | / | / |
| Gargari BP,2011 <sup>655</sup>              | Iran             | others   | 48   | 58.2 | 0     | 28.6  | / | / | / | / |
| Fidler MC, 2011 <sup>656</sup>              | USA              | medicine | 3179 | 43.8 | 79.8  | 36.9  | / | / | / | / |
| Khoo J, 2011 <sup>657</sup>                 | Australia        | diet     | 31   | 59.7 | 0     | 35.3  | / | / | / | / |
| Derosa G, 2011 <sup>658</sup>               | Italy            | medicine | 246  | 52   | 50    | 33.1  | / | / | / | / |
| Søvik TT,2011 <sup>659</sup>                | Sweden<br>Norway | surgery  | 60   | 35.6 | 70    | 55    | / | / | / | / |
| Shah M, 2011 <sup>660</sup>                 | USA              | exercise | 33   | 49.7 | 90.9  | 41.9  | / | / | / | / |

| Tanaka T, 2011 <sup>661</sup>     | Japan       | others             | 117 | 54.2 | 49.57 | 30.4 | / | / | / | / |
|-----------------------------------|-------------|--------------------|-----|------|-------|------|---|---|---|---|
| Te Morenga LA,                    | New         | diet               | 83  | 41.9 | 100   | 33.9 | / | / | / | / |
| 2011 <sup>662</sup>               | Zealand     | aict               | 03  | 41.7 | 100   | 33.7 | / | / | / | / |
| Cho JK, 2011 <sup>663</sup>       | korea       | exercise           | 35  | 45.4 | 100   | 25.6 | / | / | / | / |
| Kreider RB, 2011 <sup>664</sup>   | USA         | diet +<br>exercise | 90  | 41.4 | 100   | 33.5 | / | / | / | / |
| Harvie MN, 2011 <sup>665</sup>    | UK          | diet               | 107 | 40.0 | 100   | 30.6 | / | / | / | / |
| Njike VY, 2011 <sup>666</sup>     | USA         | others             | 116 | 52.2 | 84.48 | 30.3 | / | / | / | / |
| Choquette S, 2011 <sup>667</sup>  | Canada      | others             | 79  | 58.7 | 100   | 29.9 | / | / | / | / |
| Larsen RN, 2011 <sup>668</sup>    | Australia   | diet               | 99  | 59.2 | 48.48 |      | / | / | / | / |
| Frank I, 2011 <sup>669</sup>      | Switzerland | exercise           | 26  | 33   | 76.92 | 31.3 | / | / | / | / |
| Llaneza P, 2011 <sup>670</sup>    | Spain       | others             | 87  | 56.7 | 100   | 35   | / | / | / | / |
| DeFina LF, 2011 <sup>671</sup>    | USA         | others             | 128 | 46.3 | 68.75 | 32.6 | / | / | / | / |
| Sieverdes JC, 2011 <sup>672</sup> | USA         | others             | 164 | 46.8 | 80.5  | 33.3 | / | / | / | / |
| Raben A, 2011 <sup>673</sup>      | Denmark     | others             | 23  | 35.4 | 82.61 | 28.2 | / | / | / | / |
| Bladbjerg EM, 2010 <sup>674</sup> | Denmark     | diet               | 131 | 28.2 | 58    | 31.5 | / | / | / | / |
| Li S, 2010 <sup>675</sup>         | China       | others             | 120 | 31   | 0     | 24.5 | / | / | / | / |

| Ilanne-Parikka P , 2010 <sup>676</sup> | Finland         | exercise           | 486 | 55.4  | 66.7  | 31.2  | / | / | / | / |
|--|-----------------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Beck EJ, 2010 <sup>677</sup>           | Australia       | others             | 56  | 37.4  | 100   | 29.3  | / | / | / | / |
| Hodgson JM, 2010 <sup>678</sup>        | Australia       | others             | 74  | 57.9  | 64.86 | 30.6  | / | / | / | / |
| Michishita T, 2010 <sup>679</sup>      | Japan           | others             | 41  | 37.6  | 53.66 | 25.7  | / | / | / | / |
| Blumenthal JA, 2010 <sup>680</sup>     | USA             | diet +<br>exercise | 144 | 52    | 67    | 33.1  | / | / | / | / |
| Larson-Meyer DE , 2010 <sup>681</sup>  | USA             | diet +<br>exercise | 35  | 39    | 55.56 | 27.8  | / | / | / | / |
| Elhayany A, 2010 <sup>682</sup>        | Israel          | diet               | 179 | 55    | 48    | 31.4  | / | / | / | / |
| Sluijs I, 2010 <sup>683</sup>          | Netherlands     | others             | 346 | 58.4  | 51.7  | 27.9  | / | / | / | / |
| Rizvi ZA, 2024 <sup>684</sup>          | Pakistan        | diet               | 90  | 48.8  | 37.78 | 29.38 | / | / | / | / |
| Horváth J, 2024 <sup>685</sup>         | Hungary         | exercise           | 40  | 57.81 | 72.5  | 42.74 | / | / | / | / |
| Nemati M, 2024 <sup>686</sup>          | Iran            | others             | 68  | 27    | 0     | 32.6  | / | / | / | / |
| AlMalki SM, 2024 <sup>687</sup>        | Saudi<br>Arabia | others             | 93  | 30.3  | 69.89 | 30.8  | / | / | / | / |

| Suder A, 2024 <sup>688</sup>               | Poland  | diet +   | 44  | 34.7  | 0     | 32    | / | / | / | / |
|--|---------|----------|-----|-------|-------|-------|---|---|---|---|
| Amiri P,2024 <sup>689</sup>                | Iran    | others   | 50  | 39.12 | 50    | 33.56 | / | / | / | / |
| Rodrigo-Carbó C ,<br>2024 <sup>690</sup>   | Spain   | diet     | 117 | 57.3  | 47.86 | 35.6  | / | / | / | / |
| Stockton MB, 2024 <sup>691</sup>           | USA     | diet     | 60  | 38.3  | 81.67 | 33.2  | / | / | / | / |
| Wang Y, 2024 <sup>692</sup>                | China   | exercise | 38  | 22    | 100   | 28.7  | / | / | / | / |
| Ostadrahimi A, 2024 <sup>693</sup>         | Iran    | others   | 56  | 37.75 | 60.71 | 34.89 | / | / | / | / |
| Turner-McGrievy<br>GM, 2024 <sup>694</sup> | USA     | diet     | 159 | 48.3  | 79    | 36.9  | / | / | / | / |
| Delfan M, 2024 <sup>695</sup>              | Iran    | others   | 44  |       | 0     | 32    | / | / | / | / |
| Pammer A, 2024 <sup>696</sup>              | Austria | diet     | 41  | 63    | 43.9  | 34    | / | / | / | / |
| Duan Y, 2024 <sup>697</sup>                | China   | exercise | 36  | 42.7  | 0     | 31.1  | / | / | / | / |
| Rolland C, 2009 <sup>698</sup>             | UK      | diet     | 72  | 41.3  | 84.72 | 43.82 | / | / | / | / |
| Foster GD, 2009 <sup>699</sup>             | USA     | others   | 69  | 52.2  | 71.01 | 39    | / | / | / | / |
| Tsai Ch H, 2009 <sup>700</sup>             | Taiwan  | diet     | 120 | 43.2  | 79.17 | 32.4  | / | / | / | / |
| Fontbonne A, 2009 <sup>701</sup>           | France  | medicine | 101 | 50.7  | 66.34 | 34.6  | / | / | / | / |

| Shikany JM, 2009 <sup>702</sup>   | USA              | diet               | 24  | 34.5 | 0     | 27.8 | / | / | / | / |
|-----------------------------------|------------------|--------------------|-----|------|-------|------|---|---|---|---|
| Frisch S, 2009 <sup>703</sup>     | Germany          | others             | 200 | 47   | 69    | 33.7 | / | / | / | / |
| Nieman DC, 2009 <sup>704</sup>    | USA              | others             | 76  |      | 63.16 |      | / | / | / | / |
| Lin WY, 2009 <sup>705</sup>       | Taiwan           | diet               | 132 | 33.6 | 65.9  | 34.2 | / | / | / | / |
| Arsenault BJ, 2009 <sup>706</sup> | Canada           | exercise           | 349 | 57.3 | 100   | 32   | / | / | / | / |
| Brochu M, 2009 <sup>707</sup>     | Canada           | exercise           | 128 | 57.7 | 100   | 32.4 | / | / | / | / |
| Aasheim ET,2009 <sup>708</sup>    | Sweden<br>Norway | surgery            | 60  | 35   | 70    | 55   | / | / | / | / |
| Assunção ML, 2009 <sup>709</sup>  | Brazil           | others             | 40  | 29.8 | 100   | 31.1 | / | / | / | / |
| Shah K,2009 <sup>710</sup>        | USA              | diet +<br>exercise | 18  | 68.6 | 72.22 |      | / | / | / | / |
| Davis NJ, 2009 <sup>711</sup>     | USA              | diet               | 105 | 54   | 78.1  | 36   | / | / | / | / |
| Sacks FM, 2009 <sup>712</sup>     | USA              | diet               | 811 | 51   | 64    | 33   | / | / | / | / |
| Digenio AG, 2009 <sup>713</sup>   | USA              | lifestyle          | 376 | 44   | 86.7  | 34.4 | / | / | / | / |
| Kirk E, 2009 <sup>714</sup>       | USA              | diet               | 22  | 43.6 | 81.82 | 36.5 | / | / | / | / |
| Hursel R, 2009 <sup>715</sup>     | Netherlands      | others             | 80  | 44   | 55    | 29.6 | / | / | / | / |
| Andersson K, 2009 <sup>716</sup>  | Sweden           | lifestyle          | 126 | 49   | 79.37 | 37.4 | / | / | / | / |

| Layman DK, 2009 <sup>717</sup>    | USA       | diet               | 130 | 45.4 | 55.38 | 32.6   | / | / | / | / |
|-----------------------------------|-----------|--------------------|-----|------|-------|--------|---|---|---|---|
| Kim JY, 2008 <sup>718</sup>       | korea     | diet               | 47  |      | 100   | 27.42  | / | / | / | / |
| Lasker DA, 2008 <sup>719</sup>    | USA       | diet               | 50  | 33.6 | 0     | 47     | / | / | / | / |
| St-Onge MP, 2008 <sup>720</sup>   | USA       | others             | 31  | 37   | 90.3  | 29.7   | / | / | / | / |
| Hibi M, 2008 <sup>721</sup>       | Japan     | others             | 14  | 40   | 42.86 | 27.7   | / | / | / | / |
| Treyzon L, 2008 <sup>722</sup>    | USA       | diet               | 87  | 49.4 | 61    | 33.238 | / | / | / | / |
| Volpe SL, 2008 <sup>723</sup>     | USA       | diet +<br>exercise | 90  | 44.2 | 51.11 | 30.5   | / | / | / | / |
| Morgan LM, 2009 <sup>724</sup>    | UK        | others             | 293 | 40.3 | 73    | 31.7   | / | / | / | / |
| Lindqvist HM, 2009 <sup>725</sup> | Sweden    | others             | 35  | 47.8 | 0     | 28.3   | / | / | / | / |
| Shai I, 2008 <sup>726</sup>       | Israel    | diet               | 322 | 52   | 14    | 31     | / | / | / | / |
| Nakou E, 2008 <sup>727</sup>      | Greece    | medicine           | 54  | 44   | 79.63 | 40     | / | / | / | / |
| Pierce GL, 2008 <sup>728</sup>    | USA       | others             | 40  | 46.5 | 40    |        | / | / | / | / |
| Miyashita M, 2008 <sup>729</sup>  | Japan     | others             | 8   | 26.5 | 0     | 28.9   | / | / | / | / |
| Arciero PJ, 2008 <sup>730</sup>   | USA       | others             | 24  | 47   | 62.5  | 32.2   | / | / | / | / |
| Wycherley TP, 2008 <sup>731</sup> | Australia | exercise           | 29  | 52.4 | 44.8  | 34.2   | / | / | / | / |
| Lockwood CM, 2008 <sup>732</sup>  | USA       | diet               | 38  | 32.7 | 50    | 27.6   | / | / | / | / |

| Larson-Meyer DE, 2008 <sup>733</sup>    | USA     | diet +<br>exercise | 46  | 38    | 58.7  | 27.8  | / | / | / | / |
|---|---------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Schjerve IE, 2008 <sup>734</sup>        | Norway  | exercise           | 40  | 45.9  | 80    | 36    | / | / | / | / |
| König D, 2008 <sup>735</sup>            | Germany | diet               | 90  | 47    | 0     | 31.5  | / | / | / | / |
| Borges RL, 2007 <sup>736</sup>          | Brazil  | others             | 24  | 47.4  | 100   | 35.7  | / | / | / | / |
| Mutungi G, 2008 <sup>737</sup>          | USA     | diet               | 28  |       | 0     |       | / | / | / | / |
| Jensen L, 2008 <sup>738</sup>           | Denmark | diet               | 44  |       | 100   | 27.5  | / | / | / | / |
| Salas-Salvadó J, 2008 <sup>739</sup>    | Spain   | others             | 166 | 47.9  | 78.3  | 31.2  | / | / | / | / |
| Burton FL, 2008 <sup>740</sup>          | UK      | others             | 13  | 40    | 0     | 31.1  | / | / | / | / |
| Karandish M, 2009 <sup>741</sup>        | Iran    | others             | 44  | 25    | 100   | 28.3  | / | / | / | / |
| Burke LE, 2007 <sup>742</sup>           | USA     | diet               | 176 | 44.08 | 86.93 | 34.02 | / | / | / | / |
| Bertéus Forslund H, 2008 <sup>743</sup> | Sweden  | others             | 140 | 39.4  | 74.29 | 38.4  | / | / | / | / |
| Meckling KA, 2007 <sup>744</sup>        | Canada  | diet +<br>exercise | 60  | 43    | 100   | 30    | / | / | / | / |
| de Rougemont A, 2007 <sup>745</sup>     | France  | diet               | 38  | 38.4  | 50    | 27.3  | / | / | / | / |

| Liao FH, 2007 <sup>746</sup>                | China             | diet     | 30  | 33.4 | 80    | 29.8 | / | / | / | / |
|---|-------------------|----------|-----|------|-------|------|---|---|---|---|
| Rave K, 2007 <sup>747</sup>                 | Germany           | diet     | 31  | 51   | 58.06 | 33.9 | / | / | / | / |
| Sahin M, 2007 <sup>748</sup>                | Turkey            | medicine | 16  | 53.5 | 68.75 | 35.7 | / | / | / | / |
| Thomas TR, 2007 <sup>749</sup>              | USA               | others   | 22  | 32.6 | 54.55 | 26.6 | / | / | / | / |
| Ebbeling CB, 2007 <sup>750</sup>            | USA               | diet     | 73  | 27.6 | 79    |      | / | / | / | / |
| Steck SE, 2007 <sup>751</sup>               | USA               | others   | 48  | 35.1 | 73    | 32.7 | / | / | / | / |
| Rock CL, 2007 <sup>752</sup>                | USA               | others   | 70  | 41.1 | 100   | 34   | / | / | / | / |
| Brunerova L, 2007 <sup>753</sup>            | Czech<br>Republic | diet     | 58  | 53.1 | 0     | 33.7 | / | / | / | / |
| Maki KC, 2007 <sup>754</sup>                | USA               | diet     | 86  | 49.7 | 67.4  | 31.9 | / | / | / | / |
| Gardner CD, 2007 <sup>755</sup>             | USA               | diet     | 311 | 41   | 100   | 32   | / | / | / | / |
| Lindqvist H, 2007 <sup>756</sup>            | Sweden            | others   | 13  | 50.5 | 0     | 32.6 | / | / | / | / |
| Aubertin-Leheudre<br>M, 2007 <sup>757</sup> | Canada            | others   | 20  | 58   | 100   | 30   | / | / | / | / |
| Major GC, 2007 <sup>758</sup>               | Canada            | others   | 63  | 42.6 | 100   | 31.2 | / | / | / | / |
| Vincent HK, 2006 <sup>759</sup>             | USA               | others   | 23  | 24.5 | 0     | 33.3 | / | / | / | / |
| Bougoulia M, 2006 <sup>760</sup>            | Greece            | medicine | 71  | 36.7 | 100   | 37.9 | / | / | / | / |

| Wood RJ, 2007 <sup>761</sup>      | USA       | diet               | 29  |      | 0     | 29.7  | / | / | / | / |
|-----------------------------------|-----------|--------------------|-----|------|-------|-------|---|---|---|---|
| Burke LE, 2006 <sup>762</sup>     | USA       | others             | 182 | 44.1 | 87.4  | 34.08 | / | / | / | / |
| Vincent HK, 2006 <sup>763</sup>   | USA       | exercise           | 29  | 68.1 | 0     | 29.7  | / | / | / | / |
| McLaughlin T, 2006 <sup>764</sup> | USA       | diet               | 57  | 51   | 57.89 | 32.7  | / | / | / | / |
| Anderson JW, 2006 <sup>765</sup>  | USA       | medicine           | 292 |      | 0     |       | / | / | / | / |
| Fenkci S, 2006 <sup>766</sup>     | Turkey    | exercise           | 51  | 43.2 | 100   | 35.27 | / | / | / | / |
| Kuo CS, 2006 <sup>767</sup>       | China     | medicine           | 60  |      | 100   |       | / | / | / | / |
| Nestel P, 2007 <sup>768</sup>     | Australia | others             | 25  | 57   | 44    | 30.3  | / | / | / | / |
| Satoh N, 2006 <sup>769</sup>      | Japan     | medicine           | 30  | 46.2 | 53.33 | 32.8  | / | / | / | / |
| Turker I, 2006 <sup>770</sup>     | Turkey    | diet +<br>medicine | 27  | 45.9 | 100   | 36    | / | / | / | / |
| Ahn CW, 2006 <sup>771</sup>       | korea     | medicine           | 24  | 53.7 | 50    | 28.2  | / | / | / | / |
| Hackman RM, 2006 <sup>772</sup>   | USA       | others             | 61  | 36.9 | 100   | 32    | / | / | / | / |
| Krebs JD, 2006 <sup>773</sup>     | UK        | diet               | 93  | 44.7 | 100   | 35    | / | / | / | / |
| Wood RJ, 2006 <sup>774</sup>      | USA       | diet               | 29  |      | 0     |       | / | / | / | / |
| Löfgren P, 2005 <sup>775</sup>    | Sweden    | diet               | 40  | 35.7 | 100   | 36.9  | / | / | / | / |

|                                   | UK, The      |          |     |      |       |      |   |   |   |   |
|-----------------------------------|--------------|----------|-----|------|-------|------|---|---|---|---|
|                                   | Netherlands, |          |     |      |       |      |   |   |   |   |
|                                   | France,      |          |     |      |       |      |   |   |   |   |
| Petersen M, 2006 <sup>776</sup>   | Spain, Czech | diet     | 648 | 37   | 75.1  | 35.6 | / | / | / | / |
|                                   | Republic,    |          |     |      |       |      |   |   |   |   |
|                                   | Sweden and   |          |     |      |       |      |   |   |   |   |
|                                   | Denmark      |          |     |      |       |      |   |   |   |   |
| Wang TF, 2005 <sup>777</sup>      | China        | medicine | 60  |      | 100   | 27.1 | / | / | / | / |
| Robitaille J, 2005 <sup>778</sup> | Canada       | others   | 34  | 38.3 | 100   | 29.1 | / | / | / | / |
| Noakes M, 2005 <sup>779</sup>     | Australia    | diet     | 100 | 49   | 100   | 32   | / | / | / | / |
| Poston WS, 2005 <sup>780</sup>    | USA          | others   | 100 | 40.6 | 87    | 31.5 | / | / | / | / |
| Ebbeling CB, 2005 <sup>781</sup>  | USA          | diet     | 23  | 28.5 | 95.65 |      | / | / | / | / |
| Frank LL, 2005 <sup>782</sup>     | USA          | exercise | 173 | 60.7 | 100   | 30.4 | / | / | / | / |
| Berne C, 2005 <sup>783</sup>      | Sweden       | medicine | 220 | 59.1 | 45    | 32.8 | / | / | / | / |
| Gaullier JM, 2005 <sup>784</sup>  | Norway       | others   | 134 | 46.3 | 82.1  | 28   | / | / | / | / |
| Zemel MB, 2005 <sup>785</sup>     | USA          | others   | 34  | 40   | 79.4  | 32.6 | / | / | / | / |
| Patalay M, 2005 <sup>786</sup>    | USA          | others   | 30  |      | 100   | 29.3 | / | / | / | / |

| Pieterse Z, 2005 <sup>787</sup>       | South Africa   | diet      | 61  | 40.8  | 78.69 | 31.9  | / | / | / | / |
|---------------------------------------|----------------|-----------|-----|-------|-------|-------|---|---|---|---|
| Derosa G, 2005 <sup>788</sup>         | Italy          | medicine  | 115 | 51    | 51.3  | 33.3  | / | / | / | / |
| Maeda H, 2005 <sup>789</sup>          | Japan          | diet      | 76  | 58.6  | 63.16 | 28.8  | / | / | / | / |
| Pereira MA, 2004 <sup>790</sup>       | USA            | diet      | 39  | 30.7  | 76.9  | 33.2  | / | / | / | / |
| Aude YW, 2004 <sup>791</sup>          | USA            | diet      | 54  | 45    | 51.85 | 35.2  | / | / | / | / |
| Brinkworth GD , $2004^{792}$          | Australia      | diet      | 38  | 61.8  | 60.53 | 33.5  | / | / | / | / |
| Melanson KJ, 2004 <sup>793</sup>      | USA            | exercise  | 90  | 42.6  | 85.56 | 31.5  | / | / | / | / |
| Yesilbursa D, 2005 <sup>794</sup>     | Turkey         | medicine  | 36  | 49.7  | 80.56 | 36.1  | / | / | / | / |
| Seshadri P, 2004 <sup>795</sup>       | USA            | diet      | 78  | 55    | 0     | 44    | / | / | / | / |
| Miyashita Y, 2004 <sup>796</sup>      | Japan          | diet      | 22  | 52.4  | 27.27 | 27    | / | / | / | / |
| Flechtner-Mors M, 2004 <sup>797</sup> | Germany        | others    | 40  | 48.17 | 67.5  | 34.27 | / | / | / | / |
| Mhurchu CN, 2004 <sup>798</sup>       | New<br>Zealand | others    | 250 | 48    | 82    | 35.5  | / | / | / | / |
| Esposito K, 2004 <sup>799</sup>       | Italy          | lifestyle | 110 | 43.3  | 0     | 36.6  | / | / | / | / |
| Carels RA, 2004 <sup>800</sup>        | USA            | lifestyle | 44  | 54.7  | 100   | 36.4  | / | / | / | / |

| Stern L, 2004 <sup>801</sup>        | USA       | diet                    | 87  | 54   | 82.5  | 42.9 | / | / | / | / |
|-------------------------------------|-----------|-------------------------|-----|------|-------|------|---|---|---|---|
| Brinkworth GD , 2004 <sup>802</sup> | Australia | diet                    | 43  | 50.2 | 77.59 | 34   | / | / | / | / |
| Albert SG, 2004 <sup>803</sup>      | USA       | medicine                | 59  | 36.9 | 74.58 | 36.9 | / | / | / | / |
| Rachmani R, 2004 <sup>804</sup>     | Israel    | medicine                | 56  | 52.9 | 0     | 31.1 | / | / | / | / |
| Poston WS, 2003 <sup>805</sup>      | USA       | lifestyle +<br>medicine | 108 | 43   | 100   | 36.9 | / | / | / | / |
| Bloch KV, 2003806                   | Brazil    | medicine                | 204 | 55.8 | 0     | 36   | / | / | / | / |
| Lovejoy JC, 2003807                 | USA       | diet                    | 45  | 36.7 | 0     | 30.8 | / | / | / | / |
| Ash S, 2003 <sup>808</sup>          | Australia | diet                    | 51  | 54   | 0     | 31.7 | / | / | / | / |
| Foster GD, 2003 <sup>809</sup>      | USA       | diet                    | 63  | 44.1 | 68.25 | 39   | / | / | / | / |
| Melanson K, 2003 <sup>810</sup>     | USA       | others                  | 61  | 43.4 | 100   | 32.1 | / | / | / | / |
| Allison DB, 2003 <sup>811</sup>     | USA       | others                  | 100 | 50.2 | 80    | 34.3 | / | / | / | / |
| Esposito K, 2003 <sup>812</sup>     | Italy     | lifestyle               | 120 | 34.6 | 100   | 34.9 | / | / | / | / |
| Lantz H, 2003 <sup>813</sup>        | Sweden    | diet                    | 117 | 41.7 | 74.25 | 39.5 | / | / | / | / |
| James AP, 2003 <sup>814</sup>       | Australia | others                  | 22  | 52.2 | 0     | 35   | / | / | / | / |
| Hirose K, 2002 <sup>815</sup>       | Japan     | others                  | 35  | 55.2 | 100   | 26.9 | / | / | / | / |

| Sharman MJ, 2024 <sup>816</sup>   | USA         | diet               | 15  | 33.2  | 0     | 34.3  | / | / | / | / |
|-----------------------------------|-------------|--------------------|-----|-------|-------|-------|---|---|---|---|
| Bakris G, 2002 <sup>817</sup>     | USA         | medicine           | 532 | 52.9  | 61.09 | 35.6  | / | / | / | / |
| Hanefeld M, 2002818               | Germany     | diet               | 369 | 56.2  | 50.9  | 34.1  | / | / | / | / |
| Dunstan DW, 2002 <sup>819</sup>   | Australia   | exercise           | 29  | 67.3  | 44.8  | 32    | / | / | / | / |
| Larsen TM, 2002 <sup>820</sup>    | Netherlands | medicine           | 20  | 36    | 0     | 30.9  | / | / | / | / |
| Nieman DC, 2002 <sup>821</sup>    | USA         | diet +<br>exercise | 91  | 45.6  | 100   | 33.1  | / | / | / | / |
| Anderson JW, 2002 <sup>822</sup>  | USA         | medicine           | 327 | 43.4  | 85.02 | 36.3  | / | / | / | / |
| Miles JM, 2002 <sup>823</sup>     | USA canada  | medicine           | 504 | 53.1  | 48    | 35.4  | / | / | / | / |
| Kelley DE, 2002 <sup>824</sup>    | USA         | medicine           | 542 | 57.9  | 56    | 35.7  | / | / | / | / |
| Heilbronn LK, 2002 <sup>825</sup> | Australia   | diet               | 45  | 56.7  | 51.11 | 33.2  | / | / | / | / |
| Janssen I, 2002 <sup>826</sup>    | Canada      | diet +<br>exercise | 38  | 37.4  | 100   | 33.6  | / | / | / | / |
| Yip I, 2001 <sup>827</sup>        | USA         | diet               | 57  | 58.9  | 0     | 33    | / | / | / | / |
| Gokcel A, 2001828                 | Turkey      | medicine           | 60  | 48.11 | 100   | 38.35 | / | / | / | / |
| Volpe SL, 2001 <sup>829</sup>     | Argentina   | others             | 44  | 42.6  | 100   | 32.9  | / | / | / | / |

| Dumont M, 2001 <sup>830</sup>      | Canada    | others   | 64         | 46   | 0                     | 31    | / | / | / |   |
|------------------------------------|-----------|----------|------------|------|-----------------------|-------|---|---|---|---|
| Boozer CN, 2001 <sup>831</sup>     | USA       | others   | 67         | 41.1 | 85.07                 | 32.7  | / | / | / | , |
| DOOZEI CIN, 2001                   |           | oniers   | 07         | 41.1 | 65.07                 | 32.7  | / | / | / | / |
| Birketvedt GS, 2000 <sup>832</sup> | Sweden    | others   | 53         | 39.9 | 100                   | 27.5  | / | / | / | / |
|                                    | Norway    |          |            |      |                       |       | , | , | , | , |
| Richelsen B, 2000 <sup>833</sup>   | Denmark   | medicine | 18         | 34.9 | 100                   | 42    | / | / | / | / |
| Halimi S, 2000 <sup>834</sup>      | France    | medicine | 129        | 55   | 44.19                 | 29.9  | / | / | / | / |
| Wadden TA, 2001 <sup>835</sup>     | USA       | medicine | 43         | 47.2 | 100                   | 37.3  | / | / | / | / |
| Fujioka K, 2000 <sup>836</sup>     | USA       | diet     | 175        | 54.2 | 46.86                 | 34    | / | / | / | / |
| Ditschuneit HH ,                   | 110.4     |          |            | 4    | <b>5</b> 0.4 <b>5</b> | 22 (  | , | , | , | , |
| 2002 <sup>837</sup>                | USA       | others   | 73         | 45.2 | 79.45                 | 33.6  | / | / | / | / |
| Fogelholm M, 2000 <sup>838</sup>   | Finland   | exercise | 74         | 40   | 100                   | 34    | / | / | / | / |
| Donnelly JE, 2000 <sup>839</sup>   | USA       | exercise | 22         | 51.5 | 100                   | 31.23 | / | / | / | / |
| Golay A, 2000 <sup>840</sup>       | Spain     | diet     | 54         | 43.5 | 0                     | 38.6  | / | / | / | / |
| Mori TA,1999 <sup>841</sup>        | Australia | others   | 63         | 54.1 | 33.33                 | 31.6  | / | / | / | / |
| Vidgren HM,1999 <sup>842</sup>     | Finland   | medicine | <i>7</i> 5 | 43.2 | 80                    | 35.5  | / | / | / | / |
| Roger P, 1999 <sup>843</sup>       | France    | medicine | 127        | 55.5 | 55.9                  | 33    | / | / | / | / |
| Pittler MH,1999 <sup>844</sup>     | UK        | others   | 30         | 44   | 80                    | 26.6  | / | / | / | / |

| Ditschuneit HH ,                       | Germany     | diet     | 100 | 45.7 | 79    | 33.4 | / | / | / | / |
|--|-------------|----------|-----|------|-------|------|---|---|---|---|
| Andersen RE, 1999846                   | USA         | exercise | 40  | 42.9 | 100   | 32.9 | / | / | / | / |
| Davidson MH, 1999 <sup>847</sup>       | USA         | medicine | 880 | 43.5 | 84.2  | 36.3 | / | / | / | / |
| Charles MA, 1998 <sup>848</sup>        | France      | medicine | 324 | 49.5 | 34    | 32.5 | / | / | / | / |
| Riddle MC, 1998 <sup>849</sup>         | USA         | medicine | 132 | 58   | 58.62 | 33   | / | / | / | / |
| Marckmann P, 1998 <sup>850</sup>       | Denmark     | diet     | 36  | 44   | 0     | 35.5 | / | / | / | / |
| Sjöström L, 1998 <sup>851</sup>        | Sweden      | medicine | 683 | 44.8 | 82    | 36   | / | / | / | / |
| Agurs-Collins TD , 1997 <sup>852</sup> | USA         | exercise | 64  | 61.7 | 77    | 34.4 | / | / | / | / |
| Kraemer WJ, 1997 <sup>853</sup>        | USA         | exercise | 31  | 35.4 | 100   | 28.6 | / | / | / | / |
| Rössner S, 1997 <sup>854</sup>         | Norway      | diet     | 93  | 41   | 67.74 | 38.7 | / | / | / | / |
| Pontiroli AE, 1996 <sup>855</sup>      | Italy       | medicine | 30  | 56.8 | 66.67 | 33.3 | / | / | / | / |
| Golay A, 1996 <sup>856</sup>           | Switzerland | diet     | 43  | 43   | 79.07 | 40   | / | / | / | / |
| Pascale RW, 1995 <sup>857</sup>        | USA         | diet     | 90  | 49.6 | 100   | 36.1 | / | / | / | / |
| DeFronzo RA, 1995 <sup>858</sup>       | USA         | medicine | 721 | 54   | 69.35 | 29.4 | / | / | / | / |
| O'Kane M, 1994 <sup>859</sup>          | UK          | medicine | 19  | 57.2 | 68.42 | 36.3 | / | / | / | / |

| Giugliano D, 1993860            | Italy       | medicine           | 50 | 60.4 | 62  | 32.9 | / | / | / | / |
|---------------------------------|-------------|--------------------|----|------|-----|------|---|---|---|---|
| Puddey IB, 1992 <sup>861</sup>  | Australia   | others             | 86 | 44.3 | 0   | 29.5 | / | / | / | / |
| Wolever TM, 1992 <sup>862</sup> | Canada      | diet               | 6  | 63   | 50  | 32.1 | / | / | / | / |
| Golay A, 1992 <sup>863</sup>    | Switzerland | others             | 14 | 62   | 0   | 29   | / | / | / | / |
| Jalkanen L, 1991 <sup>864</sup> | Finland     | others             | 44 | 49   | 0   |      | / | / | / | / |
| Nieman DC,1990 <sup>865</sup>   | USA         | diet +<br>exercise | 21 | 37.5 | 100 | 29.9 | / | / | / | / |
| Lalor BC, 1990 <sup>866</sup>   | UK          | medicine           | 19 | /    | 0   | /    | / | / | / | / |

## Supplementary Table 3 The comparisons of baseline blood lipid levels between subgroups

| Subgroup                 | Z      | P               | Subgroup                | Z      | P     | Subgroup                        | Z      | P      | Subgroup         | Z      | P     |
|--------------------------|--------|-----------------|-------------------------|--------|-------|---------------------------------|--------|--------|------------------|--------|-------|
| TG                       |        |                 | TC                      |        |       | HDL-C                           |        |        | LDL-C            |        |       |
| Age<65 years old         |        |                 | Age<65 years old        |        |       | Age<65 years old                |        |        | Age<65 years old |        |       |
| vs. Age≥65years          | -0.130 | 0.897           | vs Age≥65years          | -0.411 | 0.681 | vs Age≥65years old              | -0.300 | 0.764  | vs Age≥65years   | -1.011 | 0.312 |
| old                      |        |                 | old                     |        |       |                                 |        |        | old              |        |       |
| BMI $<$ 30 kg/m $^2$ vs. | 2 222  | 0.001*          | BMI $<$ 30 kg/m $^2$ vs | -0.326 | 0.744 | BMI $<$ 30 kg/m <sup>2</sup> vs | -1.008 | 0.212  | BMI<30 kg/m² vs  | -1.609 | 0.100 |
| BMI≥30 kg/m²             | -3,222 | 0.001*          | BMI≥30 kg/m²            | -0.326 | 0.744 | BMI≥30 kg/m²                    | -1.008 | 0.313  | BMI≥30 kg/m²     | -1.009 | 0.106 |
| Male predominant         |        |                 | Male predominant        |        |       | Male predominant                |        |        | Male predominant |        |       |
| vs. female               | -1.942 | 0.052           | vs female               | -1.812 | 0.070 | vs female                       | -2.736 | 0.006* | vs female        | -0.449 | 0.653 |
| predominant              |        |                 | predominant             |        |       | predominant                     |        |        | predominant      |        |       |
| Hypertension vs.         | 2 222  | 0.0 <b>2</b> (* | Hypertension vs.        | 0.600  | 0.400 | Hypertension vs.                | 0.027  | 0.070  | Hypertension vs. | 1 01 4 | 0.21  |
| non-hypertension         | -2,232 | 0.026*          | non-hypertension        | -0.690 | 0.490 | non-hypertension                | -0.027 | 0.978  | non-hypertension | -1.014 | 0.31  |
| FBG >110mg/dL            |        |                 | FBG >110mg/dL           |        |       | FBG >110mg/dL                   |        |        | FBG >110mg/dL    |        |       |
| vs. FBG                  | -2.540 | 0.011*          | vs. FBG                 | -0.180 | 0.857 | vs. FBG                         | -2.583 | 0.100  | vs. FBG          | -1.888 | 0.059 |
| ≤110mg/dL                |        |                 | ≤110mg/dL               |        |       | ≤110mg/dL                       |        |        | ≤110mg/dL        |        |       |
| HbA1c ≥6.5% vs.          | 4.665  | 10 0014         | HbA1c ≥6.5% vs.         | 0.440  | 0.454 | HbA1c ≥6.5% vs.                 | 1 (01  | 0.001  | HbA1c ≥6.5% vs.  | 0.064  | 0.005 |
| HbA1c <6.5%              | -4.667 | <0.001*         | HbA1c <6.5%             | -0.418 | 0.676 | HbA1c <6.5%                     | -1.691 | 0.091  | HbA1c <6.5%      | -0.964 | 0.335 |

| DM combined vs.   | -5.907             | <0.001*       | DM combined vs.   | -0.801       | 0.423  | DM combined vs.   | -1.425 | 0.154 | DM combined vs.   | -0.738 | 0.460  |
|-------------------|--------------------|---------------|-------------------|--------------|--------|-------------------|--------|-------|-------------------|--------|--------|
| DM uncombined     | -3.907             | <b>\0.001</b> | DM uncombined     | -0.001       | 0.423  | DM uncombined     | -1.423 | 0.134 | DM uncombined     | -0.736 | 0.400  |
| Monotherapy vs.   |                    |               | Monotherapy vs.   |              |        | Monotherapy vs.   |        |       | Monotherapy vs.   |        |        |
| combination       | -1.581             | 0.114         | combination       | -1.340       | 0.180  | combination       | -0.382 | 0.702 | combination       | -0.484 | 0.629  |
| therapy           |                    |               | therapy           |              |        | therapy           |        |       | therapy           |        |        |
| Diet intervention |                    |               | Diet intervention |              |        | Diet intervention |        |       | Diet intervention |        |        |
| vs. non-diet      | -2.221             | 0.026*        | vs. non-diet      | -0.405       | 0.685  | vs. non-diet      | -1.232 | 0.218 | vs. non-diet      | -0.245 | 0.807  |
| intervention      |                    |               | intervention      |              |        | intervention      |        |       | intervention      |        |        |
| Exercise          |                    |               | Exercise          |              |        | Exercise          |        |       | Exercise          |        |        |
| intervention vs.  | -2.028             | 0.043*        | intervention vs.  | -0.304       | 0.761  | intervention vs.  | -1.160 | 0.246 | intervention vs.  | -0.207 | 0.836  |
| non-exercise      | -2.020             | 0.043         | non-exercise      | -0.304       | 0.761  | non-exercise      | -1.100 | 0.240 | non-exercise      | -0.207 | 0.030  |
| intervention      |                    |               | intervention      |              |        | intervention      |        |       | intervention      |        |        |
| Lifestyle         |                    |               | Lifestyle         |              |        | Lifestyle         |        |       | Lifestyle         |        |        |
| intervention vs.  | -2.143             | 0.032*        | intervention vs   | -0.979       | 0.328  | intervention vs.  | -0.081 | 0.936 | intervention vs.  | -0.800 | 0.424  |
| non-lifestyle     | <i>-</i> 2.143     | 0.032         | non-lifestyle     | -0.979       | 0.326  | non-lifestyle     | -0.061 | 0.936 | non-lifestyle     | -0.600 | 0.424  |
| intervention      |                    |               | intervention      |              |        | intervention      |        |       | intervention      |        |        |
| Medicine          | -4.500             | <0.001*       | Medicine          | <b>2 E10</b> | 0.012* | Medicine          | -1.568 | 0.117 | Medicine          | 2 (14  | 0.009* |
| intervention vs.  | <del>-4</del> .500 | \0.001"       | intervention vs.  | -2.518       | 0.012  | intervention vs.  | -1.506 | 0.117 | intervention vs.  | -2.014 | 0.009  |

| non-medicine                     | non-medicine     | non-medicine               | non-medicine     |
|----------------------------------|------------------|----------------------------|------------------|
| intervention                     | intervention     | intervention               | intervention     |
| Surgery                          | Surgery          | Surgery                    | Surgery          |
| intervention vs.<br>-1.754 0.079 | intervention vs. | intervention vs0.647 0.537 | intervention vs. |
| non-surgery                      | non-surgery      | non-surgery                | non-surgery      |
| intervention                     | intervention     | intervention               | intervention     |

TG: triglycerides; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol;


DM: diabetes mellites; BMI: body mass index; FBG: fasting blood glucose, HbA1c: glycated hemoglobin A1c.\*: *P*<0.05.

## Supplementary Table 4 Subgroup analysis of longitudinal changes in lipid profile by therapeutic regimen in overweight and obese populations


| Item        | Subgroup          | Rs     | $P_{adj}$ |          | Z              | P             |  |
|-------------|-------------------|--------|-----------|----------|----------------|---------------|--|
|             | Monotherapy       | 0.004  | 0.939     | 100.0%   |                |               |  |
|             | Combination       | -0.238 | 0.169     | 100.0%   | -2.077         | 0.058         |  |
|             | therapy           | -0.236 | 0.109     | 100.0 %  |                |               |  |
|             | With diet         | 0.059  | 0.417     | 100.0%   | -3.143         | 0.002*        |  |
|             | Without diet      | -0.012 | 0.803     | 98.70%   | -3.143         | 0.002         |  |
|             | With exercise     | -0.159 | 0.094     | 98%      | -1.774         | 0.076         |  |
| $\Delta TG$ | Without exercise  | 0.057  | 0.182     | 95%      | -1.//4         | 0.070         |  |
|             | With lifestyle    | 0.060  | 0.812     | 100%     | -1.408         | 0.159         |  |
|             | Without lifestyle | 0.019  | 0.630     | 99%      | -1.400         | 0.139         |  |
|             | With medicine     | 0.168  | 0.213     | 99.90%   | -1.162         | 0.245         |  |
|             | Without medicine  | 0.018  | 0.660     | 98.80%   | -1.102         | 0.243         |  |
|             | With surgery      | -0.006 | 0.976     | 98.10%   | -6.301         | <0.001*       |  |
|             | Without surgery   | 0.036  | 0.376     | 98.10%   | -0.301         | <b>\0.001</b> |  |
|             | Monotherapy       | -0.083 | 0.14      | 100.0%   |                |               |  |
|             | Combination       | 0.129  | 0.459     | 100.0%   | <i>-</i> 1.705 | 0.088         |  |
|             | therapy           | 0.129  | 0.439     | 100.0 /0 |                |               |  |
|             | With diet         | 0.059  | 0.428     | 98.70%   | -2.756         | 0.006*        |  |
|             | Without diet      | -0.074 | 0.120     | -3.47%   | -2.750         | 0.000         |  |
|             | With exercise     | -0.120 | 0.214     | 95.80%   | -1.044         | 0.296         |  |
| ΔΤC         | Without exercise  | -0.002 | 0.958     | 98.80%   | -1.044         | 0.290         |  |
|             | With lifestyle    | 0.159  | 0.543     | 99.30%   | -1.349         | 0.132         |  |
|             | Without lifestyle | -0.024 | 0.549     | 98.60%   | -1.349         | 0.132         |  |
|             | With medicine     | -0.055 | 0.699     | 99.40%   | -0.600         | 0.549         |  |
|             | Without medicine  | -0.028 | 0.495     | 98.50%   | -0.000         | 0.549         |  |
|             | With surgery      | -0.183 | 0.343     | 97.70%   | -5.322         | <0.001*       |  |
|             | Without surgery   | -0.008 | 0.851     | 98.70%   | -9.922         | <b>\0.001</b> |  |
| ΔHDL-C      | Monotherapy       | -0.016 | 0.777     | 100.0%   | -1.302         | 0.193         |  |
| ΔI IDL-C    | Combination       | 0.208  | 0.205     | 100.0%   | -1.302         | 0.173         |  |

|        | therapy           |        |       |        |        |         |
|--------|-------------------|--------|-------|--------|--------|---------|
|        | With diet         | 0.056  | 0.436 | 98.30% | -3.474 | 0.001*  |
|        | Without diet      | 0.027  | 0.562 | 98.90% |        |         |
|        | With exercise     | 0.104  | 0.264 | 98.50% | -1.651 | 0.099   |
|        | Without exercise  | 0.030  | 0.495 | 98.90% |        |         |
|        | With lifestyle    | -0.228 | 0.379 | 99.00% | -1.508 | 0.132   |
|        | Without lifestyle | 0.055  | 0.171 | 98.80% |        |         |
|        | With medicine     | -0.217 | 0.118 | 99.60% | -0.177 | 0.860   |
|        | Without medicine  | 0.062  | 0.128 | 99.30% |        |         |
|        | With surgery      | 0.270  | 0.149 | 95.00% | -4.804 | <0.001* |
|        | Without surgery   | 0.058  | 0.148 | 99.00% |        |         |
|        | Monotherapy       | -0.048 | 0.399 | 99.9%  |        |         |
|        | Combination       | 0.101  | 0.558 | 100.0% | -1.078 | 0.281   |
|        | therapy           |        |       |        |        |         |
|        | With diet         | 0.040  | 0.596 | 98.30% | -1.233 | 0.218   |
|        | Without diet      | -0.081 | 0.093 | 98.40% |        |         |
| ΔLDL-C | With exercise     | 0.031  | 0.749 | 97%    | -1.670 | 0.095   |
|        | Without exercise  | -0.049 | 0.273 | 99%    |        |         |
|        | With lifestyle    | 0.641  | 0.013 | 100%   | -1.188 | 0.235   |
|        | Without lifestyle | -0.050 | 0.221 | 97%    |        |         |
|        | With medicine     | -0.026 | 0.858 | 98.50% | -0.744 | 0.457   |
|        | Without medicine  | -0.049 | 0.250 | 100%   |        |         |
|        | With surgery      | -0.322 | 0.083 | 99%    | -5.287 | <0.001* |
|        | Without surgery   | -0.012 | 0.766 | 98%    |        |         |


TG: triglycerides; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol. \*: *P*<0.05.



Supplementary Figure 1 The egger's test for publication bias. A: The egger's test of triglycerides; B: The egger's test of total cholesterol; C: The egger's test of high-density lipoprotein cholesterol; D: The egger's test of low-density lipoprotein cholesterol. TG: Triglycerides; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol.



Supplementary Figure 2 Trial number of different baseline triglycerides, total cholesterol, high-density lipoprotein cholesterol categories for patients with overweight or obesity in randomized placebo-controlled trials from 1990 to 2024. A-D: Trial numbers of different baseline triglycerides (A), total cholesterol (B), high-density lipoprotein cholesterol (C), and low-density lipoprotein cholesterol (D) categories. TG: Triglycerides; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol.



Supplementary Figure 3 Subgroup analysis of trends in baseline triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol categorized by therapeutic regimen. A-D: Baseline triglycerides (TG; A), total cholesterol (TC; B), high-density lipoprotein cholesterol (HDL-C; C), and low-density lipoprotein cholesterol (LDL-C; D) trends categorized by intervention with and without diet; E-H: Baseline TG (E), TC (F), HDL-C (G), and LDL-C (H) trends categorized by intervention with and without exercise; I-L: Baseline TG (I), TC (J), HDL-C (K), and LDL-C (L) trends categorized by intervention with and without lifestyle; M-P: Baseline TG (M), TC (N), HDL-C (O), and LDL-C (P) trends categorized by intervention with and without medicine; Q-T: Baseline TG (Q), TC (R), HDL-C (S), and LDL-C (T) trends categorized by intervention with and without surgery. TG: triglycerides; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.

## **References:**

- 1. Lee M, Bok MK, Son K, et al. Bifidobacterium lactis IDCC 4301 (B. lactis Fit™) supplementation effects on body fat, serum triglyceride, and adipokine ratio in obese women: a randomized clinical trial. Food Funct. 2024;15(16):8448-8458.
- 2. Peters JC, Breen JA, Pan Z, Nicklas J, Cornier MA. A Randomized, Crossover Trial Assessing Appetite, Energy Metabolism, Blood Biomarkers, and Ad Libitum Food Intake Responses to a Mid-Morning Pecan Snack vs. an Equicaloric High-Carbohydrate Snack in Healthy Volunteers with Overweight/Obesity. Nutrients. 2024;16(13)
- 3. Okuka N, Milinkovic N, Velickovic K, et al. Beneficial effects of a new probiotic formulation on adipocytokines, appetite-regulating hormones, and metabolic parameters in obese women. Food Funct. 2024;15(14):7658-7668.
- 4. Pereira V, Barreiros-Mota I, Cortez F, et al. A randomized controlled trial of a weight loss maintenance program in adults with obesity: the WLM3P study. Eur J Clin Nutr. 2024;78(8):694-702.
- 5. Salte OBK, Olbers T, Risstad H, et al. Ten-Year Outcomes Following Roux-en-Y Gastric Bypass vs Duodenal Switch for High Body Mass Index: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(6):e2414340.
- 6. Moravcová K, Sovová M, Ožana J, et al. Comparing the Efficacy of Digital and In-Person Weight Loss Interventions for Patients with Obesity and Glycemic Disorders: Evidence from a Randomized Non-Inferiority Trial. Nutrients. 2024;16(10)
- 7. Holmberg S, Lendahls L, Alle K. "Dare to feel full"-A group treatment method for sustainable weight reduction in overweight and obese adults: A randomized controlled trial with 5-years follow-up. PLoS One. 2024;19(5):e0303021.
- 8. Eriksson JW, Pereira MJ, Kagios C, et al. Short-term effects of obesity surgery versus low-energy diet on body composition and tissue-specific glucose uptake: a randomised clinical study using whole-body integrated (18)F-FDG-PET/MRI. Diabetologia.

## 2024;67(7):1399-1412.

- 9. Gonzalez-Gil AM, Barnouin Y, Celli A, et al. Metabolic Effects of Testosterone Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism. J Clin Endocrinol Metab. 2025;110(3):e814-e826.
- 10. Keawtep P, Sungkarat S, Boripuntakul S, et al. Effects of combined dietary intervention and physical-cognitive exercise on cognitive function and cardiometabolic health of postmenopausal women with obesity: a randomized controlled trial. Int J Behav Nutr Phys Act. 2024;21(1):28.
- 11. Li S, Yuan S, Zhang J, Xu F, Zhu F. The effect of periodic resistance training on obese patients with type 2 diabetic nephropathy. Sci Rep. 2024;14(1):2761.
- 12. Lee DC, Brellenthin AG, Lanningham-Foster LM, Kohut ML, Li Y. Aerobic, resistance, or combined exercise training and cardiovascular risk profile in overweight or obese adults: the CardioRACE trial. Eur Heart J. 2024;45(13):1127-1142.
- 13. Sandby K, Magkos F, Chabanova E, et al. The effect of dairy products on liver fat and metabolic risk markers in males with abdominal obesity a four-arm randomized controlled trial. Clin Nutr. 2024;43(2):534-542.
- 14. Heinonen S, Saarinen T, Meriläinen S, et al. Roux-en-Y versus one-anastomosis gastric bypass (RYSA study): weight loss, metabolic improvements, and nutrition at 1 year after surgery, a multicenter randomized controlled trial. Obesity (Silver Spring). 2023;31(12):2909-2923.
- 15. da Silva CSO, Monteiro M, Fechine C, et al. Highlights of three metabolites HDL and reduction in blood pressure values after dietary fiber supplementation in overweight and obese normotensive women: a metabolomic study. Metabolomics. 2023;19(12):95.
- 16. Fallah F, Mahdavi R. Ameliorating effects of L-carnitine and synbiotic co-supplementation on anthropometric measures and

- cardiometabolic traits in women with obesity: a randomized controlled clinical trial. Front Endocrinol (Lausanne). 2023;14:1237882.
- 17. Lauw S, Kei N, Chan PL, et al. Effects of Synbiotic Supplementation on Metabolic Syndrome Traits and Gut Microbial Profile among Overweight and Obese Hong Kong Chinese Individuals: A Randomized Trial. Nutrients. 2023;15(19)
- 18. Bamgboye M, Adeyemi D, Agaba E, Yilme S, Adebamowo CA, Adebamowo SN. A Randomized Controlled Trial to Examine the Relationship Between Peer Mentoring for Physical Activity and Cardiometabolic Health. Glob Heart. 2023;18(1):53.
- 19. Möller F, Hedberg J, Skogar M, Sundbom M. Long-term Follow-up 15 Years After Duodenal Switch or Gastric Bypass for Super Obesity: a Randomized Controlled Trial. Obes Surg. 2023;33(10):2981-2990.
- 20. García-Cordero J, Mateos R, González-Rámila S, et al. Dietary Supplements Containing Oat Beta-Glucan and/or Green Coffee (Poly)phenols Showed Limited Effect in Modulating Cardiometabolic Risk Biomarkers in Overweight/Obese Patients without a Lifestyle Intervention. Nutrients. 2023;15(9)
- 21. Zhu R, Huttunen-Lenz M, Stratton G, et al. Associations of obesity phenotypes with weight change, cardiometabolic benefits, and type 2 diabetes incidence during a lifestyle intervention: results from the PREVIEW study. Int J Obes (Lond). 2023;47(9):833-840.
- 22. Hematinezhad Touli M, Elmieh A, Hosseinpour A. The Effect of Six-Week Aerobic Exercise Combined with ease max Incr2Green Tea Consumption on PON1 and VOand Apelin, Blood Pressure, and Blood Lipids Reduction in Young Obese Men. Arch Razi Inst. 2022;77(6):2115-2123.
- 23. Nora CL, Zhang L, Castro RJ, et al. Effects of mixed nut consumption on LDL cholesterol, lipoprotein(a), and other cardiometabolic risk factors in overweight and obese adults. Nutr Metab Cardiovasc Dis. 2023;33(8):1529-1538.

- 24. Sun J, Ruan Y, Xu N, et al. The effect of dietary carbohydrate and calorie restriction on weight and metabolic health in overweight/obese individuals: a multi-center randomized controlled trial. BMC Med. 2023;21(1):192.
- 25. Taha MM, Aneis YM, Hasanin ME, Felaya EE, Aldhahi MI, Abdeen HAA. Effect of high intensity interval training on arterial stiffness in obese hypertensive women: a randomized controlled trial. Eur Rev Med Pharmacol Sci. 2023;27(9):4069-4079.
- 26. Perin L, Camboim IG, Schneider CD, Lehnen AM. Weight loss associated with low-energy diets with different glycaemic loads does not improve arterial stiffness: a randomised clinical trial. Br J Nutr. 2023;130(11):1859-1870.
- 27. Zhang N, Zhou M, Li M, Ma G. Effects of Smartphone-Based Remote Interventions on Dietary Intake, Physical Activity, Weight Control, and Related Health Benefits Among the Older Population With Overweight and Obesity in China: Randomized Controlled Trial. J Med Internet Res. 2023;25:e41926.
- 28. Elsayed MM, Abdallah GA, Hassan SS, Nagy EN. Effect of exercise training with laser phototherapy on homeostasis balance resistant to hypercoagulability in seniors with obesity: a randomized trial. Sci Rep. 2023;13(1):3592.
- 29. Cabrera-Rode E, Cubas-Dueñas I, Acosta JR, et al. Efficacy and safety of Obex® in overweight and obese subjects: a randomised, double-blind, placebo-controlled clinical trial. BMC Complement Med Ther. 2023;23(1):58.
- 30. Maaloul R, Marzougui H, Ben Dhia I, et al. Effectiveness of Ramadan diurnal intermittent fasting and concurrent training in the management of obesity: is the combination worth the weight? Nutr Metab Cardiovasc Dis. 2023;33(3):659-666.
- 31. Muñoz-Pérez DM, González-Correa CH, Astudillo Muñoz EY, et al. Effect of 8-Week Consumption of a Dietary Pattern Based on Fruit, Avocado, Whole Grains, and Trout on Postprandial Inflammatory and Oxidative Stress Gene Expression in Obese People. Nutrients. 2023;15(2)

- 32. Saeidi A, Nouri-Habashi A, Razi O, et al. Astaxanthin Supplemented with High-Intensity Functional Training Decreases Adipokines Levels and Cardiovascular Risk Factors in Men with Obesity. Nutrients. 2023;15(2)
- 33. Quist JS, Klein AB, Færch K, et al. Effects of acute exercise and exercise training on plasma GDF15 concentrations and associations with appetite and cardiometabolic health in individuals with overweight or obesity A secondary analysis of a randomized controlled trial. Appetite. 2023;182:106423.
- 34. Delgado-Floody P, Chirosa-Ríos L, Guzmán-Guzmán IP, et al. The Social Distance Impacts from COVID-19 Pandemic on the Development of Two Orders of a Concurrent Training Programme for Morbidly Obese Patients. Int J Environ Res Public Health. 2022;19(20)
- 35. Ghorbani Y, Schwenger KJP, Sharma D, et al. Effect of faecal microbial transplant via colonoscopy in patients with severe obesity and insulin resistance: A randomized double-blind, placebo-controlled Phase 2 trial. Diabetes Obes Metab. 2023;25(2):479-490.
- 36. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091.
- 37. Kosiborod MN, Bhatta M, Davies M, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023;25(2):468-478.
- 38. Guo H, Wang L, Huang X, Shen F, Lu Y, Zhang P. Effects of low-carbohydrate vs low-fat diets on weight loss and metabolic risk factors in obese/overweight individuals with impaired glucose regulation: A randomized controlled trial. Asia Pac J Clin Nutr. 2022;31(3):512-519.

- 39. Yoshino M, Yoshino J, Smith GI, et al. Worksite-based intensive lifestyle therapy has profound cardiometabolic benefits in people with obesity and type 2 diabetes. Cell Metab. 2022;34(10):1431-1441.e5.
- 40. Goralska J, Razny U, Calder PC, et al. Glucose-Dependent Insulinotropic Polypeptide Plasma Level Influences the Effect of n-3 PUFA Supplementation. Diagnostics (Basel). 2022;12(8)
- 41. Zhaohu H, Xiao H, Hailin S, Feng H. Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China. J Diabetes Res. 2022;2022:4126995.
- 42. Seyam MK, Alqahtani M, Sirajudeen MS, Muthusamy H, Kashoo FZ, Salah MM. Effect of circuit training with low-carbohydrate diet on body composition, cardiometabolic indices, and exercise capacity in adults with mild to moderate obesity in Saudi Arabia: A randomized control trial. Medicine (Baltimore). 2022;101(33):e30054.
- 43. Osuna-Prieto FJ, Acosta FM, Perez de Arrilucea Le Floc'h UA, et al. Dihydrocapsiate does not increase energy expenditure nor fat oxidation during aerobic exercise in men with overweight/obesity: a randomized, triple-blinded, placebo-controlled, crossover trial. J Int Soc Sports Nutr. 2022;19(1):417-436.
- 44. Lange UG, Moulla Y, Schütz T, et al. Effectiveness and Tolerability of a Two-Week Hypocaloric Protein-Rich Diet Prior to Obesity Surgery with Two Different Diet Interventions: a Prospective Randomized Trial. Obes Surg. 2022;32(9):2903-2913.
- 45. Mo SJ, Lee K, Hong HJ, et al. Effects of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 on Overweight and the Gut Microbiota in Humans: Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. Nutrients. 2022;14(12)
- 46. Ataeinosrat A, Saeidi A, Abednatanzi H, et al. Intensity Dependent Effects of Interval Resistance Training on Myokines and Cardiovascular Risk Factors in Males With Obesity. Front Endocrinol (Lausanne). 2022;13:895512.

- 47. Salminen P, Grönroos S, Helmiö M, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial. JAMA Surg. 2022;157(8):656-666.
- 48. Zhang X, Xiao D, Guzman G, Edirisinghe I, Burton-Freeman B. Avocado Consumption for 12 Weeks and Cardiometabolic Risk Factors: A Randomized Controlled Trial in Adults with Overweight or Obesity and Insulin Resistance. J Nutr. 2022;152(8):1851-1861.
- 49. Senkus KE, Crowe-White KM, Bolland AC, Locher JL, Ard JD. Changes in adiponectin:leptin ratio among older adults with obesity following a 12-month exercise and diet intervention. Nutr Diabetes. 2022;12(1):30.
- 50. Haji-Ghazi Tehrani L, Mousavi SN, Chiti H, Afshar D. Effect of Atkins versus a low-fat diet on gut microbiota, and cardiometabolic markers in obese women following an energy-restricted diet: Randomized, crossover trial. Nutr Metab Cardiovasc Dis. 2022;32(7):1734-1741.
- 51. Murphy R, Plank LD, Clarke MG, et al. Effect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial. Diabetes Care. 2022;45(7):1503-1511.
- 52. Lockard B, Mardock M, Oliver JM, et al. Comparison of Two Diet and Exercise Approaches on Weight Loss and Health Outcomes in Obese Women. Int J Environ Res Public Health. 2022;19(8)
- 53. de Luis D, Izaola O, Primo D, Aller R. A Randomized Trial with Two Hypocaloric Diets with Different Lipid Profiles and Effects on Serum Omentin-1 Levels in Obese Subjects. Dis Markers. 2022;2022:6777283.

- 54. Ilich JZ, Liu PY, Shin H, Kim Y, Chi Y. Cardiometabolic Indices after Weight Loss with Calcium or Dairy Foods: Secondary Analyses from a Randomized Trial with Overweight/Obese Postmenopausal Women. Nutrients. 2022;14(5)
- 55. Ruggenenti P, Cortinovis M, Trillini M, et al. Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial). Diabetes Res Clin Pract. 2022;185:109804.
- 56. Sohn M, Na GY, Chu J, Joung H, Kim BK, Lim S. Efficacy and Safety of Lactobacillus plantarum K50 on Lipids in Koreans With Obesity: A Randomized, Double-Blind Controlled Clinical Trial. Front Endocrinol (Lausanne). 2021;12:790046.
- 57. Li S, Lin G, Chen J, et al. The effect of periodic ketogenic diet on newly diagnosed overweight or obese patients with type 2 diabetes. BMC Endocr Disord. 2022;22(1):34.
- 58. Lugones-Sánchez C, Recio-Rodríguez JI, Menéndez-Suárez M, et al. Effect of a Multicomponent mHealth Intervention on the Composition of Diet in a Population with Overweight and Obesity-Randomized Clinical Trial EVIDENT 3. Nutrients. 2022;14(2)
- 59. Kim MJ, Park S, Yang HJ, et al. Alleviation of Dyslipidemia via a Traditional Balanced Korean Diet Represented by a Low Glycemic and Low Cholesterol Diet in Obese Women in a Randomized Controlled Trial. Nutrients. 2022;14(2)
- 60. Sánchez E, Santos MD, Nuñez-Garcia M, et al. Randomized Clinical Trial to Evaluate the Morphological Changes in the Adventitial Vasa Vasorum Density and Biological Markers of Endothelial Dysfunction in Subjects with Moderate Obesity Undergoing a Very Low-Calorie Ketogenic Diet. Nutrients. 2021;14(1)
- 61. Eskandaros MS, Abbass A. Standard Biliopancreatic Limb (50 cm) Roux-en-Y Gastric Bypass Versus Long Biliopancreatic Limb (100 cm) Roux-en-Y Gastric Bypass in Patients with Body Mass Index 40-50 kg/m(2): a Randomized Prospective Study. Obes Surg. 2022;32(3):577-586.

- 62. Mateos R, García-Cordero J, Bravo-Clemente L, Sarriá B. Evaluation of novel nutraceuticals based on the combination of oat beta-glucans and a green coffee phenolic extract to combat obesity and its comorbidities. A randomized, dose-response, parallel trial. Food Funct. 2022;13(2):574-586.
- 63. de Oliveira Fialho CG, Moreira APB, Bressan J, de Cássia Gonçalves Alfenas R, Mattes R, Costa NMB. Effects of whole peanut within an energy-restricted diet on inflammatory and oxidative processes in obese women: a randomized controlled trial. J Sci Food Agric. 2022;102(8):3446-3455.
- 64. Grangeiro É D, Trigueiro MS, Siais LO, et al. Hypocaloric diet with lower meal frequency did not affect weight loss, body composition and insulin responsiveness, but improved lipid profile: a randomized clinical trial. Food Funct. 2021;12(24):12594-12605.
- 65. Schiavo L, Pierro R, Asteria C, et al. Low-Calorie Ketogenic Diet with Continuous Positive Airway Pressure to Alleviate Severe Obstructive Sleep Apnea Syndrome in Patients with Obesity Scheduled for Bariatric/Metabolic Surgery: a Pilot, Prospective, Randomized Multicenter Comparative Study. Obes Surg. 2022;32(3):634-642.
- 66. Haidari F, Shayesteh F, Mohammad-Shahi M, Jalali MT, Ahmadi-Angali K. Olive Leaf Extract Supplementation Combined with Calorie-Restricted Diet on Reducing Body Weight and Fat Mass in Obese Women: Result of a Randomized Control Trial. Clin Nutr Res. 2021;10(4):314-329.
- 67. Kafyra M, Kalafati IP, Katsareli EA, et al. The iMPROVE Study; Design, Dietary Patterns, and Development of a Lifestyle Index in Overweight and Obese Greek Adults. Nutrients. 2021;13(10)
- 68. Lee YK, Cho SY, Roh HT. Effects of 16 Weeks of Taekwondo Training on the Cerebral Blood Flow Velocity, Circulating

- Neurotransmitters, and Subjective Well-Being of Obese Postmenopausal Women. Int J Environ Res Public Health. 2021;18(20)
- 69. de Sousa ART, Freitas Junior WR, Perez EA, et al. Surgery for Obesity and Weight-Related Diseases Changes the Inflammatory Profile in Women with Severe Obesity: a Randomized Controlled Clinical Trial. Obes Surg. 2021;31(12):5224-5236.
- 70. Rajaie H, Rabiee MR, Bellissimo N, Faghih S. Independent and Combined Effects of Calcium and Vitamin D Supplementation on Blood Lipids in Overweight or Obese Premenopausal Women: A Triple-Blind Randomized Controlled Clinical Trial. Int J Prev Med. 2021;12:52.
- 71. Félix-Soriano E, Martínez-Gayo A, Cobo MJ, et al. Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women. Nutrients. 2021;13(7)
- 72. Astbury NM, Edwards RM, Ghebretinsea F, et al. Extended follow-up of a short total diet replacement programme: results of the Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET) randomised controlled trial at 3 years. Int J Obes (Lond). 2021;45(11):2432-2438.
- 73. Muñoz-Perez DM, Gonzalez-Correa CH, Astudillo-Muñoz EY, et al. Alternative Foods in Cardio-Healthy Dietary Models That Improve Postprandial Lipemia and Insulinemia in Obese People. Nutrients. 2021;13(7)
- 74. Vergara M, Hauser ME, Aronica L, et al. Associations of Changes in Blood Lipid Concentrations with Changes in Dietary Cholesterol Intake in the Context of a Healthy Low-Carbohydrate Weight Loss Diet: A Secondary Analysis of the DIETFITS Trial. Nutrients. 2021;13(6)
- 75. Cai L, Yin J, Ma X, et al. Low-carbohydrate diets lead to greater weight loss and better glucose homeostasis than exercise: a

- randomized clinical trial. Front Med. 2021;15(3):460-471.
- 76. Umphonsathien M, Rattanasian P, Lokattachariya S, Suansawang W, Boonyasuppayakorn K, Khovidhunkit W. Effects of intermittent very-low calorie diet on glycemic control and cardiovascular risk factors in obese patients with type 2 diabetes mellitus: A randomized controlled trial. J Diabetes Investig. 2022;13(1):156-166.
- 77. Paul S, Smith AAT, Culham K, et al. Shark liver oil supplementation enriches endogenous plasmalogens and reduces markers of dyslipidemia and inflammation. J Lipid Res. 2021;62:100092.
- 78. Jamka M, Mądry E, Krzyżanowska-Jankowska P, et al. The effect of endurance and endurance-strength training on body composition and cardiometabolic markers in abdominally obese women: a randomised trial. Sci Rep. 2021;11(1):12339.
- 79. Trouwborst I, Goossens GH, Astrup A, Saris WHM, Blaak EE. Sexual Dimorphism in Body Weight Loss, Improvements in Cardiometabolic Risk Factors and Maintenance of Beneficial Effects 6 Months after a Low-Calorie Diet: Results from the Randomized Controlled DiOGenes Trial. Nutrients. 2021;13(5)
- 80. Siu PM, Yu AP, Chin EC, et al. Effects of Tai Chi or Conventional Exercise on Central Obesity in Middle-Aged and Older Adults: A Three-Group Randomized Controlled Trial. Ann Intern Med. 2021;174(8):1050-1057.
- 81. Moholdt T, Parr EB, Devlin BL, Debik J, Giskeødegård G, Hawley JA. The effect of morning vs evening exercise training on glycaemic control and serum metabolites in overweight/obese men: a randomised trial. Diabetologia. 2021;64(9):2061-2076.
- 82. Leung GKW, Davis R, Huggins CE, Ware RS, Bonham MP. Does rearranging meal times at night improve cardiovascular risk factors? An Australian pilot randomised trial in night shift workers. Nutr Metab Cardiovasc Dis. 2021;31(6):1890-1902.
- 83. Cooney C, Daly E, McDonagh M, Ryan L. Evaluation of Measured Resting Metabolic Rate for Dietary Prescription in Ageing

Adults with Overweight and Adiposity-Based Chronic Disease. Nutrients. 2021;13(4)

- 84. Azizi S, Mahdavi R, Mobasseri M, Aliasgharzadeh S, Abbaszadeh F, Ebrahimi-Mameghani M. The impact of L-citrulline supplementation on glucose homeostasis, lipid profile, and some inflammatory factors in overweight and obese patients with type 2 diabetes: A double-blind randomized placebo-controlled trial. Phytother Res. 2021;35(6):3157-3166.
- 85. Biteli P, Barbalho SM, Detregiachi CRP, Dos Santos Haber JF, Chagas EFB. Dyslipidemia influences the effect of physical exercise on inflammatory markers on obese women in post-menopause: A randomized clinical trial. Exp Gerontol. 2021;150:111355.
- 86. Naing S, Ramesh G, Garcha J, Poliyedath A, Khandelwal S, Mills PK. Is the stepping-down approach a better option than multiple daily injections in obese patients with poorly controlled Type 2 diabetes on advanced insulin therapy? Endocrinol Diabetes Metab. 2021;4(2):e00204.
- 87. de Melo CM, Dos Santos Quaresma MVL, Del Re MP, et al. One-month of a low-energy diet, with no additional effect of high-protein, reduces Obstructive Sleep Apnea severity and improve metabolic parameters in obese males. Clin Nutr ESPEN. 2021;42:82-89.
- 88. Han Y, Kim AR, Lee JH, Kim M. Adiponectin and 8-epi-PGF(2α) as intermediate influencing factors in weight reduction after legume consumption: a 12-week randomised controlled trial. Br J Nutr. 2022;127(2):257-265.
- 89. de Luis D, Primo Martín D, Izaola O. Adiponectin gene variant rs266729 interacts with different macronutrient distributions of two different hypocaloric diets during nine months. Nutr Hosp. 2021;38(2):274-280. La variante del gen de la adiponectina rs266729 interactúa con diferentes distribuciones de macronutrientes de dos dietas hipocalóricas durante nueve meses.
- 90. Noer ER, Dewi L, Huriyati E, et al. The Impact of Weight Loss Program in Metabolic Profile and Body Fat Improvement among

- Indonesian Young Obese: A Randomized Clinical Trial. J Nutr Sci Vitaminol (Tokyo). 2020;66(Supplement):S308-s313.
- 91. Höchsmann C, Dorling JL, Martin CK, et al. Effects of a 2-Year Primary Care Lifestyle Intervention on Cardiometabolic Risk Factors: A Cluster-Randomized Trial. Circulation. 2021;143(12):1202-1214.
- 92. Lopes AL, Macedo RCO, Krüger RL, Friedman R, Carteri RB, Reischak-Oliveira Á. Fasted exercise does not improve postprandial lipemia responses to different meals in lean and obese subjects: A crossover, randomized clinical trial. Clin Nutr ESPEN. 2021;41:160-167.
- 93. Wheeler MJ, Green DJ, Cerin E, et al. Combined effects of continuous exercise and intermittent active interruptions to prolonged sitting on postprandial glucose, insulin, and triglycerides in adults with obesity: a randomized crossover trial. Int J Behav Nutr Phys Act. 2020;17(1):152.
- 94. Hajizadeh-Sharafabad F, Tarighat-Esfanjani A, Ghoreishi Z, Sarreshtedari M. Lutein supplementation combined with a low-calorie diet in middle-aged obese individuals: effects on anthropometric indices, body composition and metabolic parameters. Br J Nutr. 2021;126(7):1028-1039.
- 95. Zhang T, Li N, Chen SI, Hou Z, Saito A. Effects of green tea extract combined with brisk walking on lipid profiles and the liver function in overweight and obese men: A randomized, double-blinded, placebo-control trial. An Acad Bras Cienc. 2020;92(4):e20191594.
- 96. Wongpipit W, Zhang X, Miyashita M, Wong SH. Interrupting Prolonged Sitting Reduces Postprandial Glucose Concentration in Young Men With Central Obesity. J Clin Endocrinol Metab. 2021;106(2):e791-e802.
- 97. Rondanelli M, Riva A, Petrangolini G, et al. The Metabolic Effects of Cynara Supplementation in Overweight and Obese Class I

- Subjects with Newly Detected Impaired Fasting Glycemia: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Nutrients. 2020;12(11)
- 98. Glaysher MA, Ward J, Aldhwayan M, et al. The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids. Clin Nutr. 2021;40(4):2343-2354.
- 99. Fechner E, Bilet L, Peters HPF, Schrauwen P, Mensink RP. A Whole-Diet Approach Affects Not Only Fasting but Also Postprandial Cardiometabolic Risk Markers in Overweight and Obese Adults: A Randomized Controlled Trial. J Nutr. 2020;150(11):2942-2949.
- 100. Yousefi R, Parandoosh M, Khorsandi H, et al. Grape seed extract supplementation along with a restricted-calorie diet improves cardiovascular risk factors in obese or overweight adult individuals: A randomized, placebo-controlled trial. Phytother Res. 2021;35(2):987-995.
- 101. Park W, Jung WS, Hong K, Kim YY, Kim SW, Park HY. Effects of Moderate Combined Resistance- and Aerobic-Exercise for 12 Weeks on Body Composition, Cardiometabolic Risk Factors, Blood Pressure, Arterial Stiffness, and Physical Functions, among Obese Older Men: A Pilot Study. Int J Environ Res Public Health. 2020;17(19)
- 102. Brennan AM, Standley RA, Yi F, Carnero EA, Sparks LM, Goodpaster BH. Individual Response Variation in the Effects of Weight Loss and Exercise on Insulin Sensitivity and Cardiometabolic Risk in Older Adults. Front Endocrinol (Lausanne). 2020;11:632.
- 103. Jung K, Kim J, Park HY, Jung WS, Lim K. Hypoxic Pilates Intervention for Obesity: A Randomized Controlled Trial. Int J Environ Res Public Health. 2020;17(19)

- 104. Heiston EM, Gilbertson NM, Eichner NZM, Malin SK. A Low-Calorie Diet with or without Exercise Reduces Postprandial Aortic Waveform in Females with Obesity. Med Sci Sports Exerc. 2021;53(4):796-803.
- 105. Sun J, Cheng W, Fan Z, Zhang X. Influence of high-intensity intermittent training on glycolipid metabolism in obese male college students. Ann Palliat Med. 2020;9(4):2013-2019.
- 106. Haidari F, Asadi M, Mohammadi-Asl J, Ahmadi-Angali K. Effect of weight-loss diet combined with taurine supplementation on body composition and some biochemical markers in obese women: a randomized clinical trial. Amino Acids. 2020;52(8):1115-1124.
- 107. Haidari F, Aghamohammadi V, Mohammadshahi M, Ahmadi-Angali K, Asghari-Jafarabadi M. Whey protein supplementation reducing fasting levels of anandamide and 2-AG without weight loss in pre-menopausal women with obesity on a weight-loss diet. Trials. 2020;21(1):657.
- 108. Vogel C, Crovesy L, Rosado EL, Soares-Mota M. Effect of coconut oil on weight loss and metabolic parameters in men with obesity: a randomized controlled clinical trial. Food Funct. 2020;11(7):6588-6594.
- 109. Michalczyk MM, Klonek G, Maszczyk A, Zajac A. The Effects of a Low Calorie Ketogenic Diet on Glycaemic Control Variables in Hyperinsulinemic Overweight/Obese Females. Nutrients. 2020;12(6)
- 110. Moszak M, Zawada A, Juchacz A, Grzymisławski M, Bogdański P. Comparison of the effect of rapeseed oil or amaranth seed oil supplementation on weight loss, body composition, and changes in the metabolic profile of obese patients following 3-week body mass reduction program: a randomized clinical trial. Lipids Health Dis. 2020;19(1):143.
- 111. Batista-Jorge GC, Barcala-Jorge AS, Silveira MF, et al. Oral resveratrol supplementation improves Metabolic Syndrome

features in obese patients submitted to a lifestyle-changing program. Life Sci. 2020;256:117962.

- 112. Colleluori G, Chen R, Turin CG, et al. Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects. Front Endocrinol (Lausanne). 2020;11:277.
- 113. Poon ET, Little JP, Sit CH, Wong SH. The effect of low-volume high-intensity interval training on cardiometabolic health and psychological responses in overweight/obese middle-aged men. J Sports Sci. 2020;38(17):1997-2004.
- 114. Basciani S, Camajani E, Contini S, et al. Very-Low-Calorie Ketogenic Diets With Whey, Vegetable, or Animal Protein in Patients With Obesity: A Randomized Pilot Study. J Clin Endocrinol Metab. 2020;105(9)
- 115. Psota TL, Tindall AM, Lohse B, Miller PE, Petersen KS, Kris-Etherton PM. The Weight Optimization Revamping Lifestyle using the Dietary Guidelines (WORLD) Study: Sustained Weight Loss Over 12 Months. Obesity (Silver Spring). 2020;28(7):1235-1244.
- 116. Ghanim H, Batra M, Green K, et al. Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss. Diabetes Obes Metab. 2020;22(10):1742-1752.
- 117. Santos A, Rodrigues A, Rosa LPS, Noll M, Silveira EA. Traditional Brazilian Diet and Olive Oil Reduce Cardiometabolic Risk Factors in Severely Obese Individuals: A Randomized Trial. Nutrients. 2020;12(5)
- 118. Bakker N, Schoorl M, Demirkiran A, Cense HA, Houdijk APJ. Erythrocyte deformability and aggregation in morbidly obese women undergoing laparoscopic gastric bypass surgery and effects of oral omega-3 fatty acid supplementation. Clin Hemorheol Microcirc. 2020;75(3):303-311.
- 119. Kim J, Jee Y. EMS-effect of Exercises with Music on Fatness and Biomarkers of Obese Elderly Women. Medicina (Kaunas).

## 2020;56(4)

- 120. López-Gómez JJ, Izaola-Jauregui O, Primo-Martín D, et al. Effect of Two Meal Replacement strategies on Cardiovascular Risk Parameters in Advanced Age Patients with Obesity and Osteoarthritis. Nutrients. 2020;12(4)
- 121. Sadowska-Krępa E, Gdańska A, Rozpara M, Pilch W, Přidalová M, Bańkowski S. Effect of 12-Week Interventions Involving Nordic Walking Exercise and a Modified Diet on the Anthropometric Parameters and Blood Lipid Profiles in Overweight and Obese Ex-Coal Miners. Obes Facts. 2020;13(2):201-212.
- 122. Hannon BA, Edwards CG, Thompson SV, et al. Single Nucleotide Polymorphisms Related to Lipoprotein Metabolism Are Associated with Blood Lipid Changes following Regular Avocado Intake in a Randomized Control Trial among Adults with Overweight and Obesity. J Nutr. 2020;150(6):1379-1387.
- 123. Michael DR, Jack AA, Masetti G, et al. A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being. Sci Rep. 2020;10(1):4183.
- 124. Kuszewski JC, Wong RHX, Wood LG, Howe PRC. Effects of fish oil and curcumin supplementation on cerebrovascular function in older adults: A randomized controlled trial. Nutr Metab Cardiovasc Dis. 2020;30(4):625-633.
- 125. Meslier V, Laiola M, Roager HM, et al. Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake. Gut. 2020;69(7):1258-1268.
- 126. Razmpoosh E, Zare S, Fallahzadeh H, Safi S, Nadjarzadeh A. Effect of a low energy diet, containing a high protein, probiotic condensed yogurt, on biochemical and anthropometric measurements among women with overweight/obesity: A randomised controlled trial. Clin Nutr ESPEN. 2020;35:194-200.

- 127. Headland ML, Clifton PM, Keogh JB. Impact of intermittent vs. continuous energy restriction on weight and cardiometabolic factors: a 12-month follow-up. Int J Obes (Lond). 2020;44(6):1236-1242.
- 128. Bittel AJ, Bittel DC, Mittendorfer B, et al. A single bout of resistance exercise improves postprandial lipid metabolism in overweight/obese men with prediabetes. Diabetologia. 2020;63(3):611-623.
- 129. Hadi A, Sepandi M, Marx W, Moradi S, Parastouei K. Clinical and psychological responses to synbiotic supplementation in obese or overweight adults: A randomized clinical trial. Complement Ther Med. 2019;47:102216.
- 130. Dellis D, Tsilingiris D, Eleftheriadou I, et al. Carbohydrate restriction in the morning increases weight loss effect of a hypocaloric Mediterranean type diet: a randomized, parallel group dietary intervention in overweight and obese subjects. Nutrition. 2020;71:110578.
- 131. Porter Starr KN, Connelly MA, Orenduff MC, et al. Impact on cardiometabolic risk of a weight loss intervention with higher protein from lean red meat: Combined results of 2 randomized controlled trials in obese middle-aged and older adults. J Clin Lipidol. 2019;13(6):920-931.
- 132. Ratajczak M, Skrypnik D, Bogdański P, et al. Effects of Endurance and Endurance-Strength Training on Endothelial Function in Women with Obesity: A Randomized Trial. Int J Environ Res Public Health. 2019;16(21)
- 133. Fatahi S, Haghighatdoost F, Larijani B, Azadbakht L. Effect of Weight Reduction Diets Containing Fish, Walnut or Fish plus Walnut on Cardiovascular Risk Factors in Overweight and Obese Women. Arch Iran Med. 2019;22(10):574-583.
- 134. Peradze N, Farr OM, Perakakis N, Lázaro I, Sala-Vila A, Mantzoros CS. Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2

- diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial. Cardiovasc Diabetol. 2019;18(1):141.
- 135. Ghasemi E, Nayebifar S. Benefits of 10 weeks of high-intensity interval training and green tea supplementation on cardiovascular risk factors and VO(2max) in overweight women. J Res Med Sci. 2019;24:79.
- 136. Rakvaag E, Fuglsang-Nielsen R, Bach Knudsen KE, et al. Whey Protein Combined with Low Dietary Fiber Improves Lipid Profile in Subjects with Abdominal Obesity: A Randomized, Controlled Trial. Nutrients. 2019;11(9)
- 137. Cao L, Jiang Y, Li Q, Wang J, Tan S. Exercise Training at Maximal Fat Oxidation Intensity for Overweight or Obese Older Women: A Randomized Study. J Sports Sci Med. 2019;18(3):413-418.
- 138. Rosqvist F, Kullberg J, Ståhlman M, et al. Overeating Saturated Fat Promotes Fatty Liver and Ceramides Compared With Polyunsaturated Fat: A Randomized Trial. J Clin Endocrinol Metab. 2019;104(12):6207-6219.
- 139. Pavić E, Hadžiabdić MO, Mucalo I, et al. Effect of the Mediterranean diet in combination with exercise on metabolic syndrome parameters: 1-year randomized controlled trial. Int J Vitam Nutr Res. 2019;89(3-4):132-143.
- 140. Farr OM, Upadhyay J, Rutagengwa C, et al. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies. Diabetes Obes Metab. 2019;21(11):2459-2464.
- 141. Kim CO, Kim YN, Lee DC. Effects of Gelidium elegans on Weight and Fat Mass Reduction and Obesity Biomarkers in Overweight or Obese Adults: A Randomized Double-Blinded Study. Nutrients. 2019;11(7)
- 142. Abbaspour N, Roberts T, Hooshmand S, Kern M, Hong MY. Mixed Nut Consumption May Improve Cardiovascular Disease Risk Factors in Overweight and Obese Adults. Nutrients. 2019;11(7)

- 143. Lahelma M, Sädevirta S, Lallukka-Brück S, et al. Effects of Weighted Hula-Hooping Compared to Walking on Abdominal Fat, Trunk Muscularity, and Metabolic Parameters in Overweight Subjects: A Randomized Controlled Study. Obes Facts. 2019;12(4):385-396.
- 144. Haywood CJ, Prendergast LA, Lim R, Lappas M, Lim WK, Proietto J. Obesity in older adults: Effect of degree of weight loss on cardiovascular markers and medications. Clin Obes. 2019;9(4):e12316.
- 145. Angelino D, Martina A, Rosi A, et al. Glucose- and Lipid-Related Biomarkers Are Affected in Healthy Obese or Hyperglycemic Adults Consuming a Whole-Grain Pasta Enriched in Prebiotics and Probiotics: A 12-Week Randomized Controlled Trial. J Nutr. 2019;149(10):1714-1723.
- 146. Apiñaniz A, Cobos-Campos R, Sáez de Lafuente-Moríñigo A, et al. Effectiveness of randomized controlled trial of a mobile app to promote healthy lifestyle in obese and overweight patients. Fam Pract. 2019;36(6):699-705.
- 147. Tuccinardi D, Farr OM, Upadhyay J, et al. Mechanisms underlying the cardiometabolic protective effect of walnut consumption in obese people: A cross-over, randomized, double-blind, controlled inpatient physiology study. Diabetes Obes Metab. 2019;21(9):2086-2095.
- 148. Hernández-Lepe MA, Wall-Medrano A, López-Díaz JA, Juárez-Oropeza MA, Hernández-Torres RP, Ramos-Jiménez A. Hypolipidemic Effect of Arthrospira (Spirulina) maxima Supplementation and a Systematic Physical Exercise Program in Overweight and Obese Men: A Double-Blind, Randomized, and Crossover Controlled Trial. Mar Drugs. 2019;17(5)
- 149. Aller R, Izaola O, Primo D, de Luis DA. The effect of single-nucleotide polymorphisms at the ADIPOQ gene locus rs1501299 on metabolic parameters after 9 mo of a high-protein/low-carbohydrate versus a standard hypocaloric diet. Nutrition.

## 2019;65:44-49.

- 150. Smith-Ryan AE, Hirsch KR, Blue MNM, Mock MG, Trexler ET. High-Fat Breakfast Meal Replacement in Overweight and Obesity: Implications on Body Composition, Metabolic Markers, and Satiety. Nutrients. 2019;11(4)
- 151. Asano M, Kushida M, Yamamoto K, Tomata Y, Tsuji I, Tsuduki T. Abdominal Fat in Individuals with Overweight Reduced by Consumption of a 1975 Japanese Diet: A Randomized Controlled Trial. Obesity (Silver Spring). 2019;27(6):899-907.
- 152. Clayton ZS, Fusco E, Schreiber L, et al. Snack selection influences glucose metabolism, antioxidant capacity and cholesterol in healthy overweight adults: A randomized parallel arm trial. Nutr Res. 2019;65:89-98.
- 153. Bowen J, Luscombe-Marsh ND, Stonehouse W, et al. Effects of almond consumption on metabolic function and liver fat in overweight and obese adults with elevated fasting blood glucose: A randomised controlled trial. Clin Nutr ESPEN. 2019;30:10-18.
- 154. Yari Z, Rahimlou M, Poustchi H, Hekmatdoost A. Flaxseed supplementation improves anthropometric measurements, metabolic, and inflammatory biomarkers in overweight and obese adults. Int J Vitam Nutr Res. 2022;92(3-4):161-168.
- 155. Novin ZS, Ghavamzadeh S, Mehdizadeh A. The Weight Loss Effects of Branched Chain Amino Acids and Vitamin B6: A Randomized Controlled Trial on Obese and Overweight Women. Int J Vitam Nutr Res. 2018;88(1-2):80-89.
- 156. Erickson ML, Malin SK, Wang Z, Brown JM, Hazen SL, Kirwan JP. Effects of Lifestyle Intervention on Plasma Trimethylamine N-Oxide in Obese Adults. Nutrients. 2019;11(1)
- 157. Cho AR, Moon JY, Kim S, et al. Effects of alternate day fasting and exercise on cholesterol metabolism in overweight or obese adults: A pilot randomized controlled trial. Metabolism. 2019;93:52-60.
- 158. Aller R, Primo D, Izaola O, de Luis DA. Common polymorphism in the cannabinoid receptor gene type 2 (CB2R) rs3123554

are associated with metabolic changes after two different hypocaloric diets with different dietary fatty profiles. Clin Nutr. 2019;38(6):2632-2638.

- 159. Choi HR, Kim J, Lim H, Park YK. Two-Week Exclusive Supplementation of Modified Ketogenic Nutrition Drink Reserves Lean Body Mass and Improves Blood Lipid Profile in Obese Adults: A Randomized Clinical Trial. Nutrients. 2018;10(12)
- 160. Subih HS, Zueter Z, Obeidat BM, et al. A high weekly dose of cholecalciferol and calcium supplement enhances weight loss and improves health biomarkers in obese women. Nutr Res. 2018;59:53-64.
- 161. Headland ML, Clifton PM, Keogh JB. Effect of intermittent compared to continuous energy restriction on weight loss and weight maintenance after 12 months in healthy overweight or obese adults. Int J Obes (Lond). 2019;43(10):2028-2036.
- 162. Gorostegi-Anduaga I, Maldonado-Martín S, Martinez Aguirre-Betolaza A, et al. Effects on Cardiovascular Risk Scores and Vascular Age After Aerobic Exercise and Nutritional Intervention in Sedentary and Overweight/Obese Adults with Primary Hypertension: The EXERDIET-HTA Randomized Trial Study. High Blood Press Cardiovasc Prev. 2018;25(4):361-368.
- 163. Yousefi R, Mottaghi A, Saidpour A. Spirulina platensis effectively ameliorates anthropometric measurements and obesity-related metabolic disorders in obese or overweight healthy individuals: A randomized controlled trial. Complement Ther Med. 2018;40:106-112.
- 164. Oh M, Kim S, An KY, et al. Effects of alternate day calorie restriction and exercise on cardio-metabolic risk factors in overweight and obese adults: an exploratory randomized controlled study. BMC Public Health. 2018;18(1):1124.
- 165. Varsamis P, Formosa MF, Larsen RN, et al. Between-meal sucrose-sweetened beverage consumption impairs glycaemia and lipid metabolism during prolonged sitting: A randomized controlled trial. Clin Nutr. 2019;38(4):1536-1543.

- 166. Loves S, van Groningen L, Filius M, et al. High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention. J Clin Endocrinol Metab. 2018;103(11):4014-4022.
- 167. Camacho-Cardenosa A, Camacho-Cardenosa M, Brazo-Sayavera J, Burtscher M, Timón R, Olcina G. Effects of High-Intensity Interval Training Under Normobaric Hypoxia on Cardiometabolic Risk Markers in Overweight/Obese Women. High Alt Med Biol. 2018;19(4):356-366.
- 168. Kakutani R, Hokari S, Nishino A, et al. Effect of Oral Paprika Xanthophyll Intake on Abdominal Fat in Healthy Overweight Humans: A Randomized, Double-blind, Placebo-controlled Study. J Oleo Sci. 2018;67(9):1149-1162.
- 169. Oliveira-de-Lira L, Santos EMC, de Souza RF, et al. Supplementation-Dependent Effects of Vegetable Oils with Varying Fatty Acid Compositions on Anthropometric and Biochemical Parameters in Obese Women. Nutrients. 2018;10(7)
- 170. Allaire J, Vors C, Tremblay AJ, et al. High-Dose DHA Has More Profound Effects on LDL-Related Features Than High-Dose EPA: The ComparED Study. J Clin Endocrinol Metab. 2018;103(8):2909-2917.
- 171. Gram AS, Petersen MB, Quist JS, Rosenkilde M, Stallknecht B, Bladbjerg EM. Effects of 6 Months of Active Commuting and Leisure-Time Exercise on Fibrin Turnover in Sedentary Individuals with Overweight and Obesity: A Randomised Controlled Trial. J Obes. 2018;2018:7140754.
- 172. Azevedo FR, Santoro S, Correa-Giannella ML, et al. A Prospective Randomized Controlled Trial of the Metabolic Effects of Sleeve Gastrectomy with Transit Bipartition. Obes Surg. 2018;28(10):3012-3019.
- 173. Fatahi S, Daneshzad E, Kord-Varkaneh H, Bellissimo N, Brett NR, Azadbakht L. Impact of Diets Rich in Whole Grains and Fruits and Vegetables on Cardiovascular Risk Factors in Overweight and Obese Women: A Randomized Clinical Feeding Trial. J

- Am Coll Nutr. 2018;37(7):568-577.
- 174. Alcántara-Aragón V, Rodrigo-Cano S, Lupianez-Barbero A, et al. Web Support for Weight-Loss Interventions: PREDIRCAM2 Clinical Trial Baseline Characteristics and Preliminary Results. Diabetes Technol Ther. 2018;20(5):380-385.
- 175. Mundbjerg LH, Stolberg CR, Cecere S, et al. Supervised Physical Training Improves Weight Loss After Roux-en-Y Gastric Bypass Surgery: A Randomized Controlled Trial. Obesity (Silver Spring). 2018;26(5):828-837.
- 176. McKay DL, Eliasziw M, Chen CYO, Blumberg JB. A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial. Nutrients. 2018;10(3)
- 177. Lee YJ, Lee A, Yoo HJ, et al. Effect of weight loss on circulating fatty acid profiles in overweight subjects with high visceral fat area: a 12-week randomized controlled trial. Nutr J. 2018;17(1):28.
- 178. Padilla-Camberos E, Barragán-Álvarez CP, Diaz-Martinez NE, Rathod V, Flores-Fernández JM. Effects of Agave fructans (Agave tequilana Weber var. azul) on Body Fat and Serum Lipids in Obesity. Plant Foods Hum Nutr. 2018;73(1):34-39.
- 179. Ramos-Lopez O, Riezu-Boj JI, Milagro FI, Goni L, Cuervo M, Martinez JA. Differential lipid metabolism outcomes associated with ADRB2 gene polymorphisms in response to two dietary interventions in overweight/obese subjects. Nutr Metab Cardiovasc Dis. 2018;28(2):165-172.
- 180. Mateo-Gallego R, Lamiquiz-Moneo I, Perez-Calahorra S, et al. Different protein composition of low-calorie diet differently impacts adipokine profile irrespective of weight loss in overweight and obese women. Nutr Metab Cardiovasc Dis. 2018;28(2):133-142.
- 181. Shrivastava U, Fatma M, Mohan S, Singh P, Misra A. Randomized Control Trial for Reduction of Body Weight, Body Fat

- Patterning, and Cardiometabolic Risk Factors in Overweight Worksite Employees in Delhi, India. J Diabetes Res. 2017;2017:7254174.
- 182. Wagmacker DS, Petto J, Fraga AS, et al. Metabolic Reponses to a physical exercise session in women with excess body mass: randomized clinical trial. Lipids Health Dis. 2017;16(1):249.
- 183. Ando Y, Saito S, Miura H, Osaki N, Katsuragi Y. Consumption of alpha-linolenic acid-enriched diacylglycerol induces increase in dietary fat oxidation compared with alpha-linolenic acid-enriched triacylglycerol: A randomized, double-blind trial. Nutr Res. 2017;48:85-92.
- 184. Rock CL, Flatt SW, Barkai HS, Pakiz B, Heath DD. Walnut consumption in a weight reduction intervention: effects on body weight, biological measures, blood pressure and satiety. Nutr J. 2017;16(1):76.
- 185. Schiavon CA, Bersch-Ferreira AC, Santucci EV, et al. Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137(11):1132-1142.
- 186. Blomquist C, Chorell E, Ryberg M, et al. Decreased lipogenesis-promoting factors in adipose tissue in postmenopausal women with overweight on a Paleolithic-type diet. Eur J Nutr. 2018;57(8):2877-2886.
- 187. Lima RPA, do Nascimento RAF, Luna RCP, et al. Effect of a diet containing folate and hazelnut oil capsule on the methylation level of the ADRB3 gene, lipid profile and oxidative stress in overweight or obese women. Clin Epigenetics. 2017;9:110.
- 188. Ferreira TDS, Antunes VP, Leal PM, Sanjuliani AF, Klein M. The influence of dietary and supplemental calcium on postprandial effects of a high-fat meal on lipaemia, glycaemia, C-reactive protein and adiponectin in obese women. Br J Nutr.

- 2017;118(8):607-615.
- 189. O'Doherty AF, Jones HS, Sathyapalan T, Ingle L, Carroll S. The Effects of Acute Interval Exercise and Strawberry Intake on Postprandial Lipemia. Med Sci Sports Exerc. 2017;49(11):2315-2323.
- 190. Pedley CF, Case LD, Blackwell CS, Katula JA, Vitolins MZ. The 24-month metabolic benefits of the healthy living partnerships to prevent diabetes: A community-based translational study. Diabetes Metab Syndr. 2018;12(3):215-220.
- 191. Chung J, Kim K, Hong J, Kong HJ. Effects of prolonged exercise versus multiple short exercise sessions on risk for metabolic syndrome and the atherogenic index in middle-aged obese women: a randomised controlled trial. BMC Womens Health. 2017;17(1):65.
- 192. Fedewa MV, Hathaway ED, Higgins S, Forehand RL, Schmidt MD, Evans EM. Moderate, but not vigorous, intensity exercise training reduces C-reactive protein. Acta Cardiol. 2018;73(3):283-290.
- 193. Kleist B, Wahrburg U, Stehle P, et al. Moderate Walking Enhances the Effects of an Energy-Restricted Diet on Fat Mass Loss and Serum Insulin in Overweight and Obese Adults in a 12-Week Randomized Controlled Trial. J Nutr. 2017;147(10):1875-1884.
- 194. Vella CA, Taylor K, Drummer D. High-intensity interval and moderate-intensity continuous training elicit similar enjoyment and adherence levels in overweight and obese adults. Eur J Sport Sci. 2017;17(9):1203-1211.
- 195. Gulati S, Misra A, Tiwari R, Sharma M, Pandey RM, Yadav CP. Effect of high-protein meal replacement on weight and cardiometabolic profile in overweight/obese Asian Indians in North India. Br J Nutr. 2017;117(11):1531-1540.
- 196. Rodriguez-Cristobal JJ, Alonso-Villaverde C, Panisello JM, et al. Effectiveness of a motivational intervention on overweight/obese patients in the primary healthcare: a cluster randomized trial. BMC Fam Pract. 2017;18(1):74.

- 197. Vink RG, Roumans NJ, van der Kolk BW, et al. Adipose Tissue Meal-Derived Fatty Acid Uptake Before and After Diet-Induced Weight Loss in Adults with Overweight and Obesity. Obesity (Silver Spring). 2017;25(8):1391-1399.
- 198. Vors C, Drai J, Pineau G, et al. Emulsifying dietary fat modulates postprandial endotoxemia associated with chylomicronemia in obese men: a pilot randomized crossover study. Lipids Health Dis. 2017;16(1):97.
- 199. Ribeiro C, Dourado G, Cesar T. Orange juice allied to a reduced-calorie diet results in weight loss and ameliorates obesity-related biomarkers: A randomized controlled trial. Nutrition. 2017;38:13-19.
- 200. Ard JD, Carson TL, Shikany JM, et al. Weight loss and improved metabolic outcomes amongst rural African American women in the Deep South: six-month outcomes from a community-based randomized trial. J Intern Med. 2017;282(1):102-113.
- 201. Littlefield LA, Papadakis Z, Rogers KM, Moncada-Jiménez J, Taylor JK, Grandjean PW. The effect of exercise intensity and excess postexercise oxygen consumption on postprandial blood lipids in physically inactive men. Appl Physiol Nutr Metab. 2017;42(9):986-993.
- 202. Houghton D, Hallsworth K, Thoma C, et al. Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers. Clin Gastroenterol Hepatol. 2017;15(10):1596-1603.e3.
- 203. Trepanowski JF, Kroeger CM, Barnosky A, et al. Effect of Alternate-Day Fasting on Weight Loss, Weight Maintenance, and Cardioprotection Among Metabolically Healthy Obese Adults: A Randomized Clinical Trial. JAMA Intern Med. 2017;177(7):930-938.
- 204. Fathi Y, Ghodrati N, Zibaeenezhad MJ, Faghih S. Kefir drink causes a significant yet similar improvement in serum lipid profile, compared with low-fat milk, in a dairy-rich diet in overweight or obese premenopausal women: A randomized controlled

- trial. J Clin Lipidol. 2017;11(1):136-146.
- 205. Juliana N, Shahar S, Sahar MA, Ghazali AR, Manaf ZA, Noah RM. 'Her shape' intervention programme for obese women with high breast adiposity. Asia Pac J Clin Nutr. 2017;26(2):278-286.
- 206. Bonfante IL, Chacon-Mikahil MP, Brunelli DT, et al. Combined training, FNDC5/irisin levels and metabolic markers in obese men: A randomised controlled trial. Eur J Sport Sci. 2017;17(5):629-637.
- 207. Heggen E, Svendsen M, Tonstad S. Smoking cessation improves cardiometabolic risk in overweight and obese subjects treated with varenicline and dietary counseling. Nutr Metab Cardiovasc Dis. 2017;27(4):335-341.
- 208. Williams EJ, Baines KJ, Berthon BS, Wood LG. Effects of an Encapsulated Fruit and Vegetable Juice Concentrate on Obesity-Induced Systemic Inflammation: A Randomised Controlled Trial. Nutrients. 2017;9(2)
- 209. Peterli R, Wölnerhanssen BK, Vetter D, et al. Laparoscopic Sleeve Gastrectomy Versus Roux-Y-Gastric Bypass for Morbid Obesity-3-Year Outcomes of the Prospective Randomized Swiss Multicenter Bypass Or Sleeve Study (SM-BOSS). Ann Surg. 2017;265(3):466-473.
- 210. Merra G, Gratteri S, De Lorenzo A, et al. Effects of very-low-calorie diet on body composition, metabolic state, and genes expression: a randomized double-blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2017;21(2):329-345.
- 211. Pal S, Ho S, Gahler RJ, Wood S. Effect on Insulin, Glucose and Lipids in Overweight/Obese Australian Adults of 12 Months Consumption of Two Different Fibre Supplements in a Randomised Trial. Nutrients. 2017;9(2)
- 212. Bergeron N, Williams PT, Lamendella R, et al. Diets high in resistant starch increase plasma levels of trimethylamine-N-oxide, a gut microbiome metabolite associated with CVD risk. Br J Nutr. 2016;116(12):2020-2029.

- 213. Wittmann K, Sieber C, von Stengel S, et al. Impact of whole body electromyostimulation on cardiometabolic risk factors in older women with sarcopenic obesity: the randomized controlled FORMOsA-sarcopenic obesity study. Clin Interv Aging. 2016;11:1697-1706.
- 214. Veum VL, Laupsa-Borge J, Eng Ø, et al. Visceral adiposity and metabolic syndrome after very high-fat and low-fat isocaloric diets: a randomized controlled trial. Am J Clin Nutr. 2017;105(1):85-99.
- 215. Coelho R, Hermsdorff HHM, Gomide RS, Alves RDM, Bressan J. Orange juice with a high-fat meal prolongs postprandial lipemia in apparently healthy overweight/obese women. Arch Endocrinol Metab. 2017;61(3):263-268.
- 216. Kirwan JP, Malin SK, Scelsi AR, et al. A Whole-Grain Diet Reduces Cardiovascular Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial. J Nutr. 2016;146(11):2244-2251.
- 217. Madjd A, Taylor MA, Shafiei Neek L, et al. Effect of weekly physical activity frequency on weight loss in healthy overweight and obese women attending a weight loss program: a randomized controlled trial. Am J Clin Nutr. 2016;104(5):1202-1208.
- 218. Duncan S, Goodyear-Smith F, McPhee J, Zinn C, Grøntved A, Schofield G. Family-centered brief intervention for reducing obesity and cardiovascular disease risk: A randomized controlled trial. Obesity (Silver Spring). 2016;24(11):2311-2318.
- 219. Lee M, Sorn SR, Park Y, Park HK. Anthocyanin Rich-Black Soybean Testa Improved Visceral Fat and Plasma Lipid Profiles in Overweight/Obese Korean Adults: A Randomized Controlled Trial. J Med Food. 2016;19(11):995-1003.
- 220. Normandin E, Chmelo E, Lyles MF, Marsh AP, Nicklas BJ. Effect of Resistance Training and Caloric Restriction on the Metabolic Syndrome. Med Sci Sports Exerc. 2017;49(3):413-419.

- 221. de Luis D, Domingo JC, Izaola O, Casanueva FF, Bellido D, Sajoux I. Effect of DHA supplementation in a very low-calorie ketogenic diet in the treatment of obesity: a randomized clinical trial. Endocrine. 2016;54(1):111-122.
- 222. Madjd A, Taylor MA, Delavari A, Malekzadeh R, Macdonald IA, Farshchi HR. Beneficial effects of replacing diet beverages with water on type 2 diabetic obese women following a hypo-energetic diet: A randomized, 24-week clinical trial. Diabetes Obes Metab. 2017;19(1):125-132.
- 223. Mosikanon K, Arthan D, Kettawan A, Tungtrongchitr R, Prangthip P. Yeast β-Glucan Modulates Inflammation and Waist Circumference in Overweight and Obese Subjects. J Diet Suppl. 2017;14(2):173-185.
- 224. Nikseresht M, Hafezi Ahmadi MR, Hedayati M. Detraining-induced alterations in adipokines and cardiometabolic risk factors after nonlinear periodized resistance and aerobic interval training in obese men. Appl Physiol Nutr Metab. 2016;41(10):1018-1025.
- 225. Raatz SK, Johnson LK, Rosenberger TA, Picklo MJ. Twice weekly intake of farmed Atlantic salmon (Salmo salar) positively influences lipoprotein concentration and particle size in overweight men and women. Nutr Res. 2016;36(9):899-906.
- 226. Ruggenenti P, Abbate M, Ruggiero B, et al. Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. Diabetes. 2017;66(1):75-86.
- 227. Risstad H, Svanevik M, Kristinsson JA, et al. Standard vs Distal Roux-en-Y Gastric Bypass in Patients With Body Mass Index 50 to 60: A Double-blind, Randomized Clinical Trial. JAMA Surg. 2016;151(12):1146-1155.
- 228. Tomeleri CM, Ribeiro AS, Souza MF, et al. Resistance training improves inflammatory level, lipid and glycemic profiles in obese older women: A randomized controlled trial. Exp Gerontol. 2016;84:80-87.

- 229. Cox AJ, Watts AM, Zhang P, Williams LT, Cripps AW, West NP. Effects of short-term supplementation with bovine lactoferrin and/or immunoglobulins on body mass and metabolic measures: a randomised controlled trial. Int J Food Sci Nutr. 2017;68(2):219-226.
- 230. Camolas J, Santos O, Moreira P, do Carmo I. INDIVIDUO: Results from a patient-centered lifestyle intervention for obesity surgery candidates. Obes Res Clin Pract. 2017;11(4):475-488.
- 231. Valsesia A, Saris WH, Astrup A, Hager J, Masoodi M. Distinct lipid profiles predict improved glycemic control in obese, nondiabetic patients after a low-caloric diet intervention: the Diet, Obesity and Genes randomized trial. Am J Clin Nutr. 2016;104(3):566-75.
- 232. Weiss EP, Albert SG, Reeds DN, et al. Effects of matched weight loss from calorie restriction, exercise, or both on cardiovascular disease risk factors: a randomized intervention trial. Am J Clin Nutr. 2016;104(3):576-86.
- 233. Byun MS, Yu OK, Cha YS, Park TS. Korean traditional Chungkookjang improves body composition, lipid profiles and atherogenic indices in overweight/obese subjects: a double-blind, randomized, crossover, placebo-controlled clinical trial. Eur J Clin Nutr. 2016;70(10):1116-1122.
- 234. Mensinger JL, Calogero RM, Stranges S, Tylka TL. A weight-neutral versus weight-loss approach for health promotion in women with high BMI: A randomized-controlled trial. Appetite. 2016;105:364-74.
- 235. Arzola-Paniagua MA, García-Salgado López ER, Calvo-Vargas CG, Guevara-Cruz M. Efficacy of an orlistat-resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial. Obesity (Silver Spring). 2016;24(7):1454-63.
- 236. Dempsey PC, Larsen RN, Sethi P, et al. Benefits for Type 2 Diabetes of Interrupting Prolonged Sitting With Brief Bouts of

- Light Walking or Simple Resistance Activities. Diabetes Care. 2016;39(6):964-72.
- 237. Firouzjaei A, Li GC, Wang N, Liu WX, Zhu BM. Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients. Nutr Diabetes. 2016;6(5):e209.
- 238. Dutour A, Abdesselam I, Ancel P, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab. 2016;18(9):882-91.
- 239. Tan S, Wang J, Cao L, Guo Z, Wang Y. Positive effect of exercise training at maximal fat oxidation intensity on body composition and lipid metabolism in overweight middle-aged women. Clin Physiol Funct Imaging. 2016;36(3):225-30.
- 240. Ma W, Huang T, Zheng Y, et al. Weight-Loss Diets, Adiponectin, and Changes in Cardiometabolic Risk in the 2-Year POUNDS Lost Trial. J Clin Endocrinol Metab. 2016;101(6):2415-22.
- 241. Rigamonti AE, Bini S, Rocco MC, et al. Post-prandial anorexigenic gut peptide, appetite and glucometabolic responses at different eating rates in obese patients undergoing laparoscopic sleeve gastrectomy. Endocrine. 2017;55(1):113-123.
- 242. Ji M, Xia L, Cao J, Zou D. Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes. Medicine (Baltimore). 2016;95(11):e2961.
- 243. Daubenmier J, Moran PJ, Kristeller J, et al. Effects of a mindfulness-based weight loss intervention in adults with obesity: A randomized clinical trial. Obesity (Silver Spring). 2016;24(4):794-804.
- 244. Razny U, Kiec-Wilk B, Polus A, et al. Effect of caloric restriction with or without n-3 polyunsaturated fatty acids on insulin

- sensitivity in obese subjects: A randomized placebo controlled trial. BBA Clin. 2015;4:7-13.
- 245. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell Metab. 2016;23(4):591-601.
- 246. Hosseini B, Saedisomeolia A, Wood LG, Yaseri M, Tavasoli S. Effects of pomegranate extract supplementation on inflammation in overweight and obese individuals: A randomized controlled clinical trial. Complement Ther Clin Pract. 2016;22:44-50.
- 247. Li J, Armstrong CL, Campbell WW. Effects of Dietary Protein Source and Quantity during Weight Loss on Appetite, Energy Expenditure, and Cardio-Metabolic Responses. Nutrients. 2016;8(2):63.
- 248. Stroeve JH, Saccenti E, Bouwman J, et al. Weight loss predictability by plasma metabolic signatures in adults with obesity and morbid obesity of the DiOGenes study. Obesity (Silver Spring). 2016;24(2):379-88.
- 249. Le T, Flatt SW, Natarajan L, et al. Effects of Diet Composition and Insulin Resistance Status on Plasma Lipid Levels in a Weight Loss Intervention in Women. J Am Heart Assoc. 2016;5(1)
- 250. Ohara T, Muroyama K, Yamamoto Y, Murosaki S. Oral intake of a combination of glucosyl hesperidin and caffeine elicits an anti-obesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial. Nutr J. 2016;15:6.
- 251. Juraschek SP, McAdams-Demarco M, Gelber AC, et al. Effects of Lowering Glycemic Index of Dietary Carbohydrate on Plasma Uric Acid Levels: The OmniCarb Randomized Clinical Trial. Arthritis Rheumatol. 2016;68(5):1281-9.
- 252. Henson J, Davies MJ, Bodicoat DH, et al. Breaking Up Prolonged Sitting With Standing or Walking Attenuates the Postprandial Metabolic Response in Postmenopausal Women: A Randomized Acute Study. Diabetes Care. 2016;39(1):130-8.

- 253. Loftus HL, Astell KJ, Mathai ML, Su XQ. Coleus forskohlii Extract Supplementation in Conjunction with a Hypocaloric Diet Reduces the Risk Factors of Metabolic Syndrome in Overweight and Obese Subjects: A Randomized Controlled Trial. Nutrients. 2015;7(11):9508-22.
- 254. Besnier F, Lenclume V, Gérardin P, et al. Individualized Exercise Training at Maximal Fat Oxidation Combined with Fruit and Vegetable-Rich Diet in Overweight or Obese Women: The LIPOXmax-Réunion Randomized Controlled Trial. PLoS One. 2015;10(11):e0139246.
- 255. Said M, Lamya N, Olfa N, Hamda M. Effects of high-impact aerobics vs. low-impact aerobics and strength training in overweight and obese women. J Sports Med Phys Fitness. 2017;57(3):278-288.
- 256. Fisher G, Brown AW, Bohan Brown MM, et al. High Intensity Interval- vs Moderate Intensity- Training for Improving Cardiometabolic Health in Overweight or Obese Males: A Randomized Controlled Trial. PLoS One. 2015;10(10):e0138853.
- 257. Barbour JA, Howe PR, Buckley JD, Bryan J, Coates AM. Effect of 12 Weeks High Oleic Peanut Consumption on Cardio-Metabolic Risk Factors and Body Composition. Nutrients. 2015;7(9):7381-98.
- 258. Ribeiro AS, Pina FL, Dodero SR, et al. Effect of Conjugated Linoleic Acid Associated With Aerobic Exercise on Body Fat and Lipid Profile in Obese Women: A Randomized, Double-Blinded, and Placebo-Controlled Trial. Int J Sport Nutr Exerc Metab. 2016;26(2):135-44.
- 259. Rozati M, Barnett J, Wu D, et al. Cardio-metabolic and immunological impacts of extra virgin olive oil consumption in overweight and obese older adults: a randomized controlled trial. Nutr Metab (Lond). 2015;12:28.
- 260. Yang J, Wang C, Cao G, et al. Long-term effects of laparoscopic sleeve gastrectomy versus roux-en-Y gastric bypass for the

- treatment of Chinese type 2 diabetes mellitus patients with body mass index 28-35 kg/m(2). BMC Surg. 2015;15:88.
- 261. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22.
- 262. Osama AJ, Shehab Ael K. Psychological wellbeing and biochemical modulation in response to weight loss in obese type 2 diabetes patients. Afr Health Sci. 2015;15(2):503-12.
- 263. Chen IJ, Liu CY, Chiu JP, Hsu CH. Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2016;35(3):592-9.
- 264. Romero-Moraleda B, Peinado Lozano AB, Morencos Martínez E, López-Plaza B, Gómez Candela C, Calderón Montero FJ. Lipid profile response to weight loss program in overweight and obese patient is related with gender and age. Nutr Hosp. 2015;31(6):2455-64.
- 265. Rossi FE, Fortaleza AC, Neves LM, et al. Combined Training (Aerobic Plus Strength) Potentiates a Reduction in Body Fat but Demonstrates No Difference on the Lipid Profile in Postmenopausal Women When Compared With Aerobic Training With a Similar Training Load. J Strength Cond Res. 2016;30(1):226-34.
- 266. Song MY, Wang JH, Eom T, Kim H. Schisandra chinensis fruit modulates the gut microbiota composition in association with metabolic markers in obese women: a randomized, double-blind placebo-controlled study. Nutr Res. 2015;35(8):655-63.
- 267. Soto-Molina H, Pizarro-Castellanos M, Rosado-Pérez J, et al. Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial. Int J Clin Pharmacol Ther. 2015;53(7):541-9.
- 268. Mahdavi R, Namazi N, Alizadeh M, Farajnia S. Effects of Nigella sativa oil with a low-calorie diet on cardiometabolic risk

factors in obese women: a randomized controlled clinical trial. Food Funct. 2015;6(6):2041-8.

- 269. Bruun JM, Maersk M, Belza A, Astrup A, Richelsen B. Consumption of sucrose-sweetened soft drinks increases plasma levels of uric acid in overweight and obese subjects: a 6-month randomised controlled trial. Eur J Clin Nutr. 2015;69(8):949-53.
- 270. Gatterer H, Haacke S, Burtscher M, et al. Normobaric Intermittent Hypoxia over 8 Months Does Not Reduce Body Weight and Metabolic Risk Factors--a Randomized, Single Blind, Placebo-Controlled Study in Normobaric Hypoxia and Normobaric Sham Hypoxia. Obes Facts. 2015;8(3):200-9.
- 271. Mateo-Gallego R, Marco-Benedí V, Perez-Calahorra S, et al. Energy-restricted, high-protein diets more effectively impact cardiometabolic profile in overweight and obese women than lower-protein diets. Clin Nutr. 2017;36(2):371-379.
- 272. Xu M, Ng SS, Bray GA, et al. Dietary Fat Intake Modifies the Effect of a Common Variant in the LIPC Gene on Changes in Serum Lipid Concentrations during a Long-Term Weight-Loss Intervention Trial. J Nutr. 2015;145(6):1289-94.
- 273. Cho IJ, Choung SY, Hwang YC, Ahn KJ, Chung HY, Jeong IK. Aster spathulifolius Maxim extract reduces body weight and fat mass in obese humans. Nutr Res. 2016;36(7):671-8.
- 274. Robert SA, Rohana AG, Shah SA, Chinna K, Wan Mohamud WN, Kamaruddin NA. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide A pilot study. Obes Res Clin Pract. 2015;9(3):301-4.
- 275. Ghafouri K, Cooney J, Bedford DK, Wilson J, Caslake MJ, Gill JM. Moderate Exercise Increases Affinity of Large Very Low-Density Lipoproteins for Hydrolysis by Lipoprotein Lipase. J Clin Endocrinol Metab. 2015;100(6):2205-13.
- 276. Alencar MK, Beam JR, McCormick JJ, et al. Increased meal frequency attenuates fat-free mass losses and some markers of health status with a portion-controlled weight loss diet. Nutr Res. 2015;35(5):375-83.

- 277. Fuller NR, Caterson ID, Sainsbury A, et al. The effect of a high-egg diet on cardiovascular risk factors in people with type 2 diabetes: the Diabetes and Egg (DIABEGG) study-a 3-mo randomized controlled trial. Am J Clin Nutr. 2015;101(4):705-13.
- 278. McFarlin BK, Venable AS, Henning AL, et al. Natural cocoa consumption: Potential to reduce atherogenic factors? J Nutr Biochem. 2015;26(6):626-32.
- 279. Macías-Cervantes MH, Rodríguez-Soto JM, Uribarri J, Díaz-Cisneros FJ, Cai W, Garay-Sevilla ME. Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men. Nutrition. 2015;31(3):446-51.
- 280. Risstad H, Søvik TT, Engström M, et al. Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: a randomized clinical trial. JAMA Surg. 2015;150(4):352-61.
- 281. Dodevska MS, Sobajic SS, Djordjevic PB, Dimitrijevic-Sreckovic VS, Spasojevic-Kalimanovska VV, Djordjevic BI. Effects of total fibre or resistant starch-rich diets within lifestyle intervention in obese prediabetic adults. Eur J Nutr. 2016;55(1):127-37.
- 282. Rezaeipour M, Apanasenko GL, Nychyporuk VI. Investigating the effects of negative-calorie diet compared with low-calorie diet under exercise conditions on weight loss and lipid profile in overweight/obese middle-aged and older men. Turk J Med Sci. 2014;44(5):792-8.
- 283. Bajerska J, Mildner-Szkudlarz S, Walkowiak J. Effects of rye bread enriched with green tea extract on weight maintenance and the characteristics of metabolic syndrome following weight loss: a pilot study. J Med Food. 2015;18(6):698-705.
- 284. Yamauchi K, Katayama T, Yamauchi T, et al. Efficacy of a 3-month lifestyle intervention program using a Japanese-style healthy plate on body weight in overweight and obese diabetic Japanese subjects: a randomized controlled trial. Nutr J. 2014;13:108.
- 285. Moreira AP, Teixeira TF, Alves RD, et al. Effect of a high-fat meal containing conventional or high-oleic peanuts on

- post-prandial lipopolysaccharide concentrations in overweight/obese men. J Hum Nutr Diet. 2016;29(1):95-104.
- 286. Cases J, Romain C, Dallas C, Gerbi A, Cloarec M. Regular consumption of Fiit-ns, a polyphenol extract from fruit and vegetables frequently consumed within the Mediterranean diet, improves metabolic ageing of obese volunteers: a randomized, double-blind, parallel trial. Int J Food Sci Nutr. 2015;66(1):120-5.
- 287. Worsley R, Jane F, Robinson PJ, Bell RJ, Davis SR. Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. Climacteric. 2015;18(2):270-7.
- 288. Hoddy KK, Kroeger CM, Trepanowski JF, Barnosky A, Bhutani S, Varady KA. Meal timing during alternate day fasting: Impact on body weight and cardiovascular disease risk in obese adults. Obesity (Silver Spring). 2014;22(12):2524-31.
- 289. Tay J, Luscombe-Marsh ND, Thompson CH, et al. A very low-carbohydrate, low-saturated fat diet for type 2 diabetes management: a randomized trial. Diabetes Care. 2014;37(11):2909-18.
- 290. Foraker RE, Pennell M, Sprangers P, Vitolins MZ, DeGraffinreid C, Paskett ED. Effect of a low-fat or low-carbohydrate weight-loss diet on markers of cardiovascular risk among premenopausal women: a randomized trial. J Womens Health (Larchmt). 2014;23(8):675-80.
- 291. Choo J, Lee J, Cho JH, Burke LE, Sekikawa A, Jae SY. Effects of weight management by exercise modes on markers of subclinical atherosclerosis and cardiometabolic profile among women with abdominal obesity: a randomized controlled trial. BMC Cardiovasc Disord. 2014;14:82.
- van Nielen M, Feskens EJ, Rietman A, Siebelink E, Mensink M. Partly replacing meat protein with soy protein alters insulin resistance and blood lipids in postmenopausal women with abdominal obesity. J Nutr. 2014;144(9):1423-9.

- 293. Moreira Alves RD, Boroni Moreira AP, Macedo VS, et al. High-oleic peanuts: new perspective to attenuate glucose homeostasis disruption and inflammation related obesity. Obesity (Silver Spring). 2014;22(9):1981-8.
- 294. Bracale R, Petroni ML, Davinelli S, et al. Muscle uncoupling protein 3 expression is unchanged by chronic ephedrine/caffeine treatment: results of a double blind, randomised clinical trial in morbidly obese females. PLoS One. 2014;9(6):e98244.
- 295. Telles S, Sharma SK, Yadav A, Singh N, Balkrishna A. A comparative controlled trial comparing the effects of yoga and walking for overweight and obese adults. Med Sci Monit. 2014;20:894-904.
- 296. Larsen RN, Kingwell BA, Sethi P, Cerin E, Owen N, Dunstan DW. Breaking up prolonged sitting reduces resting blood pressure in overweight/obese adults. Nutr Metab Cardiovasc Dis. 2014;24(9):976-82.
- 297. Guo Y, Xing M, Sun W, Yuan X, Dai H, Ding H. Plasma nesfatin-1 level in obese patients after acupuncture: a randomised controlled trial. Acupunct Med. 2014;32(4):313-7.
- 298. Saslow LR, Kim S, Daubenmier JJ, et al. A randomized pilot trial of a moderate carbohydrate diet compared to a very low carbohydrate diet in overweight or obese individuals with type 2 diabetes mellitus or prediabetes. PLoS One. 2014;9(4):e91027.
- 299. Tapsell LC, Batterham MJ, Thorne RL, O'Shea JE, Grafenauer SJ, Probst YC. Weight loss effects from vegetable intake: a 12-month randomised controlled trial. Eur J Clin Nutr. 2014;68(7):778-85.
- 300. Lowndes J, Sinnett S, Pardo S, et al. The effect of normally consumed amounts of sucrose or high fructose corn syrup on lipid profiles, body composition and related parameters in overweight/obese subjects. Nutrients. 2014;6(3):1128-44.
- 301. Thorp AA, Kingwell BA, Sethi P, Hammond L, Owen N, Dunstan DW. Alternating bouts of sitting and standing attenuate

- postprandial glucose responses. Med Sci Sports Exerc. 2014;46(11):2053-61.
- 302. Wong AT, Chan DC, Barrett PH, Adams LA, Watts GF. Effect of  $\omega$ -3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state. J Clin Endocrinol Metab. 2014;99(8):E1427-35.
- 303. Calbet JA, Ponce-González JG, Pérez-Suárez I, de la Calle Herrero J, Holmberg HC. A time-efficient reduction of fat mass in 4 days with exercise and caloric restriction. Scand J Med Sci Sports. 2015;25(2):223-33.
- 304. Mirzaei K, Hossein-Nezhad A, Keshavarz SA, et al. Insulin resistance via modification of PGC1α function identifying a possible preventive role of vitamin D analogues in chronic inflammatory state of obesity. A double blind clinical trial study. Minerva Med. 2014;105(1):63-78.
- 305. Mellberg C, Sandberg S, Ryberg M, et al. Long-term effects of a Palaeolithic-type diet in obese postmenopausal women: a 2-year randomized trial. Eur J Clin Nutr. 2014;68(3):350-7.
- 306. Milsom VA, Malcolm RJ, Johnson GC, et al. Changes in cardiovascular risk factors with participation in a 12-week weight loss trial using a commercial format. Eat Behav. 2014;15(1):68-71.
- 307. Shirai K, Saiki A, Oikawa S, et al. The effects of partial use of formula diet on weight reduction and metabolic variables in obese type 2 diabetic patients--multicenter trial. Obes Res Clin Pract. 2013;7(1):e43-54.
- 308. Rabinovitz HR, Boaz M, Ganz T, et al. Big breakfast rich in protein and fat improves glycemic control in type 2 diabetics. Obesity (Silver Spring). 2014;22(5):E46-54.
- 309. Mielgo-Ayuso J, Barrenechea L, Alcorta P, Larrarte E, Margareto J, Labayen I. Effects of dietary supplementation with

- epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial. Br J Nutr. 2014;111(7):1263-71.
- 310. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022-9.
- 311. Alves NE, Enes BN, Martino HS, Alfenas Rde C, Ribeiro SM. Meal replacement based on Human Ration modulates metabolic risk factors during body weight loss: a randomized controlled trial. Eur J Nutr. 2014;53(3):939-50.
- Ruth MR, Port AM, Shah M, et al. Consuming a hypocaloric high fat low carbohydrate diet for 12 weeks lowers C-reactive protein, and raises serum adiponectin and high density lipoprotein-cholesterol in obese subjects. Metabolism. 2013;62(12):1779-87.
- 313. Tovar J, Nilsson A, Johansson M, Björck I. Combining functional features of whole-grain barley and legumes for dietary reduction of cardiometabolic risk: a randomised cross-over intervention in mature women. Br J Nutr. 2014;111(4):706-14.
- 314. Croymans DM, Krell SL, Oh CS, et al. Effects of resistance training on central blood pressure in obese young men. J Hum Hypertens. 2014;28(3):157-64.
- 315. Vetter ML, Wadden TA, Chittams J, et al. Effect of lifestyle intervention on cardiometabolic risk factors: results of the POWER-UP trial. Int J Obes (Lond). 2013;37 Suppl 1(0 1):S19-24.
- 316. Vinkers CD, Adriaanse MA, Kroese FM, de Ridder DT. Efficacy of a self-management intervention for weight control in overweight and obese adults: a randomized controlled trial. J Behav Med. 2014;37(4):781-92.
- 317. Botero JP, Prado WL, Guerra RL, et al. Does aerobic exercise intensity affect health-related parameters in overweight

- women? Clin Physiol Funct Imaging. 2014;34(2):138-42.
- 318. Hu X, Gao J, Zhang Q, et al. Soy fiber improves weight loss and lipid profile in overweight and obese adults: a randomized controlled trial. Mol Nutr Food Res. 2013;57(12):2147-54.
- 319. Kim SH, Abbasi F, Lamendola C, et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013;36(10):3276-82.
- 320. Bouchonville M, Armamento-Villareal R, Shah K, et al. Weight loss, exercise or both and cardiometabolic risk factors in obese older adults: results of a randomized controlled trial. Int J Obes (Lond). 2014;38(3):423-31.
- 321. Romero Moraleda B, Morencos E, Peinado AB, Bermejo L, Gómez Candela C, Benito PJ. Can the exercise mode determine lipid profile improvements in obese patients? Nutr Hosp. 2013;28(3):607-17.
- 322. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. Jama. 2013;309(21):2240-9.
- 323. Tey SL, Gray AR, Chisholm AW, Delahunty CM, Brown RC. The dose of hazelnuts influences acceptance and diet quality but not inflammatory markers and body composition in overweight and obese individuals. J Nutr. 2013;143(8):1254-62.
- 324. Nicklas JM, Sacks FM, Smith SR, et al. Effect of dietary composition of weight loss diets on high-sensitivity c-reactive protein: the Randomized POUNDS LOST trial. Obesity (Silver Spring). 2013;21(4):681-9.
- 325. Stocks T, Taylor MA, Angquist L, et al. Change in proportional protein intake in a 10-week energy-restricted low- or high-fat diet, in relation to changes in body size and metabolic factors. Obes Facts. 2013;6(3):217-27.
- 326. Wright OR, Netzel GA, Sakzewski AR. A randomized, double-blind, placebo-controlled trial of the effect of dried purple

- carrot on body mass, lipids, blood pressure, body composition, and inflammatory markers in overweight and obese adults: the QUENCH trial. Can J Physiol Pharmacol. 2013;91(6):480-8.
- 327. Kim SH, Lee SH, Ahn KY, et al. Effect of lifestyle modification on serum chemerin concentration and its association with insulin sensitivity in overweight and obese adults with type 2 diabetes. Clin Endocrinol (Oxf). 2014;80(6):825-33.
- 328. Munro IA, Garg ML. Dietary supplementation with long chain omega-3 polyunsaturated fatty acids and weight loss in obese adults. Obes Res Clin Pract. 2013;7(3):e173-81.
- 329. Astell KJ, Mathai ML, McAinch AJ, Stathis CG, Su XQ. A pilot study investigating the effect of Caralluma fimbriata extract on the risk factors of metabolic syndrome in overweight and obese subjects: a randomised controlled clinical trial. Complement Ther Med. 2013;21(3):180-9.
- 330. Tonstad S, Malik N, Haddad E. A high-fibre bean-rich diet versus a low-carbohydrate diet for obesity. J Hum Nutr Diet. 2014;27 Suppl 2:109-16.
- 331. Venojärvi M, Korkmaz A, Wasenius N, et al. 12 weeks' aerobic and resistance training without dietary intervention did not influence oxidative stress but aerobic training decreased atherogenic index in middle-aged men with impaired glucose regulation. Food Chem Toxicol. 2013;61:127-35.
- 332. Lamprecht M, Obermayer G, Steinbauer K, et al. Supplementation with a juice powder concentrate and exercise decrease oxidation and inflammation, and improve the microcirculation in obese women: randomised controlled trial data. Br J Nutr. 2013;110(9):1685-95.
- 333. Tang M, Armstrong CL, Leidy HJ, Campbell WW. Normal vs. high-protein weight loss diets in men: effects on body

- composition and indices of metabolic syndrome. Obesity (Silver Spring). 2013;21(3):E204-10.
- 334. Reimer RA, Yamaguchi H, Eller LK, et al. Changes in visceral adiposity and serum cholesterol with a novel viscous polysaccharide in Japanese adults with abdominal obesity. Obesity (Silver Spring). 2013;21(9):E379-87.
- 335. Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity (Silver Spring). 2013;21(8):1561-70.
- 336. Jakubowicz D, Barnea M, Wainstein J, Froy O. High caloric intake at breakfast vs. dinner differentially influences weight loss of overweight and obese women. Obesity (Silver Spring). 2013;21(12):2504-12.
- 337. Beebe N, Magnanti S, Katkowski L, et al. Effects of the addition of t'ai chi to a dietary weight loss program on lipoprotein atherogenicity in obese older women. J Altern Complement Med. 2013;19(9):759-66.
- 338. Unick JL, Beavers D, Bond DS, et al. The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med. 2013;126(3):236-42, 242.e1-2.
- 339. Mohler ER, 3rd, Sibley AA, Stein R, et al. Endothelial function and weight loss: comparison of low-carbohydrate and low-fat diets. Obesity (Silver Spring). 2013;21(3):504-9.
- 340. Bhutani S, Klempel MC, Kroeger CM, Trepanowski JF, Varady KA. Alternate day fasting and endurance exercise combine to reduce body weight and favorably alter plasma lipids in obese humans. Obesity (Silver Spring). 2013;21(7):1370-9.
- 341. Webber KH, Rose SA. A pilot Internet-based behavioral weight loss intervention with or without commercially available portion-controlled foods. Obesity (Silver Spring). 2013;21(9):E354-9.
- 342. Marinik EL, Frisard MI, Hulver MW, et al. Angiotensin II receptor blockade and insulin sensitivity in overweight and obese

- adults with elevated blood pressure. Ther Adv Cardiovasc Dis. 2013;7(1):11-20.
- 343. Zhu W, Cai D, Wang Y, et al. Calcium plus vitamin D3 supplementation facilitated fat loss in overweight and obese college students with very-low calcium consumption: a randomized controlled trial. Nutr J. 2013;12:8.
- 344. García-Unciti M, Izquierdo M, Idoate F, et al. Weight-loss diet alone or combined with progressive resistance training induces changes in association between the cardiometabolic risk profile and abdominal fat depots. Ann Nutr Metab. 2012;61(4):296-304.
- 345. Vix M, Diana M, Liu KH, et al. Evolution of glycolipid profile after sleeve gastrectomy vs. Roux-en-Y gastric bypass: results of a prospective randomized clinical trial. Obes Surg. 2013;23(5):613-21.
- 346. Klempel MC, Kroeger CM, Bhutani S, Trepanowski JF, Varady KA. Intermittent fasting combined with calorie restriction is effective for weight loss and cardio-protection in obese women. Nutr J. 2012;11:98.
- 347. Venojärvi M, Wasenius N, Manderoos S, et al. Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glucose regulation. Ann Med. 2013;45(2):162-70.
- 348. Ho SS, Dhaliwal SS, Hills AP, Pal S. The effect of 12 weeks of aerobic, resistance or combination exercise training on cardiovascular risk factors in the overweight and obese in a randomized trial. BMC Public Health. 2012;12:704.
- 349. Fayh AP, Lopes AL, da Silva AM, Reischak-Oliveira A, Friedman R. Effects of 5 % weight loss through diet or diet plus exercise on cardiovascular parameters of obese: a randomized clinical trial. Eur J Nutr. 2013;52(5):1443-50.
- 350. Sengupta K, Mishra AT, Rao MK, Sarma KV, Krishnaraju AV, Trimurtulu G. Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study. Lipids Health

## Dis. 2012;11:122.

- 351. Itariu BK, Zeyda M, Hochbrugger EE, et al. Long-chain n-3 PUFAs reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial. Am J Clin Nutr. 2012;96(5):1137-49.
- Whyte LJ, Ferguson C, Wilson J, Scott RA, Gill JM. Effects of single bout of very high-intensity exercise on metabolic health biomarkers in overweight/obese sedentary men. Metabolism. 2013;62(2):212-9.
- 353. Melanson KJ, Summers A, Nguyen V, et al. Body composition, dietary composition, and components of metabolic syndrome in overweight and obese adults after a 12-week trial on dietary treatments focused on portion control, energy density, or glycemic index. Nutr J. 2012;11:57.
- 354. Ponce J, Quebbemann BB, Patterson EJ. Prospective, randomized, multicenter study evaluating safety and efficacy of intragastric dual-balloon in obesity. Surg Obes Relat Dis. 2013;9(2):290-5.
- 355. Klempel MC, Kroeger CM, Varady KA. Alternate day fasting (ADF) with a high-fat diet produces similar weight loss and cardio-protection as ADF with a low-fat diet. Metabolism. 2013;62(1):137-43.
- 356. Zhang X, Qi Q, Bray GA, Hu FB, Sacks FM, Qi L. APOA5 genotype modulates 2-y changes in lipid profile in response to weight-loss diet intervention: the Pounds Lost Trial. Am J Clin Nutr. 2012;96(4):917-22.
- 357. Ke B, Shi L, Jun-jie Z, Chen DS, Meng J, Qin J. Protective effects of modified linggui zhugan decoction combined with short-term very low calorie diets on cardiovascular risk factors in obese patients with impaired glucose tolerance. J Tradit Chin Med. 2012;32(2):193-8.
- 358. Abdi H, Abbasi-Parizad P, Zhao B, et al. Effects of auricular acupuncture on anthropometric, lipid profile, inflammatory,

- and immunologic markers: a randomized controlled trial study. J Altern Complement Med. 2012;18(7):668-77.
- 359. Foster GD, Shantz KL, Vander Veur SS, et al. A randomized trial of the effects of an almond-enriched, hypocaloric diet in the treatment of obesity. Am J Clin Nutr. 2012;96(2):249-54.
- 360. Ebbeling CB, Swain JF, Feldman HA, et al. Effects of dietary composition on energy expenditure during weight-loss maintenance. Jama. 2012;307(24):2627-34.
- 361. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol. 2012;11:64.
- 362. Suliburska J, Bogdanski P, Szulinska M, Stepien M, Pupek-Musialik D, Jablecka A. Effects of green tea supplementation on elements, total antioxidants, lipids, and glucose values in the serum of obese patients. Biol Trace Elem Res. 2012;149(3):315-22.
- 363. Alizadeh M, Safaeiyan A, Ostadrahimi A, et al. Effect of L-arginine and selenium added to a hypocaloric diet enriched with legumes on cardiovascular disease risk factors in women with central obesity: a randomized, double-blind, placebo-controlled trial. Ann Nutr Metab. 2012;60(2):157-68.
- 364. Bjermo H, Iggman D, Kullberg J, et al. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am J Clin Nutr. 2012;95(5):1003-12.
- 365. Backhouse K, Sarac I, Shojaee-Moradie F, et al. Fatty acid flux and oxidation are increased by rimonabant in obese women. Metabolism. 2012;61(9):1220-3.
- 366. Kim JW, Kim DY. Effects of aerobic exercise training on serum sex hormone binding globulin, body fat index, and metabolic syndrome factors in obese postmenopausal women. Metab Syndr Relat Disord. 2012;10(6):452-7.

- 367. Greene NP, Martin SE, Crouse SF. Acute exercise and training alter blood lipid and lipoprotein profiles differently in overweight and obese men and women. Obesity (Silver Spring). 2012;20(8):1618-27.
- 368. Boesten JE, Kaper J, Stoffers HE, Kroon AA, van Schayck OC. Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE). Fam Pract. 2012;29(5):521-7.
- 369. Chen SC, Lin YH, Huang HP, Hsu WL, Houng JY, Huang CK. Effect of conjugated linoleic acid supplementation on weight loss and body fat composition in a Chinese population. Nutrition. 2012;28(5):559-65.
- 370. Elisha B, Rabasa-Lhoret R, Messier V, Abdulnour J, Karelis AD. Relationship between the body adiposity index and cardiometabolic risk factors in obese postmenopausal women. Eur J Nutr. 2013;52(1):145-51.
- 371. Maersk M, Belza A, Stødkilde-Jørgensen H, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr. 2012;95(2):283-9.
- 372. Ross AB, Bourgeois A, Macharia HN, et al. Plasma alkylresorcinols as a biomarker of whole-grain food consumption in a large population: results from the WHOLEheart Intervention Study. Am J Clin Nutr. 2012;95(1):204-11.
- 373. Andersson U, Berger K, Högberg A, Landin-Olsson M, Holm C. Effects of rose hip intake on risk markers of type 2 diabetes and cardiovascular disease: a randomized, double-blind, cross-over investigation in obese persons. Eur J Clin Nutr. 2012;66(5):585-90.
- 374. Familiari P, Costamagna G, Bléro D, et al. Transoral gastroplasty for morbid obesity: a multicenter trial with a 1-year outcome. Gastrointest Endosc. 2011;74(6):1248-58.

- 375. Dillard TH, Purnell JQ, Smith MD, et al. Omentectomy added to Roux-en-Y gastric bypass surgery: a randomized, controlled trial. Surg Obes Relat Dis. 2013;9(2):269-75.
- 376. Lee JA, Kim JW, Kim DY. Effects of yoga exercise on serum adiponectin and metabolic syndrome factors in obese postmenopausal women. Menopause. 2012;19(3):296-301.
- 377. Zunino SJ, Parelman MA, Freytag TL, et al. Effects of dietary strawberry powder on blood lipids and inflammatory markers in obese human subjects. Br J Nutr. 2012;108(5):900-9.
- 378. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612-22.
- 379. Balducci S, Zanuso S, Cardelli P, et al. Supervised exercise training counterbalances the adverse effects of insulin therapy in overweight/obese subjects with type 2 diabetes. Diabetes Care. 2012;35(1):39-41.
- 380. Valente EA, Sheehy ME, Avila JJ, Gutierres JA, Delmonico MJ, Lofgren IE. The effect of the addition of resistance training to a dietary education intervention on apolipoproteins and diet quality in overweight and obese older adults. Clin Interv Aging. 2011;6:235-41.
- 381. Farina MG, Baratta R, Nigro A, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg. 2012;22(4):565-71.
- 382. Leichtle AB, Helmschrodt C, Ceglarek U, et al. Effects of a 2-y dietary weight-loss intervention on cholesterol metabolism in moderately obese men. Am J Clin Nutr. 2011;94(5):1189-95.
- 383. Petry NM, Barry D, Pescatello L, White WB. A low-cost reinforcement procedure improves short-term weight loss

- outcomes. Am J Med. 2011;124(11):1082-5.
- 384. Brown AL, Lane J, Holyoak C, Nicol B, Mayes AE, Dadd T. Health effects of green tea catechins in overweight and obese men: a randomised controlled cross-over trial. Br J Nutr. 2011;106(12):1880-9.
- 385. Kim EK, An SY, Lee MS, et al. Fermented kimchi reduces body weight and improves metabolic parameters in overweight and obese patients. Nutr Res. 2011;31(6):436-43.
- 386. Pfeuffer M, Fielitz K, Laue C, et al. CLA does not impair endothelial function and decreases body weight as compared with safflower oil in overweight and obese male subjects. J Am Coll Nutr. 2011;30(1):19-28.
- 387. Lyon M, Wood S, Pelletier X, Donazzolo Y, Gahler R, Bellisle F. Effects of a 3-month supplementation with a novel soluble highly viscous polysaccharide on anthropometry and blood lipids in nondieting overweight or obese adults. J Hum Nutr Diet. 2011;24(4):351-9.
- 388. Dekkers JC, van Wier MF, Ariëns GA, et al. Comparative effectiveness of lifestyle interventions on cardiovascular risk factors among a Dutch overweight working population: a randomized controlled trial. BMC Public Health. 2011;11(1):49.
- 389. Farnetti S, Malandrino N, Luciani D, Gasbarrini G, Capristo E. Food fried in extra-virgin olive oil improves postprandial insulin response in obese, insulin-resistant women. J Med Food. 2011;14(3):316-21.
- 390. Venn BJ, Perry T, Green TJ, et al. The effect of increasing consumption of pulses and wholegrains in obese people: a randomized controlled trial. J Am Coll Nutr. 2010;29(4):365-72.
- 391. Chen SC, Ueng KC, Lee SH, Sun KT, Lee MC. Effect of t'ai chi exercise on biochemical profiles and oxidative stress indicators in obese patients with type 2 diabetes. J Altern Complement Med. 2010;16(11):1153-9.

- 392. Miyashita M, Sasai H, Tanaka K. Post-prandial capillary triacylglycerol responses to moderate exercise in centrally obese middle-aged men. J Sports Sci. 2010;28(12):1269-75.
- 393. Morenga LT, Williams S, Brown R, Mann J. Effect of a relatively high-protein, high-fiber diet on body composition and metabolic risk factors in overweight women. Eur J Clin Nutr. 2010;64(11):1323-31.
- 394. Pal S, Khossousi A, Binns C, Dhaliwal S, Ellis V. The effect of a fibre supplement compared to a healthy diet on body composition, lipids, glucose, insulin and other metabolic syndrome risk factors in overweight and obese individuals. Br J Nutr. 2011;105(1):90-100.
- 395. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.
- 396. Torres MR, Francischetti EA, Genelhu V, Sanjuliani AF. Effect of a high-calcium energy-reduced diet on abdominal obesity and cardiometabolic risk factors in obese Brazilian subjects. Int J Clin Pract. 2010;64(8):1076-83.
- 397. Herrera MF, Pantoja JP, Velázquez-Fernández D, et al. Potential additional effect of omentectomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in grade III obese patients undergoing laparoscopic Roux-en-Y gastric bypass: a randomized trial. Diabetes Care. 2010;33(7):1413-8.
- 398. Palacios C, Bertrán JJ, Ríos RE, Soltero S. No effects of low and high consumption of dairy products and calcium supplements on body composition and serum lipids in Puerto Rican obese adults. Nutrition. 2011;27(5):520-5.
- 399. Ferré R, Plana N, Merino J, et al. Effects of therapeutic lifestyle changes on peripheral artery tonometry in patients with abdominal obesity. Nutr Metab Cardiovasc Dis. 2012;22(2):95-102.

- 400. Pal S, Ellis V, Ho S. Acute effects of whey protein isolate on cardiovascular risk factors in overweight, post-menopausal women. Atherosclerosis. 2010;212(1):339-44.
- 401. Hermsdorff HH, Zulet M, Abete I, Martínez JA. A legume-based hypocaloric diet reduces proinflammatory status and improves metabolic features in overweight/obese subjects. Eur J Nutr. 2011;50(1):61-9.
- 402. Plotnikoff RC, Eves N, Jung M, Sigal RJ, Padwal R, Karunamuni N. Multicomponent, home-based resistance training for obese adults with type 2 diabetes: a randomized controlled trial. Int J Obes (Lond). 2010;34(12):1733-41.
- 403. Papakonstantinou E, Triantafillidou D, Panagiotakos DB, et al. A high-protein low-fat diet is more effective in improving blood pressure and triglycerides in calorie-restricted obese individuals with newly diagnosed type 2 diabetes. Eur J Clin Nutr. 2010;64(6):595-602.
- 404. Wycherley TP, Noakes M, Clifton PM, Cleanthous X, Keogh JB, Brinkworth GD. A high-protein diet with resistance exercise training improves weight loss and body composition in overweight and obese patients with type 2 diabetes. Diabetes Care. 2010;33(5):969-76.
- 405. Jorde R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med. 2010;267(5):462-72.
- 406. Hernandez TL, Sutherland JP, Wolfe P, et al. Lack of suppression of circulating free fatty acids and hypercholesterolemia during weight loss on a high-fat, low-carbohydrate diet. Am J Clin Nutr. 2010;91(3):578-85.
- 407. Ibáñez J, Izquierdo M, Martínez-Labari C, et al. Resistance training improves cardiovascular risk factors in obese women despite a significative decrease in serum adiponectin levels. Obesity (Silver Spring). 2010;18(3):535-41.

- 408. Gripeteg L, Torgerson J, Karlsson J, Lindroos AK. Prolonged refeeding improves weight maintenance after weight loss with very-low-energy diets. Br J Nutr. 2010;103(1):141-8.
- 409. Tapsell L, Batterham M, Huang XF, et al. Short term effects of energy restriction and dietary fat sub-type on weight loss and disease risk factors. Nutr Metab Cardiovasc Dis. 2010;20(5):317-25.
- 410. Armendáriz-Anguiano AL, Jiménez-Cruz A, Bacardí-Gascón M, Hurtado-Ayala L. Effect of a low glycemic load on body composition and Homeostasis Model Assessment (HOMA) in overweight and obese subjects. Nutr Hosp. 2011;26(1):170-5.
- 411. Amare F, Alemu Y, Enichalew M, Demilie Y, Adamu S. Effects of aerobic, resistance, and combined exercise training on body fat and glucolipid metabolism in inactive middle-aged adults with overweight or obesity: a randomized trial. BMC Sports Sci Med Rehabil. 2024;16(1):189.
- 412. Chen CY, Chien YW. Fresh Tomato (Lycopersicon esculentum Mill.) in the Diet Improves the Features of the Metabolic Syndrome: A Randomized Study in Postmenopausal Women. Biology (Basel). 2024;13(8)
- 413. Chandake S, Tubaki BR, Gonugade V, Sharma O. Efficacy of tryushnadya churna in metabolic syndrome with obesity A randomized double blind controlled clinical trial. J Ayurveda Integr Med. 2024;15(4):100973.
- 414. Baba Y, Azuma N, Saito Y, Takahashi K, Matsui R, Takara T. Effect of Intake of Bifidobacteria and Dietary Fiber on Resting Energy Expenditure: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparison Study. Nutrients. 2024;16(14)
- 415. Sooriyaarachchi P, Jayawardena R, Pavey T, King NA. A low-calorie meal replacement improves body composition and metabolic parameters in shift workers with overweight and obesity: a randomized, controlled, parallel group trial. Nutr Metab (Lond). 2024;21(1):32.

- 416. Lee Y, Kim N, Go S, Kim J, Park J. Sugary snack restriction enhances body composition improvement in overweight women engaging in non-face-to-face walking during COVID-19. Front Public Health. 2024;12:1396598.
- 417. Elahikhah M, Haidari F, Khalesi S, Shahbazian H, Mohammadshahi M, Aghamohammadi V. Milk protein concentrate supplementation improved appetite, metabolic parameters, adipocytokines, and body composition in dieting women with obesity: a randomized controlled trial. BMC Nutr. 2024;10(1):80.
- 418. Dotimas LG, Ojo B, Kaur A, et al. Wheat germ supplementation has modest effects on gut health markers but improves glucose homeostasis markers in adults classified as overweight: A randomized controlled pilot study. Nutr Res. 2024;127:13-26.
- 419. Govindasamy K, Gogoi H, Jebabli N, et al. The effects of kettlebell training versus resistance training using the own body mass on physical fitness and physiological adaptations in obese adults: a randomized controlled trial. BMC Sports Sci Med Rehabil. 2024;16(1):106.
- 420. Shin SM, Park JS, Kim SB, Cho YH, Seo H, Lee HS. A 12-Week, Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial for the Evaluation of the Efficacy and Safety of Lactiplantibacillus plantarum SKO-001 in Reducing Body Fat. Nutrients. 2024;16(8)
- 421. Mongkolsucharitkul P, Pinsawas B, Surawit A, et al. Diabetes-Specific Complete Smoothie Formulas Improve Postprandial Glycemic Response in Obese Type 2 Diabetic Individuals: A Randomized Crossover Trial. Nutrients. 2024;16(3)
- 422. Laouani A, Nasrallah H, Sassi A, et al. Antiobesity and Hypolipidemic Potential of Nitraria retusa Extract in Overweight/Obese Women: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Nutrients. 2024;16(2)
- 423. Khan G, Hussain MI, Gull Khan J, et al. Effect of Salvia hispanica (Chia seeds) and Foeniculum vulgare (Fennel seeds)

- against weight-loss and lipid profile in obese human subjects. Pak J Pharm Sci. 2024;37(1(Special)):231-234.
- 424. Diao Z, Molludi J, Latef Fateh H, Moradi S. Comparison of the low-calorie DASH diet and a low-calorie diet on serum TMAO concentrations and gut microbiota composition of adults with overweight/obesity: a randomized control trial. Int J Food Sci Nutr. 2024;75(2):207-220.
- 425. López-Yerena A, Padro T, de Santisteban Villaplana V, et al. Vascular and Platelet Effects of Tomato Soffritto Intake in Overweight and Obese Subjects. Nutrients. 2023;15(24)
- 426. Aghabeiglooei Z, Namazi N, Karimi M, Soleymani S, Ayati MH, Rezaeizadeh H. Effects of Komouni Formulation (Herbal Product of Persian Medicine) With a Low-Calorie Diet on Cardiometabolic Risk Factors in Overweight and Obese Women: A Triple-Blinded Randomized Clinical Trial. Iran J Pharm Res. 2023;22(1):e136114.
- 427. Tricò D, Masoni MC, Baldi S, et al. Early time-restricted carbohydrate consumption vs conventional dieting in type 2 diabetes: a randomised controlled trial. Diabetologia. 2024;67(2):263-274.
- 428. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.
- 429. Zhang X, DeScenza VR, Chaplow ZL, et al. Effect of a Telephone-Based Lifestyle Intervention on Weight, Body Composition, and Metabolic Biomarkers in Rural Ohio: Results from a Randomized Pilot Study. Nutrients. 2023;15(18)
- 430. Luo Y, Sun L, Wu Q, et al. Diet-Related Lipidomic Signatures and Changed Type 2 Diabetes Risk in a Randomized Controlled Feeding Study With Mediterranean Diet and Traditional Chinese or Transitional Diets. Diabetes Care. 2023;46(9):1691-1699.

- 431. Sordi AF, Lemos MM, de Souza Marques DC, et al. Effects of a multi-professional intervention on body composition, physical fitness and biochemical markers in overweight COVID-19 survivors: a clinical trial. Front Physiol. 2023;14:1219252.
- 432. Carter S, Hill AM, Mead LC, et al. Almonds vs. carbohydrate snacks in an energy-restricted diet: Weight and cardiometabolic outcomes from a randomized trial. Obesity (Silver Spring). 2023;31(10):2467-2481.
- 433. Clina JG, Sayer RD, Pan Z, et al. High- and normal-protein diets improve body composition and glucose control in adults with type 2 diabetes: a randomized trial. Obesity (Silver Spring). 2023;31(8):2021-2030.
- 434. Niu Y, Buranarugsa R, Kuhirunyaratn P. Comparing the Effects of Bafa Wubu Tai Chi and Traditional He-Style Tai Chi Exercises on Physical Health Risk Factors in Overweight Male College Students: A Randomized Controlled Trial. Int J Environ Res Public Health. 2023;20(14)
- 435. Grohmann T, Walker AW, Russell WR, et al. A grape seed and bilberry extract reduces blood pressure in individuals at risk of developing type 2 diabetes: the PRECISE study, a double-blind placebo-controlled cross-over intervention study. Front Nutr. 2023;10:1139880.
- 436. Sun L, Yuan Y, Li Y, Rao X. Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: A double- blind, randomized controlled clinical trial. Exp Ther Med. 2023;25(6):249.
- 437. Quaresma LS, de Oliveira Siais L, Grangeiro É D, Rosado EL. Chia Flour (Salvia hispanica L.) Intake Does Not Affect Weight Loss and Lipid Profile but Improve Systolic Blood Pressure Control in Obesity. J Am Nutr Assoc. 2023;42(4):403-410.
- 438. Aldubayan MA, Mao X, Laursen MF, et al. Supplementation with inulin-type fructans affects gut microbiota and attenuates some of the cardiometabolic benefits of a plant-based diet in individuals with overweight or obesity. Front Nutr. 2023;10:1108088.

- 439. Cho E, Kim JY, Cho B, et al. Efficacy of fermented grain using Bacillus coagulans in reducing visceral fat among people with obesity: a randomized controlled trial. Front Nutr. 2023;10:1148512.
- 440. Castaldo G, Schiavo L, Pagano I, et al. Clinical Impact of Enteral Protein Nutritional Therapy on Patients with Obesity Scheduled for Bariatric Surgery: A Focus on Safety, Efficacy, and Pathophysiological Changes. Nutrients. 2023;15(6)
- 441. Ghalichi F, Saghafi-Asl M, Kafil B, et al. Insulin Receptor Substrates Regulation and Clinical Responses Following Vanadium-Enriched Yeast Supplementation in Obese Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Biol Trace Elem Res. 2023;201(11):5169-5182.
- 442. Felipe LA, Bachi ALL, Oliveira MC, et al. Effects of Roux-en-Y gastric bypass on the metabolic profile and systemic inflammatory status of women with metabolic syndrome: randomized controlled clinical trial. Diabetol Metab Syndr. 2023;15(1):19.
- 443. Ragland TJ, Malin SK. Plasma LEAP-2 Following a Low-Calorie Diet with or without Interval Exercise in Women with Obesity. Nutrients. 2023;15(3)
- 444. Cai H, Chen Q, Duan Y, Zhao Y, Zhang X. Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. Front Endocrinol (Lausanne). 2023;14:1106868.
- 445. Turner-McGrievy GM, Wilcox S, Frongillo EA, et al. Effect of a Plant-Based vs Omnivorous Soul Food Diet on Weight and Lipid Levels Among African American Adults: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(1):e2250626.
- 446. Belany P, Kackley ML, Zhao S, et al. Effects of Hypocaloric Low-Fat, Ketogenic, and Ketogenic and Ketone Supplement Diets on Aldosterone and Renin. J Clin Endocrinol Metab. 2023;108(7):1727-1739.

- 447. Gayathri R, Abirami K, Kalpana N, et al. Effect of almond consumption on insulin sensitivity and serum lipids among Asian Indian adults with overweight and obesity- A randomized controlled trial. Front Nutr. 2022;9:1055923.
- 448. Cruvinel BAC, Alves AGP, Schincaglia RM, Silva MS. Baru nuts reduce abdominal adiposity in type 2 diabetic adults: a randomized, placebo-controlled crossover trial. Article. Revista De Nutricao-Brazilian Journal of Nutrition. 2023;36e220103.
- Hassan RHA, Bahe SMAE, Mohamed AIZ, et al. The effect of high-dose vitamin D supplementation and an exercise program to lose weight on some biochemical variables of overweight women. Article. Pedagogy of Physical Culture and Sports. 2023;27(5):353-360.
- 450. Carvalho APSd, Aranha LN, Soares LA, et al. Effect of Hypoenergetic Diet Combined With Pumpkin Seed Flour Consumption on Obese Women. research-article. International Journal of Cardiovascular Sciences. 2023;36:e20220134-e20220134.
- 451. Sohn M, Jung H, Lee WS, Kim TH, Lim S. Effect of <i > Lactobacillus </i > <i > plantarum </i > LMT1-48 on Body Fat in Overweight Subjects: A Randomized, Double- Blind, Placebo-Controlled Trial. Article. Diabetes & Metabolism Journal. 2023;47(1):92-103.
- 452. Rondanelli M, Gasparri C, Perna S, et al. A 60-Day Green Tea Extract Supplementation Counteracts the Dysfunction of Adipose Tissue in Overweight Post-Menopausal and Class I Obese Women. Article. Nutrients. 2022;14(24)5209.
- 453. Rebello CJJ, Beyl RAA, Greenway FLL, Atteberry KCC, Hoddy KKK, Kirwan JPP. Low-Energy Dense Potato- and Bean-Based Diets Reduce Body Weight and Insulin Resistance: A Randomized, Feeding, Equivalence Trial. Article. Journal of Medicinal Food. 2022;25(12):1155-1163.
- 454. Xu R, Cao Y-X, Chen Y-T, Jia Y-Q. Differential effects of intermittent energy restriction vs. continuous energy restriction

- combined high-intensity interval training on overweight/obese adults: A randomized controlled trial. Article. Frontiers in Nutrition. 2022;9979618.
- 455. Reis PCdSG, Alves AGP, Guillo LA, Neto MAdS, Trindade NR, Silva MS. Curcumin supplementation reduces blood glucose and serum lipids of Brazilian women with high waist circumference: a randomized clinical trial. Article. Archives of Endocrinology Metabolism. 2022;66(6):800-807.
- 456. Colak D, Kucic AC, Pintar T, Gaspersic R. Periodontal Therapy in Bariatric Surgery Patients with Periodontitis: Randomized Control Clinical Trial. Article. Journal of Clinical Medicine. 2022;11(22)6837.
- 457. Freer CL, George ES, Tan S-Y, Abbott G, Dunstan DW, Daly RM. Effect of progressive resistance training with weight loss compared with weight loss alone on the fatty liver index in older adults with type 2 diabetes: secondary analysis of a 12-month randomized controlled trial. Article. Bmj Open Diabetes Research & Care. 2022;10(5)e002950.
- 458. Yin W, Liu Y, Hu H, Sun J, Liu Y, Wang Z. Telemedicine management of type 2 diabetes mellitus in obese and overweight young and middle-aged patients during COVID-19 outbreak: A single-center, prospective, randomized control study. Article. Plos One. 2022;17(9)e0275251.
- 459. Coker MS, Barati Z, Murphy CJ, et al. Essential amino acid enriched meal replacement improves body composition and physical function in obese older adults: A randomized controlled trial. Article. Clinical Nutrition Espen. 2022;51:104-111.
- 460. Mohammadi-Sartang M, Babajafari S, Kohansal A, Rostami H, Pourmahmoudi A, Sohrabi Z. Effects of daily functional acorn cake consumption on insulin resistance in individuals with obesity or overweight and the metabolic syndrome: a placebo-controlled randomised clinical trial. Article. British Journal of Nutrition. 2023;129(7):1142-1150. Pii s0007114522002288.

- 461. Jamshed H, Steger FL, Bryan DR, et al. Effectiveness of Early Time-Restricted Eating for Weight Loss, Fat Loss, and Cardiometabolic Health in Adults With Obesity A Randomized Clinical Trial. Article. Jama Internal Medicine. 2022;182(9):953-962.
- 462. Roach LA, Meyer BJ, Fitton JH, Winberg P. Improved Plasma Lipids, Anti-Inflammatory Activity, and Microbiome Shifts in Overweight Participants: Two Clinical Studies on Oral Supplementation with Algal Sulfated Polysaccharide. Article. Marine Drugs. 2022;20(8)500.
- 463. Kleinloog JPD, Mensink RP, Roodt JO, Thijssen DHJ, Hesselink MKC, Joris PJ. Aerobic exercise training improves not only brachial artery flow-mediated vasodilatation but also carotid artery reactivity: A randomized controlled, cross-over trial in older men. Physiol Rep. 2022;10(16):e15395.
- 464. Pavão TP, Chemello D, Ferigollo A, et al. Acute effect of coffee on arterial stiffness and endothelial function in overweight and obese individuals: A randomized clinical trial. Clin Nutr ESPEN. 2022;50:33-40.
- 465. Castela I, Rodrigues C, Ismael S, et al. Intermittent energy restriction ameliorates adipose tissue-associated inflammation in adults with obesity: A randomised controlled trial. Clin Nutr. 2022;41(8):1660-1666.
- Chekima K, Noor MI, Ooi YBH, Yan SW, Jaweed M, Chekima B. Utilising a Real-Time Continuous Glucose Monitor as Part of a Low Glycaemic Index and Load Diet and Determining Its Effect on Improving Dietary Intake, Body Composition and Metabolic Parameters of Overweight and Obese Young Adults: A Randomised Controlled Trial. Foods. 2022;11(12)
- 467. Cipryan L, Litschmannova M, Maffetone PB, et al. Very Low-Carbohydrate High-Fat Diet Improves Risk Markers for Cardiometabolic Health More Than Exercise in Men and Women With Overfat Constitution: Secondary Analysis of a Randomized Controlled Clinical Trial. Front Nutr. 2022;9:867690.

- 468. Ali Sangouni A, Abdollahi S, Mozaffari-Khosravi H. Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial. BMC Cardiovasc Disord. 2022;22(1):212.
- 469. Timmons JF, Beatty A, Stout C, Ivory A, Carroll C, Egan B. Increased Lean Body Mass After Bodyweight-Based High Intensity Interval Training in Overweight and Obese Men. Res Q Exerc Sport. 2023;94(2):418-426.
- 470. Catley D, Puoane T, Tsolekile L, et al. Evaluation of an adapted version of the Diabetes Prevention Program for low- and middle-income countries: A cluster randomized trial to evaluate "Lifestyle Africa" in South Africa. PLoS Med. 2022;19(4):e1003964.
- 471. Mendelson M, Chacaroun S, Baillieul S, et al. Effects of high intensity interval training on sustained reduction in cardiometabolic risk associated with overweight/obesity. A randomized trial. J Exerc Sci Fit. 2022;20(2):172-181.
- 472. Ruban A, Miras AD, Glaysher MA, et al. Duodenal-Jejunal Bypass Liner for the management of Type 2 Diabetes Mellitus and Obesity: A Multicenter Randomized Controlled Trial. Ann Surg. 2022;275(3):440-447.
- 473. Li Y, Kang Y, Du Y, et al. Effects of Konjaku Flour on the Gut Microbiota of Obese Patients. Front Cell Infect Microbiol. 2022;12:771748.
- 474. Vodouhè M, Marois J, Guay V, et al. Marginal Impact of Brown Seaweed Ascophyllum nodosum and Fucus vesiculosus Extract on Metabolic and Inflammatory Response in Overweight and Obese Prediabetic Subjects. Mar Drugs. 2022;20(3)
- 475. Dimitrov Ulian M, Pinto AJ, de Morais Sato P, et al. Health at Every Size®-Based Interventions May Improve Cardiometabolic Risk and Quality of Life Even in the Absence of Weight Loss: An Ancillary, Exploratory Analysis of the Health and Wellness in Obesity Study. Front Nutr. 2022;9:598920.

- 476. Viveros-Watty PE, López-Franco O, Zepeda RC, et al. Effects on cardiometabolic risk factors after reduction of artificially sweetened beverage consumption in overweight subjects. A randomised controlled trial. Endocrinol Diabetes Nutr (Engl Ed). 2022;69(3):168-177.
- 477. Chair SY, Cai H, Cao X, Qin Y, Cheng HY, Ng MT. Intermittent Fasting in Weight Loss and Cardiometabolic Risk Reduction: A Randomized Controlled Trial. J Nurs Res. 2022;30(1):e185.
- 478. Karandish M, Mozaffari-Khosravi H, Mohammadi SM, Cheraghian B, Azhdari M. Curcumin and zinc co-supplementation along with a loss-weight diet can improve lipid profiles in subjects with prediabetes: a multi-arm, parallel-group, randomized, double-blind placebo-controlled phase 2 clinical trial. Diabetol Metab Syndr. 2022;14(1):22.
- 479. Lim SL, Ong KW, Johal J, et al. A Smartphone App-Based Lifestyle Change Program for Prediabetes (D'LITE Study) in a Multiethnic Asian Population: A Randomized Controlled Trial. Front Nutr. 2021;8:780567.
- 480. Thomsen MN, Skytte MJ, Samkani A, et al. Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial. Diabetologia. 2022;65(3):506-517.
- 481. Seeberg KA, Borgeraas H, Hofsø D, et al. Gastric Bypass Versus Sleeve Gastrectomy in Type 2 Diabetes: Effects on Hepatic Steatosis and Fibrosis: A Randomized Controlled Trial. Ann Intern Med. 2022;175(1):74-83.
- 482. Ruegsegger GN, Rappaport CI, Hill JJ, Jochum KA, Challeen ES, Roth MC. A meal enriched in saturated fat acutely impairs cognitive performance in obese men. Physiol Behav. 2022;244:113664.
- 483. Liu B, Hutchison AT, Thompson CH, Lange K, Wittert GA, Heilbronn LK. Effects of Intermittent Fasting or Calorie

- Restriction on Markers of Lipid Metabolism in Human Skeletal Muscle. J Clin Endocrinol Metab. 2021;106(3):e1389-e1399.
- 484. Cao JJ, Roemmich JN, Sheng X, Jahns L. Increasing Vegetable Intake Decreases Urinary Acidity and Bone Resorption Marker in Overweight and Obese Adults: An 8-Week Randomized Controlled Trial. J Nutr. 2021;151(11):3413-3420.
- 485. Kang C, Qiao Q, Tong Q, et al. Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial. Sci Rep. 2021;11(1):20062.
- 486. Che T, Yan C, Tian D, Zhang X, Liu X, Wu Z. Time-restricted feeding improves blood glucose and insulin sensitivity in overweight patients with type 2 diabetes: a randomised controlled trial. Nutr Metab (Lond). 2021;18(1):88.
- 487. Miller L, Thompson K, Pavlenco C, et al. The Effect of Daily Methylsulfonylmethane (MSM) Consumption on High-Density Lipoprotein Cholesterol in Healthy Overweight and Obese Adults: A Randomized Controlled Trial. Nutrients. 2021;13(10)
- 488. Batrakoulis A, Jamurtas AZ, Draganidis D, et al. Hybrid Neuromuscular Training Improves Cardiometabolic Health and Alters Redox Status in Inactive Overweight and Obese Women: A Randomized Controlled Trial. Antioxidants (Basel). 2021;10(10)
- 489. Chang WL, Azlan A, Noor SM, Ismail IZ, Loh SP. Short-Term Intake of Yellowstripe Scad versus Salmon Did Not Induce Similar Effects on Lipid Profile and Inflammatory Markers among Healthy Overweight Adults despite Their Comparable EPA+DHA Content. Nutrients. 2021;13(10)
- 490. Serna A, Marhuenda J, Arcusa R, et al. Effectiveness of a polyphenolic extract (Lippia citriodora and Hibiscus sabdariffa) on appetite regulation in overweight and obese grade I population: an 8-week randomized, double-blind, cross-over, placebo-controlled trial. Eur J Nutr. 2022;61(2):825-841.
- 491. Delgado-Floody P, Soriano-Maldonado A, Rodríguez-Pérez MA, et al. The Effects of Two Different Concurrent Training

- Configurations on Markers of Metabolic Syndrome and Fitness in Women With Severe/Morbid Obesity: A Randomised Controlled Trial. Front Physiol. 2021;12:694798.
- 492. Falkenhain K, Locke SR, Lowe DA, et al. Keyto app and device versus WW app on weight loss and metabolic risk in adults with overweight or obesity: A randomized trial. Obesity (Silver Spring). 2021;29(10):1606-1614.
- 493. Said MA, Abdelmoneim MA, Alibrahim MS, Kotb AAH. Aerobic training, resistance training, or their combination as a means to fight against excess weight and metabolic syndrome in obese students which is the most effective modality? A randomized controlled trial. Appl Physiol Nutr Metab. 2021;46(8):952-963.
- 494. Ahmadniay Motlagh H, Aalipanah E, Mazidi M, Faghih S. Effect of flaxseed consumption on central obesity, serum lipids, and adiponectin level in overweight or obese women: A randomised controlled clinical trial. Int J Clin Pract. 2021;75(10):e14592.
- 495. Te Morenga L, Mallard SR, Ormerod FB. No Effect of Added Sugars in Soft Drink Compared With Sugars in Fruit on Cardiometabolic Risk Factors: Results From a 4-Week, Randomized Controlled Trial. Front Nutr. 2021;8:636275.
- 496. Shikishima Y, Tsutsumi R, Kawakami A, Miura H, Nii Y, Sakaue H. Sudachi peel extract powder including the polymethoxylated flavone sudachitin improves visceral fat content in individuals at risk for developing diabetes. Food Sci Nutr. 2021;9(8):4076-4084.
- 497. Liddle DM, Lin X, Cox LC, et al. Daily apple consumption reduces plasma and peripheral blood mononuclear cell-secreted inflammatory biomarkers in adults with overweight and obesity: a 6-week randomized, controlled, parallel-arm trial. Am J Clin Nutr. 2021;114(2):752-763.
- 498. Wang J, Wang S, Henning SM, et al. Mixed Tree Nut Snacks Compared to Refined Carbohydrate Snacks Resulted in

- Weight Loss and Increased Satiety during Both Weight Loss and Weight Maintenance: A 24-Week Randomized Controlled Trial. Nutrients. 2021;13(5)
- 499. Grytten E, Laupsa-Borge J, Bohov P, et al. Changes in lipoprotein particle subclasses, standard lipids, and apolipoproteins after supplementation with n-3 or n-6 PUFAs in abdominal obesity: A randomized double-blind crossover study. Clin Nutr. 2021;40(5):2556-2575.
- 500. Schroor MM, Plat J, Konings M, Smeets E, Mensink RP. Effect of dietary macronutrients on intestinal cholesterol absorption and endogenous cholesterol synthesis: a randomized crossover trial. Nutr Metab Cardiovasc Dis. 2021;31(5):1579-1585.
- 501. Bhoite R, Chandrasekaran A, Pratti VL, et al. Effect of a High-Protein High-Fibre Nutritional Supplement on Lipid Profile in Overweight/Obese Adults with Type 2 Diabetes Mellitus: A 24-Week Randomized Controlled Trial. J Nutr Metab. 2021;2021:6634225.
- van der Merwe M, Moore D, Hill JL, et al. The Impact of a Dried Fruit and VegeSupplementary Table upplement and Fiber Rich Shake on Gut and Health Parameters in Female Healthcare Workers: A Placebo-Controlled, Double-Blind, Randomized Clinical Trial. Microorganisms. 2021;9(4)
- 503. Waliłko E, Napierała M, Bryśkiewicz M, Fronczyk A, Majkowska L. High-Protein or Low Glycemic Index Diet-Which Energy-Restricted Diet Is Better to Start a Weight Loss Program? Nutrients. 2021;13(4)
- Ng SC, Xu Z, Mak JWY, et al. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. Gut. 2022;71(4):716-723.
- 505. do Rosario VA, Chang C, Spencer J, et al. Anthocyanins attenuate vascular and inflammatory responses to a high fat high

- energy meal challenge in overweight older adults: A cross-over, randomized, double-blind clinical trial. Clin Nutr. 2021;40(3):879-889.
- 506. Amaro-Gahete FJ, Ponce-González JG, Corral-Pérez J, Velázquez-Díaz D, Lavie CJ, Jiménez-Pavón D. Effect of a 12-Week Concurrent Training Intervention on Cardiometabolic Health in Obese Men: A Pilot Study. Front Physiol. 2021;12:630831.
- 507. Kim KW, Shin WC, Choi MS, et al. Effects of acupuncture on anthropometric and serum metabolic parameters in premenopausal overweight and obese women: a randomized, patient- and assessor-blind, sham-controlled clinical trial. Acupunct Med. 2021;39(1):30-40.
- 508. Jiang W, Huang S, Ma S, et al. Effectiveness of companion-intensive multi-aspect weight management in Chinese adults with obesity: a 6-month multicenter randomized clinical trial. Nutr Metab (Lond). 2021;18(1):17.
- 509. D'Amuri A, Sanz JM, Capatti E, et al. Effectiveness of high-intensity interval training for weight loss in adults with obesity: a randomised controlled non-inferiority trial. BMJ Open Sport Exerc Med. 2021;7(3):e001021.
- 510. Yılmaz SK, Eskici G, Mertoğlu C, Ayaz A. Effect of different protein diets on weight loss, inflammatory markers, and cardiometabolic risk factors in obese women. J Res Med Sci. 2021;26:28.
- 511. Barnard ND, Alwarith J, Rembert E, et al. A Mediterranean Diet and Low-Fat Vegan Diet to Improve Body Weight and Cardiometabolic Risk Factors: A Randomized, Cross-over Trial. J Am Nutr Assoc. 2022;41(2):127-139.
- 512. Netto Cândido TL, da Silva LE, Cândido FG, et al. Effect of the ingestion of vegetable oils associated with energy-restricted normofat diet on intestinal microbiota and permeability in overweight women. Food Res Int. 2021;139:109951.
- 513. Abbott K, Burrows TL, Acharya S, Thota RN, Garg ML. Dietary supplementation with docosahexaenoic acid rich fish oil

increases circulating levels of testosterone in overweight and obese men. Prostaglandins Leukot Essent Fatty Acids. 2020;163:102204.

- 514. Kruschitz R, Wakolbinger M, Schindler K, et al. Effect of one-anastomosis gastric bypass on cardiovascular risk factors in patients with vitamin D deficiency and morbid obesity: A secondary analysis. Nutr Metab Cardiovasc Dis. 2020;30(12):2379-2388.
- 515. Kahleova H, Petersen KF, Shulman GI, et al. Effect of a Low-Fat Vegan Diet on Body Weight, Insulin Sensitivity, Postprandial Metabolism, and Intramyocellular and Hepatocellular Lipid Levels in Overweight Adults: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(11):e2025454.
- 516. Cheshmazar E, Hosseini AF, Yazdani B, Razmpoosh E, Zarrati M. Effects of Vitamin D Supplementation on Omentin-1 and Spexin Levels, Inflammatory Parameters, Lipid Profile, and Anthropometric Indices in Obese and Overweight Adults with Vitamin D Deficiency under Low-Calorie Diet: A Randomized Placebo Controlled Trial. Evid Based Complement Alternat Med. 2020;2020:3826237.
- 517. Bove KB, Nilsson M, Pedersen LR, et al. Comprehensive treatment of microvascular angina in overweight women a randomized controlled pilot trial. PLoS One. 2020;15(11):e0240722.
- 518. de Ligt M, Bergman M, Fuentes RM, et al. No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial. Am J Clin Nutr. 2020;112(4):1029-1038.
- 519. Bratlie M, Hagen IV, Helland A, et al. Effects of high intake of cod or salmon on gut microbiota profile, faecal output and serum concentrations of lipids and bile acids in overweight adults: a randomised clinical trial. Eur J Nutr. 2021;60(4):2231-2248.
- 520. Klomklorm A, Ruangthai R, Vaithanomsat P, Sukatta U, Phoemsapthawee J. Concurrent training and Eri silkworm pupae

- ingestion improve resting and exercise fat oxidation and energy expenditure in obese adults. J Exerc Rehabil. 2020;16(5):467-479.
- 521. Li L, Lyall GK, Martinez-Blazquez JA, et al. Blood Orange Juice Consumption Increases Flow-Mediated Dilation in Adults with Overweight and Obesity: A Randomized Controlled Trial. J Nutr. 2020;150(9):2287-2294.
- 522. Cienfuegos S, Gabel K, Kalam F, et al. Effects of 4- and 6-h Time-Restricted Feeding on Weight and Cardiometabolic Health: A Randomized Controlled Trial in Adults with Obesity. Cell Metab. 2020;32(3):366-378.e3.
- 523. Jamar G, Santamarina AB, Flygare AC, et al. Effects of the juçara fruit supplementation on metabolic parameters in individuals with obesity: a double-blind randomized controlled trial. J Nutr Biochem. 2020;83:108430.
- Goss AM, Gower B, Soleymani T, et al. Effects of weight loss during a very low carbohydrate diet on specific adipose tissue depots and insulin sensitivity in older adults with obesity: a randomized clinical trial. Nutr Metab (Lond). 2020;17:64.
- 525. Jafari-Maskouni S, Shahraki M, Daneshi-Maskooni M, Dashipour A, Shamsi-Goushki A, Mortazavi Z. Metabolic and clinical responses to Bunium Persicum (black caraway) supplementation in overweight and obese patients with type 2 diabetes: a double-blind, randomized placebo-controlled clinical trial. Nutr Metab (Lond). 2020;17:74.
- 526. Takagi T, Hayashi R, Nakai Y, et al. Dietary Intake of Carotenoid-Rich Vegetables Reduces Visceral Adiposity in Obese Japanese men-A Randomized, Double-Blind Trial. Nutrients. 2020;12(8)
- 527. Remie CME, Roumans KHM, Moonen MPB, et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Am J Clin Nutr. 2020;112(2):413-426.
- 528. Joris PJ, Draijer R, Fuchs D, Mensink RP. Effect of α-linolenic acid on vascular function and metabolic risk markers during the fasting and postprandial phase: A randomized placebo-controlled trial in untreated (pre-)hypertensive individuals. Clin Nutr.

- 2020;39(8):2413-2419.
- 529. Smeets E, Mensink RP, Joris PJ. Dietary macronutrients do not differently affect postprandial vascular endothelial function in apparently healthy overweight and slightly obese men. Eur J Nutr. 2021;60(3):1443-1451.
- 530. Campa F, Maietta Latessa P, Greco G, et al. Effects of Different Resistance Training Frequencies on Body Composition, Cardiometabolic Risk Factors, and Handgrip Strength in Overweight and Obese Women: A Randomized Controlled Trial. J Funct Morphol Kinesiol. 2020;5(3)
- 531. Reimer RA, Wharton S, Green TJ, et al. Effect of a functional fibre supplement on glycemic control when added to a year-long medically supervised weight management program in adults with type 2 diabetes. Eur J Nutr. 2021;60(3):1237-1251.
- Rock CL, Zunshine E, Nguyen HT, et al. Effects of Pistachio Consumption in a Behavioral Weight Loss Intervention on Weight Change, Cardiometabolic Factors, and Dietary Intake. Nutrients. 2020;12(7)
- 533. Vors C, Joumard-Cubizolles L, Lecomte M, et al. Milk polar lipids reduce lipid cardiovascular risk factors in overweight postmenopausal women: towards a gut sphingomyelin-cholesterol interplay. Gut. 2020;69(3):487-501.
- 534. Lopez HL, Cesareo KR, Raub B, et al. Effects of Hemp Extract on Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety in Overweight, But Otherwise Healthy Subjects. J Diet Suppl. 2020;17(5):561-586.
- AlFaris NA, Ba-Jaber AS. Effects of a low-energy diet with and without oat bran and olive oil supplements on body mass index, blood pressure, and serum lipids in diabetic women: A randomized controlled trial. Food Sci Nutr. 2020;8(7):3602-3609.
- 536. Chow LS, Manoogian ENC, Alvear A, et al. Time-Restricted Eating Effects on Body Composition and Metabolic Measures in Humans who are Overweight: A Feasibility Study. Obesity (Silver Spring). 2020;28(5):860-869.

- 537. Marco-Benedí V, Pérez-Calahorra S, Bea AM, et al. High-protein energy-restricted diets induce greater improvement in glucose homeostasis but not in adipokines comparing to standard-protein diets in early-onset diabetic adults with overweight or obesity. Clin Nutr. 2020;39(5):1354-1363.
- 538. Lin X, Liddle DM, Neizer HR, Robinson LE, Wright AJ. Acute whole apple consumption did not influence postprandial lipaemia: a randomised crossover trial. Br J Nutr. 2020;123(7):807-817.
- 539. Lorkowski SW, Brubaker G, Rotroff DM, et al. Bariatric Surgery Improves HDL Function Examined by ApoA1 Exchange Rate and Cholesterol Efflux Capacity in Patients with Obesity and Type 2 Diabetes. Biomolecules. 2020;10(4)
- 540. Tsintzas K, Jones R, Pabla P, et al. Effect of acute and short-term dietary fat ingestion on postprandial skeletal muscle protein synthesis rates in middle-aged, overweight, and obese men. Am J Physiol Endocrinol Metab. 2020;318(3):E417-e429.
- 541. Dolati S, Namiranian K, Amerian R, Mansouri S, Arshadi S, Azarbayjani MA. The Effect of Curcumin Supplementation and Aerobic Training on Anthropometric Indices, Serum Lipid Profiles, C-Reactive Protein and Insulin Resistance in Overweight Women: A Randomized, Double-Blind, Placebo-Controlled Trial. J Obes Metab Syndr. 2020;29(1):47-57.
- Edinburgh RM, Bradley HE, Abdullah NF, et al. Lipid Metabolism Links Nutrient-Exercise Timing to Insulin Sensitivity in Men Classified as Overweight or Obese. J Clin Endocrinol Metab. 2020;105(3):660-76.
- Asgary S, Soltani R, Barzegar N, Sarrafzadegan N. Evaluation on the Effects of Tamarindus Indica L. Fruit on Body Weight and Several Cardiometabolic Risk Factors in Obese and Overweight Adult Patients: A Randomized Controlled Clinical Trial. Int J Prev Med. 2020;11:24.
- 544. Perissiou M, Borkoles E, Kobayashi K, Polman R. The Effect of an 8 Week Prescribed Exercise and Low-Carbohydrate Diet

- on Cardiorespiratory Fitness, Body Composition and Cardiometabolic Risk Factors in Obese Individuals: A Randomised Controlled Trial. Nutrients. 2020;12(2)
- 545. Kuo YC, Chang HL, Cheng CF, Mündel T, Liao YH. Six-week inspiratory resistance training ameliorates endurance performance but does not affect obesity-related metabolic biomarkers in obese adults: A randomized controlled trial. Respir Physiol Neurobiol. 2020;273:103285.
- 546. Nishimura M, Muro T, Kobori M, Nishihira J. Effect of Daily Ingestion of Quercetin-Rich Onion Powder for 12 Weeks on Visceral Fat: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study. Nutrients. 2019;12(1)
- 547. Gajewska D, Kucharska A, Kozak M, Wunderlich S, Niegowska J. Effectiveness of Individual Nutrition Education Compared to Group Education, in Improving Anthropometric and Biochemical Indices among Hypertensive Adults with Excessive Body Weight: A Randomized Controlled Trial. Nutrients. 2019;11(12)
- 548. Karimi-Nazari E, Nadjarzadeh A, Masoumi R, et al. Effect of saffron (Crocus sativus L.) on lipid profile, glycemic indices and antioxidant status among overweight/obese prediabetic individuals: A double-blinded, randomized controlled trial. Clin Nutr ESPEN. 2019;34:130-136.
- 549. Tanaka Y, Hirose Y, Yamamoto Y, Yoshikai Y, Murosaki S. Daily intake of heat-killed Lactobacillus plantarum L-137 improves inflammation and lipid metabolism in overweight healthy adults: a randomized-controlled trial. Eur J Nutr. 2020;59(6):2641-2649.
- 550. Mollentze WF, Joubert G, Prins A, van der Linde S, Marx GM, Tsie KG. The safety and efficacy of a low-energy diet to induce weight loss, improve metabolic health, and induce diabetes remission in insulin-treated obese men with type 2 diabetes: a

- pilot RCT. International Journal of Diabetes in Developing Countries. 2019;39(4):618-625.
- 551. Chiang TL, Chen C, Hsu CH, Lin YC, Wu HJ. Is the goal of 12,000 steps per day sufficient for improving body composition and metabolic syndrome? The necessity of combining exercise intensity: a randomized controlled trial. BMC Public Health. 2019;19(1):1215.
- 552. Kraus WE, Bhapkar M, Huffman KM, et al. 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(9):673-683.
- 553. Malik VS, Sudha V, Wedick NM, et al. Substituting brown rice for white rice on diabetes risk factors in India: a randomised controlled trial. Br J Nutr. 2019;121(12):1389-1397.
- Aghasi M, Koohdani F, Qorbani M, et al. Beneficial effects of green cardamom on serum SIRT1, glycemic indices and triglyceride levels in patients with type 2 diabetes mellitus: a randomized double-blind placebo controlled clinical trial. J Sci Food Agric. 2019;99(8):3933-3940.
- 555. Hirsh SP, Pons M, Joyal SV, Swick AG. Avoiding holiday seasonal weight gain with nutrient-supported intermittent energy restriction: a pilot study. J Nutr Sci. 2019;8:e11.
- 556. Byrne CS, Chambers ES, Preston T, et al. Effects of Inulin Propionate Ester Incorporated into Palatable Food Products on Appetite and Resting Energy Expenditure: A Randomised Crossover Study. Nutrients. 2019;11(4)
- 557. Taylor PJ, Thompson CH, Luscombe-Marsh ND, Wycherley TP, Wittert G, Brinkworth GD. Efficacy of Real-Time Continuous Glucose Monitoring to Improve Effects of a Prescriptive Lifestyle Intervention in Type 2 Diabetes: A Pilot Study. Diabetes Ther. 2019;10(2):509-522.

- Nunes PRP, Martins FM, Souza AP, et al. Effect of high-intensity interval training on body composition and inflammatory markers in obese postmenopausal women: a randomized controlled trial. Menopause. 2019;26(3):256-264.
- 559. Ejtahed HS, Tito RY, Siadat SD, et al. Metformin induces weight loss associated with gut microbiota alteration in non-diabetic obese women: a randomized double-blind clinical trial. Eur J Endocrinol. 2019;180(3):165-176.
- 560. Schroeder EC, Franke WD, Sharp RL, Lee DC. Comparative effectiveness of aerobic, resistance, and combined training on cardiovascular disease risk factors: A randomized controlled trial. PLoS One. 2019;14(1):e0210292.
- 561. Rynarzewski J, Dicks L, Zimmermann BF, et al. Impact of a Usual Serving Size of Flavanol-Rich Cocoa Powder Ingested with a Diabetic-Suitable Meal on Postprandial Cardiometabolic Parameters in Type 2 Diabetics-A Randomized, Placebo-Controlled, Double-Blind Crossover Study. Nutrients. 2019;11(2)
- 562. Otten J, Andersson J, Ståhl J, et al. Exercise Training Adds Cardiometabolic Benefits of a Paleolithic Diet in Type 2 Diabetes Mellitus. J Am Heart Assoc. 2019;8(2):e010634.
- Aliashrafi S, Arefhosseini SR, Lotfi-Dizaji L, Ebrahimi-Mameghani M. Effect of vitamin D supplementation in combination with weight loss diet on lipid profile and sirtuin 1 in obese subjects with vitamin D deficiency: a double blind randomized clinical trial. Health Promot Perspect. 2019;9(4):263-269.
- 564. Ballin M, Lundberg E, Sörlén N, Nordström P, Hult A, Nordström A. Effects of interval training on quality of life and cardiometabolic risk markers in older adults: a randomized controlled trial. Clin Interv Aging. 2019;14:1589-1599.
- 565. de Souza RGM, Gomes AC, de Castro IA, Mota JF. A baru almond-enriched diet reduces abdominal adiposity and improves high-density lipoprotein concentrations: a randomized, placebo-controlled trial. Nutrition. 2018;55-56:154-160.

- Amozadeh H, Shabani R, Nazari M. The Effect of Aerobic Training and Green Tea Supplementation on Cardio Metabolic Risk Factors in Overweight and Obese Females: A Randomized Trial. Int J Endocrinol Metab. 2018;16(4):e60738.
- 567. Galvão Cândido F, Xavier Valente F, da Silva LE, Gonçalves Leão Coelho O, Gouveia Peluzio MDC, Gonçalves Alfenas RC. Consumption of extra virgin olive oil improves body composition and blood pressure in women with excess body fat: a randomized, double-blinded, placebo-controlled clinical trial. Eur J Nutr. 2018;57(7):2445-2455.
- Zapata-Lamana R, Henríquez-Olguín C, Burgos C, et al. Effects of Polarized Training on Cardiometabolic Risk Factors in Young Overweight and Obese Women: A Randomized-Controlled Trial. Front Physiol. 2018;9:1287.
- 569. Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343-353.
- 570. González-Sarrías A, Romo-Vaquero M, García-Villalba R, Cortés-Martín A, Selma MV, Espín JC. The Endotoxemia Marker Lipopolysaccharide-Binding Protein is Reduced in Overweight-Obese Subjects Consuming Pomegranate Extract by Modulating the Gut Microbiota: A Randomized Clinical Trial. Mol Nutr Food Res. 2018;62(11):e1800160.
- 571. Kim J, Yun JM, Kim MK, Kwon O, Cho B. Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. J Med Food. 2018;21(5):454-461.
- 572. Berk KA, Buijks HIM, Verhoeven AJM, et al. Group cognitive behavioural therapy and weight regain after diet in type 2 diabetes: results from the randomised controlled POWER trial. Diabetologia. 2018;61(4):790-799.
- 573. Madjd A, Taylor MA, Delavari A, Malekzadeh R, Macdonald IA, Farshchi HR. Effects of replacing diet beverages with

- water on weight loss and weight maintenance: 18-month follow-up, randomized clinical trial. Int J Obes (Lond). 2018;42(4):835-840.
- 574. Khezri SS, Saidpour A, Hosseinzadeh N, Amiri Z. Beneficial effects of Apple Cider Vinegar on weight management, Visceral Adiposity Index and lipid profile in overweight or obese subjects receiving restricted calorie diet: A randomized clinical trial. Article. Journal of Functional Foods. 2018;43:95-102.
- 575. Engel S, Tholstrup T, Bruun JM, Astrup A, Richelsen B, Raben A. Effect of high milk and sugar-sweetened and non-caloric soft drink intake on insulin sensitivity after 6 months in overweight and obese adults: a randomized controlled trial. Eur J Clin Nutr. 2018;72(3):358-366.
- 576. Bendtsen LQ, Blædel T, Holm JB, et al. High intake of dairy during energy restriction does not affect energy balance or the intestinal microflora compared with low dairy intake in overweight individuals in a randomized controlled trial. Appl Physiol Nutr Metab. 2018;43(1):1-10.
- 577. Jaacks LM, Sher S, Staercke C, et al. Pilot randomized controlled trial of a Mediterranean diet or diet supplemented with fish oil, walnuts, and grape juice in overweight or obese US adults. BMC Nutr. 2018;4:26.
- 578. Kempf K, Röhling M, Stichert M, et al. Telemedical Coaching Improves Long-Term Weight Loss in Overweight Persons: A Randomized Controlled Trial. Int J Telemed Appl. 2018;2018:7530602.
- 579. Mraovic T, Radakovic S, Medic DR, et al. The effects of different caloric restriction diets on anthropometric and cardiometabolic risk factors in overweight and obese females. Article. Vojnosanitetski Pregled. 2018;75(1):30-38.
- 580. Saito S, Mori A, Osaki N, Katsuragi Y. Diacylglycerol Enhances the Effects of Alpha-Linolenic Acid Against Visceral Fat: A Double-Blind Randomized Controlled Trial. Obesity (Silver Spring). 2017;25(10):1667-1675.

- 581. Aoe S, Ichinose Y, Kohyama N, et al. Effects of high  $\beta$ -glucan barley on visceral fat obesity in Japanese individuals: A randomized, double-blind study. Nutrition. 2017;42:1-6.
- 582. Gokulakrishnan K, Ranjani H, Weber MB, et al. Effect of lifestyle improvement program on the biomarkers of adiposity, inflammation and gut hormones in overweight/obese Asian Indians with prediabetes. Acta Diabetol. 2017;54(9):843-852.
- 583. Mousa A, Naderpoor N, de Courten MP, et al. Vitamin D supplementation has no effect on insulin sensitivity or secretion in vitamin D-deficient, overweight or obese adults: a randomized placebo-controlled trial. Am J Clin Nutr. 2017;105(6):1372-1381.
- 584. Saslow LR, Mason AE, Kim S, et al. An Online Intervention Comparing a Very Low-Carbohydrate Ketogenic Diet and Lifestyle Recommendations Versus a Plate Method Diet in Overweight Individuals With Type 2 Diabetes: A Randomized Controlled Trial. J Med Internet Res. 2017;19(2):e36.
- 585. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes 5-Year Outcomes. N Engl J Med. 2017;376(7):641-651.
- 586. Paquette M, Medina Larqué AS, Weisnagel SJ, et al. Strawberry and cranberry polyphenols improve insulin sensitivity in insulin-resistant, non-diabetic adults: a parallel, double-blind, controlled and randomised clinical trial. Br J Nutr. 2017;117(4):519-531.
- 587. Taghizadeh M, Farzin N, Taheri S, et al. The Effect of Dietary Supplements Containing Green Tea, Capsaicin and Ginger Extracts on Weight Loss and Metabolic Profiles in Overweight Women: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Ann Nutr Metab. 2017;70(4):277-285.
- 588. Melchart D, Löw P, Wühr E, Kehl V, Weidenhammer W. Effects of a tailored lifestyle self-management intervention

- (TALENT) study on weight reduction: a randomized controlled trial. Diabetes Metab Syndr Obes. 2017;10:235-245.
- 589. Blædel T, Holm JB, Sundekilde UK, et al. A randomised, controlled, crossover study of the effect of diet on angiopoietin-like protein 4 (ANGPTL4) through modification of the gut microbiome. J Nutr Sci. 2016;5:e45.
- 590. Alqurashi RM, Galante LA, Rowland IR, Spencer JP, Commane DM. Consumption of a flavonoid-rich açai meal is associated with acute improvements in vascular function and a reduction in total oxidative status in healthy overweight men. Am J Clin Nutr. 2016;104(5):1227-1235.
- 591. O'Neil PM, Miller-Kovach K, Tuerk PW, et al. Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes. Obesity (Silver Spring). 2016;24(11):2269-2277.
- 592. Kim H, Kim M, Kojima N, et al. Exercise and Nutritional Supplementation on Community-Dwelling Elderly Japanese Women With Sarcopenic Obesity: A Randomized Controlled Trial. J Am Med Dir Assoc. 2016;17(11):1011-1019.
- 593. Tovar J, Johansson M, Björck I. A multifunctional diet improves cardiometabolic-related biomarkers independently of weight changes: an 8-week randomized controlled intervention in healthy overweight and obese subjects. Eur J Nutr. 2016;55(7):2295-306.
- 594. Madjd A, Taylor MA, Delavari A, Malekzadeh R, Macdonald IA, Farshchi HR. Beneficial effect of high energy intake at lunch rather than dinner on weight loss in healthy obese women in a weight-loss program: a randomized clinical trial. Am J Clin Nutr. 2016;104(4):982-989.
- 595. Li X, Cai X, Ma X, et al. Short- and Long-Term Effects of Wholegrain Oat Intake on Weight Management and Glucolipid Metabolism in Overweight Type-2 Diabetics: A Randomized Control Trial. Nutrients. 2016;8(9)

- 596. Jamal SN, Moy FM, Azmi Mohamed MN, Mukhtar F. Effectiveness of a Group Support Lifestyle Modification (GSLiM) Programme among Obese Adults in Workplace: A Randomised Controlled Trial. PLoS One. 2016;11(8):e0160343.
- 597. Wolf E, Utech M, Stehle P, et al. Oral High-Dose Vitamin D Dissolved in Oil Raised Serum 25-Hydroxy-Vitamin D to Physiological Levels in Obese Patients After Sleeve Gastrectomy-A Double-Blind, Randomized, and Placebo-Controlled Trial. Obes Surg. 2016;26(8):1821-9.
- 598. Kong Z, Fan X, Sun S, Song L, Shi Q, Nie J. Comparison of High-Intensity Interval Training and Moderate-to-Vigorous Continuous Training for Cardiometabolic Health and Exercise Enjoyment in Obese Young Women: A Randomized Controlled Trial. PLoS One. 2016;11(7):e0158589.
- 599. Most J, Timmers S, Warnke I, et al. Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial. Am J Clin Nutr. 2016;104(1):215-27.
- 600. Welsh P, Cezard G, Gill JM, et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. Int J Obes (Lond). 2016;40(6):1005-11.
- 601. Järvi A, Karlström B, Vessby B, Becker W. Increased intake of fruits and vegetables in overweight subjects: effects on body weight, body composition, metabolic risk factors and dietary intake. Br J Nutr. 2016;115(10):1760-8.
- 602. Weiland A, Bub A, Barth SW, Schrezenmeir J, Pfeuffer M. Effects of dietary milk- and soya-phospholipids on lipid-parameters and other risk indicators for cardiovascular diseases in overweight or obese men two double-blind, randomised, controlled, clinical trials. Journal of nutritional science. 2016;5:e21-e21.

- 603. Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016;4(3):221-232.
- 604. Higashikawa F, Noda M, Awaya T, et al. Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects: a randomized, double-blind, placebo-controlled clinical trial. Eur J Clin Nutr. 2016;70(5):582-7.
- 605. Nelson K, Mathai ML, Ashton JF, et al. Effects of malted and non-malted whole-grain wheat on metabolic and inflammatory biomarkers in overweight/obese adults: a randomised crossover pilot study. Food Chem. 2016;194:495-502.
- 606. Madjd A, Taylor MA, Mousavi N, et al. Comparison of the effect of daily consumption of probiotic compared with low-fat conventional yogurt on weight loss in healthy obese women following an energy-restricted diet: a randomized controlled trial. Am J Clin Nutr. 2016;103(2):323-9.
- 607. Madjd A, Taylor MA, Delavari A, Malekzadeh R, Macdonald IA, Farshchi HR. Effects on weight loss in adults of replacing diet beverages with water during a hypoenergetic diet: a randomized, 24-wk clinical trial. Am J Clin Nutr. 2015;102(6):1305-12.
- 608. Rebello CJ, Burton J, Heiman M, Greenway FL. Gastrointestinal microbiome modulator improves glucose tolerance in overweight and obese subjects: A randomized controlled pilot trial. J Diabetes Complications. 2015;29(8):1272-6.
- 609. Perez A, Alos VA, Scanlan A, et al. The rationale, design, and baseline characteristics of PREVENT-DM: A community-based comparative effectiveness trial of lifestyle intervention and metformin among Latinas with prediabetes. Contemp Clin Trials. 2015;45(Pt B):320-327.
- 610. Tapsell LC, Lonergan M, Martin A, Batterham MJ, Neale EP. Interdisciplinary lifestyle intervention for weight management

- in a community population (HealthTrack study): Study design and baseline sample characteristics. Contemp Clin Trials. 2015;45(Pt B):394-403.
- 611. Tripkovic L, Muirhead NC, Hart KH, Frost GS, Lodge JK. The effects of a diet rich in inulin or wheat fibre on markers of cardiovascular disease in overweight male subjects. J Hum Nutr Diet. 2015;28(5):476-85.
- 612. Chambers ES, Viardot A, Psichas A, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2015;64(11):1744-54.
- 613. Liu Y, Cotillard A, Vatier C, et al. A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial. PLoS One. 2015;10(9):e0138646.
- 614. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386(9997):964-73.
- 615. Davinelli S, Bertoglio JC, Zarrelli A, Pina R, Scapagnini G. A Randomized Clinical Trial Evaluating the Efficacy of an Anthocyanin-Maqui Berry Extract (Delphinol®) on Oxidative Stress Biomarkers. J Am Coll Nutr. 2015;34 Suppl 1:28-33.
- 616. Shlisky JD, Durward CM, Zack MK, Gugger CK, Campbell JK, Nickols-Richardson SM. An energy-reduced dietary pattern, including moderate protein and increased nonfat dairy intake combined with walking promotes beneficial body composition and metabolic changes in women with excess adiposity: a randomized comparative trial. Food Sci Nutr. 2015;3(5):376-93.
- 617. Hu T, Yao L, Reynolds K, et al. The Effects of a Low-Carbohydrate Diet vs. a Low-Fat Diet on Novel Cardiovascular Risk

Factors: A Randomized Controlled Trial. Nutrients. 2015;7(9):7978-94.

- de Barros F, Setúbal S, Martinho JM, Monteiro AB. Early Endocrine and Metabolic Changes After Bariatric Surgery in Grade III Morbidly Obese Patients: A Randomized Clinical Trial Comparing Sleeve Gastrectomy and Gastric Bypass. Metab Syndr Relat Disord. 2015;13(6):264-71.
- 619. Austel A, Ranke C, Wagner N, Görge J, Ellrott T. Weight loss with a modified Mediterranean-type diet using fat modification: a randomized controlled trial. Eur J Clin Nutr. 2015;69(8):878-84.
- 620. Ding SA, Simonson DC, Wewalka M, et al. Adjustable Gastric Band Surgery or Medical Management in Patients With Type 2 Diabetes: A Randomized Clinical Trial. J Clin Endocrinol Metab. 2015;100(7):2546-56.
- 621. McEvoy CT, Wallace IR, Hamill LL, et al. Increasing Fruit and Vegetable Intake Has No Dose-Response Effect on Conventional Cardiovascular Risk Factors in Overweight Adults at High Risk of Developing Cardiovascular Disease. J Nutr. 2015;145(7):1464-71.
- 622. Hosseinpour-Niazi S, Mirmiran P, Hedayati M, Azizi F. Substitution of red meat with legumes in the therapeutic lifestyle change diet based on dietary advice improves cardiometabolic risk factors in overweight type 2 diabetes patients: a cross-over randomized clinical trial. Eur J Clin Nutr. 2015;69(5):592-7.
- 623. Mirtaheri E, Namazi N, Alizadeh M, Sargheini N, Karimi S. Effects of dried licorice extract with low-calorie diet on lipid profile and atherogenic indices in overweight and obese subjects: A randomized controlled clinical trial. Article. European Journal of Integrative Medicine. 2015;7(3):287-293.
- 624. Stonehouse W, Brinkworth GD, Noakes M. Palmolein and olive oil consumed within a high protein test meal have similar

- effects on postprandial endothelial function in overweight and obese men: A randomized controlled trial. Atherosclerosis. 2015;239(1):178-85.
- 625. Nowotny B, Zahiragic L, Bierwagen A, et al. Low-energy diets differing in fibre, red meat and coffee intake equally improve insulin sensitivity in type 2 diabetes: a randomised feasibility trial. Diabetologia. 2015;58(2):255-64.
- 626. Ivey KL, Hodgson JM, Kerr DA, Thompson PL, Stojceski B, Prince RL. The effect of yoghurt and its probiotics on blood pressure and serum lipid profile; a randomised controlled trial. Nutr Metab Cardiovasc Dis. 2015;25(1):46-51.
- 627. Taghizadeh M, Memarzadeh MR, Asemi Z, Esmaillzadeh A. Effect of the cumin cyminum L. Intake on Weight Loss, Metabolic Profiles and Biomarkers of Oxidative Stress in Overweight Subjects: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Ann Nutr Metab. 2015;66(2-3):117-124.
- 628. Nickols-Richardson SM, Piehowski KE, Metzgar CJ, Miller DL, Preston AG. Changes in body weight, blood pressure and selected metabolic biomarkers with an energy-restricted diet including twice daily sweet snacks and once daily sugar-free beverage. Nutr Res Pract. 2014;8(6):695-704.
- 629. Zare R, Heshmati F, Fallahzadeh H, Nadjarzadeh A. Effect of cumin powder on body composition and lipid profile in overweight and obese women. Complement Ther Clin Pract. 2014;20(4):297-301.
- 630. Sousa N, Mendes R, Abrantes C, Sampaio J, Oliveira J. A randomized study on lipids response to different exercise programs in overweight older men. Int J Sports Med. 2014;35(13):1106-11.
- 631. Hernández-Cordero S, Barquera S, Rodríguez-Ramírez S, et al. Substituting water for sugar-sweetened beverages reduces circulating triglycerides and the prevalence of metabolic syndrome in obese but not in overweight Mexican women in a

- randomized controlled trial. J Nutr. 2014;144(11):1742-52.
- 632. Schwander F, Kopf-Bolanz KA, Buri C, et al. A dose-response strategy reveals differences between normal-weight and obese men in their metabolic and inflammatory responses to a high-fat meal. J Nutr. 2014;144(10):1517-23.
- 633. Halperin F, Ding SA, Simonson DC, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014;149(7):716-26.
- 634. Choi MS, Ryu R, Seo YR, et al. The beneficial effect of soybean (Glycine max (L.) Merr.) leaf extracts in adults with prediabetes: a randomized placebo controlled trial. Food Funct. 2014;5(7):1621-30.
- Bozzetto L, Annuzzi G, Costabile G, et al. A CHO/fibre diet reduces and a MUFA diet increases postprandial lipaemia in type 2 diabetes: no supplementary effects of low-volume physical training. Acta Diabetol. 2014;51(3):385-93.
- 636. Lin PH, Wang Y, Levine E, et al. A text messaging-assisted randomized lifestyle weight loss clinical trial among overweight adults in Beijing. Obesity (Silver Spring). 2014;22(5):E29-37.
- 637. Geliebter A, Astbury NM, Aviram-Friedman R, Yahav E, Hashim S. Skipping breakfast leads to weight loss but also elevated cholesterol compared with consuming daily breakfasts of oat porridge or frosted cornflakes in overweight individuals: a randomised controlled trial. J Nutr Sci. 2014;3:e56.
- 638. Rondanelli M, Opizzi A, Faliva M, et al. Metabolic management in overweight subjects with naive impaired fasting glycaemia by means of a highly standardized extract from Cynara scolymus: a double-blind, placebo-controlled, randomized clinical trial. Phytother Res. 2014;28(1):33-41.
- 639. Liu X, Zhang G, Ye X, et al. Effects of a low-carbohydrate diet on weight loss and cardiometabolic profile in Chinese

women: a randomised controlled feeding trial. Br J Nutr. 2013;110(8):1444-53.

- 640. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013;36(8):2175-82.
- 641. Mishra S, Xu J, Agarwal U, Gonzales J, Levin S, Barnard ND. A multicenter randomized controlled trial of a plant-based nutrition program to reduce body weight and cardiovascular risk in the corporate setting: the GEICO study. Eur J Clin Nutr. 2013;67(7):718-24.
- 642. Liang Z, Wu Q, Chen B, Yu P, Zhao H, Ouyang X. Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Pract. 2013;101(1):50-6.
- 643. Munro IA, Garg ML. Prior supplementation with long chain omega-3 polyunsaturated fatty acids promotes weight loss in obese adults: a double-blinded randomised controlled trial. Food Funct. 2013;4(4):650-8.
- 644. de Bock M, Derraik JG, Brennan CM, et al. Olive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomized, placebo-controlled, crossover trial. PLoS One. 2013;8(3):e57622.
- 645. Cho SH, Yoon Y, Yang Y. The Evaluation of the Body Weight Lowering Effects of Herbal Extract THI on Exercising Healthy Overweight Humans: A Randomized Double-Blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med. 2013;2013:758273.
- 646. Azadbakht L, Izadi V, Surkan PJ, Esmaillzadeh A. Effect of a High Protein Weight Loss Diet on Weight, High-Sensitivity C-Reactive Protein, and Cardiovascular Risk among Overweight and Obese Women: A Parallel Clinical Trial. Int J Endocrinol.

## 2013;2013:971724.

- 647. Salehpour A, Shidfar F, Hosseinpanah F, et al. Vitamin D3 and the risk of CVD in overweight and obese women: a randomised controlled trial. Br J Nutr. 2012;108(10):1866-73.
- 648. Buchowski MS, Hongu N, Acra S, Wang L, Warolin J, Roberts LJ, 2nd. Effect of modest caloric restriction on oxidative stress in women, a randomized trial. PLoS One. 2012;7(10):e47079.
- 649. Munro IA, Garg ML. Dietary supplementation with n-3 PUFA does not promote weight loss when combined with a very-low-energy diet. Br J Nutr. 2012;108(8):1466-74.
- 650. Thies F, Masson LF, Rudd A, et al. Effect of a tomato-rich diet on markers of cardiovascular disease risk in moderately overweight, disease-free, middle-aged adults: a randomized controlled trial. Am J Clin Nutr. 2012;95(5):1013-22.
- 651. Rizkalla SW, Prifti E, Cotillard A, et al. Differential effects of macronutrient content in 2 energy-restricted diets on cardiovascular risk factors and adipose tissue cell size in moderately obese individuals: a randomized controlled trial. Am J Clin Nutr. 2012;95(1):49-63.
- 652. Tovar J, Nilsson A, Johansson M, et al. A diet based on multiple functional concepts improves cardiometabolic risk parameters in healthy subjects. Nutr Metab (Lond). 2012;9:29.
- 653. Taniguchi-Fukatsu A, Yamanaka-Okumura H, Naniwa-Kuroki Y, et al. Natto and viscous vegetables in a Japanese-style breakfast improved insulin sensitivity, lipid metabolism and oxidative stress in overweight subjects with impaired glucose tolerance. Br J Nutr. 2012;107(8):1184-91.
- 654. Krebs JD, Elley CR, Parry-Strong A, et al. The Diabetes Excess Weight Loss (DEWL) Trial: a randomised controlled trial of

- high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes. Diabetologia. 2012;55(4):905-14.
- 655. Gargari BP, Aghamohammadi V, Aliasgharzadeh A. Effect of folic acid supplementation on biochemical indices in overweight and obese men with type 2 diabetes. Diabetes Res Clin Pract. 2011;94(1):33-8.
- 656. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067-77.
- 657. Khoo J, Piantadosi C, Duncan R, et al. Comparing effects of a low-energy diet and a high-protein low-fat diet on sexual and endothelial function, urinary tract symptoms, and inflammation in obese diabetic men. J Sex Med. 2011;8(10):2868-75.
- 658. Derosa G, Maffioli P, Ferrari I, et al. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. J Clin Pharm Ther. 2011;36(5):592-601.
- 659. Søvik TT, Aasheim ET, Taha O, et al. Weight loss, cardiovascular risk factors, and quality of life after gastric bypass and duodenal switch: a randomized trial. Ann Intern Med. 2011;155(5):281-91.
- 660. Shah M, Snell PG, Rao S, et al. High-volume exercise program in obese bariatric surgery patients: a randomized, controlled trial. Obesity (Silver Spring). 2011;19(9):1826-34.
- 661. Tanaka T, Morita A, Kato M, et al. Congener-specific polychlorinated biphenyls and the prevalence of diabetes in the Saku Control Obesity Program (SCOP). Endocr J. 2011;58(7):589-96.
- 662. Te Morenga LA, Levers MT, Williams SM, Brown RC, Mann J. Comparison of high protein and high fiber weight-loss diets in women with risk factors for the metabolic syndrome: a randomized trial. Nutr J. 2011;10:40.
- 663. Cho JK, Lee SH, Lee JY, Kang HS. Randomized controlled trial of training intensity in adiposity. Int J Sports Med.

## 2011;32(6):468-75.

- Kreider RB, Serra M, Beavers KM, et al. A structured diet and exercise program promotes favorable changes in weight loss, body composition, and weight maintenance. J Am Diet Assoc. 2011;111(6):828-43.
- 665. Harvie MN, Pegington M, Mattson MP, et al. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond). 2011;35(5):714-27.
- 666. Njike VY, Faridi Z, Shuval K, et al. Effects of sugar-sweetened and sugar-free cocoa on endothelial function in overweight adults. Int J Cardiol. 2011;149(1):83-8.
- 667. Choquette S, Riesco É, Cormier É, Dion T, Aubertin-Leheudre M, Dionne IJ. Effects of soya isoflavones and exercise on body composition and clinical risk factors of cardiovascular diseases in overweight postmenopausal women: a 6-month double-blind controlled trial. Br J Nutr. 2011;105(8):1199-209.
- 668. Larsen RN, Mann NJ, Maclean E, Shaw JE. The effect of high-protein, low-carbohydrate diets in the treatment of type 2 diabetes: a 12 month randomised controlled trial. Diabetologia. 2011;54(4):731-40.
- 669. Frank I, Briggs R, Spengler CM. Respiratory muscles, exercise performance, and health in overweight and obese subjects. Med Sci Sports Exerc. 2011;43(4):714-27.
- 670. Llaneza P, González C, Fernandez-Iñarrea J, et al. Soy isoflavones, diet and physical exercise modify serum cytokines in healthy obese postmenopausal women. Phytomedicine. 2011;18(4):245-50.
- 671. DeFina LF, Marcoux LG, Devers SM, Cleaver JP, Willis BL. Effects of omega-3 supplementation in combination with diet and exercise on weight loss and body composition. Am J Clin Nutr. 2011;93(2):455-62.

- 672. Sieverdes JC, Sui X, Hand GA, et al. Cardiometabolic results from an armband-based weight loss trial. Diabetes Metab Syndr Obes. 2011;4:187-94.
- 673. Raben A, Møller BK, Flint A, et al. Increased postprandial glycaemia, insulinemia, and lipidemia after 10 weeks' sucrose-rich diet compared to an artificially sweetened diet: a randomised controlled trial. Food Nutr Res. 2011;55
- 674. Bladbjerg EM, Larsen TM, Due A, Jespersen J, Stender S, Astrup A. Long-term effects on haemostatic variables of three ad libitum diets differing in type and amount of fat and carbohydrate: a 6-month randomised study in obese individuals. Br J Nutr. 2010;104(12):1824-30.
- 675. Li S, Guerin-Deremaux L, Pochat M, Wils D, Reifer C, Miller LE. NUTRIOSE dietary fiber supplementation improves insulin resistance and determinants of metabolic syndrome in overweight men: a double-blind, randomized, placebo-controlled study. Appl Physiol Nutr Metab. 2010;35(6):773-82.
- 676. Ilanne-Parikka P, Laaksonen DE, Eriksson JG, et al. Leisure-time physical activity and the metabolic syndrome in the Finnish diabetes prevention study. Diabetes Care. 2010;33(7):1610-7.
- 677. Beck EJ, Tapsell LC, Batterham MJ, Tosh SM, Huang XF. Oat beta-glucan supplementation does not enhance the effectiveness of an energy-restricted diet in overweight women. Br J Nutr. 2010;103(8):1212-22.
- 678. Hodgson JM, Lee YP, Puddey IB, et al. Effects of increasing dietary protein and fibre intake with lupin on body weight and composition and blood lipids in overweight men and women. Int J Obes (Lond). 2010;34(6):1086-94.
- 679. Michishita T, Kobayashi S, Katsuya T, Ogihara T, Kawabuchi K. Evaluation of the antiobesity effects of an amino acid mixture and conjugated linoleic acid on exercising healthy overweight humans: a randomized, double-blind, placebo-controlled

- trial. J Int Med Res. 2010;38(3):844-59.
- 680. Blumenthal JA, Babyak MA, Sherwood A, et al. Effects of the dietary approaches to stop hypertension diet alone and in combination with exercise and caloric restriction on insulin sensitivity and lipids. Hypertension. 2010;55(5):1199-205.
- 681. Larson-Meyer DE, Redman L, Heilbronn LK, Martin CK, Ravussin E. Caloric restriction with or without exercise: the fitness versus fatness debate. Med Sci Sports Exerc. 2010;42(1):152-9.
- Elhayany A, Lustman A, Abel R, Attal-Singer J, Vinker S. A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study. Diabetes Obes Metab. 2010;12(3):204-9.
- 683. Sluijs I, Plantinga Y, de Roos B, Mennen LI, Bots ML. Dietary supplementation with cis-9,trans-11 conjugated linoleic acid and aortic stiffness in overweight and obese adults. Am J Clin Nutr. 2010;91(1):175-83.
- 684. Rizvi ZA, Saleem J, Zeb I, et al. Effects of intermittent fasting on body composition, clinical health markers and memory status in the adult population: a single-blind randomised controlled trial. Nutr J. 2024;23(1):147.
- 685. Horváth J, Seres I, Paragh G, Fülöp P, Jenei Z. Effect of Low- and Moderate-Intensity Aerobic Training on Body Composition Cardiorespiratory Functions, Biochemical Risk Factors and Adipokines in Morbid Obesity. Nutrients. 2024;16(23)
- 686. Nemati M, Bozorgtabar N, Hoteit M, et al. Antioxidant supplementation boosts the advantages of CrossFit workouts on oxidative and muscle damage markers in obese males. Nutr Metab (Lond). 2024;21(1):91.
- 687. AlMalki SM, Alfawaz HA, Binmoammar TA, et al. Effects of probiotics on selected anthropometrics and biochemical measures in overweight or obese Saudi subjects: a double-blind, placebo-controlled, randomised clinical trial. Public Health Nutr.

2024;27(1):e225.

- 688. Suder A, Makiel K, Targosz A, Kosowski P, Malina RM. Positive Effects of Aerobic-Resistance Exercise and an Ad Libitum High-Protein, Low-Glycemic Index Diet on Irisin, Omentin, and Dyslipidemia in Men with Abdominal Obesity: A Randomized Controlled Trial. Nutrients. 2024;16(20)
- 689. Amiri P, Hosseini SA, Saghafi-Asl M, Roshanravan N, Tootoonchian M. Expression of PGC-1α, PPAR-α and UCP1 genes, metabolic and anthropometric factors in response to sodium butyrate supplementation in patients with obesity: a triple-blind, randomized placebo-controlled clinical trial. Eur J Clin Nutr. 2024;
- 690. Rodrigo-Carbó C, Madinaveitia-Nisarre L, Pérez-Calahorra S, et al. Low-calorie, high-protein diets, regardless of protein source, improve glucose metabolism and cardiometabolic profiles in subjects with prediabetes or type 2 diabetes and overweight or obesity. Diabetes Obes Metab. 2025;27(1):268-279.
- 691. Stockton MB, Pence J, Davis A, Bloomer RJ. Impact of an Active Nutrition Program on Weight Loss and Metabolic Health in Overweight and Obese Adults: A Randomized Controlled Trial. Cureus. 2024;16(10):e72545.
- 692. Wang Y, Yang X, Deng J, et al. Combined high-intensity interval and resistance training improves cardiorespiratory fitness more than high-intensity interval training in young women with overweight/obesity: a randomized controlled trial. Front Endocrinol (Lausanne). 2024;15:1450944.
- 693. Ostadrahimi A, Khajebishak Y, Moradi F, Payahoo L. The effect of Oleoylethanolamide supplementation on lipid profile, fasting blood sugar and dietary habits in obese people: a randomized double-blind placebo-control trial. BMC Endocr Disord. 2024;24(1):210.

- 694. Turner-McGrievy GM, Wilcox S, Frongillo EA, et al. Impact of diet adherence on weight and lipids among African American participants randomized to vegan or omnivorous diets. Obes Sci Pract. 2024;10(5):e70009.
- 695. Delfan M, Radkia F, Juybari RA, et al. Unveiling the Effects of Interval Resistance Training and Chlorella Vulgaris Supplementation on Meteorin-like Protein and Oxidative Stress in Obese Men. Curr Dev Nutr. 2024;8(9):104428.
- 696. Pammer A, Obermayer A, Stadler JT, et al. Effects of dietary interventions and intermittent fasting on HDL function in obese individuals with T2DM: a randomized controlled trial. Cardiovasc Diabetol. 2024;23(1):339.
- 697. Duan Y, Lu G. A Randomized Controlled Trial to Determine the Impact of Resistance Training versus Aerobic Training on the Management of FGF-21 and Related Physiological Variables in Obese Men with Type 2 Diabetes Mellitus. J Sports Sci Med. 2024;23(1):495-503.
- 698. Rolland C, Hession M, Murray S, Wise A, Broom I. Randomized clinical trial of standard dietary treatment versus a low-carbohydrate/high-protein diet or the LighterLife Programme in the management of obesity\*. J Diabetes. 2009;1(3):207-17.
- 699. Foster GD, Borradaile KE, Vander Veur SS, et al. The effects of a commercially available weight loss program among obese patients with type 2 diabetes: a randomized study. Postgrad Med. 2009;121(5):113-8.
- 700. Tsai Ch H, Chiu WC, Yang NC, Ouyang CM, Yen YH. A novel green tea meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. Int J Food Sci Nutr. 2009;60 Suppl 6:151-9.
- 701. Fontbonne A, Diouf I, Baccara-Dinet M, Eschwege E, Charles MA. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Diabetes Metab. 2009;35(5):385-91.

- 702. Shikany JM, Phadke RP, Redden DT, Gower BA. Effects of low- and high-glycemic index/glycemic load diets on coronary heart disease risk factors in overweight/obese men. Metabolism. 2009;58(12):1793-801.
- 703. Frisch S, Zittermann A, Berthold HK, et al. A randomized controlled trial on the efficacy of carbohydrate-reduced or fat-reduced diets in patients attending a telemedically guided weight loss program. Cardiovasc Diabetol. 2009;8:36.
- 704. Nieman DC, Cayea EJ, Austin MD, Henson DA, McAnulty SR, Jin F. Chia seed does not promote weight loss or alter disease risk factors in overweight adults. Nutr Res. 2009;29(6):414-8.
- 705. Lin WY, Wu CH, Chu NF, Chang CJ. Efficacy and safety of very-low-calorie diet in Taiwanese: a multicenter randomized, controlled trial. Nutrition. 2009;25(11-12):1129-36.
- 706. Arsenault BJ, Côté M, Cartier A, et al. Effect of exercise training on cardiometabolic risk markers among sedentary, but metabolically healthy overweight or obese post-menopausal women with elevated blood pressure. Atherosclerosis. 2009;207(2):530-3.
- 707. Brochu M, Malita MF, Messier V, et al. Resistance training does not contribute to improving the metabolic profile after a 6-month weight loss program in overweight and obese postmenopausal women. J Clin Endocrinol Metab. 2009;94(9):3226-33.
- 708. Aasheim ET, Björkman S, Søvik TT, et al. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch. Am J Clin Nutr. 2009;90(1):15-22.
- 709. Assunção ML, Ferreira HS, dos Santos AF, Cabral CR, Jr., Florêncio TM. Effects of dietary coconut oil on the biochemical and anthropometric profiles of women presenting abdominal obesity. Lipids. 2009;44(7):593-601.
- 710. Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intrahepatic fat

- content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring). 2009;17(12):2162-8.
- 711. Davis NJ, Tomuta N, Schechter C, et al. Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate diet versus a low-fat diet on weight and glycemic control in type 2 diabetes. Diabetes Care. 2009;32(7):1147-52.
- 712. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859-73.
- 713. Digenio AG, Mancuso JP, Gerber RA, Dvorak RV. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial. Ann Intern Med. 2009;150(4):255-62.
- 714. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology. 2009;136(5):1552-60.
- 715. Hursel R, Westerterp-Plantenga MS. Green tea catechin plus caffeine supplementation to a high-protein diet has no additional effect on body weight maintenance after weight loss. Am J Clin Nutr. 2009;89(3):822-30.
- 716. Andersson K, Karlström B, Fredén S, Petersson H, Ohrvall M, Zethelius B. A two-year clinical lifestyle intervention program for weight loss in obesity. Food Nutr Res. 2008;52
- 717. Layman DK, Evans EM, Erickson D, et al. A moderate-protein diet produces sustained weight loss and long-term changes in body composition and blood lipids in obese adults. J Nutr. 2009;139(3):514-21.
- 718. Kim JY, Kim JH, Lee DH, Kim SH, Lee SS. Meal replacement with mixed rice is more effective than white rice in weight control, while improving antioxidant enzyme activity in obese women. Nutr Res. 2008;28(2):66-71.
- 719. Lasker DA, Evans EM, Layman DK. Moderate carbohydrate, moderate protein weight loss diet reduces cardiovascular

- disease risk compared to high carbohydrate, low protein diet in obese adults: A randomized clinical trial. Nutr Metab (Lond). 2008;5:30.
- 720. St-Onge MP, Bosarge A, Goree LL, Darnell B. Medium chain triglyceride oil consumption as part of a weight loss diet does not lead to an adverse metabolic profile when compared to olive oil. J Am Coll Nutr. 2008;27(5):547-52.
- 721. Hibi M, Takase H, Yasunaga K, et al. Greater fat oxidation with diacylglycerol oil consumption for 14 days compared with triacylglycerol oil consumption in overweight men and women. Int J Obes (Lond). 2008;32(12):1841-7.
- 722. Treyzon L, Chen S, Hong K, et al. A controlled trial of protein enrichment of meal replacements for weight reduction with retention of lean body mass. Nutr J. 2008;7:23.
- 723. Volpe SL, Kobusingye H, Bailur S, Stanek E. Effect of diet and exercise on body composition, energy intake and leptin levels in overweight women and men. J Am Coll Nutr. 2008;27(2):195-208.
- 724. Morgan LM, Griffin BA, Millward DJ, et al. Comparison of the effects of four commercially available weight-loss programmes on lipid-based cardiovascular risk factors. Public Health Nutr. 2009;12(6):799-807.
- 725. Lindqvist HM, Langkilde AM, Undeland I, Sandberg AS. Herring (Clupea harengus) intake influences lipoproteins but not inflammatory and oxidation markers in overweight men. Br J Nutr. 2009;101(3):383-90.
- 726. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359(3):229-41.
- 727. Nakou E, Filippatos TD, Liberopoulos EN, et al. Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. Expert Opin Pharmacother.

- 2008;9(10):1629-39.
- 728. Pierce GL, Beske SD, Lawson BR, et al. Weight loss alone improves conduit and resistance artery endothelial function in young and older overweight/obese adults. Hypertension. 2008;52(1):72-9.
- 729. Miyashita M. Effects of continuous versus accumulated activity patterns on postprandial triacylglycerol concentrations in obese men. Int J Obes (Lond). 2008;32(8):1271-8.
- 730. Arciero PJ, Gentile CL, Pressman R, et al. Moderate protein intake improves total and regional body composition and insulin sensitivity in overweight adults. Metabolism. 2008;57(6):757-65.
- 731. Wycherley TP, Brinkworth GD, Noakes M, Buckley JD, Clifton PM. Effect of caloric restriction with and without exercise training on oxidative stress and endothelial function in obese subjects with type 2 diabetes. Diabetes Obes Metab. 2008;10(11):1062-73.
- 732. Lockwood CM, Moon JR, Tobkin SE, et al. Minimal nutrition intervention with high-protein/low-carbohydrate and low-fat, nutrient-dense food supplement improves body composition and exercise benefits in overweight adults: A randomized controlled trial. Nutr Metab (Lond). 2008;5:11.
- 733. Larson-Meyer DE, Newcomer BR, Heilbronn LK, et al. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity (Silver Spring). 2008;16(6):1355-62.
- 734. Schjerve IE, Tyldum GA, Tjønna AE, et al. Both aerobic endurance and strength training programmes improve cardiovascular health in obese adults. Clin Sci (Lond). 2008;115(9):283-93.
- 735. König D, Deibert P, Frey I, Landmann U, Berg A. Effect of meal replacement on metabolic risk factors in overweight and

- obese subjects. Ann Nutr Metab. 2008;52(1):74-8.
- 736. Borges RL, Ribeiro-Filho FF, Carvalho KM, Zanella MT. Impact of weight loss on adipocytokines, C-reactive protein and insulin sensitivity in hypertensive women with central obesity. Arg Bras Cardiol. 2007;89(6):409-14.
- 737. Mutungi G, Ratliff J, Puglisi M, et al. Dietary cholesterol from eggs increases plasma HDL cholesterol in overweight men consuming a carbohydrate-restricted diet. J Nutr. 2008;138(2):272-6.
- 738. Jensen L, Sloth B, Krog-Mikkelsen I, et al. A low-glycemic-index diet reduces plasma plasminogen activator inhibitor-1 activity, but not tissue inhibitor of proteinases-1 or plasminogen activator inhibitor-1 protein, in overweight women. Am J Clin Nutr. 2008;87(1):97-105.
- 739. Salas-Salvadó J, Farrés X, Luque X, et al. Effect of two doses of a mixture of soluble fibres on body weight and metabolic variables in overweight or obese patients: a randomised trial. Br J Nutr. 2008;99(6):1380-7.
- 740. Burton FL, Malkova D, Caslake MJ, Gill JM. Energy replacement attenuates the effects of prior moderate exercise on postprandial metabolism in overweight/obese men. Int J Obes (Lond). 2008;32(3):481-9.
- 741. Karandish M, Shockravi S, Jalali MT, Haghighizadeh MH. Effect of calcium supplementation on lipid profile in overweight or obese Iranian women: a double-blind randomized clinical trial. Eur J Clin Nutr. 2009;63(2):268-72.
- 742. Burke LE, Hudson AG, Warziski MT, et al. Effects of a vegetarian diet and treatment preference on biochemical and dietary variables in overweight and obese adults: a randomized clinical trial. Am J Clin Nutr. 2007;86(3):588-96.
- 743. Bertéus Forslund H, Klingström S, Hagberg H, Löndahl M, Torgerson JS, Lindroos AK. Should snacks be recommended in obesity treatment? A 1-year randomized clinical trial. Eur J Clin Nutr. 2008;62(11):1308-17.

- Meckling KA, Sherfey R. A randomized trial of a hypocaloric high-protein diet, with and without exercise, on weight loss, fitness, and markers of the Metabolic Syndrome in overweight and obese women. Appl Physiol Nutr Metab. 2007;32(4):743-52.
- 745. de Rougemont A, Normand S, Nazare JA, et al. Beneficial effects of a 5-week low-glycaemic index regimen on weight control and cardiovascular risk factors in overweight non-diabetic subjects. Br J Nutr. 2007;98(6):1288-98.
- 746. Liao FH, Shieh MJ, Yang SC, Lin SH, Chien YW. Effectiveness of a soy-based compared with a traditional low-calorie diet on weight loss and lipid levels in overweight adults. Nutrition. 2007;23(7-8):551-6.
- Rave K, Roggen K, Dellweg S, Heise T, tom Dieck H. Improvement of insulin resistance after diet with a whole-grain based dietary product: results of a randomized, controlled cross-over study in obese subjects with elevated fasting blood glucose. Br J Nutr. 2007;98(5):929-36.
- 748. Sahin M, Tanaci N, Yucel M, Tutuncu NB, Guvener N. The effect of single-dose orlistat on postprandial serum glucose, insulin and glucagon-like peptide-1 levels in nondiabetic obese patients. Clin Endocrinol (Oxf). 2007;67(3):346-50.
- 749. Thomas TR, Liu Y, Linden MA, Rector RS. Interaction of exercise training and n-3 fatty acid supplementation on postprandial lipemia. Appl Physiol Nutr Metab. 2007;32(3):473-80.
- 750. Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. Jama. 2007;297(19):2092-102.
- 751. Steck SE, Chalecki AM, Miller P, et al. Conjugated linoleic acid supplementation for twelve weeks increases lean body mass in obese humans. J Nutr. 2007;137(5):1188-93.
- 752. Rock CL, Pakiz B, Flatt SW, Quintana EL. Randomized trial of a multifaceted commercial weight loss program. Obesity

- (Silver Spring). 2007;15(4):939-49.
- 753. Brunerova L, Smejkalova V, Potockova J, Andel M. A comparison of the influence of a high-fat diet enriched in monounsaturated fatty acids and conventional diet on weight loss and metabolic parameters in obese non-diabetic and Type 2 diabetic patients. Diabet Med. 2007;24(5):533-40.
- 754. Maki KC, Rains TM, Kaden VN, Raneri KR, Davidson MH. Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults. Am J Clin Nutr. 2007;85(3):724-34.
- 755. Gardner CD, Kiazand A, Alhassan S, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. Jama. 2007;297(9):969-77.
- 756. Lindqvist H, Langkilde AM, Undeland I, Rådendal T, Sandberg AS. Herring (Clupea harengus) supplemented diet influences risk factors for CVD in overweight subjects. Eur J Clin Nutr. 2007;61(9):1106-13.
- 757. Aubertin-Leheudre M, Lord C, Khalil A, Dionne IJ. Effect of 6 months of exercise and isoflavone supplementation on clinical cardiovascular risk factors in obese postmenopausal women: a randomized, double-blind study. Menopause. 2007;14(4):624-9.
- 758. Major GC, Alarie F, Doré J, Phouttama S, Tremblay A. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr. 2007;85(1):54-9.
- 759. Vincent HK, Bourguignon CM, Vincent KR, Weltman AL, Bryant M, Taylor AG. Antioxidant supplementation lowers exercise-induced oxidative stress in young overweight adults. Obesity (Silver Spring). 2006;14(12):2224-35.

- 760. Bougoulia M, Triantos A, Koliakos G. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women. Hormones (Athens). 2006;5(4):259-69.
- 761. Wood RJ, Fernandez ML, Sharman MJ, et al. Effects of a carbohydrate-restricted diet with and without supplemental soluble fiber on plasma low-density lipoprotein cholesterol and other clinical markers of cardiovascular risk. Metabolism. 2007;56(1):58-67.
- Burke LE, Styn MA, Steenkiste AR, Music E, Warziski M, Choo J. A randomized clinical trial testing treatment preference and two dietary options in behavioral weight management: preliminary results of the impact of diet at 6 months--PREFER study. Obesity (Silver Spring). 2006;14(11):2007-17.
- 763. Vincent HK, Bourguignon C, Vincent KR. Resistance training lowers exercise-induced oxidative stress and homocysteine levels in overweight and obese older adults. Obesity (Silver Spring). 2006;14(11):1921-30.
- 764. McLaughlin T, Carter S, Lamendola C, et al. Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults. Am J Clin Nutr. 2006;84(4):813-21.
- 765. Anderson JW, Schwartz SM, Hauptman J, et al. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial. Ann Pharmacother. 2006;40(10):1717-23.
- 766. Fenkci S, Sarsan A, Rota S, Ardic F. Effects of resistance or aerobic exercises on metabolic parameters in obese women who are not on a diet. Adv Ther. 2006;23(3):404-13.
- 767. Kuo CS, Pei D, Yao CY, Hsieh MC, Kuo SW. Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2006;60(8):906-10.

- 768. Nestel P, Fujii A, Zhang L. An isoflavone metabolite reduces arterial stiffness and blood pressure in overweight men and postmenopausal women. Atherosclerosis. 2007;192(1):184-9.
- 769. Satoh N, Shimatsu A, Yamada K, et al. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism. 2006;55(6):786-93.
- 770. Turker I, Guvener Demirag N, Tanaci N, Uslu Tutar N, Kirbas I. Effects of orlistat plus diet on postprandial lipemia and brachial artery reactivity in normolipidemic, obese women with normal glucose tolerance: A prospective, randomized, controlled Study. Curr Ther Res Clin Exp. 2006;67(3):159-73.
- 771. Ahn CW, Kim CS, Nam JH, et al. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Clin Endocrinol (Oxf). 2006;64(4):444-9.
- Hackman RM, Havel PJ, Schwartz HJ, et al. Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial. Int J Obes (Lond). 2006;30(10):1545-56.
- 773. Krebs JD, Browning LM, McLean NK, et al. Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. Int J Obes (Lond). 2006;30(10):1535-44.
- Wood RJ, Volek JS, Liu Y, Shachter NS, Contois JH, Fernandez ML. Carbohydrate restriction alters lipoprotein metabolism by modifying VLDL, LDL, and HDL subfraction distribution and size in overweight men. J Nutr. 2006;136(2):384-9.
- T75. Löfgren P, Andersson I, Wahrenberg H, Hoffstedt J. No difference in lipolysis or glucose transport of subcutaneous fat cells between moderate-fat and low-fat hypocaloric diets in obese women. Horm Metab Res. 2005;37(12):734-40.
- 776. Petersen M, Taylor MA, Saris WH, et al. Randomized, multi-center trial of two hypo-energetic diets in obese subjects: high-

- versus low-fat content. Int J Obes (Lond). 2006;30(3):552-60.
- 777. Wang TF, Pei D, Li JC, et al. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2005;59(7):746-50.
- 778. Robitaille J, Fontaine-Bisson B, Couture P, Tchernof A, Vohl MC. Effect of an oat bran-rich supplement on the metabolic profile of overweight premenopausal women. Ann Nutr Metab. 2005;49(3):141-8.
- 779. Noakes M, Keogh JB, Foster PR, Clifton PM. Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr. 2005;81(6):1298-306.
- 780. Poston WS, Haddock CK, Pinkston MM, et al. Weight loss with meal replacement and meal replacement plus snacks: a randomized trial. Int J Obes (Lond). 2005;29(9):1107-14.
- 781. Ebbeling CB, Leidig MM, Sinclair KB, Seger-Shippee LG, Feldman HA, Ludwig DS. Effects of an ad libitum low-glycemic load diet on cardiovascular disease risk factors in obese young adults. Am J Clin Nutr. 2005;81(5):976-82.
- 782. Frank LL, Sorensen BE, Yasui Y, et al. Effects of exercise on metabolic risk variables in overweight postmenopausal women: a randomized clinical trial. Obes Res. 2005;13(3):615-25.
- 783. Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. Diabet Med. 2005;22(5):612-8.
- 784. Gaullier JM, Halse J, Høye K, et al. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. J Nutr. 2005;135(4):778-84.

- 785. Zemel MB, Richards J, Mathis S, Milstead A, Gebhardt L, Silva E. Dairy augmentation of total and central fat loss in obese subjects. Int J Obes (Lond). 2005;29(4):391-7.
- 786. Patalay M, Lofgren IE, Freake HC, Koo SI, Fernandez ML. The lowering of plasma lipids following a weight reduction program is related to increased expression of the LDL receptor and lipoprotein lipase. J Nutr. 2005;135(4):735-9.
- 787. Pieterse Z, Jerling JC, Oosthuizen W, et al. Substitution of high monounsaturated fatty acid avocado for mixed dietary fats during an energy-restricted diet: effects on weight loss, serum lipids, fibrinogen, and vascular function. Nutrition. 2005;21(1):67-75.
- 788. Derosa G, Cicero AF, Murdolo G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab. 2005;7(1):47-55.
- 789. Maeda H, Yamamoto R, Hirao K, Tochikubo O. Effects of agar (kanten) diet on obese patients with impaired glucose tolerance and type 2 diabetes. Diabetes Obes Metab. 2005;7(1):40-6.
- 790. Pereira MA, Swain J, Goldfine AB, Rifai N, Ludwig DS. Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. Jama. 2004;292(20):2482-90.
- 791. Aude YW, Agatston AS, Lopez-Jimenez F, et al. The national cholesterol education program diet vs a diet lower in carbohydrates and higher in protein and monounsaturated fat: a randomized trial. Arch Intern Med. 2004;164(19):2141-6.
- 792. Brinkworth GD, Noakes M, Parker B, Foster P, Clifton PM. Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with type 2 diabetes: one-year follow-up of a randomised trial. Diabetologia. 2004;47(10):1677-86.
- 793. Melanson KJ, Dell'Olio J, Carpenter MR, Angelopoulos TJ. Changes in multiple health outcomes at 12 and 24 weeks

- resulting from 12 weeks of exercise counseling with or without dietary counseling in obese adults. Nutrition. 2004;20(10):849-56.
- 794. Yesilbursa D, Serdar Z, Serdar A, Sarac M, Coskun S, Jale C. Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels. Int J Obes (Lond). 2005;29(1):142-5.
- 795. Seshadri P, Iqbal N, Stern L, et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med. 2004;117(6):398-405.
- 796. Miyashita Y, Koide N, Ohtsuka M, et al. Beneficial effect of low carbohydrate in low calorie diets on visceral fat reduction in type 2 diabetic patients with obesity. Diabetes Res Clin Pract. 2004;65(3):235-41.
- 797. Flechtner-Mors M, Biesalski HK, Jenkinson CP, Adler G, Ditschuneit HH. Effects of moderate consumption of white wine on weight loss in overweight and obese subjects. Int J Obes Relat Metab Disord. 2004;28(11):1420-6.
- 798. Mhurchu CN, Poppitt SD, McGill AT, et al. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord. 2004;28(9):1149-56.
- 799. Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. Jama. 2004;291(24):2978-84.
- 800. Carels RA, Darby LA, Cacciapaglia HM, Douglass OM. Reducing cardiovascular risk factors in postmenopausal women through a lifestyle change intervention. J Womens Health (Larchmt). 2004;13(4):412-26.
- 801. Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med. 2004;140(10):778-85.
- 802. Brinkworth GD, Noakes M, Keogh JB, Luscombe ND, Wittert GA, Clifton PM. Long-term effects of a high-protein,

- low-carbohydrate diet on weight control and cardiovascular risk markers in obese hyperinsulinemic subjects. Int J Obes Relat Metab Disord. 2004;28(5):661-70.
- 803. Albert SG, Mooradian AD. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. J Clin Endocrinol Metab. 2004;89(2):695-701.
- 804. Rachmani R, Bar-Dayan Y, Ronen Z, Levi Z, Slavachevsky I, Ravid M. The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study. Diabetes Obes Metab. 2004;6(1):63-8.
- 805. Poston WS, Reeves RS, Haddock CK, et al. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. Int J Obes Relat Metab Disord. 2003;27(12):1486-93.
- 806. Bloch KV, Salles GF, Muxfeldt ES, Da Rocha Nogueira A. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial. J Hypertens. 2003;21(11):2159-65.
- 807. Lovejoy JC, Bray GA, Lefevre M, et al. Consumption of a controlled low-fat diet containing olestra for 9 months improves health risk factors in conjunction with weight loss in obese men: the Ole' Study. Int J Obes Relat Metab Disord. 2003;27(10):1242-9.
- 808. Ash S, Reeves MM, Yeo S, Morrison G, Carey D, Capra S. Effect of intensive dietetic interventions on weight and glycaemic control in overweight men with Type II diabetes: a randomised trial. Int J Obes Relat Metab Disord. 2003;27(7):797-802.
- 809. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348(21):2082-90.
- 810. Melanson K, Gootman J, Myrdal A, Kline G, Rippe JM. Weight loss and total lipid profile changes in overweight women consuming beef or chicken as the primary protein source. Nutrition. 2003;19(5):409-14.

- 811. Allison DB, Gadbury G, Schwartz LG, et al. A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. Eur J Clin Nutr. 2003;57(4):514-22.
- 812. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. Jama. 2003;289(14):1799-804.
- 813. Lantz H, Peltonen M, Agren L, Torgerson JS. Intermittent versus on-demand use of a very low calorie diet: a randomized 2-year clinical trial. J Intern Med. 2003;253(4):463-71.
- 814. James AP, Watts GF, Barrett PH, et al. Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men. Metabolism. 2003;52(2):136-41.
- 815. Hirose K, Tajima K, Miura S. A Model Obesity Control Program Focusing on a Healthy Diet and Gentle Exercise in Aichi Cancer Center Hospital. Asian Pac J Cancer Prev. 2002;3(2):149-154.
- 816. Sharman MJ, Gómez AL, Kraemer WJ, Volek JS. Very low-carbohydrate and low-fat diets affect fasting lipids and postprandial lipemia differently in overweight men. J Nutr. 2004;134(4):880-5.
- 817. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002;20(11):2257-67.
- 818. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2002;4(6):415-23.
- 819. Dunstan DW, Daly RM, Owen N, et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care. 2002;25(10):1729-36.

- 820. Larsen TM, Toubro S, van Baak MA, et al. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr. 2002;76(4):780-8.
- 821. Nieman DC, Brock DW, Butterworth D, Utter AC, Nieman CC. Reducing diet and/or exercise training decreases the lipid and lipoprotein risk factors of moderately obese women. J Am Coll Nutr. 2002;21(4):344-50.
- 822. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002;10(7):633-41.
- 823. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25(7):1123-8.
- 824. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care. 2002;25(6):1033-41.
- 825. Heilbronn LK, Noakes M, Clifton PM. The effect of high- and low-glycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control. J Am Coll Nutr. 2002;21(2):120-7.
- 826. Janssen I, Fortier A, Hudson R, Ross R. Effects of an energy-restrictive diet with or without exercise on abdominal fat, intermuscular fat, and metabolic risk factors in obese women. Diabetes Care. 2002;25(3):431-8.
- 827. Yip I, Go VL, DeShields S, et al. Liquid meal replacements and glycemic control in obese type 2 diabetes patients. Obes Res. 2001;9 Suppl 4:341s-347s.
- 828. Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care. 2001;24(11):1957-60.

- 829. Volpe SL, Huang HW, Larpadisorn K, Lesser, II. Effect of chromium supplementation and exercise on body composition, resting metabolic rate and selected biochemical parameters in moderately obese women following an exercise program. J Am Coll Nutr. 2001;20(4):293-306.
- 830. Dumont M, Mauriège P, Bergeron J, Després JP, Prud'homme D. Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men. Int J Obes Relat Metab Disord. 2001;25(8):1136-43.
- 831. Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes Relat Metab Disord. 2001;25(3):316-24.
- 832. Birketvedt GS, Aaseth J, Florholmen JR, Ryttig K. Long-term effect of fibre supplement and reduced energy intake on body weight and blood lipids in overweight subjects. Acta Medica (Hradec Kralove). 2000;43(4):129-32.
- 833. Richelsen B, Pedersen SB, Kristensen K, et al. Regulation of lipoprotein lipase and hormone-sensitive lipase activity and gene expression in adipose and muscle tissue by growth hormone treatment during weight loss in obese patients. Metabolism. 2000;49(7):906-11.
- 834. Halimi S, Le Berre MA, Grangé V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract. 2000;50(1):49-56.
- 835. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med. 2001;161(2):218-27.
- 836. Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic

- parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2000;2(3):175-87.
- 837. Ditschuneit HH, Frier HI, Flechtner-Mors M. Lipoprotein responses to weight loss and weight maintenance in high-risk obese subjects. Eur J Clin Nutr. 2002;56(3):264-70.
- 838. Fogelholm M, Kukkonen-Harjula K, Nenonen A, Pasanen M. Effects of walking training on weight maintenance after a very-low-energy diet in premenopausal obese women: a randomized controlled trial. Arch Intern Med. 2000;160(14):2177-84.
- 839. Donnelly JE, Jacobsen DJ, Heelan KS, Seip R, Smith S. The effects of 18 months of intermittent vs. continuous exercise on aerobic capacity, body weight and composition, and metabolic fitness in previously sedentary, moderately obese females. Int J Obes Relat Metab Disord. 2000;24(5):566-72.
- 840. Golay A, Allaz AF, Ybarra J, et al. Similar weight loss with low-energy food combining or balanced diets. Int J Obes Relat Metab Disord. 2000;24(4):492-6.
- 841. Mori TA, Bao DQ, Burke V, Puddey IB, Watts GF, Beilin LJ. Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects. Am J Clin Nutr. 1999;70(5):817-25.
- 842. Vidgren HM, Agren JJ, Valve RS, Karhunen LJ, Rissanen AM, Uusitupa MI. The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects. Clin Pharmacol Ther. 1999;66(3):315-22.
- 843. Roger P, Auclair J, Drain P. Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo. J Diabetes Complications. 1999;13(2):62-7.
- 844. Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr. 1999;53(5):379-81.

- 845. Ditschuneit HH, Flechtner-Mors M, Johnson TD, Adler G. Metabolic and weight-loss effects of a long-term dietary intervention in obese patients. Am J Clin Nutr. 1999;69(2):198-204.
- 846. Andersen RE, Wadden TA, Bartlett SJ, Zemel B, Verde TJ, Franckowiak SC. Effects of lifestyle activity vs structured aerobic exercise in obese women: a randomized trial. Jama. 1999;281(4):335-40.
- 847. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. Jama. 1999;281(3):235-42.
- 848. Charles MA, Morange P, Eschwège E, André P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care. 1998;21(11):1967-72.
- 849. Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care. 1998;21(7):1052-7.
- 850. Marckmann P, Toubro S, Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr. 1998;52(5):329-33.
- 851. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167-72.
- 852. Agurs-Collins TD, Kumanyika SK, Ten Have TR, Adams-Campbell LL. A randomized controlled trial of weight reduction and exercise for diabetes management in older African-American subjects. Diabetes Care. 1997;20(10):1503-11.
- 853. Kraemer WJ, Volek JS, Clark KL, et al. Physiological adaptations to a weight-loss dietary regimen and exercise programs in

- women. J Appl Physiol (1985). 1997;83(1):270-9.
- 854. Rössner S, Flaten H. VLCD versus LCD in long-term treatment of obesity. Int J Obes Relat Metab Disord. 1997;21(1):22-6.
- 855. Pontiroli AE, Pacchioni M, Piatti PM, Cassisa C, Camisasca R, Pozza G. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. J Clin Endocrinol Metab. 1996;81(10):3727-32.
- 856. Golay A, Allaz AF, Morel Y, de Tonnac N, Tankova S, Reaven G. Similar weight loss with low- or high-carbohydrate diets. Am J Clin Nutr. 1996;63(2):174-8.
- 857. Pascale RW, Wing RR, Butler BA, Mullen M, Bononi P. Effects of a behavioral weight loss program stressing calorie restriction versus calorie plus fat restriction in obese individuals with NIDDM or a family history of diabetes. Diabetes Care. 1995;18(9):1241-8.
- 858. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541-9.
- 859. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med. 1994;11(1):105-10.
- 860. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol. 1993;44(2):107-12.
- 861. Puddey IB, Parker M, Beilin LJ, Vandongen R, Masarei JR. Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension. 1992;20(4):533-41.
- 862. Wolever TM, Jenkins DJ, Vuksan V, Jenkins AL, Wong GS, Josse RG. Beneficial effect of low-glycemic index diet in overweight NIDDM subjects. Diabetes Care. 1992;15(4):562-4.

- 863. Golay A, Koellreutter B, Bloise D, Assal JP, Würsch P. The effect of muesli or cornflakes at breakfast on carbohydrate metabolism in type 2 diabetic patients. Diabetes Res Clin Pract. 1992;15(2):135-41.
- 864. Jalkanen L. The effect of a weight reduction program on cardiovascular risk factors among overweight hypertensives in primary health care. Scand J Soc Med. 1991;19(1):66-71.
- 865. Nieman DC, Haig JL, Fairchild KS, De Guia ED, Dizon GP, Register UD. Reducing-diet and exercise-training effects on serum lipids and lipoproteins in mildly obese women. Am J Clin Nutr. 1990;52(4):640-5.
- 866. Lalor BC, Bhatnagar D, Winocour PH, et al. Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. Diabet Med. 1990;7(3):242-5.